Patent Application
20100234351
The present invention relates to a fused pyrimidine compound having a growth factor receptor tyrosine kinase inhibitory activity, which is useful for the prophylaxis or treatment of cancer, a production method thereof and use thereof.
The gene of cell growth factor and growth factor receptor is called a protooncogene and plays a key role in the pathology of human tumor. The epithelial cell growth factor receptor family (erbB) includes EGFR, HER2, HER3 and HER4, which are type I receptor type tyrosine kinases. These erbB family express in various cell groups, and are deeply involved in the control of the growth and differentiation of cells and the control of suppression of cell death (apoptosis suppression).
For example, high expression of EGFR and HER2, and homeostatic activation of receptors are empirically known to transform cells.
It is also known that high expression and simultaneous expression of each of these receptors are poor prognostic factors in various cancer patients.
These receptors are bound with many peptide ligands such as EGF, TGFα and the like, and binding of the ligand promotes homo- or heterodimerization of the receptors. This induces increase of kinase activity from self-phosphorylation or transphosphorylation of the receptors, and causes activation of downstream signaling pathway (MAPK, Akt) via a protein bound with a particular phosphorylated tyrosine residue. This is the substance of the receptor activity of the above-mentioned cell growth, differentiation, cell death suppression and the like, which is considered to be responsible for the high expression of receptor in cancer and malignant degeneration of cancer due to topical increase in the ligand concentration.
Many cancers are associated with the high expression of EGFR or HER2. For example, breast cancer (20-30%), ovarian cancer (20-40%), non-small cell lung cancer (30-60%), colorectal cancer (40-80%), prostate cancer (10-60%), bladder cancer (30-60%), kidney cancer (20-40%) and the like can be mentioned. Moreover, receptor expression and prognosis are correlated, and receptor expression is a poor prognostic factor in breast cancer, non-small cell lung cancer and the like.
In recent years, clinical use of a humanized anti-HER2 antibody (Trastuzumab) against HER2 highly expressing breast cancer, clinical, trial of anti-EGFR antibody and clinical trials of several low molecular weight receptor enzyme inhibitors have demonstrated a potential of these drugs against HER2 or EGFR for therapeutic drugs for cancer. While these drugs show a tumor growth inhibitory action in clinical and non-clinical trials, they are known to induce inhibition of receptor enzyme activity and suppression of downstream signaling pathway. Therefore, a compound inhibiting EGFR or HER2 kinase, or inhibiting activation of EGFR or HER2 kinase is effective as a therapeutic drug for cancer.
As a compound that inhibits receptor type tyrosine kinases including HER2/EGFR kinase, fused heterocyclic compounds (e.g., WO97/13771, WO98/02437, WO00/44728, WO01/19828, WO2005/118588), quinazoline derivatives (e.g., WO02/02552, WO01/98277, WO03/049740, WO03/050108), thienopyrimidine derivatives (e.g., WO03/053446), aromatic azole derivatives (e.g., WO98/03648, WO01/77107, WO03/031442) and the like are known; however, there is no HER2 kinase inhibitory substance to the present that has been marketed as a therapeutic drug for cancer.
The present invention aims at provision of a compound having a superior tyrosine kinase inhibitory action, which is highly safe and sufficiently satisfactory as a pharmaceutical product.
The present inventors have conducted intensive studies in an attempt to solve the aforementioned problems and found that the compounds represented by the following formula (I) and a salt thereof (sometimes to be referred to as compound (I) in the present specification) have a superior tyrosine kinase inhibitory action. Further studies have resulted in the completion of the present invention.
Accordingly, the present invention relates to the following:
[1] A compound represented by the formula:
wherein
ring A is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring,
ring B is an optionally substituted aryl group or an optionally substituted heteroaryl group,
X1 is a group represented by —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3—
wherein ring Aa is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, and other symbols are as defined in the above-mentioned [1], or a salt thereof.
[3] The compound of the above-mentioned [1], which is a compound represented by the formula:
wherein
ring Ab is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring,
formula is a single bond or a double bond,
R2b is a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, and
other symbols are as defined in the above-mentioned [1], or a salt thereof.
[4] The compound of the above-mentioned [1], which is a compound represented by the formula:
wherein
ring Ad is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring,
formula is a single bond or a double bond,
ring Bd is an optionally further substituted phenyl group or an optionally further substituted pyridyl group,
ring Cd is an optionally substituted phenyl group,
X2d is a group represented by —O—, —S—, —SO—, —SO2—, —CH2— or —CO—NR5d— (wherein R5d is a hydrogen atom, or an optionally substituted C1-6 alkyl group),
m is an integer of 0 to 5,
R1d is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom,
R2d is a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, and
R3d is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3d is optionally bonded to the carbon atom on ring Bd to form an optionally substituted ring structure,
or a salt thereof.
[5] The compound of the above-mentioned [4], wherein
R1d is a hydrogen atom or a C1-6 alkyl group,
(i) a C1-6 alkyl group substituted by substituents selected from the group consisting of
(a) hydroxy,
(b) —NH—CO—(CH2)p—SO2—C1-6 alkyl (p is an integer of 0.1 to 6),
(c) —NH—CO—C1-6 alkyl-hydroxy,
(d) —NH—CO— (CH2)p′—C1-6 alkoxy-C1-6 alkoxy (p′ is an integer of 1 to 6),
(e) C1-6 alkoxyimino substituted by substituents selected from the group consisting of (1) hydroxy, (2) C1-6 alkoxy, (3) di-C1-6 alkylamino, (4) C1-6 alkylsulfonyl and (5) 5- to 8-membered heterocyclic group containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom,
(f) C1-6 alkylamino having cyano,
(g) C1-6 alkylamino having halogen atom,
(h) C1-6 alkylamino having hydroxy,
(i) C1-6 alkylamino having C1-6 alkoxy,
(j) C1-6 alkylamino having C1-6 alkylsulfonyl
optionally having hydroxy,
(k) di-C1-6 alkylamino optionally having 1 or 2 substituents selected from the group consisting of (1) hydroxy, (2) cyano, (3) halogen atom and (4) C1-6 alkylsulfonyl,
(l) C3-7 cycloalkylamino optionally having hydroxy,
(m) 5- to 8-membered heterocyclyl-amino containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom,
(o) 5- to 8-membered cyclic amino optionally having C1-6 alkoxy or a C1-6 alkylsulfonyl,
(p) N—C1-6 alkyl-N—C3-7 cycloalkylamino optionally having C1-6 alkylsulfonyl,
(q) cyano,
(r) C1-6 alkylamino having C1-6 alkoxy optionally having hydroxy or a C1-6 alkoxy, and
(s) 5- to 8-membered heterocycle containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, which is optionally substituted by substituents selected from the group consisting of oxo, C1-6 alkylsulfonyl and C1-6 alkoxy,
(ii) a C2-6 alkenyl group having (a) hydroxy, (b) di-C1-6 alkylamino or (c) C1-6 alkoxy-carbonyl,
(iii) a C1-6 alkoxy-carbonyl group,
(iv) a group represented by —CO—NRaRb
wherein
Ra is a hydrogen atom or a C1-6 alkyl group, and
Rb is
(a) hydroxy,
(b) C1-6 alkylsulfonyl, and
(c) C1-6 alkyl optionally having C1-6 alkylsulfonyl,
(vi) a carboxy group,
(vii) an amino group optionally substituted by C1-6 alkoxy-carbonyl optionally having C1-6 alkylsulfonyl, or
(viii) a 5- to 8-membered heterocyclic group containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, which optionally has C1-6 alkyl,
R3d is a hydrogen atom,
ring Bd is a phenyl group optionally further substituted by C1-6 alkyl group or halogen atom, or a pyridyl group optionally further substituted by C1-6 alkyl group or halogen atom,
ring Cd is a phenyl group optionally substituted by substituents selected from the group consisting of
(i) optionally halogenated C1-6 alkyl,
(ii) C1-6 alkoxy optionally having halogen atom or C3-7 cycloalkyl,
(iii) C1-6 alkyl-carbamoyl optionally having hydroxy,
(iv) halogen atom,
(v) cyano,
(vi) C1-6 alkylthio optionally having halogen atom,
(vii) C1-6 alkylsulfinyl optionally having halogen atom, and
(viii) C1-6 alkylsulfonyl optionally having halogen atom or C3-7 cycloalkyl,
X2d is a group represented by —O— or —S—, and
m is 0 or 1.
[6] The compound of the above-mentioned [1], which is a compound represented by the formula:
wherein
ring Af is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring,
formula is a single bond or a double bond,
ring Bf is an optionally further substituted phenyl group or an optionally further substituted pyridyl group,
ring Df is an optionally substituted aromatic heterocyclic group,
X2f is a group represented by —O—, —S—, —SO—, —SO2—, —CH2— or —CO—NR5f— (wherein R5f is a hydrogen atom, or an optionally substituted C1-6 alkyl group),
n is an integer of 0 to 5,
R1f is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom,
R2f is a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, and
R3f is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3f is optionally bonded to the carbon atom on ring Bf to form an optionally substituted ring structure,
or a salt thereof.
[7] The compound of the above-mentioned [6], wherein
R1f is a hydrogen atom or a C1-6 alkyl group,
(i) a C1-6 alkyl group optionally having hydroxy,
(ii) a C1-6 alkoxy-carbonyl group,
(iii) a group represented by —CO—NRcRd
wherein
Rc is a hydrogen atom, and
Rd is
(a) a C1-6 alkyl group optionally substituted by substituents selected from the group consisting of (1) C1-6 alkoxy, (2) C1-6 alkoxy optionally having substituents selected from the group consisting of (1′) hydroxy, (2′) cyano and (3′) C1-6 alkoxy, and (3) C1-6 alkylsulfonyl optionally having hydroxy,
(b) a C3-7 cycloalkyl group, or
(c) a C1-6 alkoxy group optionally substituted by C1-6 alkylsulfonyl,
(iv) a 5- to 8-membered cyclic amino-carbonyl group optionally substituted by substituents selected from the group consisting of
(a) hydroxy, and
(b) C1-6 alkyl optionally having hydroxy, or
(v) a carboxy group,
R3f is a hydrogen atom,
ring Bf is a phenyl group optionally further substituted by C1-6 alkyl group,
Xf is a group represented by —O—,
n is 0, and
ring Df is a 5- or 6-membered monocyclic aromatic heterocycle containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, which is optionally substituted by C1-6 alkyl group.
[8] The compound of the above-mentioned [1], which is a compound represented by the formula:
wherein
ring Ah is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring,
formula is a single bond or a double bond,
ring Bh is an optionally further substituted phenyl group or an optionally further substituted pyridyl group,
ring Eh is an optionally further substituted piperidyl group,
X2h is a group represented by —O—, —S—, —SO—, —SO2—, —CH2— or —CO—NR5h— (wherein R5h is a hydrogen atom or an optionally substituted C1-6 alkyl group),
R1h is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom,
R2h is a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom,
R3h is a hydrogen atom, or an optionally substituted aliphatic hydrocarbon group, or R3h is optionally bonded to the carbon atom on ring Bh to form an optionally substituted ring structure, and
R4h is a hydrogen atom or an acyl group, or a salt thereof.
[9] The compound of the above-mentioned [8], wherein
R1h is a hydrogen atom,
(i) a C1-6 alkyl group optionally substituted by hydroxy,
(ii) a C1-6 alkoxy-carbonyl group,
(iii) a group represented by —CO—NReRf
wherein
Re is a hydrogen atom or a C1-6 alkyl group,
Rf is
(a) hydroxy,
(b) C1-6 alkylsulfonyl, and
(c) C1-6 alkyl optionally having C1-6 alkylsulfonyl,
R3h is a hydrogen atom,
ring Bh is a phenyl group optionally further substituted by halogen atom,
X2h is a group represented by —O—, and
R4h is (1) a C3-7 cycloalkyl-carbonyl group, (2) a C1-6 alkoxy-carbonyl group, or (3) a 5- to 8-membered heterocyclyl-carbonyl group containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, which optionally has 1 or 2 C1-6 alkyls.
[10] A following compound;
N-(tert-butyl)-3-(2-chloro-4-{[6-({methyl[2-(methylsulfonyl)ethyl]amino}methyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl]amino}phenoxy)benzamide, or
wherein
ring A is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, ring B is an optionally substituted aryl group or an optionally substituted heteroaryl group,
X1 is a group represented by —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3—
wherein
wherein
ring A is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, ring B is an optionally substituted aryl group or an optionally substituted heteroaryl group,
X1 is a group represented by —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3—
wherein
ring A is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, ring B is an optionally substituted aryl group or an optionally substituted heteroaryl group,
X1 is a group represented by —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3—
wherein
ring A is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring,
ring B′ is an optionally substituted aryl group or an optionally substituted heteroaryl group,
X1 is a group represented by —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3—
wherein R11 is a C1-6 alkyl group, R12 is a group represented by —CHO or —COOR13 (wherein R13 is a C1-6 alkyl group.), and other symbols are as defined in the above-mentioned [1],
or a salt thereof, to an intramolecular dehydrating condensation reaction in the presence of a base, and, as necessary, subjecting the resulting compound to a substituent conversion reaction.
[19] A production method of the compound of the above-mentioned [1] or a salt thereof, which comprises reacting a compound represented by the formula:
wherein Q is a leaving group, and other symbols are as defined in the above-mentioned [1],
or a salt thereof and a compound represented by the formula:
wherein G is a hydrogen atom or a metal atom, and other symbols are as defined in the above-mentioned [1], or a salt thereof.
[20] The compound of the above-mentioned [1], which is a compound represented by the formula:
wherein
ring Ac is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring,
ring Bc is an optionally further substituted phenyl group or an optionally further substituted pyridyl group,
ring Cc is an optionally substituted phenyl group,
X2 is a group represented by —O—, —S—, —SO—, —SO2—, —CH2— or —CO—NR5— (wherein R5 is a hydrogen atom or an optionally substituted C1-6 alkyl group),
m is an integer of 0 to 5,
other symbols are as defined in the above-mentioned [1], and
R3 is optionally bonded to the carbon atom on ring Bc to form an optionally substituted ring structure, or a salt thereof.
[21], The compound of the above-mentioned [1], which is a compound represented by the formula:
wherein
ring Ae is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring,
ring Be is an optionally further substituted phenyl group or an optionally further substituted pyridyl group,
ring De is an optionally substituted aromatic heterocyclic group,
X2 is a group represented by —O—, —S—, —SO—, —SO2—, —CH2— or —CO—NR5— (wherein R5 is a hydrogen atom, or an optionally substituted C1-6 alkyl group),
n is an integer of 0 to 5,
other symbols are as defined in the above-mentioned [1], and
R3 is optionally bonded to the carbon atom on ring Be to form an optionally substituted ring structure, or a salt thereof.
[22] The compound of the above-mentioned [1], which is a compound represented by the formula:
wherein
ring Ag is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring,
ring Bg is an optionally further substituted phenyl group or an optionally further substituted pyridyl group,
ring Eg is an optionally further substituted piperidyl group,
R4 is a hydrogen atom or an acyl group,
X2 is a group represented by —O—, —S—, —SO—, —SO2, —CH2— or —CO—NR5— (wherein R5 is a hydrogen atom or an optionally substituted C1-6 alkyl group),
other symbols are as defined in the above-mentioned [1], and
R3 is optionally bonded to the carbon atom on ring Bg to form an optionally substituted ring structure, or a salt thereof.
[23] The compound of the above-mentioned [1], wherein R1 is a hydrogen atom or a C1-6 alkyl group.
[24] The compound of the above-mentioned [1], wherein R1 is a hydrogen atom.
[25] The compound of the above-mentioned [1], wherein R2 is an optionally substituted hydrocarbon group, an acyl group or an amino group optionally substituted by acyl group.
[26] The compound of the above-mentioned [1], wherein R3 is a hydrogen atom or a C1-6 alkyl group.
[27] The compound of the above-mentioned [3], wherein R2b is
(i) a C1-6 alkyl group optionally substituted by substituents selected from the group consisting of
(a) hydroxy,
(b) —NH—CO—(CH2)p—SO2—C1-6 alkyl (p is an integer of 1 to 6), and
(c) —NH—CO—C1-6 alkyl-hydroxy,
(ii) a C1-6 alkoxy-carbonyl group,
(iii) a group represented by —CO—NRa0Rb0
(a) hydroxy,
(b) C1-6 alkylsulfonyl, and
(c) C1-6 alkyl optionally having hydroxy or C1-6 alkylsulfonyl,
(v) a carboxy group, or
(vi) an amino group optionally substituted by C1-6 alkoxy-carbonyl optionally having C1-6 alkylsulfonyl.
[28] The compound of the above-mentioned [1], which is a compound represented by the formula:
wherein
ring Ai is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring,
formula is a single bond or a double bond,
R2i is a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom when R2i is —R2i, and an oxo group, an optionally substituted alkylidene group or an optionally substituted imino group when
R2i is ═R2i,
other symbols are as defined in the above-mentioned [1], and
R2i and R3 are optionally bonded to each other to form an optionally substituted ring structure,
or a salt thereof.
The present invention can provide a compound having a superior tyrosine kinase inhibitory action, which is low toxic and sufficiently satisfactory as a pharmaceutical product, a production method thereof and use thereof.
Each symbol used in the present specification is described in detail in the following.
In the present specification, unless otherwise specified, as the “halogen atom” (and “halogen” in substituent), fluorine atom, chlorine atom, bromine atom and iodine atom can be mentioned.
In the present specification, unless otherwise specified, as the “alkyl group”, a straight chain or branched alkyl group having 1 to 10 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, heptyl, octyl, nonyl, decyl and the like can be mentioned.
In the present specification, unless otherwise specified, as the “C1-8 alkyl group”, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, heptyl, octyl and the like can be mentioned.
In the present specification, unless otherwise specified, as the “C1-6 alkyl group”, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl and the like can be mentioned.
In the present specification, unless otherwise specified, as the “C1-4 alkyl group”, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl can be mentioned.
In the present specification, unless otherwise specified, as the “alkenyl group”, an alkenyl group having 2 to 10 carbon atoms, for example, ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 3-hexenyl, 5-hexenyl, 1-heptenyl, 1-octenyl and the like can be mentioned. Of these, C2-6 alkenyl group is preferable.
In the present specification, unless otherwise specified, as the “C2-4 alkenyl group”, for example, ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl and the like can be mentioned.
In the present specification, unless otherwise specified, as the “alkynyl group”, an alkynyl group having 2 to 10 carbon atoms, for example, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-heptynyl, 1-octynyl and the like can be mentioned. Of these, C2-6 alkynyl group is preferable.
In the present specification, unless otherwise specified, as the “C2-4 alkynyl group”, for example, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl and the like can be mentioned.
In the present specification, unless otherwise specified, as the “cycloalkyl group”, a cycloalkyl group having 3 to 10 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[3.2.2]nonyl, bicyclo[3.3.1]nonyl, bicyclo[4.2.1]nonyl, bicyclo[4.3.1]decyl, adamantyl and the like can be mentioned. Of these, C3-7 cycloalkyl group is preferable.
In the present specification, unless otherwise specified, as the “C5-8 cycloalkyl group”, for example, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl can be mentioned.
In the present specification, unless otherwise specified, as the “C3-7 cycloalkyl group”, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl can be mentioned.
In the present specification, unless otherwise specified, as the “cycloalkenyl group”, a cycloalkenyl group having 3 to 10 carbon atoms, for example, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2-cyclohexen-1-yl, 3-cyclohexen-1-yl and the like can be mentioned.
In the present specification, unless otherwise specified, as the “cycloalkadienyl group”, a cycloalkadienyl group having 4 to 10 carbon atoms, for example, 2,4-cyclopentadien-1-yl, 2,4-cyclohexadien-1-yl, 2,5-cyclohexadien-1-yl and the like can be mentioned. Of these, C5-7 cycloalkadiene group is preferable.
In the present specification, unless otherwise specified, the term “aryl group” encompasses a monocyclic aryl group and a fused polycyclic aryl group. As the “aryl group”, an aryl group having 6 to 18-carbon atoms, for example, phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl, biphenylyl and the like can be mentioned.
In the present specification, unless otherwise specified, as the “C6-14 aryl group”, for example, phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl, biphenylyl and the like can be mentioned.
In the present specification, unless otherwise specified, as the “aralkyl group”, an aralkyl group having 7 to 15 carbon atoms, for example, benzyl, phenethyl, phenylpropyl, naphthylmethyl and biphenylylmethyl can be mentioned.
In the present specification, unless otherwise specified, as the “alkanoyl group”, an alkanoyl group having 1 to 7 carbon atoms, for example, formyl and C1-6 alkyl-carbonyl (e.g., acetyl, propionyl, butyryl, valeryl and pivaloyl) can be mentioned.
In the present specification, unless otherwise specified, as the “C1-6 alkoxy group”, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, n-pentyloxy and n-hexyloxy and the like can be mentioned.
In the present specification, unless otherwise specified, as the “C1-4 alkylene”, for example, —CH2—, —CH2CH2—, —(CH2)3—, —(CH2)4, —CH(CH3)—, —C(CH3)2—, —CH(CH3)CH2—, —CH2CH(CH3)—, —C(CH3)2CH2— and —CH2C(CH3)2— can be mentioned.
In the present specification, unless otherwise specified, as the “C1-3 alkylenedioxy group”, for example, methylenedioxy, ethylenedioxy, propylenedioxy and the like can be mentioned.
In the present specification, unless otherwise specified, as the “alkylidene group” of the “optionally substituted alkylidene group”, an alkylidene group having 1 to 10 carbon atoms can be mentioned. Of these, a C1-6 alkylidene group (e.g., methylidene, ethylidene, propylidene, isopropylidene, butenylidene and the like) is preferable. The “alkylidene group” is, for example, optionally substituted by not less than 1 (preferably 1 to 5, more preferably 1 to 3) substituent selected from the below-mentioned substituent group U.
In the present specification, unless otherwise specified, as the “hydrocarbon group” of the “optionally substituted hydrocarbon group”, for example, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a cycloalkadienyl group, an aryl group, an aralkyl group, an arylalkenyl group, a cycloalkyl-alkyl group and the like can be mentioned. Of these, a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group, a C3-10 cycloalkyl group, a C3-10 cycloalkenyl group, a C4-10 cycloalkadienyl group, a C6-14 aryl group, a C7-15 aralkyl group, a C8-13 arylalkenyl group, a C3-10 cycloalkyl-C1-6 alkyl group and the like preferable.
The above-mentioned C3-10 cycloalkyl group, C3-10 cycloalkenyl group and C4-10 cycloalkadienyl group may be condensed with a benzene ring, and as such fused ring groups, for example, indanyl, dihydronaphthyl, tetrahydronaphthyl, fluorenyl and the like can be mentioned. As the above-mentioned hydrocarbon group, a crosslinking hydrocarbon group such as norbornanyl, adamantyl and the like, and the like can be mentioned.
As the C8-13 arylalkenyl group, for example, styryl and the like can be mentioned.
As the C3-10 cycloalkyl-C1-6 alkyl group, for example, cyclopropylmethyl, cyclohexylmethyl and the like can be mentioned.
As the above-mentioned “hydrocarbon group”, for example, a chain hydrocarbon group such as a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group and the like optionally has 1 to 3 substituents at substitutable position(s).
As such substituents, for example,
(1) a C3-10 cycloalkyl group optionally substituted by 1 to 3 substituents selected from the group consisting of
(1-1) halogen atom;
(1-2) hydroxy;
(1-3) carboxyl;
(1-4) sulfo;
(1-5) cyano;
(1-6) azido;
(1-7) nitro;
(1-8) nitroso;
(1-9) optionally halogenated C1-4 alkyl;
(1-10) optionally halogenated C2-4 alkenyl;
(1-11) optionally halogenated C2-4 alkynyl;
(1-12) C3-7 cycloalkyl;
(1-13) C6-18 aryl;
(1-14) C6-18 aryl-C1-6 alkyl;
(1-15) formyl;
(1-16) optionally halogenated C1-6 alkyl-carbonyl;
(1-17) optionally halogenated C1-6 alkoxy-carbonyl;
(1-18) optionally halogenated C1-6 alkylsulfonyl;
(1-19) carbamoyl;
(1-20) carbamoyl mono- or di-substituted by optionally halogenated C1-6 alkyl group;
(1-21) mono- or di-C6-14 arylcarbamoyl;
(1-22) thiocarbamoyl optionally mono- or di-substituted by optionally halogenated C1-6 alkyl;
(1-23) ureido optionally mono- or di-substituted by optionally halogenated C1-6 alkyl;
(1-24) mono or di-C6-14 arylureido;
(1-25) sulfamoyl optionally mono- or di-substituted by optionally halogenated C1-6 alkyl;
(1-26) optionally halogenated C1-6 alkoxy;
(1-27) optionally halogenated C2-6 alkenyloxy;
(1-28) C3-10 cycloalkyloxy;
(1-29) C7-15 aralkyloxy;
(1-30) C6-14 aryloxy;
(1-31) C1-6 alkyl-carbonyloxy;
(1-32) C3-10 cycloalkyl-C1-6 alkyloxy;
(1-33) C1-6 alkylsulfonyloxy;
(1-34) thiol;
(1-35) optionally halogenated C1-6 alkylthio;
(1-36) C7-15 aralkylthio;
(1-37) C6-14 arylthio;
(1-38) C1-6 alkylsulfinyl;
(1-39) oxo;
(1-40) C1-3 alkylenedioxy;
(1-41) hydroxyimino optionally substituted by C1-6 alkyl; (hereinafter the substituents of the above-mentioned (1-1)-(1-41) are sometimes collectively referred to as “substituent group S”);
(2) a C6-18 aryl group optionally substituted by 1 to 3 substituents selected from the above-mentioned substituent group S;
(3) a heterocyclic group optionally substituted by 1 to 3 substituents selected from the above-mentioned substituent group S;
(4) an amino group optionally substituted by 1 or 2 substituents selected from the group consisting of
(4-1) C1-6 alkyl optionally substituted by substituents selected from the group consisting of halogen atom, hydroxy, cyano, C3-7 cycloalkyl, C1-6 alkylsulfonyl, C1-6 alkoxy, hydroxy-C1-6 alkoxy, hydroxy-C1-6 alkylsulfonyl, C1-6 alkoxy-C1-6 alkoxy and the like;
(4-2) optionally halogenated C2-4 alkenyl;
(4-3) optionally halogenated C2-4 alkynyl;
(4-4) C3-7 cycloalkyl optionally substituted by substituents selected from the group consisting of halogen atom, hydroxy, C3-7 cycloalkyl, C1-6 alkylsulfonyl, C1-6 alkoxy and the like;
(4-5) C6-14 aryl;
(4-6) C7-15 aralkyl;
(4-7) 5- to 8-membered heterocycle containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom;
(4-8) formyl;
(4-9) C1-6 alkyl-carbonyl optionally substituted by substituents selected from the group consisting of halogen atom, hydroxy, C3-7 cycloalkyl, C1-6 alkylsulfonyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkoxy and the like;
(4-10) C1-6 alkoxy-carbonyl optionally substituted by C1-6 alkylsulfonyl;
(4-11) C6-14 aryl-carbonyl;
(4-12) C7-15 aralkyl-carbonyl;
(4-13) C3-7 cycloalkyl-carbonyl;
(4-14) C1-6 alkyl-carbamoyl;
(4-15) C6-14 aryl-carbamoyl;
(4-16) C7-15 aralkyl-carbamoyl;
(4-17) C1-6 alkylsulfonyl;
(4-18) C6-14 arylsulfonyl;
(4-19) C7-15 aralkylsulfonyl;
(4-20) C1-6 alkoxy optionally substituted by substituents selected from the group consisting of halogen atom, hydroxy, C3-7 cycloalkyl, C1-6 alkylsulfonyl, C1-6 alkoxy, 5- to 8-membered heterocyclic group optionally substituted by 1 to 3 substituents selected from the above-mentioned substituent group S, containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, and the like; (hereinafter the substituents of the above-mentioned (4-1)-(4-20) are sometimes collectively referred to as “substituent group T”);
(5) an amidino group;
(6) a formyl group or an optionally halogenated C1-6 alkyl-carbonyl group;
(7) an optionally halogenated C1-6 alkoxy-carbonyl group;
(8) a C1-6 alkylsulfonyl group optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group, a C1-6 alkoxy group;
(9) a carbamoyl group optionally substituted by 1 or 2 substituents selected from substituent group T;
(10) a thiocarbamoyl group optionally mono- or di-substituted by optionally halogenated C1-6 alkyl group;
(11) an ureido group optionally substituted by 1 or 2 substituents selected from substituent group T;
(12) a sulfamoyl group optionally substituted by 1 or 2 substituents selected from substituent group T;
(13) a carboxyl group;
(14) a hydroxy group;
(15) a C1-6 alkoxy group optionally substituted by 1 to 3 substituents selected from the group consisting of halogen atom, cyano group, hydroxy group, carboxyl group, C1-6 alkylsulfonyl group, C1-6 alkoxy group and C1-6 alkoxy-carbonyl group;
(16) an optionally halogenated C2-6 alkenyloxy group;
(17) a C3-10 cycloalkyloxy group optionally substituted by 1 to 3 substituents selected from the above-mentioned substituent group S;
(18) a C7-15 aralkyloxy group optionally substituted by 1 to 3 substituents selected from the above-mentioned substituent S group;
(19) a C6-14 aryloxy group optionally substituted by 1 to 3 substituents selected from the above-mentioned substituent group S;
(20) a C1-6 alkyl-carbonyloxy group;
(21) a thiol group;
(22) an optionally halogenated C1-6 alkylthio group;
(23) a C7-15 aralkylthio group optionally substituted by 1 to 3 substituents selected from the above-mentioned substituent group S;
(24) a C6-14 arylthio group optionally substituted by 1 to 3 substituents selected from the above-mentioned substituent group S;
(25) a sulfo group;
(26) a cyano group;
(27) an azido group;
(28) a nitro group;
(29) a nitroso group;
(30) a halogen atom;
(31) a C1-6 alkylsulfinyl group;
(32) an oxo group;
(33) a C3-10 cycloalkyl-C1-6 alkyloxy group;
(34) a C1-3 alkylenedioxy group;
(35) a hydroxyimino group optionally substituted by a C1-6 alkyl group;
(36) a 5- to 8-membered heterocycle optionally substituted by 1 to 3 substituents selected from the above-mentioned substituent group S, containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom-sulfonyl group;
(37) a C6-18 aryl-sulfonyl group optionally substituted by 1 to 3 substituents selected from the above-mentioned substituent group S;
(38) a group represented by the formula: —(CH2)u—Rx;
(39) a group represented by the formula: —(CH2)u-Z1x-optionally halogenated C1-4 alkyl;
(40) a group represented by the formula: —(CH2)u-Z1x-C3-7 cycloalkyl;
(41) a group represented by the formula: —(CH2)u-Z2x-(CH2)v—Rx;
(42) a group represented by the formula: —(CH2)u-Z2x-(CH2)v-Z1x-optionally halogenated C1-4 alkyl;
(43) a group represented by the formula: —(CH2)u-Z2x-(CH2)v-Z1x-C3-7 cycloalkyl;
(44) a group represented by the formula: —(CH2)u-Z1x-heterocycle optionally substituted by 1 to 3 substituents selected from substituent group S;
(45) a group represented by the formula: —(CH2)u-Z2x-C1-4 alkoxy;
(46) a group represented by the formula: —(CH2)u-Z2x-(CH2)v-Z1x-(CH2)v-Z1x-C1-4 alkyl;
(47) an imino group optionally substituted by substituents selected from substituent group T;
(in the present specification, the substituents of the above-mentioned (1)-(47) are sometimes referred to as “substituent group U”) and the like can be mentioned. When the number of the substituents is not less than 2, respective substituents may be the same, or different.
In formulas of the above-mentioned substituents (38)-(46),
u is an integer of 0 to 4,
v is an integer of 1 to 4,
Rx is hydroxy, carboxy, cyano, nitro, —NR1xR2x, —CONR1xR2x or —SO2NR1xR2x,
Z1x is —O—, —CO—, —C(OH)R3x—, —C(═N—OR3x)—, —S—, —SO—, —SO2—, —N(COR3x)—, —N(CO2R4x)—, —N(SO2R4x)—, —CO—O—, —O—CO—, —CO—NR3x—, —NR3x—CO—, —NR3x—CO2—, —NR3x—CO—NH—, —NR3x—SO2— or —NR3x—C(—NH)—NH—, and
Z2x is —O—, —CO—, —C(OH)R3x—, —C(═N—OR3x)—, —S—, —SO—, —SO2—, —NR3x—, —N(COR3x)—, —N(CO2R4x)—, —N(SO2R4x)—, —CO—O—, —O—CO—, —CO—NR3x—, —NR3x—CO, —NR3x—CO2—, —NR3x—CO—NH—, —NR3x—C(═NH)—NH—, —NR3x—SO2— or —SO2—NR3x—.
In the above-mentioned formulas, (CH2)u and (CH2)v are optionally substituted by not less than 1 (preferably 1 to 5, more preferably 1 to 3) substituent selected from the group consisting of, for example, halogen atom, optionally halogenated C1-4 alkyl and hydroxy, and when u or v is not less than 2, —CH2CH2— which is a part of (CH2)u and (CH2)v may be substituted by —CH═CH— or —C≡C—.
In the above-mentioned formulas, R1x and R2x are the same or different and each is a hydrogen atom or a C1-4 alkyl, or R1x and R2x are optionally bonded to each other to form a ring structure with a nitrogen atom. In the above-mentioned formulas, moreover, R3x is a hydrogen atom or a C1-4 alkyl, and R4x is a C1-4 alkyl.
When R1x and R2x are bonded to each other to form ring structure with nitrogen atom, as the nitrogen-containing heterocyclic group, for example, 3 to 8-membered (preferably 5- or 6-membered) saturated or unsaturated (preferably saturated) aliphatic heterocyclic group such as azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, heptamethyleneimino, morpholinyl, thiomorpholinyl, piperazinyl, homopiperazinyl and the like can be mentioned.
The above-mentioned hydrocarbon group having a ring structure such as C3-10 cycloalkyl group, C3-10 cycloalkenyl group, C4-10 cycloalkadienyl group, C6-14 aryl group, C7-15 aralkyl group, C8-13 arylalkenyl group and C3-10 cycloalkyl-C1-6 alkyl group and the like, which are exemplarily recited as the “hydrocarbon group”, may have 1 to 3 substituents at substitutable position (s).
As such substituents, for example,
(i) a substituent selected from substituent group U;
(ii) a C1-10 alkyl group optionally substituted by 1 to 3 substituents selected from substituent group U;
(iii) a C2-10 alkenyl group optionally substituted by 1 to 3 substituents selected from substituent group U;
(in the present specification, the substituents of the above-mentioned (i)-(iii) are sometimes collectively referred to as “substituent group V”) and the like can be mentioned. When the number of the substituents is not less than 2, respective substituents may be the same or different.
In the present specification, unless otherwise specified, as the “heterocyclic group” of the “optionally substituted heterocyclic group” and “heterocyclyl-” in the substituents, an aromatic heterocyclic group and a non-aromatic heterocyclic group can be mentioned.
As the aromatic heterocyclic group, for example, a 4- to 7-membered (preferably 5- or 6-membered) monocyclic aromatic heterocyclic group containing, as a ring-constituting atom besides carbon atoms, 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom and a 8 to 12-membered fused aromatic heterocyclic group can be mentioned. As the fused aromatic heterocyclic group, for example, a group derived from a fused ring wherein a ring corresponding to such 4- to 7-membered monocyclic aromatic heterocyclic group, and 1 or 2 rings selected from the group consisting of a 5- or 6-membered ring containing 1 or 2 nitrogen atoms, a 5-membered ring containing one sulfur atom, a benzene ring and the like are condensed, and the like can be mentioned.
As preferable examples of the aromatic heterocyclic group,
monocyclic aromatic heterocyclic groups such as furyl (e.g., 2-furyl, 3-furyl), thienyl (e.g., 2-thienyl, 3-thienyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl), pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl), pyrazinyl (e.g., 2-pyrazinyl), pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), imidazolyl (e.g., 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), pyrazolyl (e.g., 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), isothiazolyl (e.g., 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (e.g., 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxadiazolyl (e.g., 1,2,4-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl), thiadiazolyl (e.g., 1,3,4-thiadiazol-2-yl), triazolyl (e.g., 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,3-triazol-1-yl, 1,2,3-triazol-2-yl, 1,2,3-triazol-4-yl), tetrazolyl (e.g., tetrazol-1-yl, tetrazol-5-yl), triazinyl (e.g., 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl) and the like; fused aromatic heterocyclic groups such as quinolyl (e.g., 2-quinolyl, 3-quinolyl, 4-quinolyl, 6-quinolyl), isoquinolyl (e.g., 3-isoquinolyl), quinazolyl (e.g., 2-quinazolyl, 4-quinazolyl), quinoxalyl (e.g., 2-quinoxalyl, 6-quinoxalyl), benzofuryl (e.g., 2-benzofuryl, 3-benzofuryl), benzothienyl (e.g., 2-benzothienyl, 3-benzothienyl), benzoxazolyl (e.g., 2-benzoxazolyl), benzisoxazolyl (e.g., 7-benzisoxazolyl), benzothiazolyl (e.g., 2-benzothiazolyl), benzimidazolyl (e.g., benzimidazol-1-yl, benzimidazol-2-yl, benzimidazol-5-yl), benzotriazolyl (e.g., 1H-1,2,3-benzotriazol-5-yl), indolyl (e.g., indol-1-yl, indol-2-yl, indol-3-yl, indol-5-yl), indazolyl (e.g., 1H-indazol-3-yl), pyrrolopyrazinyl (e.g., 1H-pyrrolo[2,3-b]pyrazin-2-yl, 1H-pyrrolo[2,3-b]pyrazin-6-yl), imidazopyridinyl (e.g., 1H-imidazo[4,5-b]pyridin-2-yl, 1H-imidazo[4,5-c]pyridin-2-yl, 2H-imidazo[1,2-a]pyridin-3-yl), imidazopyrazinyl (e.g., 1H-imidazo[4,5-b]pyrazin-2-yl), pyrazolopyridinyl (e.g., 1H-pyrazolo[4,3-c]pyridin-3-yl), pyrazolothienyl (e.g., 2H-pyrazolo[3,4-b]thiophen-2-yl), pyrazolotriazinyl (e.g., pyrazolo[5,1-c][1,2,4]triazin-3-yl) and the like; and the like can be mentioned.
As the non-aromatic heterocyclic group, for example, a 4- to 7-membered (preferably 5- or 6-membered) monocyclic non-aromatic heterocyclic group containing, as a ring-constituting atom besides carbon atoms, 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom and a 8 to 12-membered fused non-aromatic heterocyclic group can be mentioned. As the fused non-aromatic heterocyclic group, for example, a group derived from a fused ring wherein a ring corresponding to such 4- to 7-membered monocyclic non-aromatic heterocyclic group, and 1 or 2 rings selected from the group consisting of a 5- or 6-membered ring containing 1 or 2 nitrogen atoms, a 5-membered ring containing one sulfur atom, a benzene ring and the like are condensed, and the like can be mentioned.
As preferable examples of the non-aromatic heterocyclic group,
monocyclic non-aromatic heterocyclic group such as oxetanyl (e.g., 2-oxetanyl, 3-oxetanyl), pyrrolidinyl (e.g., 1-pyrrolidinyl, 2-pyrrolidinyl), piperidinyl (e.g., piperidino, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl), morpholinyl (e.g., morpholino), thiomorpholinyl (e.g., thiomorpholino), piperazinyl (e.g., 1-piperazinyl, 2-piperazinyl, 3-piperazinyl), hexamethyleneiminyl (e.g., hexamethyleneimine-1-yl), oxazolidinyl (e.g., oxazolidin-2-yl), thiazolidinyl (e.g., thiazolidin-2-yl), imidazolidinyl (e.g., imidazolidin-2-yl, imidazolidin-3-yl), oxazolinyl (e.g., oxazolin-2-yl), thiazolinyl (e.g., thiazolin-2-yl), imidazolinyl (e.g., imidazolin-2-yl, imidazolin-3-yl), dioxolyl (e.g., 1,3-dioxol-4-yl), dioxolanyl (e.g., 1,3-dioxolane-4-yl), dihydrooxadiazolyl (e.g., 4,5-dihydro-1,2,4-oxadiazol-3-yl), 2-thioxo-1,3-oxazolidin-5-yl, pyranyl (e.g., 4-pyranyl), tetrahydropyranyl (e.g., 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl), thiopyranyl (e.g., 4-thiopyranyl), tetrahydrothiopyranyl (e.g., 2-tetrahydrothiopyranyl, 3-tetrahydrothiopyranyl, 4-tetrahydrothiopyranyl), 1-oxidetetrahydrothiopyranyl (e.g., 1-oxidetetrahydrothiopyran-4-yl), 1,1-dioxidetetrahydrothiopyranyl (e.g., 1,1-dioxidetetrahydrothiopyran-4-yl), tetrahydrofuryl (e.g., tetrahydrofuran-3-yl, tetrahydrofuran-2-yl), pyrazolidinyl (e.g., pyrazolidin-1-yl, pyrazolidin-3-yl), pyrazolinyl (e.g., pyrazolin-1-yl), tetrahydropyrimidinyl (e.g., tetrahydropyrimidin-1-yl), dihydrotriazolyl (e.g., 2,3-dihydro-1H-1,2,3-triazol-1-yl), tetrahydrotriazolyl (e.g., 2,3,4,5-tetrahydro-1H-1,2,3-triazol-1-yl) and the like; fused non-aromatic heterocyclic group such as dihydroindolyl (e.g., 2,3-dihydro-1H-isoindol-1-yl), dihydroisoindolyl (e.g., 1,3-dihydro-2H-isoindol-2-yl), dihydrobenzofuranyl (e.g., 2,3-dihydro-1-benzofuran-5-yl), dihydrobenzodioxynyl (e.g., 2,3-dihydro-1,4-benzodioxynyl), dihydrobenzodioxepinyl (e.g., 3,4-dihydro-2H-1,5-benzodioxepinyl), tetrahydrobenzofuranyl (e.g., 4,5,6,7-tetrahydro-1-benzofuran-3-yl), chromenyl (e.g., 4H-chromen-2-yl, 2H-chromen-3-yl), dihydroquinolinyl (e.g., 1,2-dihydroquinolin-4-yl), tetrahydroquinolinyl (e.g., 1,2,3,4-tetrahydroquinolin-4-yl), dihydroisoquinolinyl (e.g., 1,2-dihydroisoquinolin-4-yl), tetrahydroisoquinolinyl (e.g., 1,2,3,4-tetrahydroisoquinolin-4-yl), dihydrophthalazinyl (e.g., 1,4-dihydrophthalazin-4-yl) and the like;
and the like can be mentioned.
The “heterocyclic group” of the “optionally substituted heterocyclic group” optionally has 1 to 3 substituents at substitutable positions. As such substituents, for example, substituents selected from above-mentioned Substituent Group V can be mentioned. When the number of the substituents is not less than 2, respective substituents may be the same or different.
In the present specification, unless otherwise specified, as the “heteroaryl group”, the above-mentioned monocyclic aromatic heterocyclic group and fused aromatic heterocyclic group and the like can be mentioned. As the fused aromatic heterocyclic group, a heterocycle wherein the above-mentioned 5- or 6-membered monocyclic aromatic heterocyclic group has been condensed with a benzene ring, or a heterocycle wherein the same or different two heterocycles from the above-mentioned 5- or 6-membered monocyclic aromatic heterocyclic groups have been condensed is preferable.
In the present specification, unless otherwise specified, as the “aliphatic hydrocarbon group” of the “optionally substituted aliphatic hydrocarbon group”, a linear or branched aliphatic hydrocarbon group having 1 to 10 carbon atoms (preferably, 1 to 8 carbon atoms) can be mentioned. As the “aliphatic hydrocarbon group”, for example, a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group and a C3-10 cycloalkyl group can be mentioned (each group is as defined above).
The “aliphatic hydrocarbon group” is optionally substituted by substituents selected from Substituent Group U, particularly, 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxy, C1-4 alkyloxy, C1-4 alkyl-carbonyl, carboxy, C1-4 alkoxy-carbonyl, cyano, carbamoyl, sulfamoyl, nitro, amino, C1-4 alkyl-carbonylamino, C1-4 alkoxy-carbonylamino and C1-4 alkylsulfonylamino.
In the present specification, unless otherwise specified, as the “acyl group”, for example, —COR21, —CO—OR21, —SO2R21, —SOR21, —PO(OR21)(OR22), —CO—NR23R24, —CO—N(OR23)R24, —CS—NR23R24 [wherein R21 and R22 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group. R23 and R24 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group, or R23 and R24 may in combination form, together with the adjacent nitrogen atom, optionally substituted nitrogen-containing heterocycle] and the like can be mentioned. As the “nitrogen-containing heterocycle”, for example, a 3- to 8-membered nitrogen-containing heterocycle containing, as a ring constituent atom besides carbon atoms, at least one nitrogen atom, and further optionally containing 1 or 2 heteroatoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom can be mentioned. As preferable examples of the nitrogen-containing heterocycle, 5- or 6-membered cyclic amino optionally containing oxygen atom (e.g., 1-pyrrolidinyl group, piperidinyl, 1-piperazinyl, morpholinyl) can be mentioned. The “nitrogen-containing heterocycle” optionally has 1 to 3 substituents at substitutable position(s). As such substituents, for example, the substituents selected from the above-mentioned Substituent group V can be mentioned. When the number of the substituents is not less than 2, respective substituents may be the same or different.
In the present specification, unless otherwise specified, the “amino group” of the “optionally substituted amino group”, the “carbamoyl group” of the “optionally substituted carbamoyl group”, the “ureido group” of the “optionally substituted ureido group” and the “sulfamoyl group” of the “optionally substituted sulfamoyl group” optionally have 1 or 2 substituents at substitutable position(s). As such substituents, for example, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an acyl group and the like can be mentioned. Of these, 1 or 2 substituents selected from Substituent Group T are preferable. When the number of the substituents is not less than 2, respective substituents may be the same or different.
When the nitrogen atom constituting the above-mentioned amino group, carbamoyl group, ureido group or sulfamoyl group is substituted by two substituents, these substituents may in combination form, together with the adjacent nitrogen atom, a nitrogen-containing heterocycle. As the “nitrogen-containing heterocycle”, for example, a 3 to 8-membered nitrogen-containing heterocycle containing, as a ring-constituting atom besides carbon atoms, at least one nitrogen atom and optionally further containing one or two heteroatoms selected from the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom can be mentioned. As preferable examples of the nitrogen-containing heterocycle, a 5- or 6-membered cyclic amino optionally containing an oxygen atom (e.g., 1-pyrrolidinyl group, piperidinyl, 1-piperazinyl, morpholinyl) can be mentioned. The “nitrogen-containing heterocycle” may have 1 to 3 substituents at substitutable position. As such substituents, for example, substituents selected from the above-mentioned Substituent group V can be mentioned. When the number of the substituents is not less than 2, respective substituents may be the same or different.
In the present specification, unless otherwise specified, as the substituent of the “optionally substituted imino group”, for example, the substituent selected from the above-mentioned substituent group T can be mentioned.
In the present specification, unless otherwise specified, as the “optionally substituted group bonded via a carbon atom”, (1) an optionally substituted hydrocarbon group, (2) an acyl group, (3) an optionally substituted heterocyclic group, which has a bond on a carbon atom, (4) a cyano group and the like can be mentioned.
In the present specification, unless otherwise specified, as the “optionally substituted group bonded via a nitrogen atom”, (1) a nitro group, (2) a group represented by the formula: —NR25R26 [wherein R25 is a hydrogen, an optionally substituted hydrocarbon group, an acyl group, an optionally substituted heterocyclic group, a group represented by the formula: —O—R27 (wherein R27 is a hydrogen atom or an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an acyl group), or formula: —S(O)t—R28 (wherein t is an integer of 0 to 2, R28 is a hydrogen atom, or an optionally substituted hydrocarbon group), R26 is a hydrogen atom, an optionally substituted hydrocarbon group or an acyl group, or R25 and R26 are bonded and may in combination form, together with the adjacent nitrogen atom, an optionally substituted cyclic amino group] can be mentioned.
In the present specification, unless otherwise specified, as the “optionally substituted group bonded via an oxygen atom”, a group represented by the formula: —O—R29 (wherein R29 is a hydrogen atom, or an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an acyl group) can be mentioned.
In the present specification, unless otherwise specified, as the “optionally, substituted group bonded via a sulfur atom”, a group represented by the formula: —S(O)t—R30 (wherein t is an integer of 0 to 2, R30 is a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group) can be mentioned.
In the present specification, unless otherwise specified, as the “nitrogen-containing 7-membered or 8-membered ring”, for example, 7- or 8-membered nitrogen-containing heterocycle containing one nitrogen atom, and further optionally containing 1 to 3 (preferably 1 or 2, more preferably 1) hetero atoms selected from the group consisting of, for example, nitrogen atom, oxygen atom, sulfur atom and the like (e.g., azepin, azepan, azocine, azocane and the like) can be mentioned.
Specific examples of a fused ring of the “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring A, and a pyrimidine ring, in the above-mentioned formula (I) include
wherein each symbol is as defined above, and the like.
The “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring A optionally has, besides R1 group and R2 group, 1 to 3 substituents at substitutable position (s). As such substituent, for example, a substituent selected from the above-mentioned Substituent group V can be mentioned. When the number of the substituents is not less than 2, respective substituents may be the same or different.
In the above-mentioned formula (I), as the “aryl group” for B, phenyl is preferable.
In addition, as the “heteroaryl group” for B, the aforementioned “5- or 6-membered monocyclic aromatic heterocyclic group” is preferable, and pyridyl is more preferable.
The “aryl group” or the “heteroaryl group” may be optionally substituted by a group represented by the formula —Y2—W
wherein Y2 represents a bond, or formula —X2—(CH2)m— [wherein X2 is a group represented by —O—, —S—, —SO—, —SO2—, —CH2— or —CO—NR5— (wherein R5 is a hydrogen atom, or an optionally substituted C1-6 alkyl group), and m is an integer of 0 to 5]. In the formula, W represents a C6-18 aryl group, a heterocyclic group, a C3-7 cycloalkyl group, a carbamoyl group, an ureido group, a C6-18 is aryl-carbonyl group or a C6-18 aryl-C1-4 alkyl-carbonyl group, each of which is optionally substituted.
As the substituent for the C6-18 aryl group, the heterocyclic group, the C3-7 cycloalkyl group, the C6-18 aryl-carbonyl group or the C6-18 aryl-C1-4 alkyl-carbonyl group, for example, halogen atom, cyano, azido, nitro, nitroso, optionally substituted hydrocarbon group, hydroxy group optionally having optionally substituted hydrocarbon group, thiol group optionally having optionally substituted hydrocarbon group, optionally substituted heterocyclic group, hydroxy group optionally having optionally substituted heterocyclic group, thiol group optionally having optionally substituted heterocyclic group, acyl group, optionally substituted amino group, optionally substituted ureido group, optionally substituted hydrocarbon-sulfonyl group, optionally substituted hydrocarbon-sulfinyl group and the like can be mentioned.
As the substituent for the carbamoyl group or ureido group, for example, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an acyl group and the like can be mentioned.
As the Y2, —O— or —OCH2— is preferable.
As the “C6-18 aryl group” for W, phenyl is preferable.
As the “heterocyclic group” for W, the aforementioned 5- or 6-membered monocyclic aromatic heterocyclic group or 5- or 6-membered saturated aliphatic heterocyclic group is preferable, and pyridyl or piperidyl is more preferable.
The “aryl group” or the “heteroaryl group” for B optionally has, besides a group represented by the formula —Y2—W, 1 to 5, same or different substituents at any substitutable position(s). As such substituent, for example, a substituent selected from the above-mentioned substituent group V can be mentioned.
The “C1-4 alkylene” for Y1 is optionally substituted by 1 to 3 substituents selected from substituent group U.
As the X1, —NR3— (wherein R3 is as defined above) is preferable, as the R3, a hydrogen atom or a C1-6 alkyl group is preferable.
When R2 is —R2, as the “optionally substituted group bonded via a carbon atom” of the “optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom” for R2, an “optionally substituted hydrocarbon group” or an “acyl group” is preferable.
When R2 is —R2, as the “optionally substituted group bonded via a nitrogen atom” of the “optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom” for R2, an optionally substituted amino group is preferable.
When R2 is —R2, as the R2, an optionally substituted hydrocarbon group, an acyl group, or an optionally substituted amino group is preferable.
As the “optionally substituted group bonded via a carbon atom” of the “optionally substituted group bonded via a carbon atom or a sulfur atom” for R1, an “optionally substituted hydrocarbon group” is preferable.
As the R1, a hydrogen atom or a C1-6 alkyl group is preferable. Of these, a hydrogen atom is preferable.
As the “ring structure” when the optionally substituted ring structure was formed by R3 bonded to the carbon atom or heteroatom on the aryl group or heteroaryl group for B, a saturated or unsaturated (preferably saturated) 4- to 8-membered (preferably 5- or 6-membered) nitrogen-containing heterocycle can be mentioned, specifically,
is
and the like.
The “ring structure” optionally has 1 to 5 (preferably 1 to 3, more preferably 1 or 2), the same or different substituents at any substitutable positions. As such substituents, for example, substituents selected from the above-mentioned Substituent Group V can be mentioned.
R1 and R2 are optionally bonded to each other to form an optionally substituted ring structure. As the “ring structure”, a saturated or unsaturated (preferably saturated) 4- to 8-membered (preferably 5- to 7-membered) heterocycle can be mentioned. When R1 and R2 are bonded to each other to form an optionally substituted ring structure, for example,
wherein A′ is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, and other symbols are as defined above, and the like can be mentioned.
R2 and R3 are optionally bonded to each other to form an optionally substituted ring structure. As the “ring structure”, a saturated or unsaturated (preferably saturated) 4- to 8-membered (preferably 5- to 7-membered) heterocycle can be mentioned. When R2 and R3 are bonded to each other to form an optionally substituted ring structure, for example,
wherein A″ is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, and other symbols are as defined above, and the like can be mentioned.
The “ring structure” formed by R1 and R2, or R2 and R3, which are bonded to each other, optionally has 1 to 5 (preferably 1 to 3, more preferably 1 or 2), same or different substituents selected from the above-mentioned substituent group V at any substitutable position(s).
As compound (I), the following compounds (Ia)-(Ih) and the like are preferably used,
A compound represented by
wherein ring Aa is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, and other symbols are as defined above, or a salt thereof.
Specific examples of the fused ring of the “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Aa and a pyrimidine ring include
wherein each symbol is as defined above, and the like.
The “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Aa optionally has, besides R1 group and R2 group, 1 to 3 substituents at substitutable position(s). As such substituent, for example, a substituent selected from the above-mentioned substituent group V can be mentioned. When the number of the substituents is not less than 2, respective substituents may be the same or different.
wherein ring Ab is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, L is 1 or 2, formula is a single bond or a double bond, R2b is a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, and other symbols are as defined above.
In the above-mentioned formula, as the “optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom” for R2b, those similar to the “optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom” for R2 can be used.
As R2b,
(i) a C1-6 alkyl group optionally substituted by substituents selected from the group consisting of
(a) hydroxy,
(b) —NH—CO—(CH2) P—SO2—C1-6 alkyl (p is an integer of 1 to 6),
(c) —NH—CO—C1-6 alkyl-hydroxy,
(d) —NH—CO—(CH2)p′—C1-6 alkoxy-C1-6 alkoxy (p′ is an integer of 1-6),
(e) C1-6 alkoxyimino optionally substituted by substituent selected from the group consisting qf (1) hydroxy, (2) C1-6 alkoxy, (3) di-C1-6 alkylamino, (4) C1-6 alkylsulfonyl and (5) 5- to 8-membered heterocyclic group containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom,
(f) C1-6 alkylamino having cyano,
(g) C1-6 alkylamino having halogen atom,
(h) C1-6 alkylamino having hydroxy,
(i) C1-6 alkylamino having C1-6 alkoxy,
(j) C1-6 alkylamino having C1-6 alkylsulfonyl optionally having hydroxy,
(k) di-C1-6 alkylamino optionally having 1 or 2 substituents selected from the group consisting of (1) hydroxy, (2), cyano, (3) halogen atom and (4) C1-6 alkylsulfonyl,
(l) C3-7 cycloalkylamino optionally having hydroxy,
(m) 5- to 8-membered heterocyclyl-amino containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom,
(o) 5- to 8-membered cyclic amino optionally having C1-6 alkoxy or C1-6 alkylsulfonyl,
(p) N—C1-6 alkyl-N—C3-7 cycloalkylamino optionally having C1-6 alkylsulfonyl,
(q) cyano,
(r) C1-6 alkylamino having C1-6 alkoxy optionally having hydroxy or C1-6 alkoxy, and
(s) 5- to 8-membered heterocycle substituted by substituents selected from the group consisting of oxo, C1-6 alkylsulfonyl, and C1-6 alkoxy, and containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom,
(ii) a C2-6 alkenyl group having (a) hydroxy, (b) di-C1-6 alkylamino or (c) C1-6 alkoxy-carbonyl,
(iii) a C1-6 alkoxy-carbonyl group,
(iv) a group represented by —CO—NRaRb
wherein Ra is a hydrogen atom or a C1-6 alkyl group, Rb is a group represented by
(a) hydroxy,
(b) C1-6 alkylsulfonyl, and
(c) C1-6 alkyl optionally having C1-6 alkylsulfonyl,
(vi) a carboxy group,
(vii) an amino group optionally substituted by C1-6 alkoxy-carbonyl optionally having C1-6 alkylsulfonyl, or
(viii) a 5- to 8-membered heterocyclic group optionally having C1-6 alkyl, and containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, besides carbon atoms is preferable.
Specific examples of the fused ring of the “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Ab and a pyrimidine ring include the following structures:
wherein each symbol is as defined above.
The “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Ab optionally has, besides R1 group and R2b group, 1 to 3 substituents at substitutable position(s). As such substituent, for example, a substituent selected from the above-mentioned substituent group V can be mentioned. When the number of substituents is not less than 2, respective substituents may be the same or different.
A compound represented by
wherein ring Ac is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, ring Bc is an optionally further substituted phenyl group or an optionally further substituted pyridyl group, ring Cc is an optionally substituted phenyl group, X2 is a group represented by —O—, —S—, —SO—, —SO2—, —CH2— or —CO—NR5— (wherein R5 is a hydrogen atom, or an optionally substituted C1-6 alkyl group), m is an integer of 0 to 5, and other symbols are as defined above, R3 may be bonded to the carbon atom on ring Bc to form an optionally substituted ring structure, or a salt thereof.
In the above-mentioned formula, as the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Ac, those similar to the above-mentioned “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Aa can be used.
As the substituent for the “optionally substituted phenyl group” for ring Cc, for example, 1 to 5, same or different substituents selected from the above-mentioned substituent group V can be used.
As the substituent for the “optionally further substituted phenyl group” or the “optionally further substituted pyridyl group” for ring Bc, for example, 1 to 4, same or different substituents selected from the above-mentioned substituent group V can be used.
As the “optionally substituted ring structure” formed by R3 bonded to the carbon atom on ring Bc, those similar to the “optionally substituted ring structure” formed by R3 bonded to the carbon atom on ring B can be used.
A compound represented by
wherein ring Ad is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, L is 1 or 2,
formula is a single bond or a double bond, ring Bd is an optionally further substituted phenyl group or an optionally further substituted pyridyl group,
ring Cd is an optionally substituted phenyl group,
X2d is a group represented by —O—, —S—, —SO—, —SO2, —CH2— or —CO—NR5d— (wherein R5d is a hydrogen atom, or an optionally substituted C1-6 alkyl group),
m is an integer of 0 to 5,
R1d is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom,
R2d is a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom,
R3d represents a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3d is optionally bonded to the carbon atom on ring Bd to form an optionally substituted ring structure, or a salt thereof.
Specific examples of the “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Ad include 7-membered or 8-membered ring shown by the following structures:
wherein each symbol is as defined above.
The “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Ad optionally has, besides R1d group and R2d group, 1 to 3 substituents at substitutable position (s). As such substituent, for example, a substituent selected from the above-mentioned substituent group V can be mentioned. When the number of the substituents is not less than 2, respective substituents may be the same or different.
As the further substituents for the “optionally further substituted phenyl group” or the “optionally further substituted pyridyl group” for ring Bd, those similar to ring Bc can be used, and C1-6 alkyl group or halogen atom is preferable.
As the further substituents for ring Cd, those similar to ring Cc can be used, and optionally halogenated C1-6 alkyl, optionally halogenated C1-6 alkoxy, C1-6 alkyl-carbamoyl or halogen atom is preferable.
As X2d, those similar to X2 can be used. When X2d is —CONR5d—, as the substituent for the “optionally substituted C1-6 alkyl group” represented by R5d, those similar to R5 can be used.
As “—X2d—(CH2)m—”, —O— or —O—CH2— is preferable.
As the “optionally substituted group bonded via a carbon atom, or a sulfur atom” for R1d, those similar to the “optionally substituted group bonded via a carbon atom or a sulfur atom” for R1 can be used.
As the R1d, a hydrogen atom or a C1-6 alkyl group is preferable.
As the “optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom” for R2d, those similar to the “optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom” for R2 can be used.
As R2d,
(i) a C1-6 alkyl group optionally substituted by substituents selected from the group consisting of
(a) hydroxy,
(b) —NH—CO—(CH2)p—SO2—C1-6 alkyl (p is an integer of 1 to 6),
(c) —NH—CO—C1-6 alkyl-hydroxy,
(d) —NH—CO—(CH2)p′—C1-6 alkoxy-C1-6 alkoxy (p′ is an integer of 1 to 6),
(e) C1-6 alkoxyimino optionally substituted substituent selected from the group consisting of (1) hydroxy, (2) C1-6 alkoxy, (3) di-C1-6 alkylamino, (4) C1-6 alkylsulfonyl and (5) 5- to 8-membered heterocyclic group containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom,
(f) C1-6 alkylamino having cyano,
(g) C1-6 alkylamino having halogen atom,
(h) C1-6 alkylamino having hydroxy,
(i) C1-6 alkylamino having C1-6 alkoxy,
(j) C1-6 alkylamino having C1-6 alkylsulfonyl optionally having hydroxy,
(k) di-C1-6 alkylamino optionally having 1 or 2 substituents selected from the group consisting of (1) hydroxy, (2) cyano, (3) halogen atom and (4) C1-6 alkylsulfonyl,
(l) C3-7 cycloalkylamino optionally having hydroxy,
(m) 5- to 8-membered heterocyclyl-amino containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom,
(o) 5- to 8-membered cyclic amino optionally having C1-6 alkoxy or C1-6 alkylsulfonyl,
(p) N—C1-6 alkyl-N—C3-7 cycloalkylamino optionally having C1-6 alkylsulfonyl,
(q) cyano,
(r) C1-6 alkylamino having C1-6 alkoxy optionally having hydroxy or C1-6 alkoxy, and
(s) 5- to 8-membered heterocycle optionally substituted by substituents selected from the group consisting of oxo, C1-6 alkylsulfonyl, and C1-6 alkoxy, and containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom besides carbon atoms,
(ii) a C2-6 alkenyl group having (a) hydroxy, (b) di-C1-6 alkylamino or (c) C1-6 alkoxy-carbonyl,
(iii) a C1-6 alkoxy-carbonyl group,
(iv) a group represented by —CO—NRaRb
wherein Ra is a hydrogen atom or a C1-6 alkyl group,
(a) hydroxy,
(b) C1-6 alkylsulfonyl, and
(c) C1-6 alkyl optionally having C1-6 alkylsulfonyl,
(vi) a carboxy group,
(vii) an amino group optionally substituted by C1-6 alkoxy-carbonyl optionally having C1-6 alkylsulfonyl, or
(viii) a 5- to 8-membered heterocyclic group optionally having C1-6 alkyl, and containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom is preferable.
As the substituent for the “optionally substituted aliphatic hydrocarbon group” for R3d, those similar to R3 can be used.
As the R3d, a hydrogen atom is preferable.
As the “optionally substituted ring structure” formed by R3d bonded to the carbon atom on ring Bd, those similar to the “optionally substituted ring structure” formed by R3 bonded to the carbon atom on ring B can be used.
As the preferable embodiment for compound (Id), compound (Id)
wherein
ring Ad is a nitrogen-containing 7-membered or 8-membered ring (preferably 7-membered ring) without a substituent other than R1d and R2d,
L is 1 or 2 (preferably 1),
R1d is a hydrogen atom or a C1-6 alkyl group,
(i) a C1-6 alkyl group optionally substituted by substituents selected from the group consisting of
(a) hydroxy,
(b) —NH—CO—(CH2)p—SO2—C1-6 alkyl (p is an integer of 1 to 6),
(c) —NH—CO—C1-6 alkyl-hydroxy,
(d) —NH—CO—(CH2)p′—C1-6 alkoxy-C1-6 alkoxy (p′ is an integer of 1 to 6),
(e) C1-6 alkoxyimino optionally substituted by
substituents selected from the group consisting of (1) hydroxy, (2) C1-6 alkoxy, (3) di-C1-6 alkylamino, (4) C1-6 alkylsulfonyl and (5) 5- to 8-membered heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom besides carbon atoms,
(f) C1-6 alkylamino having cyano,
(g) C1-6 alkylamino having halogen atom,
(h) C1-6 alkylamino having hydroxy,
(i) C1-6 alkylamino having C1-6 alkoxy,
(j) C1-6 alkylamino having C1-6 alkylsulfonyl optionally having hydroxy,
(k) di-C1-6 alkylamino optionally having 1 or 2 substituents selected from the group consisting of (1) hydroxy, (2) cyano, (3) halogen atom and (4) C1-6 alkylsulfonyl,
(l) C3-7 cycloalkylamino optionally having hydroxy,
(m) 5- to 8-membered heterocyclyl-amino containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom,
(o) 5- to 8-membered cyclic amino optionally having C1-6 alkoxy or C1-6 alkylsulfonyl,
(p) N—C1-6 alkyl-N—C3-7 cycloalkylamino optionally having C1-6 alkylsulfonyl.
(q) cyano,
(r) C1-6 alkylamino having C1-6 alkoxy optionally having hydroxy or C1-6 alkoxy, and
(s) 5- to 8-membered heterocycle substituted by substituents selected from the group consisting of oxo, C1-6 alkylsulfonyl, and C1-6 alkoxy, containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom,
(ii) a C2-6 alkenyl group having (a) hydroxy, (b) di-C1-6 alkylamino or (c) C1-6 alkoxy-carbonyl,
(iii) a C1-6 alkoxy-carbonyl group,
(iv) a group represented by —CO—NRaRb
wherein Ra is a hydrogen atom or a C1-6 alkyl group,
(a) hydroxy,
(b) C1-6 alkylsulfonyl, and
(c) C1-6 alkyl optionally having C1-6 alkylsulfonyl,
(vi) a carboxy group,
(vii) an amino group optionally substituted by C1-6 alkoxy-carbonyl optionally having C1-6 alkylsulfonyl, or
(viii) a 5- to 8-membered heterocyclic group optionally having C1-6 alkyl, and containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom,
R3d is a hydrogen atom,
ring Bd is a phenyl group optionally further substituted by a C1-6 alkyl group or a halogen atom, or a pyridyl group optionally further substituted by a C1-6 alkyl group or a halogen atom (preferably, a phenyl group optionally further substituted by a C1-6 alkyl group or a halogen atom),
ring Cd is a phenyl group optionally substituted by substituents selected from the group consisting of
(i) optionally halogenated C1-6 alkyl,
(ii) C1-6 alkoxy optionally having halogen atom or C3-7 cycloalkyl,
(iii) C1-6 alkyl-carbamoyl optionally having hydroxy,
(iv) halogen atom,
(v) cyano,
(vi) C1-6 alkylthio optionally having halogen atom,
(vii) C1-6 alkylsulfinyl optionally having halogen atom, and
(viii) C1-6 alkylsulfonyl optionally having halogen atom or C3-7 cycloalkyl,
X2d is a group represented by —O— or —S—,
m is 0 or 1, can be mentioned.
A compound represented by
wherein ring Ae is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, ring Be is an optionally further substituted phenyl group or an optionally further substituted pyridyl group, ring De is an optionally substituted aromatic heterocyclic group, X2 is a group represented by —O—, —S—, —SO—, —SO2—, —CH2— or —CO—NR5— (wherein R5 is a hydrogen atom, or an optionally substituted C1-6 alkyl group), n is an integer of 0 to 5, other symbols are as defined above, and R3 may be bonded to the carbon atom on ring Be to form optionally substituted ring structure, or a salt thereof.
In the above-mentioned formula, as the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Ae, those similar to the above-mentioned “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Aa can be used.
As the “aromatic heterocyclic group” of the “optionally substituted aromatic heterocyclic group” represented by ring De, those similar to the aforementioned “heteroaryl” can be used. Of those, a 5- or 6-membered monocyclic aromatic heterocyclic group is preferable as ring De.
As the substituent of the “optionally substituted aromatic heterocyclic group” represented by ring De, 1 to 5, same or different substituents selected from the above-mentioned substituent group V are used.
As the substituent of the “optionally further substituted phenyl group” or “optionally further substituted pyridyl group” represented by ring B % 1 to 4, same or different substituents selected from the above-mentioned substituent group V are used.
As the ring Be, an “optionally further substituted phenyl group” is preferable.
As the “optionally substituted ring structure” formed by R3 bonded to the carbon atom on ring Be, those similar to the “optionally substituted ring structure” formed by R3 bonded to the carbon atom on ring B can be used.
A compound represented by
wherein ring Af is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring,
formula is a single bond or a double bond,
ring Bf is an optionally further substituted phenyl group or an optionally further substituted pyridyl group,
ring Df is an optionally substituted aromatic heterocyclic group,
X2f is a group represented by —O—, —S—, —SO—, —SO2, —CH2— or —CO—NR5f— (wherein R5f is a hydrogen atom, or an optionally substituted C1-6 alkyl group),
n is an integer of 0 to 5,
R1f is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom,
R2f is a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, and
R3f is a hydrogen atom, or an optionally substituted aliphatic hydrocarbon group, or R3f is optionally bonded to the carbon atom on ring Bf to form an optionally substituted ring structure, or a salt thereof.
Specific examples the “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Af include 7-membered or 8-membered ring shown by the following structures:
wherein each symbol is as defined above.
The “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Af optionally has, besides R1f group and R2f group, 1 to 3 substituents at substitutable position (s). As such substituent, for example, a substituent selected from the above-mentioned substituent group V can be mentioned. When the number of the substituents is not less than 2, respective substituents may be the same or different.
As the “aromatic heterocycle” of the “optionally substituted aromatic heterocycle” for ring Df, those similar to ring De can be used. Of those, a 5- or 6-membered monocyclic aromatic heterocyclic group is preferable, and a pyridine ring is more preferable.
As the substituent of the “optionally substituted aromatic heterocycle” represented by ring Df, those similar to the above-mentioned substituent group V can be used. Of those, a C1-6 alkyl group is preferable.
As the further substituent of the “optionally further substituted phenyl group” or “optionally further substituted pyridyl group” represented by ring Bf, those similar to ring Be can be used. Of those, a C1-6 alkyl group or a halogen atom is preferable.
As ring Be, a phenyl group optionally further substituted by C1-6 alkyl group or halogen atom is preferable.
As X2f, those similar to X2 can be used. When X2f is —CONR5f—, as the substituent of the “optionally substituted C1-6 alkyl group” represented by R5f, those similar to R5 can be used.
As the “—X2f—(CH2)n—”, —O— or —O—CH2— is preferable.
As the “optionally substituted group bonded via a carbon atom or a sulfur atom” represented by R1f, those similar to the “optionally substituted group bonded via a carbon atom or a sulfur atom” represented by R1 can be used.
As the R1f, a hydrogen atom or a C1-6 alkyl group is preferable.
As the “optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom” represented by R2f, those similar to the “optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom” represented by R2 can be used.
As R2f,
(i) a C1-6 alkyl group optionally having hydroxy,
(ii) a C1-6 alkoxy-carbonyl group,
(iii) a group represented by —CO—NRcRd
wherein Rc is a hydrogen atom,
(a) a hydroxy, and
(b) a C1-6 alkyl optionally having hydroxy, or
(v) a carboxy group
is preferable.
As the substituent of the “optionally substituted aliphatic hydrocarbon group” represented by ring R3f, those similar to R3 can be used.
As the R3f, a hydrogen atom is preferable.
As the “optionally substituted ring structure” formed by R3f bonded to the carbon atom on ring Bf, those similar to the “optionally substituted ring structure” formed by R3 bonded to the carbon atom on ring B can be used.
A preferable embodiment of compound (If) is compound (If) wherein
ring Af is a nitrogen-containing 7-membered or 8-membered ring (preferably 7-membered ring) without a substituent other than R1d and R2d,
L is 1 or 2 (preferably 1),
R1f is a hydrogen atom or a C1-6 alkyl group,
(i) a C1-6 alkyl group optionally having hydroxy,
(ii) a C1-6 alkoxy-carbonyl group,
(iii) a group represented by —CO—NRcRd
wherein Rc is a hydrogen atom,
(a) hydroxy, and
(b) C1-6 alkyl optionally having hydroxy, or
(v) a carboxy group,
R3f is a hydrogen atom,
ring Bf is a phenyl group optionally further substituted by a C1-6 alkyl group,
Xf is a group represented by —O—,
n is 0, and
ring Df is a 5- or 6-membered monocyclic aromatic heterocycle optionally substituted by C1-6 alkyl group, and containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom.
A compound represented by
wherein ring Ag is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, ring Bg is an optionally further substituted phenyl group or an optionally further substituted pyridyl group, ring Eg is an optionally further substituted piperidyl group, R4 is a hydrogen atom or an acyl group, X2 is a group represented by —O—, —S—, —SO—, —SO2—, —CH2— or —CO—NR5— (wherein R5 is a hydrogen atom, or an optionally substituted C1-6 alkyl group), other symbols are as defined above, and R3 is optionally bonded to the carbon atom on ring Bg to form an optionally substituted ring structure, or a salt thereof.
In the above-mentioned formula, as the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” represented by ring Ag, those similar to the above-mentioned “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” represented by ring Aa can be used.
As the further substituent of the “optionally further substituted piperidyl group” represented by ring Eg, for example, 1 to 4, same or different substituents selected from the above-mentioned substituent group V can be used.
As the further substituent of the “optionally further substituted phenyl group” or “optionally further substituted pyridyl group” represented by ring Bg, for example, 1 to 4, same or different substituents selected from the above-mentioned substituent group V can be used.
As the ring Bg, an “optionally further substituted phenyl group” is preferable.
As the “acyl group” represented by R4, those mentioned above can be used.
As the “optionally substituted ring structure” formed by R3g bonded to the carbon atom on ring Bg, those similar to the “optionally substituted ring structure” formed by R3 bonded to the carbon atom on ring B can be used.
A compound represented by
wherein ring Ah is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, L is 1 or 2,
formula is a single bond or a double bond, ring Bh is an optionally further substituted phenyl group or an optionally further substituted pyridyl group,
ring Eh is an optionally further substituted piperidyl group,
X2h is a group represented by —O—, —S—, —SO—, —SO2—, —CH2— or —CO—NR5h— (wherein R5h is a hydrogen atom, or an optionally substituted C1-6 alkyl group),
R1h is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom,
R2h is a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom,
R3h is a hydrogen atom, or an optionally substituted aliphatic hydrocarbon group, or R3h is optionally bonded to the carbon atom on ring Bh to form an optionally substituted ring structure, and
R4h is a hydrogen atom or an acyl group, or a salt thereof.
Specific examples of the “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Ah include the 7-membered ring and 8-membered ring shown by the following structures:
wherein each symbol is as defined above.
The “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Ah optionally has, besides R1h group and R2h group, 1 to 3 substituents at substitutable position(s). As such substituent, for example, a substituent selected from the above-mentioned substituent group V can be mentioned. When the number of the substituents is not less than 2, respective substituents may be the same or different.
As the further substituent of the “optionally further substituted piperidyl group” represented by ring Eh, those similar to ring Eg can be used.
As the further substituent of the “optionally further substituted phenyl group” or “optionally, further substituted pyridyl group” represented by ring Bh, those similar to ring Be can be used. Of those, a halogen atom is preferable.
As the ring Bh, a phenyl group optionally substituted by halogen atom is preferable.
As X2h, those similar to X2 can be used. When X2h is —CONR5h—, as the substituent of the “optionally substituted C1-6 alkyl group” represented by R5h, those similar to R5 can be used.
As “—X2h—”, —O— is preferable.
As the “optionally substituted group bonded via a carbon atom or a sulfur atom” represented by R1h, those similar to the “optionally substituted group bonded via a carbon atom or a sulfur atom” represented by R1 can be used.
As R1h, a hydrogen atom is preferable.
As the “optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom” represented by R2h, those similar to the “optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom” represented by R2 can be used.
As R2h,
(i) a C1-6 alkyl group optionally substituted by hydroxy,
(ii) a C1-6 alkoxy-carbonyl group,
(iii) a group represented by —CO—NReRf
wherein Re is a hydrogen atom or a C1-6 alkyl group.
(a) hydroxy,
(b) C1-6 alkylsulfonyl, and
(c) C1-6 alkyl optionally having C1-6 alkylsulfonyl is preferable.
As the “acyl group” for R4h, those similar to R4 can be used.
As R4h, a C3-7 cycloalkyl-carbonyl group or a C1-6 alkoxy-carbonyl group is preferable.
As the substituent of the “optionally substituted aliphatic hydrocarbon group” represented by R3h, those similar to R3 can be used.
As R3h, a hydrogen atom is preferable.
As the “optionally substituted ring structure” formed by R3h bonded to the carbon atom on ring Bh, those similar to the “optionally substituted ring structure” formed by R3 bonded to the carbon atom on ring B can be used.
A preferable embodiment of compound (Ih) is compound (Ih)
wherein
ring Ah is a nitrogen-containing 7-membered or 8-membered ring (preferably 7-membered ring) without a substituent other than R1h and R2h,
L is 1 or 2 (preferably 1),
R1h is a hydrogen atom,
(i) a C1-6 alkyl group optionally substituted by hydroxy,
(ii) a C1-6 alkoxy-carbonyl group,
(iii) a group represented by —CO—NReRf
wherein Re is a hydrogen atom or a C1-6 alkyl group, and
(a) hydroxy,
(b) C1-6 alkylsulfonyl, and
(c) C1-6 alkyl optionally having C1-6 alkylsulfonyl,
R3h is a hydrogen atom,
ring Bh is a phenyl group optionally further substituted by a halogen atom,
X2h is a group represented by —O—, and
R4h is 5- to 8-membered heterocyclyl-carbonyl group optionally having 1 or 2 substituents selected from the group consisting of (1) C3-7 cycloalkyl-carbonyl group, (2) C1-6 alkoxy-carbonyl group and (3) C1-6 alkyl, and containing, besides carbon atoms, 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom.
wherein ring Ai is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, L is 1 or 2, formula is a single bond or a double bond, R2i is, a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom when
R2i is —R2i, and an oxo group, an optionally substituted alkylidene group, or an optionally substituted imino group when
R2i is ═R2i, other symbols are as defined above, and R2i and R3 may be bonded to each other to form an optionally substituted ring structure.
In the above-mentioned formula, as the “optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom” represented by R2i, those similar to the “optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom” represented by R2 can be used.
As R2i, a group represented by ═O, ═CH—CO—OR6i, ═CH—CO—NHR6i, ═CH—CO—NR6iR7i, ═CH—CH2—OR6i, ═CH—CH2—NHR6i, ═CH—CH2—NR6iR7i, ═CH—CH2—S(O)qR6i or ═N—O—R6i [wherein R6i and R7i are the same or different and each is a hydrogen atom or an optionally substituted C1-6 alkyl group, and q is 1 or 2], is preferable.
Here, as the “optionally substituted C1-6 alkyl group” represented by R6i or R7i, those similar to the “optionally substituted C1-6 alkyl group” represented by R5 can be used. Alternatively, when R2i is ═CH—CO—NR6iR7i or ═CH—CH2—NR6iR7i, R6i and R7i may form nitrogen-containing heterocycle together with the adjacent nitrogen atom.
As the “nitrogen-containing heterocycle”, for example, a 3- to 8-membered nitrogen-containing heterocycle containing, as a ring constituent atom besides carbon atom, at least 1 nitrogen atom, and optionally further having 1 or 2 heteroatoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom can be mentioned. As the preferable examples of the nitrogen-containing heterocycle, 5- or 6-membered cyclic amino optionally containing oxygen atom (e.g., 1-pyrrolidinyl, piperidinyl, 1-piperazinyl, morpholinyl) can be mentioned.
The “nitrogen-containing heterocycle” of the “optionally substituted nitrogen-containing heterocycle” optionally has 1 to 3 substituents at substitutable position (s). As such substituent, for example, a substituent selected from the above-mentioned substituent group V can be mentioned. When the number of the substituents is not less than 2, respective substituents may be the same or different.
Specific examples of the fused ring of the “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Ai and a pyrimidine ring include the following structures:
wherein each symbol is as defined above.
The “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring Ai optionally has, besides R11 group and R2i group, 1 to 3 substituents at substitutable position (s). As such substituent, for example, a substituent selected from the above-mentioned substituent group V can be mentioned. When the number of the substituents is not less than 2, respective substituents may be the same or different.
As the “ring structure” when R2i and R3 are bonded to each other to form an optionally substituted ring structure, a saturated or unsaturated (preferably saturated) 4- to 8-membered (preferably 5- to 7-membered) heterocycle can be mentioned. When R2i and R3 are bonded to each other to form an optionally substituted ring structure, for example,
wherein each symbol is as defined above, and the like can be mentioned.
The “ring structure” formed by R2i and R3 are bonded to each other may have 1 to 5 (preferably 1 to 3, more preferably 1 or 2), same or different substituents selected from the above-mentioned substituent group V, at any substitutable positions.
As compound (I), the following compound or a salt thereof is particularly preferable.
As a salt of the compounds represented by each of the aforementioned formulas, for example, metal salts, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids and the like can be mentioned.
As preferable examples of the metal salts, alkali metal salts such as sodium salt, potassium salt and the like; alkaline earth metal salts such as calcium salt, magnesium salt, barium salt and the like; aluminum salt and the like can be mentioned.
As preferable examples of the salts with organic
bases, salts with trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, tromethamine[tris(hydroxymethyl)methylamine], t-butylamine, cyclohexylamine, dicyclohexylamine, N,N′-dibenzylethylenediamine and the like can be mentioned.
As preferable examples of the salts with inorganic acids, salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like can be mentioned.
As preferable examples of the salts with organic acids, salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like can be mentioned.
As preferable examples of the salts with basic amino acids, salts with arginine, lysine, ornithine and the like can be mentioned.
As preferable examples of the salts with acidic amino acids, salts with, aspartic acid, glutamic acid and the like can be mentioned.
Of those, pharmaceutically acceptable salts are preferable. For example, when a compound has an acidic functional group therein, salts with inorganic bases such as alkali metal salts (e.g., sodium salt, potassium salt and the like), alkaline earth metal salts (e.g., calcium salt, magnesium salt, barium salt and the like) and the like, ammonium salt and the like can be mentioned. When a compound has a basic functional group therein, salts with inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like, and salts with organic acids such as acetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, p-toluenesulfonic acid and the like can be mentioned.
Compound (I) of the present invention can be obtained by, for example, the method shown by the following scheme or a method analogous thereto and the like.
Each compound in the following schemes includes salts, and as such salts, for example, those similar to the salts of compound (I) and the like can be used.
The compound obtained in each step can be used as a reaction mixture or as a crude product in the next reaction. In addition, the compound can be isolated from a reaction mixture according to a conventional method, and can be easily purified by a separation means such as recrystallization, distillation, chromatography and the like.
Schematic reaction formulas are shown in the following, wherein each symbol of the compounds is as defined above.
Compound (I) of the present invention can be produced, for example, by reacting a compound represented by the formula:
wherein Q is a leaving group, and other symbols are as defined above, or a salt thereof and a compound represented by the formula:
wherein G is a hydrogen atom or a metal atom, and other symbols are as defined above, or a salt thereof.
When X1 is —NR3—Y1—, —O— or —S—, G is mainly a hydrogen atom, but may be an alkali metal such as lithium, sodium, potassium, cesium and the like, or an alkaline earth metal such as magnesium, calcium and the like. When X1 is —CHR3—, G is preferably a metal such as lithium, halogenated magnesium, copper, zinc and the like.
Compound (III) or a salt thereof is preferably used in an amount of 1 to 5 equivalent, preferably 1 to 2 equivalent, relative to compound (II) and the reaction is preferably carried out in a solvent. In addition, a base or an ammonium salt may be used in an amount of about 1 to 10 equivalent, preferably 1 to 2 equivalent.
In the aforementioned formula, as the leaving group for Q, a halogen atom such as chlorine, bromine, iodine and the like, a group represented by the formula —S(O)kRa (wherein k is 0, 1 or 2, Ra is a lower (C1-4)alkyl group such as methyl, ethyl, propyl and the like), benzyl group, a C6-10 aryl group such as phenyl, tolyl and the like, and the like.] or a group represented by the formula —ORa (wherein Ra is as defined above.) can be used.
As the solvent in the aforementioned reaction, for example, halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like, aromatic hydrocarbons such as benzene, toluene, xylene and the like, alcohols such as methanol, ethanol, isopropanol, t-butanol and the like, ethers such as diethyl ether, tetrahydrofuran, dioxane and the like, acetone, acetonitrile, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, 1-methyl-2-pyrrolidone, dimethyl sulfoxide, hexamethylphosphoramide, water, a mixed solvent thereof and the like can be used.
As the base in the aforementioned reaction, an inorganic base, an organic base and the like can be used. Specifically, for example, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, triethylamine, N-ethyldiisopropylamine, pyridine, N,N-dimethylaminopyridine, sodium methoxide, sodium ethoxide, potassium t-butoxide, sodium hydride, sodium amide, diazabicycloundecene (DBU) and the like can be used.
As the ammonium salt in the aforementioned reaction, pyridine hydrochloride, pyridine hydrobromide, pyridinium p-toluenesulfonate, quinoline hydrochloride, isoquinoline hydrochloride, pyrimidine hydrochloride, pyrazine hydrochloride, triazine hydrochloride, trimethylamine hydrochloride, triethylamine hydrochloride, N-ethyldiisopropylamine hydrochloride and the like can be used.
The aforementioned reaction can be carried out under cooling, at room temperature or under heating (about 40 to 200° C., preferably about 40 to 160° C.), and the reaction time is generally about 1 to 30 hr, preferably about 1 to 20 hr, more preferably about 1 to 10 hr.
Compound (I) wherein X1 is —SO— or —SO2— can be produced by subjecting compound (I) wherein X1 is —S— to an oxidization reaction. As the oxidant therefor, for example, metachloroperbenzoic acid, hydrogen peroxide, peroxyacetic acid, t-butylhydroperoxide, peroxysulfuric acid potassium, potassium permanganate, sodium perboronate, sodium periodate, sodium hypochlorite, halogen and the like can be used. When compound (I) wherein X1 is —SO— is to be produced, the oxidant is used in an about 1 to 1.5 equivalent amount relative to the starting compound, and when compound (I) wherein X1 is —SO2— is to be produced, it is used in an about 2 to 3 equivalent amount. The reaction solvent is hot particularly limited as long as it does not react with the oxidant and, for example, halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like, aromatic hydrocarbons such as benzene, toluene, xylene and the like, alcohols such as methanol, ethanol, isopropanol, t-butanol and the like, ethers such as diethyl ether, tetrahydrofuran, dioxane and the like, carboxylic acids such as acetic acid, trifluoroacetic acid and the like, acetonitrile, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, 1-methyl-2-pyrrolidone, dimethyl sulfoxide, water, a mixed solvent thereof and the like can be used. The reaction can be carried out under cooling, at room temperature or under heating, reaction time is generally about 1 to 20 hr, preferably about 1 to 10 hr.
A compound within the scope of the present invention can be also produced by applying means known per se to the obtained compound (I) of the present invention for introduction of substituents and conversion of functional groups. For conversion of substituents, a known conventional method can be used. For example, conversion to carboxy group by hydrolysis of ester, conversion to carbamoyl group by amidation of carboxy group, conversion to hydroxymethyl group by reduction of carboxy group, conversion to alcohol compound by reduction or alkylation of carbonyl group, reductive amination of carbonyl group, oximation of carbonyl group, acylation of amino group, alkylation of amino group, substitution and amination of active halogen by amine, alkylation of hydroxy group, substitution and amination of hydroxy group and the like can be mentioned. When a reactive substituent that causes non-objective reaction is present during the introduction of substituents and conversion of functional groups, a protecting group is introduced in advance as necessary into the reactive substituent by a means known per se, and the protecting group is removed by a means known per se after the objective reaction, whereby the compound within the scope of the present invention can be also produced.
As the starting compound (III) of this production method, a commercially available one is used or can be produced by a means known per se.
The starting compound (II) of this production method can be produced by, for example, a method shown by the following scheme. Here, compounds (IIa), (IIb), (IIc), (IId) and (IIe) are encompassed in compound (II).
wherein Q1 and Q2 are each a halogen atom, k is 1 or 2, and other symbols are as defined above.
As Method A, compound (IIa) can be produced by reacting compound (IV) with a halogenating agent. As Method B, compound (IV) is reacted with a thionating agent to give compound (V), which is then reacted with a compound represented by RaQ2 in the presence of a base to give compound (IIb), which is further subjected to an oxidation reaction to give compound (IIc). As Method C, compound (IIa) is reacted with a compound represented by RzOH in the presence of a base to give compound (IId).
As the halogenating agent in Method A, for example, about 1 to 100 equivalent of phosphorus oxychloride, phosphorus pentachloride, phosphorus trichloride, thionyl chloride, sulfuryl chloride, phosphorus tribromide and the like can be used. In this case, the reaction may be carried out in the presence of a base such as diethylaniline, dimethylaniline, pyridine and the like. While the reaction may be carried out without solvent, as a reaction solvent, for example, halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; ethers such as diethyl ether, tetrahydrofuran, dioxane and the like; acetonitrile, ethyl acetate and the like may be used. The reaction is carried out under cooling, at room temperature or under heating, and the reaction time is generally about 1 to 20 hr, preferably about 1 to 10 hr.
As the thionating agent used in the production step from compound (IV) to compound (V) in Method B, for example, about 1 to 5 equivalent of a Lawesson reagent, phosphorus pentasulfide and the like can be used. As the reaction solvent, for example, halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; ethers such as diethyl ether, tetrahydrofuran, dioxane and the like; and the like can be used. The reaction is carried out at room temperature or under heating, and the reaction time is generally about 1 to 20 hr, preferably about 1 to 10 hr.
As RaQ2 in the production step from compound (V) to compound (IIb) in Method B, for example, about 1 to 5 quivalent of methyl iodide, benzyl chloride, benzyl bromide and the like can be used, and as the base, for example, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, triethylamine, N-ethyldiisopropylamine, pyridine, N,N-dimethylaminopyridine, sodium methoxide, sodium ethoxide, potassium t-butoxide, sodium hydride, sodium amide, diazabicycloundecene (DBU) and the like can be used. As the reaction solvent, for example, halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; alcohols such as methanol, ethanol, isopropanol, t-butanol and the like; ethers such as diethyl ether, tetrahydrofuran, dioxane and the like; acetone, acetonitrile, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, 1-methyl-2-pyrrolidone, dimethyl sulfoxide, hexamethylphosphoramide, water or a mixed solvent thereof and the like can be used. The reaction is carried out under cooling, at room temperature or under heating, and the reaction time is generally about 1 to 20 hr, preferably about 1 to 10 hr.
As the oxidizing agent in the production step from compound (IIb) to compound (IIc) in Method B, for example, m-chloroperbenzoic acid, hydrogen peroxide, peracetic acid, t-butyl hydroperoxide, potassium peroxysulfate, potassium permanganate, sodium perborate, sodium periodate, sodium hypochlorite, halogen and the like can be used. When compound (IIc) wherein k=1 is produced, the oxidizing agent is used in about 1 to 1.5 equivalent relative to compound (IIb), and when compound (IIc) wherein k=2 is produced, it is used in about 2 to 3 equivalent relative to compound (IIb). The reaction solvent is not particularly limited as long as it does not react with the oxidizing agent and, for example, halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; alcohols such as methanol, ethanol, isopropanol, t-butanol and the like; ethers such as diethyl ether, tetrahydrofuran, dioxane and the like; carboxylic acids such as acetic acid, trifluoroacetic acid and the like; acetonitrile, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, 1-methyl-2-pyrrolidone, dimethyl sulfoxide, water or a mixed solvent thereof and the like can be used. The reaction is carried out under cooling, at room temperature or under heating, and the reaction time is generally about 1 to 20 hr, preferably about 1 to 10 hr.
As RaOH in the production step from compound (IIa) to compound (IId) in Method C, for example, about 1 to 10 equivalent of methanol, ethanol, phenol and the like can be used, and as the base, for example, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, triethylamine, N-ethyldiisopropylamine, pyridine, N,N-dimethylaminopyridine, sodium methoxide, sodium ethoxide, potassium t-butoxide, sodium hydride, sodium amide, diazabicycloundecene (DBU) and the like can be used. As a reaction solvent, for example, halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; ethers such as diethyl ether, tetrahydrofuran, dioxane and the like; acetone, acetonitrile, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, 1-methyl-2-pyrrolidone, dimethyl sulfoxide, hexamethylphosphoramide, water or a mixed solvent thereof and the like can be used. The reaction is carried out under cooling, at room temperature or under heating, and the reaction time is generally about 1 to 20 hr, preferably about 1 to 10 hr.
Depending on the kind of the substituent of starting compound (II), a starting compound (II) having a different substituent can be produced by substituent conversion from, as a starting material, a compound produced by the above-mentioned production method. For the substituent conversion, a known general method can be used. For example, conversion to carbamoyl group by hydrolysis and amidation of ester, conversion to hydroxymethyl group by reduction of carboxy group, conversion to alcohol compound by reduction or alkylation of carbonyl group, reductive amination of carbonyl group, oximation of carbonyl group, acylation of amino group, alkylation of amino group, substitution and amination of active halogen by amine, alkylation of hydroxy group, substitution and amination of hydroxy group and the like can be mentioned. When a reactive substituent that causes non-objective reaction is present during the introduction of substituents and conversion of functional groups, a protecting group is introduced in advance as necessary into the reactive substituent by a means known per se, and the protecting group is removed by a means known per se after the objective reaction, whereby the starting compound (II) can be also produced.
Compound (I) can also be produced by subjecting a compound represented by the formula
wherein R11 is a C1-6 alkyl group, R12 is a group represented by —CHO or —COOR13 (wherein R13 is a C1-6 alkyl group), and other symbols are as defined above, or a salt thereof to an intramolecular dehydrating condensation reaction in the presence of a base and, where necessary, subjecting the compound to a substituent conversion reaction.
For example, a compound represented by the formula
wherein ring AA is an optionally further substituted azepin ring or an optionally substituted azocine ring, and other symbols are as defined above, or a salt thereof [hereinafter sometimes to be referred to as compound (Iaa)] can be produced by the method shown by the next formula. In the formula, the “azepin ring” or “azocine ring” of the “optionally substituted azepin ring” or “optionally substituted azocine ring” for ring AA optionally has, besides “R11—O—CO— group” and R1 group, 1 to 3 substituents at substitutable position(s).
As such substituent, for example, the substituent selected from the above-mentioned Substituent group V can be mentioned. When the number of the substituents is not less than 2, respective substituents may be the same or different.
wherein ring AB is an optionally further substituted nitrogen-containing 7-membered or 8-membered ring, and other symbols are as defined above.
In the formula, the “nitrogen-containing 7-membered or 8-membered ring” of the “optionally further substituted nitrogen-containing 7-membered or 8-membered ring” for ring AB optionally has, besides “R11—O—CO— group” and R1 group, 1 to 3 substituents at substitutable position(s). As such substituent, for example, the substituent selected from above-mentioned Substituent group V can be mentioned. When the number of the substituents is not less than 2, respective substituents may be the same or different.
Compound (X1) and compound (XII) can be produced by subjecting compound (X) to a Dieckmann (type) condensation reaction (J. P. Schaefer and J. J. Bloomfield, Org. Reactions, 1967, 15, 1). Compound (XII) can be produced by subjecting compound (X1) to catalytic hydrogenation or reduction reaction using sodium borohydride and the like. Compound (Iaa) can be produced by subjecting compound (XII) to dehydrating reaction by a conventional method.
In compound (X), when R12 is “—CHO”, compound (Iaa) can be directly produced from compound (X) by reaction the compound using dimethyl carbonate, DMF and the like as a reaction solvent, in the presence of 1 to 5 equivalent of a base (sodium methoxide, sodium hydride, etc.) at 0 to 100° C. (preferably 20 to 60° C.) for 1 to 100 hr (preferably 1 to 50 hr).
In addition, compound (Iaa) can be produced, for example, by reacting starting material compound (IIaa) or (IIab), that can be produced by a method shown in the following formula, with compound (III).
wherein each symbol is as defined above.
Compound (XIV) or compound (XV) can be produced by subjecting compound (XIII) to a Dieckmann (type) condensation reaction (J. P. Schaefer and J. J. Bloomfield, Org. Reactions, 1967, 15, 1). Compound (XV) can be produced by subjecting compound (XIV) to catalytic hydrogenation or reduction reaction using sodium borohydride and the like. Compound (IIaa) can be produced by subjecting compound (XV) to dehydrating reaction by a conventional method.
Compound (XV) can be directly produced from compound (XIII) by reacting compound (XIII) wherein R12 is “—CHO” in dimethyl carbonate, DMF and the like as a reaction solvent in the presence of 1 to 5 equivalent of a base (sodium methoxide, sodium hydride, etc.) at 0 to 100° C. (preferably 20 to 60° C.) for 1 to 100 hr (preferably 1 to 50 hr).
Compound (IIab) can be produced by reacting compound (IIaa), wherein Q is an alkoxy group, with a halogenating agent (phosphoryl chloride, etc.) without solvent or in the presence of a solvent such as 1,2-dimethoxyethane, 1,2-dichloroethane and the like at room temperature to 150° C. for 1 to 200 hr, preferably 50 to 150 hr.
Compound (Iaa) can be produced by reacting compound (IIaa) or compound (IIab) with compound (III) according to a method for producing compound (I) by reacting the aforementioned compound (II) with compound (III) or a modification thereof.
A compound within the range of the present invention can be produced by introducing a substituent into the obtained compound (Iaa) or converting a functional group thereof by a method known per se. For example, by subjecting —CO—O—R11 group, which is a substituent on ring AA of compound (Iaa), to substituent conversion or conversion of functional group, various compounds shown below can be produced.
wherein Rac is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an acyl group, and other symbols are as defined above.
—CO—O—R11 group of ring AA of compound (Iaa) is hydrolyzed by a method known per se to lead to carboxylic acid, whereby compound (Iab) is obtained, which is then reacted with an amine derivative to give compound (Iac), which is an amide derivative. A condensation reaction of the carboxylic acid derivative and the amine derivative is performed by peptide synthesis by a method known per se.
wherein each symbol is as defined above.
Compound (Iad), which is an alcohol derivative, can be synthesized by a general reduction reaction using sodium borohydride and the like, using an ester compound (Iaa) or carboxylic acid obtained by hydrolysis thereof or a mixed acid anhydride or acid halide derived therefrom as a starting material,
wherein Raf is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an acyl group, and other symbols are as defined above.
Compound (Iaf) having ether can be produced by converting a hydroxy group of alcohol compound (Iad) to a leaving group Q by a method known per se to give compound (Iae), and converting the compound to an ether compound method by a known per se. Compound (Iaf) can also be directly produced from alcohol compound (Iad) under general etherification conditions.
wherein Rag is a group bonded via a nitrogen atom or a sulfur atom, and optionally substituted, and other symbols are as defined above.
A sulfide compound and an amino compound can also be produced by converting a hydroxy group of alcohol compound (Iad) to a leaving group Q, and then according to a method known per se. A sulfone compound and a sulfoxide compound can be produced by subjecting a sulfide compound to, for example, oxidation using peracid such as 3-chloroperbenzoic acid and the like or hydroperoxide and the like.
Compound (I), which is the resultant product of this reaction, may be produced as a single compound or in the form of a mixture.
Compound (I) of the present invention thus obtained can be isolated and purified at a high purity from a reaction mixture by a means known per se, for example, solvent extraction, concentration, neutralization, filtration, crystallization, recrystallization, column chromatography, high performance liquid chromatography and the like.
When compound (I) is obtained as a free form, it can be converted to a desired salt by a method known per se or a modification thereof; conversely, when compound (I) is obtained as a salt, it can be converted to a free form or other desired salt by a method known per se or a modification thereof.
When compound (I) has isomers such as optical isomer, stereoisomer, positional isomer, rotational isomer and the like, and any isomers and mixtures are encompassed in compound (I). For example, when compound (I) has an optical isomer, an optical isomer separated from a racemate is also encompassed in compound (I). These isomers can be obtained as independent products by a synthesis means or a separation means (concentration, solvent extraction, column chromatography, recrystallization and the like) known per se.
The compound (I) may be a crystal, and both a single crystal and crystal mixtures are encompassed in compound (I). Crystals can be produced by crystallization according to crystallization methods known per se.
Compound (I) may be a solvate (e.g., hydrate, etc.) or a non-solvate, both of which are encompassed in compound (I).
A compound labeled with an isotope (e.g., 3H, 14C, 35S, 125I and the like) is also encompassed in compound (I).
A prodrug of compound (I) or a salt thereof (hereinafter referred to as compound (I)) means a compound which is converted to compound (I) with a reaction due to an enzyme, an gastric acid, etc. under the physiological condition in the living body, that is, a compound which is converted to compound (I) with oxidation, reduction, hydrolysis, etc. according to an enzyme; a compound which is converted to compound (I) by hydrolysis, etc. due to gastric acid, etc. A prodrug for compound (I) may be a compound obtained by subjecting an amino group in compound (I) to an acylation, alkylation or phosphorylation (e.g., a compound obtained by subjecting an amino group in compound (I) to an eicosanoylation, alanylation, pentylaminocarbonylatioh, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylation, tetrahydrofuranylation, pyrrolidylmethylation, pivaloyloxymethylation and tert-butylation, etc.); a compound obtained by subjecting a hydroxy group in compound (I) to an acylation, alkylation, phosphorylation or boration (e.g., a compound obtained by subjecting an hydroxy group in compound (I) to an acetylation, palmitoylation, propanoylation, pivaloylation, succinylation, fumarylation, alanylation, dimethylaminomethylcarbonylation, etc.); a compound obtained by subjecting a carboxyl group in compound (I) to an esterification or amidation (e.g., a compound obtained by subjecting a carboxyl group in compound (I) to an ethyl esterification, phenyl esterification, carboxymethyl esterification, dimethylaminomethyl esterification, pivaloyloxymethyl esterification, ethoxycarbonyloxyethyl esterification, phthalidyl esterification, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl esterification, cyclohexyloxycarbonylethyl esterification and methylamidation, etc.) and the like. These compounds can be produced from compound (I) by a method known per se.
A prodrug for compound (I) may also be one which is converted into compound (I) under a physiological condition, such as those described in IYAKUHIN no KAIHATSU (Development of Pharmaceuticals), Vol. 7, Design of Molecules, p. 163-198, Published by HIROKAWA SHOTEN (1990).
The compound (I) of the present invention, or a salt thereof or a prodrug thereof (hereinafter referred to as the compound of the present invention) possesses tyrosine kinase-inhibiting activity and can be used for the prophylaxis or treatment of tyrosine kinase-dependent diseases in mammals. Tyrosine kinase-dependent diseases include diseases characterized by increased cell proliferation due to abnormal tyrosine kinase enzyme activity. Furthermore, the compound of the present invention specifically inhibits HER2 kinase and/or EGFR kinase and is therefore also useful as a therapeutic agent for suppressing the growth of HER2 and/or EGFR kinase-expressing cancer, or a preventive agent for preventing the transition of hormone-dependent cancer to hormone-independent cancer. In addition, the compound is useful as a pharmaceutical agent because it shows low toxicity (e.g., acute toxicity, chronic toxicity, genetic toxicity, reproductive toxicity, cardiotoxicity, drug interaction, carcinogenicity and the like), high water solubility, and is superior in stability, pharmacokinetics (absorption, distribution, metabolism, excretion and the like) and efficacy expression.
That is, the compound of the present invention can be used as a safe agent for the prophylaxis or treatment of diseases caused by abnormal cell growth such as various cancers (particularly breast cancer (including progressive breast cancer, for example, invasive ductal carcinoma, ductal cancer in situ, inflammatory breast cancer, etc.), prostate cancer (e.g., hormone-dependent prostate cancer, non-hormone dependent prostate cancer, etc.), pancreatic cancer (e.g., pancreatic duct cancer, etc.), gastric cancer (e.g., papillary adenocarcinoma, mucinous adenocarcinoma, adenosquamous cancer, etc.), lung cancer (e.g., non-small cell lung cancer, small cell lung cancer, malignant mesothelioma, etc.), colon cancer (e.g., gastrointestinal stromal tumor, etc.), colorectal cancer (e.g., familial colorectal cancer, hereditary nonpolyposis colorectal cancer, gastrointestinal stromal tumor, etc.), small intestine cancer, rectal cancer (e.g., gastrointestinal stromal tumor, etc.), esophagus cancer, duodenal cancer, cancer of tongue, cancer of pharynx (e.g., nasopharyngeal carcinoma, oropharyngeal cancer, hypopharyngeal cancer, etc.), brain tumor (e.g., pineal astrocytoma, pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, etc.), neurinoma, non-small cell lung cancer, small cell lung cancer, liver cancer (e.g., primary liver cancer, Extrahepatic Bile Duct Cancer, etc.), kidney cancer (e.g., renal cell carcinoma, renal pelvis and ureter transitional cell cancer, etc.), cancer of the bile duct, cancer of the uterine body, uterine cervical cancer, ovarian cancer (e.g., ovarian epithelial cancer, extragonadal germ cell tumor, ovarian germ cell tumor, ovarial low malignant potential tumor, etc.), urinary bladder cancer, skin cancer (e.g., ocular melanoma, Merkel cell carcinoma, etc.), hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer (e.g., medullary thyroid cancer, etc.), bone tumor (e.g., osteosarcoma, Ewing's tumor, uterus sarcoma, soft tissue sarcoma, etc.), vascular fibroma, retinoblastoma, penile cancer, solid cancer in childhood, Kaposi's sarcoma, Kaposi's sarcoma derived from AIDS, maxillary tumor, fibrous histiocytoma, leiomyosarcoma, rhabdomyosarcoma, leukemia (e.g., acute myeloid leukemia, acute lymphoblastic leukemia, etc.), etc.), atherosclerosis, angiogenesis (e.g., angiogenesis associated with growth of solid cancer or sarcoma, angiogenesis associated with tumor metastasis, and angiogenesis associated with diabetic retinopathy, etc.), viral disease (HIV infection, etc.) and the like.
The tyrosine kinase-dependent disease further includes cardiovascular diseases associated with abnormal tyrosine kinase enzyme activity. Accordingly, the compound of the present invention can also be used as an agent for the prophylaxis or treatment of cardiovascular diseases such as restenosis.
The compound of the present invention is useful as an anti-cancer agent for the prophylaxis or treatment of cancer, particularly breast cancer (including progressive breast cancer), ovarian cancer, colorectal cancer, small intestine cancer, gastric cancer, esophagus cancer, prostate cancer, lung cancer, pancreatic cancer, kidney cancer, colon cancer, and the like.
The compound of the present invention shows low toxicity and can be used as a pharmaceutical agent as it is, or as a pharmaceutical composition in admixture with a commonly known pharmaceutically acceptable carrier, etc. in mammals (e.g., humans, horses, bovines, dogs, cats, rats, mice, rabbits, pigs, monkeys, and the like).
In addition to the compound of the present invention, other active ingredients, for example, the following hormonal therapeutic agents, anticancer agents (e.g., chemotherapeutic agents, immunotherapeutic agents and pharmaceutical agents inhibiting the action of cell growth factors or cell growth factor receptors), and the like may be contained in a pharmaceutical composition.
For administration of the compound of the present invention as a pharmaceutical agent for mammals such as humans, it can be administered orally in the form of, for example, tablets, capsules (including soft capsules and microcapsules), powders, granules and the like, or parenterally in the form of injections, suppositories, pellets and the like. Examples of the “parenteral administration” include intravenous administration, intramuscular administration, subcutaneous administration, intra-tissue administration, intranasal administration, intradermal administration, instillation administration, intracerebral administration, intrarectal administration, intravaginal administration, intraperitoneal administration, intratumoral administration, administration to the juxtaposition of tumor and administration directly to the lesion.
The dose of the compound of the present invention varies depending on the administration route, symptoms and the like. For example, when it is administered orally as an anticancer agent to a patient (body weight 40 to 80 kg) with breast cancer or prostate cancer, its dose is, for example, 0.5 to 100 mg/kg body weight per day, preferably 1 to 50 mg/kg body weight per day, and more preferably 1 to 25 mg/kg body weight per day. This amount may be administered once or in 2 or 3 divided portions daily.
The compound of the present invention can be safely administered orally or parenterally (e.g., topical, rectal, intravenous administrations, etc.) as a single agent, or a pharmaceutical composition containing a pharmacologically acceptable carrier such as tablet (including sugar-coated tablet, film-coated tablet), powder, granule, capsule, liquid, emulsion, suspension, injection, suppository, sustained release preparation, plaster and the like, according to a conventional method (e.g., a method described in the Japanese Pharmacopoeia, etc.).
Moreover, a combination of (1) administration of an effective amount of the compound of the present invention and (2) 1 to 3 kinds selected from the group consisting of (i) administration of an effective amount of other anticancer agents, (ii) administration of an effective amount of hormonal therapeutic agents and (iii) non-drug therapy can prevent and/or treat cancer more effectively. The non-drug therapy is exemplified by surgery, radiotherapy, gene therapy, thermotherapy, cryotherapy, laser cauterization, and the like, and two or more of these may be combined.
For example, the compound of the present invention can be administered to the same subject simultaneously with hormonal therapeutic agents, anticancer agents (e.g., chemotherapeutic agents, immunotherapeutic agents, or pharmaceutical agents inhibiting the action of cell growth factors or cell growth factor receptors) (hereafter to be briefly referred to as a concomitant drug).
Although the compound of the present invention exhibits excellent anticancer action even when used as a simple agent, its effect can be enhanced by using it in combination with one or more of the concomitant drug(s) mentioned above (multiple drug therapy).
Examples of the “hormonal therapeutic agents” include fosfestrol, diethylstylbestrol, chlorotrianisene, medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, cyproterone acetate, danazol, dienogest, asoprisnil, allylestrenol, gestrinone, nomegestrol, Tadenan, mepartricin, raloxifene, ormeloxifene, levormeloxifene, anti-estrogens (e.g., tamoxifen citrate, toremifene citrate, and the like), ER down regulator (e.g., fulvestrant, and the like), human menopausal gonadotrophin, follicle stimulating hormone, pill preparations, mepitiostane, testrolactone, aminoglutethimide, LH-RH agonists (e.g., goserelin acetate, buserelin, leuprorelin, and the like), droloxifene, epitiostanol, ethinylestradiol sulfonate, aromatase inhibitors (e.g., fadrozole hydrochloride, anastrozole, retrozole, exemestane, vorozole, formestane, and the like), anti-androgens (e.g., flutamide, bicartamide, nilutamide, and the like), 5α-reductase inhibitors (e.g., finasteride, dutasteride, epristeride, and the like), aderenal cortex hormone drugs (e.g., dexamethasone, prednisolone, betamethasone, triamcinolone, and the like), androgen synthesis inhibitors (e.g., abiraterone, and the like), retinoid and drugs that retard retinoid metabolism (e.g., liarozole, and the like), etc. and LH-RH agonists (e.g., goserelin acetate, buserelin, leuprorelin) are preferable.
Examples of the “chemotherapeutic agents” include alkylating agents, antimetabolites, anticancer antibiotics, plant-derived anticancer agents, and the like.
Examples of the “alkylating agents” include nitrogen mustard, nitrogen mustard-N-oxide hydrochloride, chlorambutyl, cyclophosphamide, ifosfamide, thiotepa, carboquone, improsulfan tosylate, busulfan, nimustine hydrochloride, mitobronitol, melphalan, dacarbazine, ranimustine, sodium estramustine phosphate, triethylenemelamine, carmustine, lomustine, streptozocin, pipobroman, etoglucid, carboplatin, cisplatin, miboplatin, nedaplatin, oxaliplatin, altretamine, ambamustine, dibrospidium hydrochloride, fotemustine, prednimustine, pumitepa, ribomustin, temozolomide, treosulphan, trophosphamide, zinostatin stimalamer, adozelesin, cystemustine, bizelesin, and the like.
Examples of the “antimetabolites” include mercaptopurine, 6-mercaptopurine riboside, thioinosine, methotrexate, enocitabine, cytarabine, cytarabine ocfosfate, ancitabine hydrochloride, 5-FU drugs (e.g., fluorouracil, tegafur, UFT, doxifluridine, carmofur, gallocitabine, emmitefur, and the like), aminopterine, leucovorin calcium, tabloid, butocine, folinate calcium, levofolinate calcium, cladribine, emitefur, fludarabine, gemcitabine, hydroxycarbamide, pentostatin, piritrexim, idoxuridine, mitoguazone, thiazophrine, ambamustine, and the like.
Examples of the “anticancer antibiotics” include actinomycin-D, actinomycin-C, mitomycin-C, chromomycin-A3, bleomycin hydrochloride, bleomycin sulfate, peplomycin sulfate, daunorubicih hydrochloride, doxorubicin hydrochloride, aclarubicin hydrochloride, pirarubicin hydrochloride, epirubicin hydrochloride, neocarzinostatin, mithramycin, sarcomycin, carzinophilin, mitotane, zorubicin hydrochloride, mitoxantrone hydrochloride, idarubicin hydrochloride, and the like.
Examples of the “plant-derived anticancer agents” include etoposide, etoposide phosphate, vinblastine sulfate, vincristine sulfate, vindesine sulfate, teniposide, paclitaxel, docetaxel, vinorelbine, and the like.
Examples of the “immunotherapeutic agents (BRM)” include picibanil, krestin, sizofuran, lentinan, ubenimex, interferons, interleukins, macrophage colony-stimulating factor, granulocyte colony-stimulating factor, erythropoietin, lymphotoxin, BCG vaccine, Corynebacterium parvum, levamisole, polysaccharide K, procodazole, and the like.
Example of the “cell growth factor” in the “pharmaceutical agents inhibiting the action of cell growth factors or cell growth factor receptors”, there may be mentioned any substances that promote cell proliferation, which are normally peptides having not more than 20,000 molecular weight that are capable of exhibiting their activity at low concentrations by binding to a receptor, including (1) EGF (epidermal growth factor) or substances possessing substantially the same activity as it [e.g., EGF, heregulin (HER2 ligand), and the like], (2) insulin or substances possessing substantially the same activity as it [e.g., insulin, IGF (insulin-like growth factor)-1, IGF-2, and the like], (3) FGF (fibroblast growth factor) or substances possessing substantially the same activity as it [e.g., acidic FGF, basic FGF, KGF (keratinocyte growth factor), FGF-10, and the like], (4) other cell growth factors [e.g., CSF (colony stimulating factor), EPO (erythropoietin), IL-2 (interleukin-2), NGF (nerve growth factor), PDGF (platelet-derived growth factor), TGF-β (transforming growth factor-β), HGF (hepatocyte growth factor), VEGF (vascular endothelial growth factor), and the like], and the like.
Examples of the “cell growth factor receptors” include any receptors capable of binding to the aforementioned growth factors, including EGF receptor, heregulin receptor (HER2), insulin receptor, IGF receptor, FGF receptor-1 or FGF receptor-2, and the like.
Examples of the “pharmaceutical agents inhibiting the action of cell growth factor” include trastuzumab (Herceptin (trade mark): HER2 antibody), imatinib mesylate, ZD1839 or cetuximab, antibody to VEGF (e.g., bevacizumab), antibody to VEGF receptor, gefitinib, erlotinib, and the like.
In addition to the aforementioned drugs, L-asparaginase, aceglatone, procarbazine hydrochloride, protoporphyrin-cobalt complex salt, mercuric hematoporphyrin-sodium, topoisomerase I inhibitors (e.g., irinotecan, topotecan, and the like), topoisomerase II inhibitors (e.g., sobuzoxane, and the like), differentiation inducers (e.g., retinoid, vitamin D, and the like), angiogenesis inhibitors (e.g., thalidomide, SU11248, and the like), α-blockers (e.g., tamsulosin hydrochloride, naftopidil, urapidil, alfuzosin, terazosin, prazosin, silodosin, and the like), serine/threonine kinase inhibitor, endothelin receptor antagonist (e.g., atrasentan, and the like), proteasome inhibitor (e.g., bortezomib, and the like), Hsp 90 inhibitors (e.g., 17-AAG, and the like), spironolactone, minoxidil, 11α-hydroxyprogesterone, bone resorption inhibiting/metastasis suppressing agent (e.g., zoledronic acid, alendronic acid, pamidronic acid, etidronic acid, ibandronic acid, clodronic acid) and the like can be used.
Of those mentioned above, LH-RH agonists (e.g., goserelin acetate, buserelin, leuprorelin, and the like), trastuzumab (HER2 antibody) and the like are preferable as concomitant drugs.
When the compound of the present invention and the concomitant drug are used in combination, the administration time of the compound of the present invention and the concomitant drug is not restricted, and the compound of the present invention and the concomitant drug can be administered to the subject simultaneously, or may be administered at different times. The dosage of the concomitant drug may be determined according to the dose clinically used, and can be appropriately selected depending on the subject, administration route, disease, combination of the drugs and the like.
The administration mode of the compound of the present invention and the concomitant drug is not particularly restricted, and the compound of the present invention and the concomitant drug only need to be combined at the time of administration. Examples of such administration mode include the following methods: (1) The compound of the present invention and the concomitant drug are simultaneously produced to give a single preparation which is administered. (2) The compound of the present invention and the concomitant drug are separately produced to give two kinds of preparations which are administered simultaneously by the same administration route. (3) The compound of the present invention and the concomitant drug are separately produced to give two kinds of preparations which are administered by the same administration route at different times. (4) The compound of the present invention and the concomitant drug are separately produced to give two kinds of preparations which are administered simultaneously by different administration routes. (5) The compound of the present invention and the concomitant drug are separately produced to give two kinds of preparations which are administered by different administration routes at different times (e.g., the compound of the present invention and the concomitant drug are administered in this order, or vice versa).
The present invention is explained in detail in the following by referring to Examples, Preparation Examples and Experimental Examples, which are not to be construed as limitative.
Under hydrogen atmosphere, a mixture of 4-aminobutanoic acid (20.6 g), 4-methoxybenzaldehyde (29.9 g), 10% palladium-carbon (4.0 g), ethanol (300 mL) and 1N aqueous sodium hydroxide (200 mL) was stirred at room temperature for 7 days. Palladium-carbon was removed by filtration, and ethanol was evaporated under reduced pressure. Tetrahydrofuran (200 mL) was added to the residue, and di-tert-butyl dicarbonate (43 g) was added thereto dropwise at room temperature. The mixture was stirred at room temperature for 3 hr and extracted with hexane. The aqueous layer was acidified using 1N hydrochloric acid and extracted with diethyl ether. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give 4-[(tert-butoxycarbonyl)(4-methoxybenzyl)amino]butanoic acid (62.7 g) as an orange oil. To a solution of 4-[(tert-butoxycarbonyl)(4-methoxybenzyl)amino]butanoic acid (62.7 g) in methanol (240 mL) was added dropwise thionyl chloride (47 mL) at −10° C. After the dropwise addition was completed, the mixture was stirred at room temperature for 24 hr, and concentrated under reduced pressure. Methanol was added to the residue and the mixture was further concentrated. The precipitated crystals were collected by filtration. The crystals were washed with diethyl ether to give the title compound (42.0 g) as colorless crystals.
1H-NMR (DMSO-d6) δ: 1.82-1.96 (2H, m), 2.44 (2H, t, J=7.4 Hz), 2.80-2.92 (2H, m), 3.60 (3H, s), 3.77 (3H, s), 4.04 (2H, t, J=5.7 Hz), 6.98 (2H, d, J=8.7 Hz), 7.47 (2H, d, J=8.7 Hz), 9.08-9.25 (2H, m).
The mixture of tert-butyl 4-bromobutanoate (5.0 g) and 4-methoxybenzylamine (8.8 mL) was stirred at room temperature for 5 days. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (hexane:ethyl acetate=3:1→2:1→1:1→ethyl acetate→ethyl acetate:methanol=19:1) to give the title compound (4.55 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.43 (9H, s), 1.74-1.83 (2H, m), 2.27 (2H, t, J=7.4 Hz), 2.63 (2H, t, J=7.1 Hz), 3.72 (2H, s), 3.80 (3H, s), 6.86 (2H, d, J=8.6 Hz), 7.23 (2H, d, J=8.6 Hz).
Using 4-aminopentanoic acid (5.0 g), 4-methoxybenzaldehyde (6.39 g), 10% palladium-carbon (1.0 g), methanol (65 mL), 1N aqueous sodium hydroxide solution (43 ml), tetrahydrofuran (100 mL), di-tert-butyl dicarbonate (9.32 g), thionyl chloride (10.5 mL) and methanol (120 mL), a similar reaction as in Reference Example 1 was carried out to give the title compound (11.0 g) as colorless crystals.
1H-NMR (DMSO-d6) δ: 1.47-1.70 (4H, m), 2.34 (2H, t, J=6.9 Hz), 2.80-2.91 (2H, m), 3.59 (3H, s), 3.77 (3H, s), 4.04 (2H, s), 6.99 (2H, d, J=8.7 Hz), 7.44 (2H, d, J=8.7 Hz), 8.92 (2H, br s).
To a solution of 4,6-dichloropyrimidine-5-carbaldehyde (15.0 g) in acetonitrile (1500 mL) were successively added potassium phosphate (39.6 g) and methyl 4-[(4-methoxybenzyl)amino]butanoate hydrochloride (23.2 g), and the mixture was stirred at room temperature for 21 hr. The reaction mixture was concentrated under reduced pressure. To the residue was added water, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=95:5→67:33) to give the title compound (26.0 g) as a yellow oil.
1H-NMR (CDCl3) δ: 1.89-2.00 (2H, m), 2.30 (2H, t, J=7.3 Hz), 3.60-3.67 (2H, m), 3.65 (3H, s), 3.78 (3H, s), 4.55 (2H, s), 6.82 (2H, br d, J=8.8 Hz), 7.00 (2H, br d, J=8.8 Hz), 8.38 (1H, s), 10.19 (1H, s).
To a solution of methyl 4-[(6-chloro-5-formylpyrimidin-4-yl)(4-methoxybenzyl)amino]butanoate (11.0 g) in N,N-dimethylformamide (110 mL) were successively added sodium carbonate (3.10 g) and 3-chloro-4-[3-(trifluoromethyl)phenoxy]aniline (8.39 g), and the mixture was stirred at 60° C. for 108 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=90:10→50:50). The obtained oil was dissolved in dimethyl carbonate (230 mL). To the solution was added 28% sodium methoxide-methanol solution (12.3 g) and the mixture was stirred at room temperature for 15 hr. The reaction mixture was neutralized by IN hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by basic silica gel column chromatography (eluent, hexane:ethyl acetate=90:10→50:50) to give the title compound (8.44 g) as a yellow oil.
1H-NMR (CDCl3) δ: 2.66 (2H, t, J=4.6 Hz), 3.30-3.40 (2H, m), 3.78 (3H, s), 3.81 (3H, s), 4.87 (2H, s), 6.81-6.91 (3H, m), 7.03-7.14 (2H, m), 7.19-7.29 (3H, m), 7.30-7.36 (1H, m), 7.37-7.47 (2H, m), 7.68 (1H, s), 7.75 (1H, d, J=2.7 Hz), 8.24 (1H, s).
To a solution of methyl 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-9-(4-methoxybenzyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (8.43 g) in 1,2-dichloroethane (85 mL) was added trifluoroacetic acid (85 mL), and the mixture was stirred at 70° C. for 14 hr. The reaction mixture was concentrated under reduced pressure. To the residue was added a saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=80:20→0:100) to give the title compound (6.08 g) as a yellow powder.
1H-NMR (CDCl3) δ: 2.87-2.94 (2H, m), 3.48-3.58 (2H, m), 3.82 (3H, s), 5.89 (1H, t, J=4.5 Hz), 6.87 (1H, s), 7.06 (1H, d, J=8.8 Hz), 7.10 (1H, dd, J=7.7, 2.5 Hz), 7.21 (1H, s), 7.30-7.49 (3H, m), 7.67 (1H, s), 7.75 (1H, d, J=2.5 Hz), 8.13 (1H, s).
To a solution of methyl 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (5.95 g) in tetrahydrofuran (170 mL) and ethanol (170 mL) was added 1N aqueous sodium hydroxide solution (40 mL), and the mixture was stirred at room temperature for 15 hr. To the reaction mixture was added 1N hydrochloric acid to adjust the pH to 3 to 4, and the mixture was diluted with water. The precipitate was filtered and dried to give the title compound (4.45 g) as a pale-yellow powder.
1H-NMR (DMSO-d6) δ: 2.65-2.78 (2H, m), 3.19-3.48 (2H, m), 7.13-7.29 (3H, m), 7.45 (1H, d, J=7.7 Hz), 7.51-7.64 (2H, m), 7.71 (1H, s), 7.84 (1H, d, J=2.5 Hz), 7.89 (1H, t, J=4.8 Hz), 7.99 (1H, s), 9.40 (1H, s).
Using methyl 4-[(6-chloro-5-formylpyrimidin-4-yl)(4-methoxybenzyl)amino]butanoate (3.00 g), N,N-dimethylformamide (30 mL), sodium carbonate (843 mg), tert-butyl 4-(4-amino-2-chlorophenoxy)piperidine-1-carboxylate (2.60 g), 28% sodium methoxide-methanol solution (3.80 g) and dimethyl carbonate (80 mL), a similar reaction as in Example 1 (ii) was carried out to give the title compound (3.32 g) as an orange oil.
1H-NMR (CDCl3) δ: 1.48 (9H, s), 1.75-1.97 (4H, m), 2.65 (2H, t, J=4.5 Hz), 3.30-3.37 (2H, m), 3.37-3.48 (2H, m), 3.63-3.75 (2H, m), 3.77 (3H, s), 3.81 (3H, s), 4.43-4.52 (1H, m), 4.85 (2H, s), 6.70 (1H, s), 6.87 (2H, br d, J=8.8 Hz), 6.95 (1H, d, J=8.8 Hz), 7.23 (2H, br d, J=8.5 Hz), 7.29 (1H, dd, J=8.8, 2.7 Hz), 7.55 (1H, d, J=2.7 Hz), 7.66 (1H, s), 8.20 (1H, s).
To a solution of methyl 4-[(4-{[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy}-3-chlorophenyl)amino]-9-(4-methoxybenzyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (3.31 g) in 1,2-dichloroethane (33 mL) was added trifluoroacetic acid (33 mL), and the mixture was stirred at 70° C. for 14 hr. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in tetrahydrofuran (30 mL) and cooled to 0° C. To the mixture were successively added triethylamine (5 mL) and cyclopentanecarbonyl chloride (0.62 mL), and the mixture was stirred at room temperature for 15 hr. Furthermore, cyclopentanecarbonyl chloride (0.31 mL) was added to the mixture and stirred for 2 hr. To the reaction mixture was added a saturated aqueous solution of sodium hydrogencarbonate, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=33:67→0:100→ethyl acetate:methanol=95:5), and further crystallized from diisopropyl ether/ethyl acetate to give the title compound (1.89 g) as a yellow powder.
1H-NMR (CDCl3) δ: 1.51-1.96 (12H, m), 2.86-2.98 (3H, m), 3.46-3.57 (3H, m), 3.71-3.79 (3H, m), 3.81 (3H, s), 4.49-4.64 (1H, m), 5.85 (1H, t, J=4.9 Hz), 6.75 (1H, s), 6.95 (1H, d, J=8.8 Hz), 7.24-7.35 (1H, m), 7.55 (1H, d, J=2.5 Hz), 7.66 (1H, m), 8.08 (1H, s).
To a 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL) were successively added 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of cyclopropylamine in N,N-dimethylformamide (0.5 mL), and the mixture was stirred at room temperature for 21 hr. 5% Aqueous sodium hydrogen carbonate solution was added to the reaction mixture and the mixture was extracted with dichloromethane. The organic layer was dried and concentrated under reduced pressure. The residue was separated by preparative liquid chromatography (0.1% trifluoroacetic acid containing acetonitrile/0.1% trifluoroacetic acid containing water, 5%→100%) to collect the objective fraction, which was concentrated under reduced pressure to give the title compound (13.3 mg).
LC-MS found 516 (M+H)+ (exact MS calcd for C25H21ClF3N5O2 515).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 4-(2-furyl)butan-2-amine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (27.4 mg).
LC-MS found 598 (M+H)+ (exact MS calcd for C30H27ClF3N5O3 597).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-aminoethanol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (27.4 mg).
LC-MS found 520 (M+H)+ (exact MS calcd for C24H21ClF3N5O3 519).
To 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL) were successively added 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of methylamine hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), and the mixture was stirred at room temperature for 21 hr. To the reaction mixture was added 5% aqueous sodium hydrogen carbonate solution, and the mixture was extracted with dichloromethane. The organic layer was dried, and concentrated under reduced pressure. The residue was subjected to preparative liquid chromatography (0.1% trifluoroacetic acid containing acetonitrile/0.1% trifluoroacetic acid containing water, 5%→100%) to collect the objective fraction, and the fraction was concentrated under reduced pressure to give the title compound (19.9 mg).
LC-MS found 490 (M+H)+ (exact MS calcd for C23H19ClF3N5O2 489).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of isobutylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (25.0 mg).
LC-MS found 532 (M+H)+ (exact MS calcd for C26H25ClF3N5O2 531).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of tert-butylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (18.4 mg).
LC-MS found 532 (M+H)+ (exact MS calcd for C26H25ClF3N5O2 531).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 3-amino-1-propanol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (26.2 mg).
LC-MS found 534 (M+H)+ (exact MS calcd for C25H23ClF3N5O3 533).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of ethylamine hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (23.8 mg).
LC-MS found 504 (M+H)+ (exact MS calcd for C24H21ClF3N5O2 503).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochlorides 1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of pyrrolidin-3-ol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (27.1 mg).
LC-MS found 546 (M+H)+ (exact MS calcd for C26H23ClF3N5O3 545).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido [4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of N,N-dimethylethane-1,2-diamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (32.9 mg).
LC-MS found 547 (M+H)+ (exact MS calcd for C26H26ClF3N6O2 546).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-ethoxyethylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (23.6 mg).
LC-MS found 548 (M+H)+ (exact MS calcd for C26H25ClF3N5O3 547).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and, 0.15 M solution of N-(2-methoxyethyl)methylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (26.0 mg).
LC-MS found 548 (M+H)+ (exact MS calcd for C26H25ClF3N5O3 547).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-amino-2-methyl-1-propanol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (20.4 mg).
LC-MS found 548 (M+H)+ (exact MS calcd for C26H25ClF3N5O3 547).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of furfurylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (25.9 mg).
LC-MS found 556 (M+H)+ (exact MS calcd for C27H21ClF3N5O3 555).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of N,O-dimethylhydroxylamine hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (24.5 mg).
LC-MS found 520 (M+H)+ (exact MS calcd for C24H21ClF3N5O3 519).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of cyclohexylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (25.0 mg).
LC-MS found 558 (M+H)+ (exact MS calcd for C28H27ClF3N5O2 557).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of N-(2-aminoethyl)acetamide in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (25.9 mg).
LC-MS found 561 (M+H)+ (exact MS calcd for C26H24ClF3N6O3 560).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of N,N-dimethyl-1,3-propanediamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (30.1 mg).
LC-MS found 561 (M+H)+ (exact MS calcd for C27H28ClF3N6O2 560).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-(2-aminoethoxy)ethanol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (27.1 mg).
LC-MS found 564 (M+H)+ (exact MS calcd for C26H25ClF3N5O4 563).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-(aminomethyl)pyridine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (33.0 mg).
LC-MS found 567 (M+H)+ (exact MS calcd for C28H22ClF3N6O2 566).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-(2-aminoethyl)pyridine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (35.9 mg).
LC-MS found 581 (M+H)+ (exact MS calcd for C29H24ClF3N6O2 580).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 4-(2-aminoethyl)pyridine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (36.1 mg).
LC-MS found 581 (M+H)+ (exact MS calcd for C29H24ClF3N6O2 580).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 3-(2-aminoethyl)pyridine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (35.9 mg).
LC-MS found 581 (M+H)+ (exact MS calcd for C29H24ClF3N6O2 580).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 3-(1H-imidazol-1-yl)-1-propylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (30.7 mg).
LC-MS found 584 (M+H)+ (exact MS calcd for C28H25ClF3N7O2 583).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-(2-thienyl)ethylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (25.4 mg).
LC-MS found 586 (M+H)+ (exact MS calcd for C28H23ClF3N5O2S 585).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 1-(2-aminoethyl)piperidine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (7.8 mg).
LC-MS found 587 (M+H)+ (exact MS calcd for C29H30ClF3N6O2 586).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 1-methyl-4-(aminomethyl)piperidin-4-amine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (34.2 mg).
LC-MS found 587 (M+H)+ (exact MS calcd for C29H30ClF3N6O2 586).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of (1-methylpiperidin-2-yl)methaneamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (36.8 mg).
LC-MS found 587 (M+H)+ (exact MS calcd for C28H23ClF3N5O2S 586).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 4-(2-aminoethyl)morpholine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (34.6 mg).
LC-MS found 589 (M+H)+ (exact MS calcd for C28H28ClF3N6O3 588).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-[2-(methylamino)ethyl]pyridine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (32.0 mg).
LC-MS found 595 (M+H)+ (exact MS calcd for C30H26ClF3N6O2 594).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-amino-1-phenylethanol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (26.1 mg).
LC-MS found 596 (M+H)+ (exact MS calcd for C30H25ClF3N5O3 595).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of N-methyl-2-(methylsulfonyl)ethaneamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (28.2 mg).
LC-MS found 596 (M+H)+ (exact MS calcd for C26H25ClF3N5O4S 595).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-amino-1-(pyridin-2-yl)ethanol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (27.6 mg).
LC-MS found 597 (M+H)+ (exact MS calcd for C29H24ClF3N6O3 596).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2,4-difluorobenzylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (26.9 mg).
LC-MS found 602 (M+H)+ (exact MS calcd for C29H21ClF5N5O2 601).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 3-(methylsulfonyl)pyrrolidine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (29.8 mg).
LC-MS found 608 (M+H)+ (exact MS calcd for C27H25ClF3N5O4S 607).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of ethyl N-methylglycinate hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (26.5 mg).
LC-MS found 576 (M+H)+ (exact MS calcd for C27H25ClF3N5O4 575).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2,2′-[(3-aminopropyl)imino]diethanol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (29.7 mg).
LC-MS found-621 (M+H)+ (exact MS calcd for C29H32ClF3N6O4 620).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-(1,3-thiazol-2-yl)ethylamine hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (19.6 mg).
LC-MS found 587 (M+H)+ (exact MS calcd for C27H22ClF3N6O2S 586).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of amino(phenyl)acetonitrile hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (23.5 mg).
LC-MS found 591 (M+H)+ (exact MS calcd for C30H22ClF3N6O2 590).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 2-(1H-imidazol-4-yl)ethylamine dihydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.02 mL), a similar reaction as in Example 7 was carried out to give the title compound (25.1 mg).
LC-MS found 570 (M+H)+ (exact MS calcd for C27H23ClF3N7O2 569).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 1-(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (29.3 mg).
LC-MS found 647 (M+H)+ (exact MS calcd for C32H26ClF3N8O2 646).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 4-amino-1-benzylpiperidine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (35.7 mg).
LC-MS found 649 (M+H)+ (exact MS calcd for C34H32ClF3N6O2 648).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 1-benzyl-3-(methylamino)pyrrolidine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (32.7 mg).
LC-MS found 649 (M+H)+ (exact MS Calcd for C34H32ClF3N6O2 648).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 1-(4-benzylmorpholin-2-yl)methylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (42.6 mg).
LC-MS found 665 (M+H)+ (exact MS calcd for C34H32ClF3N6O3 664).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-phenyl-1-pyridin-2-ylmethylamine hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (35.4 mg).
LC-MS found 643 (M+H)+ (exact MS calcd for C34H26ClF3N6O2 642).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 2-(phenylsulfonyl)ethylamine hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (23.4 mg).
LC-MS found 644 (M+H)+ (exact MS calcd for C30H25ClF3N5O4S 643).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 2-[(pyridin-2-yl)sulfonyl]ethylamine dihydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (30.5 mg).
LC-MS found 645 (M+H)+ (exact MS calcd for C29H24ClF3N6O4S 644).
Using 0.1 M solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-[2-(methylsulfonyl)ethyl]piperazine dihydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (30.4 mg).
LC-MS found 651 (M+H)+ (exact MS calcd for C29H30ClF3N6O4S 650).
Methyl 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (1.83 g) was dissolved in a mixed solvent of tetrahydrofuran (60 mL)/ethanol (60 mL). 1N aqueous sodium hydroxide solution (10 mL) was added to the mixture and stirred for 5 hr at room temperature. IN hydrochloric acid was added to the reaction mixture, the pH was adjusted to 3 to 4, and the mixture was diluted with water. The precipitate was collected by filtration, washed with diethyl ether and dried to give the title compound (1.23 g) as a pale-yellow powder.
1H-NMR (DMSO-d6) δ: 1.40-2.05 (12H, m), 2.62-2.78 (2H, m), 2.90-3.08 (1H, m), 3.24-3.53 (4H, m), 3.64-3.82 (2H, m), 4.52-4.73 (1H, m), 7.17 (1H, d, J=9.0 Hz), 7.38 (1H, dd, J=9.0 Hz, 2.5 Hz), 7.61 (1H, d, J=2.5 Hz), 7.68 (1H, s), 7.79 (1H, t, J=4.9 Hz), 7.91 (1H, s), 9.16 (1H, s), 12.23 (1H, s).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of cyclopropylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (27.0 mg).
LC-MS found 551 (M+H)+ (exact MS calcd for C29H35ClN6O3 550).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 4-(2-furyl)butane-2-amine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (28.4 mg).
LC-MS found 633 (M+H)+ (exact MS calcd for C34H41ClN6O4 632).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochlorides 1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-aminoethanol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (28.1 mg).
LC-MS found 555 (M+H)+ (exact MS calcd for C28H35ClN6O4 554).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of methylamine hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (27.2 mg).
LC-MS found 525 (M+H)+ (exact MS calcd for C27H33ClN6O3 524).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of isobutylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (28.6 mg).
LC-MS found 567 (M+H)+ (exact MS calcd for C30H39ClN6O3 566).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of tert-butylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (22.1 mg).
LC-MS found 567 (M+H)+ (exact MS calcd for C30H39ClN6O3 566).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 3-amino-1-propanol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (23.8 mg).
LC-MS found 569 (M+H)+ (exact MS calcd for C30H39ClN6O3 568).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of ethylamine hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (26.4 mg).
LC-MS found 539 (M+H)+ (exact MS calcd for C28H35ClN6O3 538).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of pyrrolidin-3-ol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (29.0 mg).
LC-MS found 581 (M+H)+ (exact MS calcd for C30H37ClN6O4 580).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of N,N-dimethylethane-1,2-diamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (32.9 mg).
LC-MS found 582 (M+H)+ (exact MS calcd for C30H40ClN7O3 581).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-ethoxyethylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (28.7 mg).
LC-MS found 583 (M+H)+ (exact MS calcd for C30H39ClN6O4 582).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of N-(2-methoxyethyl)methylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (28.5 mg).
LC-MS found 583 (M+H)+ (exact MS calcd for C30H39ClN6O4 582).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-amino-2-methyl-1-propanol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (16.9 mg).
LC-MS found 583 (M+H)+ (exact MS calcd for C30H39ClN6O4 582).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of furfurylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (28.9 mg).
LC-MS found 591 (M+H)+ (exact MS calcd for C31H35ClN6O4 590).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of N,O-dimethylhydroxylamine hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (20.8 mg).
LC-MS found 555 (M+H)+ (exact MS calcd for C28H35ClN6O4 554).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of cyclohexylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (26.3 mg).
LC-MS found 593 (M+H)+ (exact MS calcd for C32H41ClN6O3 592).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of N-(2-aminoethyl)acetamide in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (25.1 mg).
LC-MS found 596 (M+H)+ (exact MS calcd for C30H38ClN7O4 595).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of N,N-dimethyl-1,3-propanediamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (31.5 mg).
LC-MS found 596 (M+H)+ (exact MS calcd for C31H42ClN7O3 595).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-(2-aminoethoxy)ethanol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (26.1 mg).
LC-MS found 599 (M+H)+ (exact MS calcd for C30H39ClN6O5 598).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-(aminomethyl)pyridine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (33.0 mg).
LC-MS found 602 (M+H)+ (exact MS calcd for C32H36ClN7O3 601).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-(2-aminoethyl)pyridine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (34.8 mg).
LC-MS found 616 (M+H)+ (exact MS calcd for C33H38ClN7O3 615).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 4-(2-aminoethyl)pyridine in N,N-dimethylformamide (0.5 mL), a similar reaction, as in Example 4 was carried out to give the title compound (36.2 mg).
LC-MS found 616 (M+H)+ (exact MS calcd for C33H3E3ClN7O3 615).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 3-(2-aminoethyl)pyridine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (35.1 mg).
LC-MS found 616 (M+H)+ (exact MS calcd for C33H38ClN7O3 615).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 3-(1H-imidazol-1-yl)-1-propylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (32.7 mg).
LC-MS found 619 (M+H)+ (exact MS calcd for C32H39ClN8O3 618).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-(2-thienyl)ethylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (28.1 mg).
LC-MS found 621 (M+H)+ (exact MS calcd for C32H37ClN6O3S 620).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 1-(2-aminoethyl)piperidine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (35.5 mg).
LC-MS found 622 (M+H)+ (exact MS calcd for C33H44ClN7O3 621).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 1-methyl-4-(aminomethyl)piperidin-4-amine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (35.8 mg).
LC-MS found 622 (M+H)+ (exact MS calcd for C33H44ClN7O3 621).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of (1-methylpiperidin-2-yl)methaneamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (38.8 mg).
LC-MS found 622 (M+H)+ (exact MS calcd for C33H44ClN7O3 621).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 4-(2-aminoethyl)morpholine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (37.5 mg).
LC-MS found 624 (M+H)+ (exact MS calcd for C32H42ClN7O4 623).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-[2-(methylamino)ethyl]pyridine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (34.8 mg).
LC-MS found 630 (M+H)+ (exact MS calcd for C34H40ClN7O3 629).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-amino-1-phenylethanol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (24.6 mg).
LC-MS found 631 (M+H)+ (exact MS calcd for C34H39ClN6O4 630).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of N-methyl-2-(methylsulfonyl)ethylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (29.2 mg).
LC-MS found 631 (M+H)+ (exact MS calcd for C30H39ClN6O5S 630).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2-amino-1-pyridin-2-ylethanol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (27.7 mg).
LC-MS found 632 (M+H)+ (exact MS calcd for C33H38ClN7O4 631).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2,4-difluorobenzylamine in N,N-dimethylformamide (0.5 mL), a similar reaction, as in Example 4 was carried out to give the title compound (28.9 mg).
LC-MS found 637 (M+H)+ (exact MS calcd for C33H35ClF2N6O3 636).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 3-(methylsulfonyl)pyrrolidine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (30.1 mg).
LC-MS found 643 (M+H)+ (exact MS calcd for C31H39ClN6O5S 642).
Production of ethyl N-({4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl}carbonyl)-N-methylglycinate trifluoroacetate
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of ethyl N-methylglycinate hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (26.7 mg).
LC-MS found 611 (M+H)+ (exact MS calcd for C31H39ClN6O5 610).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 2,2′-[(3-aminopropyl)imino]diethanol in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (37.7 mg).
LC-MS found 656 (M+H)+ (exact MS calcd for C33H46ClN7O5 655).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-(1,3-thiazol-2-yl)ethylamine hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (28.1 mg).
LC-MS found 622 (M+H)+ (exact MS calcd for C31H36ClN7O3S 621).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of amino(phenyl)acetonitrile hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (26.8 mg).
LC-MS found 626 (M+H)+ (exact MS calcd for C34H36ClN7O3 625).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 2-(1H-imidazol-4-yl)ethylamine dihydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.02 mL), a similar reaction as in Example 7 was carried out to give the title compound (22.9 mg).
LC-MS found 605 (M+H)+ (exact MS calcd for C31H37ClN8O3 604).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 1-(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (31.1 mg).
LC-MS found 682 (M+H)+ (exact MS calcd for C36H40ClN9O3 681).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 4-amino-1-benzylpiperidine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (41.6 mg).
LC-MS found 684 (M+H)+ (exact MS calcd for C38H46ClN7O3 683).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 1-benzyl-3-(methylamino)pyrrolidine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (46.8 mg).
LC-MS found 684 (M+H)+ (exact MS calcd for C38H46ClN7O3 683).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL) and 0.15 M solution of 1-(4-benzylmorpholin-2-yl)methylamine in N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 4 was carried out to give the title compound (39.2 mg).
LC-MS found 700 (M+H)+ (exact MS calcd for C38H46ClN7O4 699).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-phenyl-1-pyridin-2-ylmethylamine hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (39.4 mg).
LC-MS found 678 (M+H)+ (exact MS calcd for C38H40ClN7O3 677).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 2-(phenylsulfonyl)ethylamine hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (20.8 mg).
LC-MS found 679 (M+H)+ (exact MS calcd for C34H39ClN6O5S 678).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 2-[(pyridin-2-yl)sulfonyl]ethylamine hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (46.5 mg).
LC-MS found 680 (M+H)+ (exact MS calcd for C33H38ClN7O5S 679).
Using 0.1 M solution of 4-[(3-chloro-4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (0.5 mL), 0.15 M solution of 1-[2-(methylsulfonyl)ethyl]piperazine hydrochloride in N,N-dimethylformamide (0.5 mL) and triethylamine (0.01 mL), a similar reaction as in Example 7 was carried out to give the title compound (32.7 mg).
LC-MS found 686 (M+H)+ (exact MS calcd for C33H44ClN7O5S 685).
A mixture of methyl 4-[(6-chloro-5-formylpyrimidin-4-yl)(4-methoxybenzyl)amino]butanoate (2.50 g), 3-methyl-4-[(6-methylpyridin-3-yl)oxy]aniline (1.42 g) and potassium carbonate (0.92 g) in N,N-dimethylformamide (25 mL) was stirred at room temperature for 6 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=3:1→1:3) to give the title compound (3.08 g) as pale-yellow amorphous.
1H-NMR (CDCl3) δ: 1.96-2.10 (2H, m), 2.25 (3H, s), 2.33 (2H, t, J=7.2 Hz), 2.52 (3H, s), 3.56 (2H, t, J=7.4 Hz), 3.65 (3H, s), 3.81 (3H, s), 4.79 (2H, s), 6.85-6.90 (3H, m), 7.05-7.11 (2H, m), 7.16 (2H, d, J=8.4 Hz), 7.45-7.51 (2H, m), 8.24-8.26 (1H, m), 8.29 (1H, s), 9.80 (1H, s), 11.07 (1H, s).
To a solution of methyl 4-[[5-formyl-6-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)pyrimidin-4-yl](4-methoxybenzyl)amino]butanoate (3.08 g) in dimethyl carbonate (30 mL) was added 28% sodium methoxide-methanol solution (3.20 g), and the mixture was stirred at room temperature for 12 hr and at 50° C. for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with aqueous sodium bicarbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=1:1→ethyl acetate) to give the title compound (2.79 g) as yellow amorphous.
1H-NMR (CDCl3) δ: 2.25 (3H, s), 2.53 (3H, s), 2.64 (2H, t, J=4.8 Hz), 3.35 (2H, t, J=4.8 Hz), 3.78 (3H, s), 3.81 (3H, s), 4.86 (2H, s), 6.77 (1H, s), 6.86-6.90 (3H, m), 7.06-7.13 (2H, m), 7.18-7.30 (3H, m), 7.37 (1H, d, J=2.4 Hz), 7.70 (1H, s), 8.22 (1H, s), 8.27 (1H, s).
Using methyl 9-(4-methoxybenzyl)-4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (450 mg), trifluoroacetic acid (5.0 mL) and 1,2-dichloroethane (5.0 mL), a similar reaction as in Example 1 (iii) was carried out to give the title compound (308 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.25 (3H, s), 2.52 (3H, s), 2.90 (2H, t, J=4.8 Hz), 3.52 (2H, q, J=4.8 Hz), 3.81 (3H, s), 5.72-5.80 (1H, m), 6.77 (1H, br s), 6.86 (1H, d, J=8.7 Hz), 7.05-7.11 (2H, m), 7.21-7.28 (1H, m), 7.34 (1H, d, J=2.4 Hz), 7.68 (1H, s), 8.08 (1H, s), 8.24-8.25 (1H, m).
To a solution of methyl 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (200 mg) in tetrahydrofuran (10 mL) and ethanol (10 mL) was added 1N aqueous sodium hydroxide solution (1.5 mL) at room temperature. The mixture was stirred at room temperature for 4 hr, 1N hydrochloric acid (1.5 mL) was added thereto, and the mixture was concentrated under reduced pressure. The precipitated crystals were collected by filtration. The crystals were washed with ethanol and water to give the title compound (175 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 2.11 (3H, s), 2.41 (3H, s), 2.63-2.72 (2H, m), 3.24-3.38 (2H, m), 6.85 (1H, d, J=8.7 Hz), 7.12 (1H, dd, J=8.7, 2.7 Hz), 7.19 (1H, d, J=8.7 Hz), 7.31 (1H, dd, J=8.7, 2.7 Hz), 7.40 (1H, d, J= 2.7 Hz), 7.68 (1H, s), 7.71-7.78 (1H, m), 7.89 (1H, s), 8.12 (1H, d, J=2.7 Hz), 9.13 (1H, s), 12.16 (1H, br s).
To 0.12 M solution of 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (500 μL) were added 0.12 M solution of methylamine hydrochloride in N,N-dimethylformamide (500 μL) and 0.18 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (500 μL), and the mixture was stirred at room temperature overnight. The reaction mixture was charged to MP-TosH column, and washed with ethyl acetate (2×2.0 mL) and methanol (2×2.0 mL). The solution containing the objective substance was collected by using 1 M ammonia-methanol solution (2.0 mL). The solution was concentrated under reduced pressure and the residue was separated by liquid chromatography (column: C18, mobile phase: 0.1% formic acid containing acetonitrile/0.1% formic acid containing water, 5%->95%). The objective fraction was concentrated under reduced pressure to give the title compound (6.6 mg).
LC-MS found 417 (M+H)+ (exact MS calcd for C23H24N6O2 416)
Using 0.12 M solution of 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (500 μL), 0.12 M solution of cyclopropylamine in N,N-dimethylformamide (500 μL) and 0.18 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (500 μL), a similar reaction as in Example 102 was carried out to give the title compound (6.1 mg).
LC-MS found 443 (M+H)+ (exact MS calcd for C25H26N6O2 442)
Using 0.12 M solution of 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (500 μL), 0.12 M solution of isobutylamine in N,N-dimethylformamide (500 μL) and 0.18 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (500 μL), a similar reaction as in Example 102 was carried out to give the title compound (11.9 mg).
LC-MS found 459 (M+H)+ (exact MS calcd for C26H30N6O2 458)
Using 0.12 M solution of 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (500 μL), 0.12 M solution of tert-butylamine in N,N-dimethylformamide (500 μL) and 0.18 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (500 μL), a similar reaction as in Example 102 was carried out to give the title compound (3.5 mg). LC-MS found 459 (M+H)+ (exact MS calcd for C26H30N6O2 458)
Using 0.12 M solution of 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (500 μL), 0.12 M solution of pyrrolidine in N,N-dimethylformamide (500 μL) and 0.18 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (500 μL), a similar reaction as in Example 102 was carried out to give the title compound (11.3 mg).
LC-MS found 457 (M+H)+ (exact MS calcd for C26H28N6O2 456)
Using 0.12 M solution of 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (500 μL), 0.12 M solution of morpholine in N,N-dimethylformamide (500 μL) and 0.18 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (500 μL), a similar reaction as in Example 102 was carried out to give the title compound (7.6 mg).
LC-MS found 473 (M+H)+ (exact MS calcd for C26H28N6O3 472)
Using 0.12 M solution of 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (500 μL), 0.12 M solution of (2S)-pyrrolidine-2-methanol in N,N-dimethylformamide (500 μL) and 0.18 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (500 μL), a similar reaction as in Example 102 was carried out to give the title compound (9.1 mg).
LC-MS found 487 (M+H)+ (exact MS calcd for C27H30N6O3 486)
Using 0.12 M solution of 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid in N,N-dimethylformamide (500 μL), 0.12 M solution of 3-piperidinol in N,N-dimethylformamide (500 μL) and 0.18 M solution of 1-hydroxybenzotriazole/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride=1/1 in N,N-dimethylformamide (500 μL), a similar reaction as in Example 102 was carried out to give the title compound (1.1 mg).
LC-MS found 487 (M+H)+ (exact MS calcd for C27H30N6O3 486)
To a solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (90.3 mg) in tetrahydrofuran (0.5 mL) and N,N-dimethylformamide (0.5 mL) were successively added 2-(methylsulfonyl)ethylamine (34.6 mg), 1-hydroxybenzotriazole (39.1 mg), triethylamine (0.08 mL) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (107 mg), and the mixture was stirred at room temperature for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, ethyl acetate:methanol=100:0→90:10) to give the title compound (44.1 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 2.64-2.75 (2H, m), 3.03 (3H, s), 3.27-3.41 (4H, m), 3.53-3.65 (2H, m), 7.14-7.24 (3H, m), 7.27 (1H, d, J=9.1 Hz), 7.46 (1H, d, J=8.0 Hz), 7.55-7.66 (2H, m), 7.73 (1H, t, J=4.7 Hz), 7.92 (1H, d, J=2.8 Hz), 7.99 (1H, s), 8.24 (1H, t, J=5.5 Hz), 9.13 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (89.4 mg), 2-methoxyethylamine (0.025 mL), 1-hydroxybenzotriazole (39.4 mg), triethylamine (0.08 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (115 mg), tetrahydrofuran (0.5 mL) and N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 110 was carried out to give the title compound (59.4 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 2.63-2.74 (2H, m), 3.26 (3H, s), 3.29-3.45 (6H, m), 7.13-7.23 (3H, m), 7.26 (1H, d, J=9.1 Hz), 7.42-7.50 (1H, m), 7.55-7.65 (2H, m), 7.68 (1H, t, J=4.5 Hz), 7.89 (1H, d, J=2.8 Hz), 7.98 (1H, s), 8.04 (1H, t, J=5.6 Hz), 9.13 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (120 mg), allylamine (0.03 mL), 1-hydroxybenzotriazole (52.9 mg), triethylamine (0.1 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (148 mg), tetrahydrofuran (0.75 mL) and N,N-dimethylformamide (0.75 mL), a similar reaction as in Example 110 was carried out to give the title compound (70.0 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 2.66-2.76 (2H, m), 3.30-3.41 (2H, m), 3.77-3.87 (2H, m), 5.03-5.23 (2H, m), 5.77-5.95 (1H, m), 7.14-7.23 (3H, m), 7.26 (1H, d, J=8.9 Hz), 7.46 (1H, d, J=7.7 Hz), 7.54-7.65 (2H, m), 7.70 (1H, t, J=4.6 Hz), 7.89 (1H, d, J=2.6 Hz), 7.98 (1H, s), 8.17 (1H, t, J=5.7 Hz), 9.13 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (99.9 mg), 2-aminoethanol (0.02 mL), 1-hydroxybenzotriazole (44.3 mg), triethylamine (0.1 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (87.3 mg), tetrahydrofuran (0.5 mL) and N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 110 was carried out to give the title compound (68.8 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 2.64-2.72 (2H, m), 3.19-3.29 (2H, m), 3.29-3.39 (2H, m), 3.42-3.52 (2H, m), 4.70 (1H, t, J=5.6 Hz), 7.14-7.23 (3H, m), 7.26 (1H, d, J=8.8 Hz), 7.46 (1H, d, J=8.0 Hz), 7.55-7.71° (3H, m), 7.90 (1H, d, J=2.5 Hz), 7.95-8.03 (2H, m), 9.11 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (151 mg), 1-amino-2-methyl-2-propanol (58.0 mg), 1-hydroxybenzotriazole (65.8 mg), triethylamine (0.1 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (93.7 mg), tetrahydrofuran (0.7 mL) and N,N-dimethylformamide (0.7 mL), a similar reaction as in Example 110 was carried out to give the title compound (120 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 1.26 (6H, s), 2.49 (1H, br s), 2.78-2.86 (2H, m), 3.39 (2H, d, J=6 Hz), 3.51-3.59 (2H, m), 5.79 (1H, t, J=4.7 Hz), 6.33 (1H, t, J=6 Hz), 7.03 (1H, d, J=8.9 Hz), 7.09 (1H, dd, J=8.0 Hz, 2.0 Hz), 7.21 (1H, s), 7.32 (1H, d, J=7.9 Hz), 7.37-7.43 (3H, m), 7.44-8.49 (1H, m), 7.75 (1H, d, J=2.0 Hz), 8.12 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (103 mg), 1-(3-aminopropyl)imidazole (0.035 mL), 1-hydroxybenzotriazole (44.7 mg), triethylamine (0.1 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (62.7 mg), tetrahydrofuran (0.5 mL) and N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 110 was carried out to give the title compound (46.8 mg) as a pale-yellow powder.
1H-NMR (DMSO-d6) δ: 1.85-1.97 (2H, m), 2.66-2.74 (2H, m), 3.14 (2H, q, J=6.6 Hz), 3.29-3.39 (2H, m), 4.00 (2H, t, J=6.9 Hz), 6.86-6.89 (1H, m), 7.15-7.22 (4H, m), 7.25 (1H, d, J=8.9 Hz), 7.46 (1H, d, J=7.7 Hz), 7.56-7.66 (3H, m), 7.69 (1H, t, J=4.6 Hz), 7.92 (1H, d, J=2.6 Hz), 7.99 (1H, s), 8.05 (1H, t, J=5.6 Hz), 9.19 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (101 mg), tert-butylamine (0.03 mL), 1-hydroxybenzotriazole (42.9 mg), triethylamine (0.1 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (63.7 mg), tetrahydrofuran (0.5 mL) and N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 110 was carried out to give the title compound (62.6 mg) as a pale-yellow powder.
1H-NMR (DMSO-d6) δ: 1.33 (9H, s), 2.61-2.69 (2H, m), 3.27-3.40 (2H, m), 7.01 (1H, s), 7.14-7.24 (2H, m), 7.26 (1H, d, J=8.9 Hz), 7.37 (1H, s), 7.46 (1H, d, J=1.1 Hz), 7.54-7.67 (3H, m), 7.95 (1H, d, J=2.6 Hz), 7.99 (1H, s), 9.16 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (101 mg), N-(2-aminoethyl)acetamide (0.03 mL), 1-hydroxybenzotriazole (44.0 mg), triethylamine (0.1 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (59.6 mg), tetrahydrofuran (0.5 mL) and N,N-dimethylformamide (0.5 mL), a similar reaction as in Example 110 was carried out to give the title compound (69.5 mg) as a pale-yellow powder.
1H-NMR (DMSO-d6) δ: 1.79 (3H, s), 2.65-2.75 (2H, m), 3.11-3.26 (4H, m), 3.29-3.39 (2H, m), 7.14-7.23 (3H, m), 7.26 (1H, d, J=9.4 Hz), 7.46 (1H, d, J=6.9 Hz), 7.55-7.74 (3H, m), 7.92 (1H, d, J=1.9 Hz), 7.95-8.02 (2H, m), 8.06 (1H, t, J=4.8 Hz), 9.11 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (151 mg), 4-amino-2-methyl-2-butanol hydrochloride (78.2 mg), 1-hydroxybenzotriazole (64.8 mg), triethylamine (0.2 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (95.3 mg), tetrahydrofuran (0.7 mL) and N,N-dimethylformamide (0.7 mL), a similar reaction as in Example 110 was carried out to give the title compound (74.0 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 1.12 (6H, s), 1.53-1.68 (2H, m), 2.63-2.74 (2H, m), 3.19-3.30 (2H, m), 3.30-3.42 (2H, m), 4.31 (1H, s), 7.11-7.23 (3H, m), 7.26 (1H, d, J=8.9 Hz), 7.46 (1H, d, J=8.1 Hz), 7.54-7.72 (3H, m), 7.85-7.94 (2H, m), 7.98 (1H, s), 9.10 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (120 mg), 2-(2-aminoethoxy)ethanol (0.038 mL), 1-hydroxybenzotriazole (51.5 mg), triethylamine (0.1 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (71.7 mg), tetrahydrofuran (0.6 mL) and N,N-dimethylformamide (0.6 mL), a similar reaction as in Example 110 was carried out to give the title compound (91.0 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 2.65-2.73 (2H, m), 3.28-3.40 (4H, m), 3.40-3.54 (6H, m), 4.58 (1H, t, J=5.4 Hz), 7.14-7.23 (3H, m), 7.26 (1H, d, J=8.9 Hz), 7.46 (1H, d, J=7.7 Hz), 7.55-7.65 (2H, m), 7.68 (1H, t, J=4.7 Hz), 7.90 (1H, d, J=2.5 Hz), 7.98 (1H, s), 8.03 (1H, t, J=5.5 Hz), 9.13 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (111 mg), 5-aminopentan-1-ol (45.3 mg), 1-hydroxybenzotriazole (47.7 mg), triethylamine (0.05 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (69.5 mg), tetrahydrofuran (0.6 mL) and N,N-dimethylformamide (0.6 mL), a similar reaction as in Example 110 was carried out to give the title compound (81.3 mg) as a pale-yellow powder.
1H-NMR (DMSO-d6) δ: 1.24-1.55 (6H, m), 2.64-2.74 (2H, m), 3.09-3.22 (2H, m), 3.29-3.43 (4H, m), 4.35 (1H, t, J=5.1 Hz), 7.12-7.23 (3H, m), 7.26 (1H, d, J=8.8 Hz), 7.46 (1H, d, J=8.0 Hz), 7.56-7.64 (2H, m), 7.67 (1H, t, J=4.7 Hz), 7.91 (1H, d, J=2.7 Hz), 7.93-8.01 (2H, m), 9.14 (1H, s).
To the solution of pentane-1,2,5-triol (5.00 g) in acetone (150 mL) were successively added p-toluenesulfonic acid (794 mg) and 2,2-dimethoxypropane (10.5 mL), and the mixture was stirred at room temperature for 1.5 hr. The reaction mixture was concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=80:20→50:50) to give the title compound (3.79 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.37 (3H, s), 1.42 (3H, s), 1.57-1.77 (4H, m), 2.05 (1H, br s), 3.53 (1H, t, J=7.3 Hz), 3.60-3.77 (2H, m), 4.00-4.21 (2H, m).
3-(2,2-Dimethyl-1,3-dioxolan-4-yl)propan-1-ol (1.00 g) was dissolved in ethyl acetate (20 mL). Triethylamine (2 mL) and methanesulfonyl chloride (0.55 mL) were successively added to the solution, and the mixture was stirred at 0° C. for 1 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=80:20→34:66) to give the title compound (1.47 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.35 (3H, s), 1.41 (3H, s), 1.59-2.02 (4H, m), 3.01 (3H, s), 3.54 (1H, t, J=6.8 Hz), 3.98-4.20 (2H, m), 4.28 (2H, dt, J=6.2 Hz, 1.8 Hz).
To the solution of 3-(2,2-dimethyl-1,3-dioxolan-4-yl)propyl methanesulfonate (1.46 g) in N,N-dimethylformamide (20 mL) was added sodium diformylimide (882 mg), the mixture was stirred at 70° C. for 2.5 hr. The reaction mixture was concentrated under reduced pressure. Water was added to the residue, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=80:20→34:66) to give the title compound (772 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.34 (3H, s), 1.39 (3H, s), 1.45-1.85 (4H, m), 3.50 (1H, t, J=7.3 Hz), 3.58-3.81 (2H, m), 3.93-4.20 (2H, m), 8.84 (2H, s).
N-[3-(2,2-dimethyl-1,3-dioxolan-4-yl)propyl]-N-formylformamide (772 mg) was dissolved in ethanol (20 mL). 6N Hydrochloric acid (6 mL) was added to the solution, and the mixture was stirred at 60° C. for 22 hr. The reaction mixture was concentrated under reduced pressure to give the title compound (552 mg) as an orange oil.
1H-NMR (DMSO-d6) δ: 1.15-1.35 (1H, m), 1.40-1.80 (3H, m), 2.68-2.85 (2H, m), 3.15-3.35 (2H, m), 3.35-3.51 (1H, m), 3.71-4.34 (2H, m), 7.92 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (151 mg), 5-aminopentane-1,2-diol hydrochloride (97.3 mg), 1-hydroxybenzotriazole (67.9 mg), triethylamine (0.3 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (90.2 mg), tetrahydrofuran (0.7 mL) and N,N-dimethylformamide (0.7 mL), a similar reaction as in Example 110 was carried out to give the title compound (64.0 mg) as a yellow powder.
1H-NMR (DMSO-d6) δ: 1.12-1.34 (1H, m), 1.35-1.72 (3H, m), 2.64-2.74 (2H, m), 3.08-3.47 (7H, m), 4.37-4.48 (2H, m), 7.12-7.22 (3H, m), 7.25 (1H, d, J=8.8 Hz), 7.41-7.50 (1H, m), 7.56-7.70 (3H, m), 7.88-8.02 (3H, m), 9.12 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (130 mg), 2-(2-methoxyethoxy)ethylamine hydrochloride (68.3 mg), 1-hydroxybenzotriazole (58.4 mg), triethylamine (0.4 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (79.8 mg), tetrahydrofuran (0.7 mL) and N,N-dimethylformamide (0.7 mL), a similar reaction as in Example 110 was carried out to give the title compound (95.8 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 2.65-2.73 (2H, m), 3.21 (3H, s), 3.28-3.39 (4H, m), 3.39-3.57 (6H, m), 7.14-7.23 (3H, m), 7.26 (1H, d, J=8.7 Hz), 7.46 (1H, d, J=7.6 Hz), 7.56-7.65 (2H, m), 7.68 (1H, t, J=4.4 Hz), 7.89 (1H, d, J=2.7 Hz), 7.98 (1H, s), 8.06 (1H, t, J=5.5 Hz), 9.15 (1H, s).
To a solution of 2-(benzyloxy)ethanol (4.6 mL) and 2,2-dimethyloxirane (8.30 g) in toluene (40 mL) was added 50% aqueous sodium hydroxide solution (8 mL), and the mixture was stirred at 100° C. for 28 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was dissolved in tetrahydrofuran (50 mL), and triethylamine (9 mL) and benzoyl chloride (3.8 mL) were successively added to the solution and the mixture was stirred at 0° C. for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=80:20→33:67) to give the title compound (4.34 g) as a pale-orange oil.
1H-NMR (CDCl3) δ: 1.21 (6H, s), 2.60 (1H, br s), 3.33 (2H, s), 3.61-3.67 (2H, m), 3.68-3.74 (2H, m), 4.57 (2H, s), 7.26-7.41 (5H, m).
To a solution of 1-[2-(benzyloxy)ethoxy]-2-methyl-2-propanol (4.34 g) in methanol (45 mL) was added 10% palladium-carbon (410 mg), and the mixture was stirred at room temperature for 5 days under hydrogen atmosphere. The mixture was filtrated through Celite to remove palladium-carbon, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=50:50→0:100→ethyl acetate:methanol=95:5) to give the title compound (2.32 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.23 (6H, s), 1.71 (1H, br s), 2.49 (1H, br s), 3.34 (2H, s), 3.55-3.70 (2H, m), 3.70-3.85 (2H, m).
To a solution of 1-(2-hydroxyethoxy)-2-methyl-2-propanol (1.12 g) in pyridine (10 mL) was added p-toluenesulfonyl chloride (1.93 g) under ice-cooling, and the mixture was stirred for 13 hr while raising the temperature to room temperature. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=80:20→33:67) to give the title compound (1.74 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.15 (6H, s), 2.14 (1H, br s), 2.45 (3H, s), 3.25 (2H, s), 3.66-3.73 (2H, m), 4.17-4.23 (2H, m), 7.35 (2H, br d, J=8 Hz), 7.81 (2H, br d, J=8 Hz).
Using 2-(2-hydroxy-2-methylpropoxy)ethyl 4-methylbenzenesulfonate (1.73 g), sodium diformylimide (756 mg) and N,N-dimethylformamide (20 mL), a similar reaction as in Example 121 (iii) was carried out to give the title compound (162 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.17 (6H, s), 2.27 (1H, s), 3.28 (2H, s), 3.66 (2H, t, J=5.4 Hz), 3.79-4.02 (2H, m), 8.88 (2H, s).
Using N-formyl-N-[2-(2-hydroxy-2-methylpropoxy)ethyl]formamide (162 mg), 6N hydrochloric acid (0.4 mL) and ethanol (5 mL), a similar reaction as in Example 121 (iv) was carried out to give the title compound (119 mg) as a white solid.
1H-NMR (DMSO-d6) δ: 1.09 (6H, s), 2.88-3.05 (2H, m), 3.21 (2H, s), 3.61 (2H, t, J=5.2 Hz), 8.02 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (150 mg), 1-(2-aminoethoxy)-2-methyl-2-propanol hydrochloride (119 mg), 1-hydroxybenzotriazole (128 mg), triethylamine (0.45 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (209 mg), tetrahydrofuran (0.7 mL) and N,N-dimethylformamide (0.7 mL), a similar reaction as in Example 110 was carried out to give 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-N-[2-(2-hydroxy-2-methylpropoxy)ethyl]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxamide. To the solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-N-[2-(2-hydroxy-2-methylpropoxy)ethyl]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxamide in ethyl acetate (3 mL) was added 4N hydrochloric acid/ethyl acetate (0.1 mL). The mixture was stirred at room temperature for 0.5 hr and concentrated under reduced pressure. The residue was crystallized from diisopropyl ether/ethanol to give the title compound (88.8 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 1.03 (6H, s), 2.68-2.81 (2H, m), 3.17 (2H, s), 3.28-3.40 (2H, m), 3.41-3.58 (4H, m), 7.15-7.28 (3H, m), 7.32 (1H, d, J=8.9 Hz), 7.45-7.58 (2H, m), 7.63 (1H, t, J=7.9 Hz), 7.82 (1H, d, J=2.6 Hz), 8.20 (1H, s), 8.41 (1H, t, J=5.4 Hz), 8.52 (1H, s), 10.17 (1H, s).
To the solution of 2-(2-bromoethoxy)tetrahydro-2H-pyran (3 mL) and 3-methylbutane-1,3-diol (2.08 g) in toluene (40 mL) were added 50% aqueous sodium hydroxide solution (10 mL) and tetra-n-butylammonium hydrogen sulfate (673 mg), and the mixture was stirred at 40° C. for 17 hr. Water was added to the reaction mixture and the mixture was extracted with toluene. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent, hexane:ethyl acetate=90:/10→33/:67) to give the title compound (3.41 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.25 (6H, s), 1.44-1.91 (8H, m), 3.34 (1H, s), 3.46-3.68 (4H, m), 3.75 (2H, t, J=6 Hz), 3.80-3.94 (2H, m), 4.56-4.70 (1H, m).
2-Methyl-4-[2-(tetrahydro-2H-pyran-2-yloxy)ethoxy]butan-2-ol (3.40 g) was dissolved in methanol (40 mL). 4N Hydrochloric acid/ethyl acetate (4 mL) was added thereto and the mixture was stirred at room temperature for 2 hr. Additional 4N hydrochloric acid/ethyl acetate (1 mL) was added thereto, and the mixture was stirred for 1 hr. The reaction mixture was concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=50:50→0:100→ethyl acetate:methanol=95:5) to give the title compound (1.57 g) as a pale-yellow oil.
1H-NMR (CDCl3) δ: 1.26 (6H, s), 1.79 (2H, t, J=5.9 Hz), 3.50-3.66 (2H, m), 3.68-3.84 (4H, m).
Using 4-(2-hydroxyethoxy)-2-methylbutan-2-ol (1.00 g), pyridine (6 mL) and p-toluenesulfonyl chloride (1.81 g), a similar reaction as in Example 123 (iii) was carried out to give the title compound (1.41 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.21 (6H, s), 1.7.2 (2H, t, J=5.9 Hz), 2.45 (3H, s), 2.61 (1H, s), 3.58-3.76 (4H, m), 4.06-4.26 (2H, m), 7.34 (2H, br d, J=8 Hz), 7.79 (2H, br d, J=8 Hz).
Using 2-(3-hydroxy-3-methylbutoxy)ethyl 4-methylbenzenesulfonate (1.40 g), N,N-dimethylformamide (15 mL) and sodium diformylazanide (618 mg), a similar reaction as in Example 121 (iii) was carried out to give the title compound (305 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.22 (6H, s), 1.73 (2H, t, J=6 Hz), 2.88 (1H, s), 3.60 (2H, t, J=5.4 Hz), 3.66 (2H, t, J=6 Hz), 3.79-4.01 (2H, m), 8.87 (2H, s).
Using N-formyl-N-[2-(3-hydroxy-3-methylbutoxy)ethyl]formamide (305 mg), 6N hydrochloric acid (1.3 mL) and ethanol (10 mL), a similar reaction as in Example 121 (iv) was carried out to give the title compound (265 mg) as a colorless oil.
1H-NMR (DMSO-d6) δ: 1.10 (6H, s), 1.61-1.78 (2H, m), 2.83-3.04 (2H, m), 3.46-3.68 (4H, m), 4.28 (1H, br s), 8.08 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (150 mg), 4-(2-aminoethoxy)-2-methyl-2-butanol hydrochloride (89.0 mg), 1-hydroxybenzotriazole (88.1 mg), triethylamine (0.45 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (121 mg), tetrahydrofuran (0.7 mL) and N,N-dimethylformamide (0.7 mL), a similar reaction as in Example 110 was carried out to give the title compound (142 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 1.05 (6H, s), 1.61 (2H, t, J=7.2 Hz), 2.60-2.79 (2H, m), 3.22-3.39 (4H, m), 3.40-3.55 (4H, m), 4.17 (1H, s), 7.12-7.22 (3H, m), 7.26 (1H, d, J=8.9 Hz), 7.46 (1H, d, J=7.5 Hz), 7.56-7.64 (2H, m), 7.68 (1H, t, J=4.6 Hz), 7.89 (1H, d, J=2.6 Hz), 7.98 (1H, s), 8.03 (1H, t, J=5.4 Hz), 9.12 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (129 mg), 1-(2-aminoethyl)-4-hydroxypiperidine (59.8 mg), 1-hydroxybenzotriazole (59.5 mg), triethylamine (0.1 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (82.4 mg), tetrahydrofuran (0.7 mL) and N,N-dimethyl formamide (0.7 mL), a similar reaction as in Example 110 was carried out to give the title compound (91.8 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 1.24-1.45 (2H, m), 1.57-1.75 (2H, m), 2.04 (2H, t, J=10 Hz), 2.38 (2H, t, J=7.0 Hz), 2.60-2.78 (4H, m), 3.18-3.49 (5H, m), 4.49 (1H, d, J=4.2 Hz), 7.11-7.22 (3H, m), 7.25 (1H, d, J=8.7 Hz), 7.45 (1H, d, J=7.6 Hz), 7.54-7.64 (2H, m), 7.67 (1H, t, J=4.4 Hz), 7.84-7.94 (2H, m), 7.98 (1H, s), 9.12 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (129 mg), 5-methoxy-1-pentylamine hydrochloride (60.0 mg), 1-hydroxybenzotriazole (55.2 mg), triethylamine (0.2 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (76.6 mg), tetrahydrofuran (0.7 mL) and N,N-dimethyl form/amide (0.7 mL), a similar reaction as in Example 110 was carried out to give the title compound (108 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 1.24-1.40 (2H, m), 1.39-1.59 (4H, m), 2.62-2.76 (2H, m), 3.10-3.22 (2H, m), 3.18 (3H, s), 3.24-3.41 (4H, m), 7.11-7.22 (3H, m), 7.26 (1H, d, J=8.7 Hz), 7.46 (1H, d, J=8.0 Hz), 7.55-7.72 (3H, m), 7.90 (1H, d, J=2.7 Hz), 7.93-8.04 (2H, m), 9.14 (1H, s).
Using 2-(2-bromoethoxy)tetrahydro-2H-pyran (8.00 g), 3-(benzyloxy)propan-1-ol (6.61 g), tetra-n-butylammonium hydrogen sulfate (1.31 g), toluene (80 mL) and 50% aqueous sodium hydroxide solution (20 mL), a similar reaction as in Example 124 (i) was carried out to give the title compound (6.19 g) as a yellow oil.
1H-NMR (CDCl3) δ: 1.42-2.00 (8H, m), 3.42-3.68 (8H, m), 3.77-3.94 (2H, m), 4.51 (2H, s), 4.58-4.71 (1H, m), 7.22-7.45 (5H, m).
To a solution of 2-{2-[3-(benzyloxy)propoxy]ethoxy}tetrahydro-2H-pyran (3.09 g) in methanol (30 mL) was added 6N hydrochloric acid (2.8 mL), and the mixture was stirred at room temperature for 31 hr. 1N aqueous sodium hydroxide solution was added to the reaction mixture and the mixture was concentrated under reduced pressure. The residue was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=90:10→33:67) to give the title compound (2.02 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.84-1.98 (2H, m), 2.01-2.13 (1H, m), 3.50-3.65 (6H, m), 3.66-3.79 (2H, m), 4.51 (2H, s), 7.15-7.53 (5H, m).
To a solution of 2-[3-(benzyloxy)propoxy]ethanol (2.00 g) in tetrahydrofuran (20 mL) was added 1,8-diazabicyclo[5,4,0]-7-undecene (3 mL) and diphenylphosphoryl azide (2.5 mL) under ice-cooling, and the mixture was stirred at room temperature for 0.5 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=90/10→50/50) to give 2-[3-(benzyloxy)propoxy]ethyl diphenyl phosphate. The obtained compound (4.10 g) was dissolved in N,N-dimethylformamide (50 mL). Sodium azide (906 mg) was added to the mixture and the mixture was stirred at 50° C. for 4 hr and at 80° C. for 24 hr. The reaction mixture was concentrated under reduced pressure. Water was added thereto and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=95/5→67/33) to give the title compound (2.10 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.81-2.00 (2H, m), 3.26-3.41 (2H, m), 3.51-3.71 (6H, m), 4.51 (2H, s), 7.18-7.44 (5H, m).
To a solution of {[3-(2-azidoethoxy)propoxy]methyl}benzene (2.10 g) in tetrahydrofuran (20 mL) were added water (2 mL) and triphenylphosphine (2.59 g), and the mixture was stirred at room temperature for 24 hr. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in methanol (30 mL). Triethylamine (3.5 mL) and di-tert-butyl dicarbonate (3 mL) were successively added thereto and the mixture was stirred at room temperature for 3 hr. The reaction mixture was concentrated under reduced pressure. Water was added to the residue and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=90:10→67:33) to give the title compound (2.70 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.44 (9H, s), 1.82-1.94 (2H, m), 3.23-3.34 (2H, m), 3.46 (2H, t, J=5.1 Hz), 3.50-3.59 (4H, m), 4.51 (2H, s), 4.88 (1H, br s), 7.18-7.41 (5H, m).
Using tert-butyl {2-[3-(benzyloxy)propoxy]ethyl}carbamate (2.69 g), 10% palladium-carbon (308 mg) and methanol (30 mL), a similar reaction as in Example 123 (ii) was carried out to give the title compound (1.78 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.45 (9H, s), 1.76-1.91 (2H, m), 2.24 (1H, br s), 3.32 (2H, q, J=5 Hz), 3.51 (2H, t, J=5 Hz), 3.63 (2H, t, J=6 Hz), 3.77 (2H, t, J=6 Hz), 4.86 (1H, br s).
tert-Butyl [2-(3-hydroxypropoxy)ethyl]carbamate (802 mg) was dissolved in ethanol (10 mL). 6N hydrochloric acid (3 mL) was added to the solution and the mixture was stirred at 50° C. for 22 hr. The reaction mixture was concentrated under reduced pressure to give the title compound (562 mg) as a colorless oil.
1H-NMR (DMSO-d6) δ: 1.54-1.78 (2H, m), 2.82-3.06 (2H, m), 3.21-3.65 (6H, m), 8.03 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (131 mg), 3-(2-aminoethoxy)-1-propanol hydrochloride (64.6 mg), 1-hydroxybenzotriazole (54.9 mg), triethylamine (0.4 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (81.2 mg), tetrahydrofuran (0.7 mL) and N,N-dimethylformamide (0.7 mL), a similar reaction as in Example 110 was carried out to give the title compound (115 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 1.56-1.70 (2H, m), 2.64-2.72 (2H, m), 3.27-3.39 (4H, m), 3.39-3.50 (6H, m), 4.37 (1H, t, J=355.1 Hz), 7.13-7.22 (3H, m), 7.26 (1H, d, J=8.7 Hz), 7.46 (1H, d, J=8.0 Hz), 7.55-7.65 (2H, m), 7.68 (1H, t, J=4.5 Hz), 7.90 (1H, d, J=2.7 Hz), 7.98 (1H, s), 8.03 (1H, t, J=5.5 Hz), 9.14 (1H, s).
To a suspension of 60% sodium hydride (dispersion in mineral oil, 220 mg) in tetrahydrofuran (30 mL) was added a solution of tert-butyl [2-(3-hydroxypropoxy)ethyl]carbamate (948 mg) in tetrahydrofuran (10 mL) under ice-cooling, and the mixture was stirred at 0° C. for 0.5 hr. Methyl iodide (0.3 mL) was added dropwise to the reaction solution, and the mixture was stirred at room temperature for 18 hr. To the reaction mixture was added saturated aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=95:5→50:50) to give the title compound (631 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.45 (9H, s), 1.76-1.94 (2H, m), 3.20-3.40 (2H, m), 3.34 (3H, s), 3.40-3.61 (6H, m), 4.94 (1H, br s).
Using tert-butyl [2-(3-methoxypropoxy)ethyl]carbamate (625 mg), 6N hydrochloric acid (2 mL) and ethanol (5 mL), a similar reaction as in Example 127 (vi) was carried out to give the title compound (457 mg) as a colorless oil.
1H-NMR (DMSO-d6) δ: 1.68-1.83 (2H, m), 2.94 (2H, t, J=5.5 Hz), 3.22 (3H, s), 3.38 (2H, t, J=6.4 Hz), 3.47 (2H, t, J=6.4 Hz), 3.55 (2H, t, J=5.5 Hz), 8.03 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (130 mg), 2-(3-methoxypropoxy)ethylamine hydrochloride (69.8 mg), 1-hydroxybenzotriazole (56.6 mg), triethylamine (0.4 mL), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (79.7 mg), tetrahydrofuran (0.7 mL) and N,N-dimethylformamide (0.7 mL), a similar reaction as in Example 110 was carried out to give the title compound (123 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 1.64-1.77 (2H, m), 2.63-2.74 (2H, m), 3.16 (3H, s), 3.27-3.39 (6H, m), 3.39-3.50 (4H, m), 7.12-7.22 (3H, m), 7.26 (1H, d, J=8.7 Hz), 7.46 (1H, d, J=7.6 Hz), 7.55-7.65 (2H, m), 7.68 (1H, t, J=4.5 Hz), 7.89 (1H, d, J=2.7 Hz), 7.98 (1H, s), 8.04 (1H, t, J=5.5 Hz), 9.14 (1H, s).
A solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (400 mg) in tetrahydrofuran (10 mL) was cooled to −10° C. Triethylamine (0.175 mL) and isobutyl chloroformate (0.12 mL) were added to the solution and the mixture was stirred at −10° C. for 15 min. A solution of sodium borohydride (127 mg) in methanol (2 mL) was added dropwise to the reaction solution, and the mixture was stirred at −10° C. for 30 min. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=50:50→0:100), and crystallized from diisopropyl ether-ethyl acetate to give the title compound (220 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 2.39-2.47 (2H, m), 3.28-3.37 (2H, m), 4.03 (2H, d, J=5 Hz), 4.86 (1H, t, J=5 Hz), 6.47 (1H, s), 7.14-7.20 (2H, m), 7.22 (1H, d, J=8.8 Hz), 7.32 (1H, t, J=4.5 Hz), 7.45 (1H, d, J=8.0 Hz), 7.55-7.64 (2H, m), 7.88 (1H, d, J=2.5 Hz), 7.93 (1H, s), 8.79 (1H, s).
To the solution of [4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl]methanol (103 mg) in tetrahydrofuran (1 mL) were added diazabicyclo[5,4,0]-7-undecene (0.1 mL) and diphenylphosphoryl azide (0.07 mL), and the mixture was stirred at 40° C. for 0.5 hr. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=67:33→0:100) and crystallized from hexane-diisopropyl ether to give the title compound (80 mg) as pale-orange crystals.
1H-NMR (CDCl3) δ: 2.57-2.64 (2H, m), 3.51-3.59 (2H, m), 3.95 (2H, s), 5.62 (1H, t, J=4.1 Hz), 6.29 (1H, s), 6.51 (1H, s), 7.05 (1H, d, J=8.9 Hz), 7.10 (1H, dd, J= 8 Hz, 2.1 Hz), 7.17-7.21 (1H, m), 7.29-7.38 (2H, m), 7.42 (1H, t, J=8 Hz), 7.72 (1H, d, J=2.6 Hz), 8.13 (1H, s).
To a solution of 6-(azidomethyl)-N-{3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-amine (70.1 mg) in tetrahydrofuran (0.6 mL) and water (0.06 mL) was added triphenylphosphine (42.2 mg), and the mixture was stirred at room temperature for 24 hr. The reaction mixture was concentrated under reduced pressure, and the residue was separated and purified by basic silica gel column chromatography (eluent, hexane:ethyl acetate=10:90→0:100→ethyl acetate:methanol=90:10). The purified substance was dissolved in ethyl acetate (1 mL). 4N Hydrochloric acid/ethyl acetate (0.1 mL) was added to the solution, and the mixture was stirred for 1 hr. The reaction mixture was concentrated under reduced pressure to give 6-(aminomethyl)-N-{3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-amine dihydrochloride. Using the obtained compound (76.8 mg), 3-hydroxy-3-methylbutanoic acid (27.8 mg), 1-hydroxybenzotriazole (30.4 mg), triethylamine (0.2 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (44.2 mg), tetrahydrofuran (0.4 mL) and N,N-dimethylformamide (0.4 mL), a similar reaction as in Example 110 was carried out to give the title compound (38.3 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 1.15 (6H, s), 2.26 (2H, s), 2.35-2.44 (2H, m), 3.27-3.37 (2H, m), 3.88 (2H, d, J=5.5 Hz), 4.87 (1H, s), 6.44 (1H, s), 7.15-7.21 (2H, m), 7.24 (1H, d, J=8.9 Hz), 7.35 (1H, t, J=4.6 Hz), 7.45 (1H, d, J=7.7 Hz), 7.56-7.66 (2H, m), 7.88 (1H, d, J=2.5 Hz), 7.93 (1H, s), 7.98 (1H, t, J=5.5 Hz), 8.77 (1H, s).
Using 6-(azidomethyl)-N-{3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-amine (65.3 mg), triphenylphosphine (39.8 mg), tetrahydrofuran (0.6 mL), water (0.06 mL), di-tert-butyl dicarbonate (0.1 mL), triethylamine (0.1 mL) and methanol (1 mL), a similar reaction as in Example 127 (iv) was carried out to give tert-butyl {[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl]methyl}carbamate. Using the obtained compound (73.8 mg), ethanol (2 mL) and 6N hydrochloric acid (0.15 mL), a similar reaction as in Example 127 (vi) was carried out to give the title compound (46.1 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 2.53-2.62 (2H, m), 3.45 (2H, br s), 3.57-3.71 (2H, m), 6.74 (1H, s), 7.16-7.27 (2H, m), 7.31 (1H, d, J=9.1 Hz), 7.49 (1H, d, J=8.0 Hz), 7.57-7.70 (2H, m), 7.91 (1H, d, J=2.7 Hz), 8.20 (1H, s), 8.26 (1H, br s), 8.38 (3H, br s), 9.87 (1H, br s).
Using 6-(aminomethyl)-N-{3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-amine dihydrochloride (40.0 mg), (methylsulfonyl)acetic acid (17.4 mg), 1-hydroxybenzotriazole (21.7 mg), triethylamine (0.1 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (31.6 mg), tetrahydrofuran (0.3 mL) and N,N-dimethylformamide (0.3 mL), a similar reaction as in Example 110 was carried out to give the title compound (19.2 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 2.36-2.45 (2H, m), 3.12 (3H, s), 3.26-3.38 (2H, m), 3.92 (2H, d, J=5.7 Hz), 4.12 (2H, s), 6.49 (1H, s), 7.15-7.21 (2H, m), 7.24 (1H, d, J=8.7 Hz), 7.36 (1H, t, J=4.7 Hz), 7.45 (1H, d, J=7.6 Hz), 7.55-7.67 (2H, m), 7.91 (1H, d, J=2.7 Hz), 7.94 (1H, s), 8.54 (1H, t, J=5.7 Hz), 8.72 (1H, s).
To the solution of 4,6-dichloro-5-formylpyrimidine (0.50 g) in acetonitrile (5.0 mL) were added potassium phosphate (0.60 g) and 3-chloro-4-[3-(trifluoromethoxy)phenoxy]aniline (0.858 g) at room temperature. The mixture was stirred at room temperature for 16 hr, and ethyl acetate was added to the reaction mixture. The mixture was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. To the solution of the residue in N,N-dimethylformamide (15 mL) were added methyl 4-[(4-methoxybenzyl)amino]butanoate hydrochloride (0.775 g) and sodium carbonate (0.30 g) at room temperature. The mixture was stirred at room temperature for 20 hr. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=9:1→1:1) to give the title compound (0.32 g) as yellow amorphous.
1H-NMR (CDCl3) δ: 1.97-2.10 (2H, m), 2.33 (2H, t, J=7.2 Hz), 3.51-3.61 (2H, m), 3.66 (3H, s), 3.82 (3H, s), 4.80 (2H, s), 6.79-6.95 (5H, m), 7.07 (1H, d, J=8.7 Hz), 7.17 (2H, d, J=9.0 Hz), 7.29-7.34 (1H, m), 7.53 (1H, dd, J=8.7, 2.7 Hz), 8.02 (1H, d, J=2.7 Hz), 8.33 (1H, s), 9.81 (1H, s), 11.22 (1H, s).
To the solution of methyl 4-[[6-({3-chloro-4-[3-(trifluoromethoxy)phenoxy]phenyl}amino)-5-formylpyrimidin-4-yl](4-methoxybenzyl)amino]butanoate (0.32 g) in dimethyl carbonate (6.0 mL) was added 28% sodium methoxide-methanol solution (0.28 g) at room temperature. The mixture was stirred at room temperature for 4 days. Ethyl acetate was added to the mixture. The mixture was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=9:1→3:2) to give the title compound (273 mg) as pale-yellow amorphous.
1H-NMR (CDCl3) δ: 2.67 (2H, d, J=4.8 Hz), 3.36 (2H, d, J=4.8 Hz), 3.78 (3H, s), 3.81 (3H, s), 4.87 (2H, s), 6.78-6.96 (6H, m), 7.07 (1H, d, J=8.7 Hz), 7.23 (2H, d, J=8.4 Hz), 7.29-7.35 (1H, m), 7.39 (1H, dd, J=8.7, 2.4 Hz), 7.68 (1H, s), 7.74 (1H, d, J=2.4 Hz), 8.24 (1H, s).
To the solution of methyl 4-({3-chloro-4-[3-(trifluoromethoxy)phenoxy]phenyl}amino)-9-(4-methoxybenzyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (251 mg) in 1,2-dichloroethane (3.0 mL) was added trifluoroacetic acid (3.0 mL) at room temperature. The mixture was stirred at 70° C. for 18 hr and concentrated under reduced pressure. The residue was basified by adding aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=4:1→1:1) and crystallized from ethyl acetate-diisopropyl ether to give the title compound (84 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.91 (2H, t, J=4.8 Hz), 3.53 (2H, q, J=4.8 Hz), 3.82 (3H, s), 5.79-5.87 (1H, m), 6.82-6.88 (3H, m), 6.90-6.96 (1H, m), 7.07 (1H, d, J=8.7 Hz), 7.29-7.35 (1H, m), 7.38 (1H, dd, J=8.7, 2.7 Hz), 7.67 (1H, s), 7.74 (1H, d, J=2.7 Hz), 8.13 (1H, s).
To the solution of methyl 4-[(4-{[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy}-3-chlorophenyl)amino]-9-(4-methoxybenzyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (268 mg) in 1,2-dichloroethane (3.0 mL) was added trifluoroacetic acid (3.0 mL) at room temperature, and the mixture was stirred at 70° C. for 18 hr. The mixture was concentrated under reduced pressure, and tetrahydrofuran (10 mL) and triethylamine (0.49 mL) were added to the residue. Di-tert-butyl dicarbonate (0.096 mL) was additionally added to the residue at room temperature. The mixture was stirred at room temperature for 2 hr. Water was added thereto and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=1:1→ethyl acetate) to give the title compound (149 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.47 (9H, s), 1.75-1.96 (4H, m), 2.89 (2H, t, J=4.5 Hz), 3.36-3.46 (2H, m), 3.49-3.54 (2H, m), 3.64-3.72 (2H, m), 3.81 (3H, s), 4.43-4.51 (1H, m), 5.72-5.80 (1H, m), 6.74 (1H, s), 6.95 (1H, d, J=9.0 Hz), 7.28 (1H, dd, J=9.0, 2.7 Hz), 7.55 (1H, d, J=2.7 Hz), 7.66 (1H, s), 8.08 (1H, s).
To a solution of 4,6-dichloro-5-formylpyrimidine (0.50 g) in tetrahydrofuran (10 mL) were added triethylamine (0.39 mL) and 3-chloro-4-(3-chlorophenoxy)aniline (0.718 g) at room temperature. The mixture was stirred at room temperature for 16 hr, and ethyl acetate was added thereto. The mixture was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give the title compound (968 mg) as yellow crystals.
1H-NMR (CDCl3) δ: 6.84-6.88 (1H, m), 6.94-6.96 (1H, m), 7.05-7.11 (2H, m), 7.23-7.29 (1H, m), 7.50 (1H, dd, J=8.7, 2.7 Hz), 7.97 (1H, d, J=2.7 Hz), 8.59 (1H, s), 10.47 (1H, s), 11.14 (1H, s).
To the mixture of 4-chloro-6-{[3-chloro-4-(3-chlorophenoxy)phenyl]amino}pyrimidine-5-carbaldehyde (968 mg) and sodium carbonate (390 mg) in N,N-dimethylformamide (5.0 mL) was added a mixture of methyl 4-[(4-methoxybenzyl)amino]butanoate hydrochloride (671 mg) and triethylamine (0.38 mL) in N,N-dimethylformamide. The mixture was stirred at room temperature for 20 hr. Water was added to the mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=4:1→3:2) to give the title compound (431 mg) as yellow amorphous.
1H-NMR (CDCl3) δ: 1.99-2.10 (2H, m), 2.33 (2H, t, J=7.4 Hz), 3.57 (2H, t, J=7.5 Hz), 3.65 (3H, s), 3.81 (3H, s), 4.79 (2H, s), 6.83-6.94 (4H, m), 7.03-7.07 (2H, m), 7.17 (2H, d, J=9.0 Hz), 7.22 (1H, d, J=8.4 Hz), 7.51 (1H, dd, J=8.7, 2.7 Hz), 7.99 (1H, d, J=2.7 Hz), 8.32 (1H, s), 9.81 (1H, s), 11.20 (1H, s).
Using methyl 4-[(6-{[3-chloro-4-(3-chlorophenoxy)phenyl]amino}-5-formylpyrimidin-4-yl)(4-methoxybenzyl)amino]butanoate (431 mg), a solution of sodium methoxide in methanol (28%, 0.39 g) and dimethyl carbonate (4.0 mL), a similar reaction as in Example 132 (ii) was carried out to give the title compound (312 mg) as yellow amorphous.
1H-NMR (CDCl3) δ: 2.66 (2H, t, J=4.8 Hz), 3.35 (2H, t, J=4.8 Hz), 3.78 (3H, s), 3.81 (3H, s), 4.87 (2H, s), 6.83-6.90 (4H, m), 6.94 (1H, t, J=2.1 Hz), 7.06 (2H, d, J=8.4 Hz), 7.21-7.27 (3H, m), 7.38 (1H, dd, J=8.7, 2.4 Hz), 7.68 (1H, s), 7.73 (1H, d, J=2.4 Hz), 8.24 (1H, s).
Using methyl 4-{[3-chloro-4-(3-chlorophenoxy)phenyl]amino}-9-(4-methoxybenzyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (312 mg), trifluoroacetic acid (3.0 mL) and 1,2-dichloroethane (3.0 mL), a similar reaction as in Example 132 (iii) was carried out to give the title compound (203 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.89-2.92 (2H, m), 3.50-3.56 (2H, m), 3.82 (3H, s), 5.78-5.86 (1H, m), 6.82-6.89 (2H, m), 6.93-6.95 (1H, m), 7.04-7.07 (2H, m), 7.22 (1H, d, J=8.7 Hz), 7.37 (1H, dd, J=8.7, 2.4 Hz), 7.67 (1H, s), 7.73 (1H, d, J=2.4 Hz), 8.12 (1H, s).
To a solution of methyl 3-(2-chloro-4-nitrophenoxy)benzoate (4.81 g) in ethanol (30 mL) and tetrahydrofuran (20 mL) was added 1N aqueous sodium hydroxide solution (19.1 mL) at room temperature. The mixture was stirred at room temperature for 3 days, and concentrated under reduced pressure. The residue was acidified by adding 1N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The precipitated crystals were collected by filtration. The crystals were washed with diisopropyl ether and hexane to give the title compound (4.28 g) as colorless crystals.
1H-NMR (CDCl3) δ: 6.94 (1H, d, J=9.0 Hz), 7.33-7.37 (1H, m), 7.54-7.59 (1H, m), 7.76-7.78 (1H, m), 7.98-8.02 (1H, m), 8.10 (1H, dd, J=9.0, 2.7 Hz), 8.41 (1H, d, J=2.7 Hz).
To the solution of 3-(2-chloro-4-nitrophenoxy)benzoic acid (4.0 g) and N,N-dimethylformamide (0.2 mL) in tetrahydrofuran (60 mL) was added thionyl chloride (1.49 mL) at room temperature. The mixture was stirred at room temperature for 1 hr and concentrated under reduced pressure. A solution of the residue in tetrahydrofuran (20 mL) was added dropwise to a solution of tert-butylamine (1.30 g) and triethylamine (2.85 mL) in tetrahydrofuran (30 mL) at 0° C. The mixture was stirred at room temperature for 14 hr. Aqueous sodium bicarbonate solution was added to the mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give the title compound (4.43 g) as pale-yellow amorphous.
1H-NMR (CDCl3) δ: 1.47 (9H, s), 5.92 (1H, br s), 6.91 (1H, d, J=9.0 Hz), 7.15-7.22 (1H, m), 7.44-7.57 (3H, m), 8.07 (1H, dd, J=9.0, 2.7 Hz), 8.39 (1H, t, J=2.7 Hz).
A mixture of N-(tert-butyl)-3-(2-chloro-4-nitrophenoxy)benzamide (4.43 g), reduced iron (3.80 g) and calcium chloride (0.76 g) in 15% water-containing ethanol (130 mL) was heated under reflux for 14 hr. The insoluble material was removed by filtration and the filtrate was concentrated under reduced pressure. Water was added to the residue, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=9:1→1:1) to give the title compound (2.60 g) as orange amorphous.
1H-NMR (CDCl3) δ: 1.45 (9H, s), 3.70 (2H, br s), 5.91 (1H, br s), 6.57 (1H, dd, J=8.4, 2.7 Hz), 6.78 (1H, d, J=8.4 Hz), 6.90 (1H, d, J=8.4 Hz), 6.92-7.01 (1H, m), 7.24-7.33 (3H, m).
Using 4,6-dichloro-5-formylpyrimidine (365 mg), tert-butyl 4-[(4-methoxybenzyl)amino]butanate (613 mg), potassium phosphate (0.87 g) and acetonitrile (36 mL), a similar reaction as in Example 1 (i) was carried out to give the title compound (492 mg) as a pale-yellow oil.
1H-NMR (CDCl3) δ: 1.42 (9H, s), 1.84-1.96 (2H, m), 2.21 (2H, t, J=7.2 Hz), 3.63 (2H, t, J=7.2 Hz), 3.79 (3H, s), 4.58 (2H, s), 6.82 (2H, d, J=8.7 Hz), 7.00 (2H, d, J=8.7 Hz), 8.38 (1H, s), 10.18 (1H, s).
A mixture of tert-butyl 4-[(6-chloro-5-formylpyrimidin-4-yl)(4-methoxybenzyl)amino]butanoate (300 mg), 3-(4-amino-2-chlorophenoxy)-N-(tert-butyl)benzamide (228 mg) and sodium carbonate (76 mg) in N,N-dimethylformamide (3.0 mL) was stirred at 40° C. for 4 days. Water was added to reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=4:1→1:1) to give the title compound (303 mg) as pale-yellow amorphous.
1H-NMR (CDCl3) δ: 1.41 (9H, s), 1.46 (9H, s), 1.92-2.04 (2H, m), 2.23 (2H, t, J=7.2 Hz), 3.56 (2H, t, J=7.5 Hz), 3.81 (3H, s), 4.80 (2H, s), 5.91 (1H, br s), 6.89 (2H, d, J=8.7 Hz), 7.01 (1H, d, J=8.7 Hz), 7.02-7.06 (1H, m), 7.17 (2H, d, J=8.7 Hz), 7.30-7.44 (3H, m), 7.49 (1H, dd, J=8.7, 2.7 Hz), 7.98 (1H, d, J=2.7 Hz), 8.31 (1H, s), 9.80 (1H, s), 11.17 (1H, s).
Using tert-butyl 4-[{6-[(4-{3-[(tert-butylamino)carbonyl]phenoxy}-3-chlorophenyl)amino]-5-formylpyrimidin-4-yl}(4-methoxybenzyl)amino]butanoate (303 mg), 28% sodium methoxide-methanol solution (0.25 g) and dimethyl carbonate (6.0 mL), a similar reaction as in Example 132 (ii) was carried out to give the title compound (235 mg) as pale-yellow amorphous.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.62-2.68 (2H, m), 3.31-3.39 (2H, m), 3.79 (3H, s), 3.81 (3H, s), 4.87 (2H, s), 5.93 (1H, br s), 6.86-6.89 (3H, m), 7.02 (1H, d, J=9.0 Hz), 7.04-7.08 (1H, m), 7.23 (2H, d, J=8.4 Hz), 7.32-7.44 (4H, m), 7.69 (1H, s), 7.73 (1H, d, J=2.4 Hz), 8.23 (1H, s).
Using methyl 4-[(4-{3-[(tert-butylamino)carbonyl]phenoxy}-3-chlorophenyl)amino]-9-(4-methoxybenzyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (230 mg), trifluoroacetic acid (3.0 mL) and 1,2-dichloroethane (3.0 mL), a similar reaction as in Example 132 (iii) was carried out to give the title compound (111 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.89-2.92 (2H, m), 3.51-3.56 (2H, m), 3.83 (3H, s), 5.78-5.85 (1H, m), 5.93 (1H, br s), 6.91 (1H, s), 7.01 (1H, d, J=8.4 Hz), 7.03-7.08 (1H, m), 7.31-7.43 (4H, m), 7.68 (1H, s), 7.72 (1H, d, J=2.7 Hz), 8.11 (1H, s).
The mixture of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 3-aminopropane-1,2-diol (38 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (80 mg), 1-hydroxybenzotriazole monohydrate (64 mg) and triethylamine (30 μL) in N,N-dimethyl formamide (5.0 mL) was stirred at room temperature for 3 days. Water was added to reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, ethyl acetate→ethyl acetate:methanol=3:1) to give the title compound (78 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 2.65-2.75 (2H, m), 3.03-3.15 (1H, m), 3.24-3.45 (5H, m), 3.52-3.63 (1H, m), 4.57 (1H, t, J=5.9 Hz), 4.82 (1H, d, J=5.1 Hz), 7.15-7.23 (3H, m), 7.27 (1H, d, J=9.0 Hz), 7.46 (1H, d, J=8.4 Hz), 7.53-7.73 (3H, m), 7.91 (1H, d, J=2.4 Hz), 7.96-8.02 (2H, m), 9.14 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 3-amino-2,2-dimethylpropan-1-ol (43 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (80 mg), 1-hydroxybenzotriazole monohydrate (64 mg), triethylamine (30 μL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (72 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 0.93 (6H, s), 2.81 (2H, t, J=4.5 Hz), 3.23-3.27 (4H, m), 3.55-3.60 (2H, m), 3.70 (1H, t, J=6.6 Hz), 5.67-5.75 (1H, m), 6.23-6.31 (1H, m), 7.05 (1H, d, J=8.7 Hz), 7.06-7.14 (2H, m), 7.22 (1H, br s), 7.30-7.46 (3H, m), 7.50 (1H, s), 7.77 (1H, d, J=3.0 Hz), 8.14 (1H, s).
A solution of tert-butyl (3-bromopropyl)carbamate (2.05 g), sodium methanesulfinate (1.05 g) and pyridine (0.83 g) in N,N-dimethylformamide (20 mL) was stirred at 60° C. for 2 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=1:1→1:4) to give the title compound (1.34 g) as a white solid.
1H-NMR (CDCl3) δ: 1.44 (9H, s), 2.01-2.11 (2H, m), 2.93 (3H, s), 3.05-3.10 (2H, m), 3.27-3.33 (2H, m), 4.62-4.80 (1H, m).
To a solution of tert-butyl [3-(methylsulfonyl)propyl]carbamate (1.34 g) in tetrahydrofuran (20 mL) was added 6N hydrochloric acid (5.0 mL) at room temperature. The mixture was stirred at 60° C. for 20 hr, and concentrated under reduced pressure. Ethanol was added to the residue and the mixture was concentrated again. The precipitated crystals were collected by filtration. The crystals were washed with diisopropyl ether to give the title compound (0.89 g) as colorless crystals.
1H-NMR (DMSO-d6) δ: 1.95-2.05 (2H, m), 2.91 (2H, t, J=7.5 Hz), 3.00 (3H, s), 3.26 (2H, t, J=7.8 Hz), 8.04 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 3-(methylsulfonyl)-1-propylamine hydrochloride (73 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (80 mg), 1-hydroxybenzotriazole monohydrate (64 mg), triethylamine (30 μL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (91 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.16-2.26 (2H, m), 2.87 (2H, t, J=4.8 Hz), 2.95 (3H, s), 3.23 (2H, t, J=6.3 Hz), 3.52-3.60 (4H, m), 5.69-5.76 (1H, m), 6.76-6.84 (1H, m), 7.06 (1H, d, J=8.7 Hz), 7.08-7.12 (1H, m), 7.15-7.20 (1H, m), 7.22-7.28 (1H, m), 7.30-7.34 (1H, m), 7.40-7.45 (2H, m), 7.53 (1H, dd, J=8.7, 2.4 Hz), 7.75 (1H, d, J=2.4 Hz), 8.12 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), tetrahydrofurfurylamine (43 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (80 mg), 1-hydroxybenzotriazole monohydrate (64 mg), triethylamine (88 μL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (102 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.50-1.70 (2H, m), 1.84-2.08 (2H, m), 2.82 (2H, t, J=4.8 Hz), 3.17-3.26 (1H, m), 3.53-3.58 (2H, m), 3.70-3.92 (3H, m), 3.99-4.08 (1H, m), 5.66-5.73 (1H, m), 6.25-6.33 (1H, m), 7.04 (1H, d, J=8.4 Hz), 7.05-7.11 (1H, m), 7.21 (1H, br s), 7.30-7.33 (1H, m), 7.39-7.48 (4H, m), 7.78 (1H, d, J=2.7 Hz), 8.12 (1H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), trans-4-aminocyclohexanol (48 mg), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (80 mg), 1-hydroxybenzotriazole monohydrate (64 mg), triethylamine (88 μl) and N,N-dimethylformamide (5.0 mL), a Similar reaction as in Example 136 was carried out to give, the title compound (97 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.18-1.60 (4H, m), 1.98-2.11 (4H, m), 2.76 (2H, t, J=4.5 Hz), 3.51-3.69 (2H, m), 3.76-3.93 (2H, m), 5.45-5.51 (1H, m), 5.66-5.74 (1H, m), 7.04 (1H, d, J=9.0 Hz), 7.06-7.11 (1H, m), 7.18-7.23 (1H, m), 7.30-7.35 (1H, m), 7.38-7.44 (4H, m), 7.78 (1H, d, J=2.7 Hz), 8.12 (1H, s).
To a solution of tert-butyl [2-(2-hydroxyethoxy)ethyl]carbamate (2.1 g),
triphenylphosphine (3.21 g) and imidazole (0.83 g) in dichloromethane (40 mL) was added iodine (2.85 g) at 0° C. The mixture was stirred at room temperature for 20 hr. Water was added to the mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Diethyl ether was added to the residue, and the precipitated crystals were removed by filtration.
The filtrate was concentrated, and the residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=9:1->3:1) to give the title compound (2.55 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.45 (9H, s), 3.26 (2H, t, J=6.6 Hz), 3.30-3.35 (2H, m), 3.55 (2H, t, J=5.3 Hz), 3.71 (2H, t, J=6.6 Hz), 4.83-5.01 (1H, m).
Using tert-butyl [2-(2-iodoethoxy)ethyl]carbamate (2.55 g), sodium methanesulfinate (1.07 g), pyridine (0.85 mL) and N,N-dimethylformamide (30 mL), a similar reaction as in Example 138 (i) was carried out to give the title compound (2.05 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.44 (9H, s), 3.00 (3H, s), 3.23 (2H, t, J=5.3 Hz), 3.28-3.38 (2H, m), 3.56 (2H, t, J=5.4 Hz), 3.91 (2H, t, J=5.4 Hz), 4.74-4.87 (1H, m).
Using tert-butyl {2-[2-(methylsulfonyl)ethoxy]ethyl}carbamate (2.05 g), 6N hydrochloric acid (5.0 mL) and tetrahydrofuran (20 mL), a similar reaction as in Example 138 (ii) was carried out to give the title compound (1.43 g) as colorless crystals.
1H-NMR (DMSO-d6) δ: 2.98 (2H, t, J=5.4 Hz), 3.02 (3H, s), 3.40 (2H, t, J=5.7 Hz), 3.64 (2H, t, J=5.4 Hz), 3.82 (2H, t, J=5.7 Hz), 8.00 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 2-[2-(methylsulfonyl)ethoxy]ethylamine hydrochloride (85.5 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (80.6 mg), 1-hydroxybenzotriazole monohydrate (64 mg), triethylamine (88 μL) and N,N-dimethyl formamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (97 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.86-2.89 (2H, m), 2.94 (3H, s), 3.32 (2H, t, J=5.1 Hz), 3.54-3.64 (4H, m), 3.70 (2H, t, J=4.5 Hz), 4.00 (2H, t, J=5.1 Hz), 5.67-5.75 (1H, m), 6.80-6.88 (1H, m), 7.05 (1H, d, J=8.7 Hz), 7.08-7.11 (1H, m), 7.15-7.22 (2H, m), 7.27-7.31 (1H, m), 7.39-7.45 (1H, m), 7.47 (1H, dd, J=8.7, 2.7 Hz), 7.55 (1H, s), 7.74 (1H, d, J=2.7 Hz), 8.10 (1H, s).
To a solution of tert-butyl (3-hydroxy-2,2-dimethylpropyl)carbamate (3.0 g) and triethylamine (4.1 mL) in tetrahydrofuran (50 mL) was added methanesulfonyl chloride (1.71 mL) at 0° C. The mixture was stirred at 0° C. for 4 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. To a solution of the residue in N,N-dimethylformamide (50 mL) was added sodium methanethiolate (1.03 g) at room temperature. The mixture was stirred at 70° C. for 18 hr. Sodium methanethiolate (0.31 g) was added to the reaction mixture and the mixture was further stirred at 70° C. for 20 hr. Water was added to reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=9:1→2:1) to give the title compound (2.99 g) as a colorless oil.
1H-NMR (CDCl3) δ: 0.97 (6H, s), 1.47 (9H, s), 2.12 (3H, s), 2.45 (2H, s), 3.05 (2H, d, J=6.6 Hz), 4.61-4.75 (1H, m).
To a solution of tert-butyl [2,2-dimethyl-3-(methylthio)propyl]carbamate (2.99 g) in dichloromethane (120 mL) was added 3-chloroperbenzoic acid (70%, 6.63 g) at 0° C. The mixture was stirred at 0° C. for 2 hr. Aqueous sodium thiosulfate solution was added to the reaction mixture, and the mixture was stirred at room temperature for 30 min. The mixture was extracted with ethyl acetate, and the organic layer was washed with aqueous sodium bicarbonate solution, saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=3:1→4:1→ethyl acetate) to give the title compound (3.46 g) as colorless, crystals.
1H-NMR (CDCl3) δ: 1.19 (6H, s), 1.44 (9H, s), 2.94 (3H, s), 3.00 (2H, s), 3.23 (2H, d, J=7.2 Hz), 5.03-5.15 (1H, m).
Using tert-butyl [2,2-dimethyl-3-(methylsulfonyl)propyl]carbamate (3.46 g), 6N hydrochloric acid (20 mL) and tetrahydrofuran (60 mL), a similar reaction as in Example 138 (ii) was carried out to give the title compound (2.44 g) as colorless crystals.
1H-NMR (DMSO-d6) δ: 1.17 (6H, s), 2.89-2.98 (2H, m), 3.01 (3H, s), 3.42 (2H, s), 8.16 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 2,2-dimethyl-3-(methylsulfonyl)-1-propylamine hydrochloride (85 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (80.6 mg), 1-hydroxybenzotriazole monohydrate (64 mg), triethylamine (88 μl) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (92 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.24 (6H, s), 2.85-2.95 (5H, m), 3.10 (2H, s), 3.47-3.58 (4H, m), 5.68-5.75 (1H, m), 7.05 (1H, d, J=8.7 Hz), 7.08-7.18 (2H, m), 7.26 (1H, s), 7.29-7.45 (4H, m), 7.56 (1H, dd, J=8.7, 2.4 Hz), 7.71 (1H, d, J=2.4 Hz), 8.10 (1H, s).
Using 4-{[3-chloro-4-(3-chlorophenoxy)phenyl]amino}-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (106 mg), 2-(2-aminoethoxy)ethanol (57 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (104 mg), 1-hydroxybenzotriazole monohydrate (83 mg), triethylamine (0.11 mL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give 4-{[3-chloro-4-(3-chlorophenoxy)phenyl]amino}-N-[2-(2-hydroxyethoxy)ethyl]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxamide. To a solution of 4-{[3-chloro-4-(3-chlorophenoxy)phenyl]amino}-N-[2-(2-hydroxyethoxy)ethyl]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxamide in ethanol (2.0 mL) was added 4N hydrochloric acid/ethyl acetate (0.5 mL) at room temperature. The mixture was concentrated under reduced pressure and crystallized from ethanol-ethyl acetate to give the title compound (80 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 2.70-2.79 (2H, m), 3.27-3.37 (2H, m), 3.40-3.54 (8H, m), 6.91-6.94 (1H, m), 7.00-7.02 (1H, m), 7.18-7.22 (2H, m), 7.29 (1H, d, J=9.0 Hz), 7.39-7.45 (1H, m), 7.52 (1H, dd, J=9.0, 2.5 Hz), 7.80 (1H, d, J= 2.5 Hz), 8.21 (1H, s), 8.41-8.50 (1H, m), 8.52-8.69 (1H, m), 10.18-10.31 (1H, m).
A mixture of tert-butyl (3-bromopropyl)carbamate (1.02 g), 1H-1,2,4-triazole (0.35 g), potassium carbonate (0.87 g) in acetone (30 mL) was stirred at 70° C. for 12 hr, and concentrated under reduced pressure. Water was added to the residue and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, ethyl acetate->ethyl acetate:methanol=97:3→4:1) to give the title compound (0.93 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.45 (9H, s), 2.02-2.11 (2H, m), 3.16 (2H, td, J=6.3, 6.3 Hz), 4.24 (2H, t, J=6.8 Hz), 4.63-4.81 (1H, m), 7.95 (1H, s), 8.14 (1H, s).
Using tert-butyl [3-(1H-1,2,4-triazol-1-yl)propyl]carbamate (0.93 g), 6N hydrochloric acid (5.0 mL) and tetrahydrofuran (10 mL), a similar reaction as in Example 138 (ii) was carried out to give the title compound (761 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 2.05-2.14 (2H, m), 2.70-2.83 (2H, m), 4.33 (2H, t, J=6.8 Hz), 8.10 (3H, br s), 8.14 (1H, s), 8.76 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 3-(1H-1,2,4-triazol-1-yl)-1-propylamine hydrochloride (84 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (80.6 mg), 1-hydroxybenzotriazole monohydrate (64 mg), triethylamine (88 μL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (58 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.11-2.23 (2H, m), 2.76-2.83 (2H, m), 3.43-4.50 (2H, m), 3.52-3.57 (2H, m), 4.32 (2H, t, J=6.3 Hz), 5.66-5.72 (1H, m), 6.10-6.20 (1H, m), 7.04 (1H, d, J=8.7 Hz), 7.06-7.12 (1H, m), 7.19-7.22 (1H, m), 7.23-7.35 (2H, m), 7.40-7.46 (2H, m), 7.52 (1H, br s), 7.80 (1H, d, J=2.7 Hz), 7.93 (1H, s), 8.13 (1H, s), 8.17 (1H, s).
To a solution of pyrazole (0.35 g) in tetrahydrofuran (15 mL) was added 60% sodium hydride (dispersion in mineral oil, 0.22 g) at 0° C. The mixture was stirred at 0° C. for 1 hr, and tert-butyl (3-bromopropyl)carbamate (1.05 g) was added thereto. The mixture was stirred at 50° C. for 20 hr. Water was added to the mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=1:1→ethyl acetate) to give the title compound (0.96 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.44 (9H, s), 1.98-2.07 (2H, m), 3.07-3.13 (2H, m), 4.19 (2H, t, J=6.6 Hz), 4.68-4.82 (1H, m), 6.24 (1H, dd, J=2.1, 1.5 Hz), 7.40 (1H, d, J=2.1 Hz), 7.49 (1H, d, J=1.5 Hz).
Using tert-butyl [3-(1H-pyrazol-1-yl)propyl]carbamate (0.96 g), 6N hydrochloric acid (5.0 mL) and tetrahydrofuran (10 mL), a similar reaction as in Example 138 (ii) was carried out to give the title compound (747 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 2.01-2.11 (2H, m), 2.64-2.79 (2H, m), 4.23 (2H, t, J=6.8 Hz), 6.25 (1H, dd, J=2.1, 1.8 Hz), 7.47 (1H, d, J=1.8 Hz), 7.78 (1H, d, J=2.1 Hz), 8.11 (3H, br s).
(iii) Production of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-N-[3-(1H-pyrazol-1-yl)propyl]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxamide
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 3-(1H-pyrazol-1-yl)-1-propylamine hydrochloride (83.2 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (80.6 mg), 1-hydroxybenzotriazole monohydrate (64 mg), triethylamine (88 μL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (100 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.06-2.17 (2H, m), 2.82 (2H, t, J=204.5 Hz), 3.33-3.84 (2H, m), 3.53-3.57 (2H, m), 4.30 (2H, t, J=6.2 Hz), 5.66-5.75 (1H, m), 6.28-6.29 (1H, m), 6.95-7.06 (2H, m), 7.08-7.12 (1H, m), 7.18-7.22 (1H, m), 7.29-7.35 (1H, m), 7.36-7.48 (6H, m), 7.74 (1H, d, J=2.4 Hz), 8.13 (1H, s).
To a solution of methyl 4-[(4-{[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy}-3-chlorophenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (1.5 g) in tetrahydrofuran (30 mL) and ethanol (30 mL) was added 1N aqueous sodium hydroxide solution (10 mL) at room temperature. The mixture was stirred at room temperature for 3 days. 1N hydrochloric acid (10 mL) was added to the reaction mixture, and the mixture was concentrated under reduced pressure. The precipitated crystals were collected by filtration and washed with water to give the title compound (1.34 g) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.41 (9H, s), 1.51-1.65 (2H, m), 1.81-1.91 (2H, m), 2.64-2.75 (2H, m), 3.21-3.41 (4H, m), 3.53-3.64 (2H, m), 4.50-4.59 (1H, m), 7.15 (1H, d, J=9.0 Hz), 7.37 (1H, dd, J=9.0, 2.7 Hz), 7.61 (1H, d, J=2.7 Hz), 7.67 (1H, s), 7.77 (1H, t, J=5.0 Hz), 7.91 (1H, s), 9.13 (1H, s).
To a solution of 4-[(4-{[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy}-3-chlorophenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (0.50 g) and 4-methylmorpholine (0.122 mL) in tetrahydrofuran (5.0 mL) was added isopropyl chlorocarbonate (0.138 mL) at 0° C. The mixture was stirred at 0° C. for 2 hr, and an insoluble material was removed by filtration. The filtrate was added dropwise to a mixed solution of sodium borohydride (37 mg) in tetrahydrofuran (3.0 mL) and water (3.0 mL) at 0° C. The mixture was stirred at 0° C. for 1 hr and extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, ethyl acetate→ethyl acetate:methanol=85:15) to give the title compound (368 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.47 (9H, s), 1.50-1.66 (1H, m), 1.75-1.95 (3H, m), 2.53 (2H, t, J=4.8 Hz), 3.33-3.44 (2H, m), 3.49-3.54 (2H, m), 3.62-3.73 (2H, m), 4.23 (2H, s), 4.41-4.50 (1H, m), 5.45-5.52 (1H, m), 6.32 (1H, s), 6.48 (1H, s), 6.93 (1H, d, J=8.7 Hz), 7.26 (1H, dd, J=8.7, 2.7 Hz), 7.52 (1H, d, J=2.7 Hz), 8.06 (1H, s).
To a solution of tert-butyl (2-bromoethyl)carbamate (2.48 g) and 2-mercaptoethanol (0.87 g) in ethanol (25 mL) was added a solution of sodium methoxide in methanol (28%, 2.15 g) at room temperature. The mixture was stirred at room temperature for 3 days and concentrated under reduced pressure. Water was added to the residue, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=4:1→ethyl acetate) to give the title compound (2.18 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.45 (9H, s), 2.2-2.38 (1H, m), 2.66
(2H, t, J=6.6 Hz), 2.75 (2H, t, J=5.7 Hz), 3.28-3.39 (2H, m), 3.72-3.78 (2H, m), 4.79-4.96 (1H, m).
(ii) Production of tert-butyl {2-[(2-hydroxyethyl)sulfonyl]ethyl}carbamate
Using tert-butyl 2-[(2-hydroxyethyl)thio]ethyl}carbamate (1.18 g), 3-chloroperbenzoic acid (70%, 2.89 g) and dichloromethane-(20 mL), a similar reaction as in Example 142 (ii) was carried out to give the title compound (1.31 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.44 (9H, s), 2.31-2.65 (1H, m), 3.25 (2H, t, J=5.3 Hz), 3.34 (2H, t, J=6.1 Hz), 3.62-3.69 (2H, m), 4.14 (2H, t, J=5.3 Hz), 5.09-5.16 (1H, m).
(iii) Production of 2-[(2-aminoethyl)sulfonyl]ethanol hydrochloride
Using tert-butyl {2-[(2-hydroxyethyl)sulfonyl]ethyl}carbamate (1.31 g), 6N hydrochloric acid (3.0 mL) and tetrahydrofuran (20 mL), a similar reaction as in Example 138 (ii) was carried out to give the title compound (927 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 3.22 (2H, t, J=7.4 Hz), 3.37 (2H, t, J=5.6 Hz), 3.50 (2H, t, J=7.4 Hz), 3.80 (2H, t, J=5.6 Hz), 7.85-8.35 (3H, m).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 2-[(2-aminoethyl)sulfonyl]ethanol hydrochloride (80 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (80.6 mg), 1-hydroxybenzotriazole monohydrate (64 mg), triethylamine (88 μL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (100 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.52-2.64 (1H, m), 2.84 (2H, t, J=4.7 Hz), 3.29 (2H, t, J=5.1 Hz), 3.41-3.45 (2H, m), 3.50-3.55 (2H, m), 3.93-3.99 (2H, m), 4.15 (2H, t, J=5.1 Hz), 5.77 (1H, t, J=4.8 Hz), 6.74 (1H, t, J=6.3 Hz), 7.03 (1H, d, J=9.0 Hz), 7.05-7.11 (1H, m), 7.18-7.23 (1H, m), 7.30-7.45 (4H, m), 7.53 (1H, dd, J=9.0, 2.7 Hz), 7.80 (1H, d, J=2.7 Hz), 8.12 (1H, s).
Using tert-butyl (2-hydroxy-1,1-dimethylethyl)carbamate (2.50 g), methanesulfonyl chloride (1.53 mL), triethylamine (3.68 mL), tetrahydrofuran (75 mL), sodium methanethiolate (1.25 g) and N,N-dimethylformamide (30 mL), a similar reaction as in Example 142 (i) was carried out to give the title compound (1.94 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.34 (6H, s), 1.43 (9H, s), 2.15 (3H, s), 2.88 (2H, s), 4.65 (1H, br s).
Using tert-butyl [1,1-dimethyl-2-(methylthio)ethyl]carbamate (1.94 g), 3-chloroperbenzoic acid (70%, 4.79 g) and dichloromethane (50 mL), a similar reaction as in Example 142 (ii) was carried out to give the title compound (2.22 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.44 (9H, s), 1.52 (6H, s), 2.92 (3H, s), 3.58 (2H, s), 4.79 (1H, s).
Using tert-butyl [1,1-dimethyl-2-(methylsulfonyl)ethyl]carbamate (2.2 g), 6N hydrochloric acid (3.0 mL) and tetrahydrofuran (20 mL), a similar reaction as in Example 138 (i) was carried out to give the title compound (1.55 g) as colorless crystals.
1H-NMR (DMSO-d6) δ: 1.47 (6H, s), 3.13 (3H, s), 3.60 (2H, s), 8.30 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 2-methyl-1-(methylsulfonyl)-2-propylamine hydrochloride (79 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (80.6 mg), 1-hydroxybenzotriazole monohydrate (64 mg), triethylamine (88 μL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (97 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.69 (6H, s), 2.84 (2H, t, J=4.4 Hz), 2.97 (3H, s), 3.50-3.55 (2H, m), 3.62 (2H, s), 5.62-5.71 (1H, m), 6.35 (1H, s), 7.03 (1H, d, J=8.7 Hz), 7.05-7.10 (1H, m), 7.16-7.33 (4H, m), 7.38-7.44 (1H, m), 7.53 (1H, dd, J=8.7, 2.7 Hz), 7.89 (1H, d, J=2.7 Hz), 8.13 (1H, s).
To a solution of 2-aminoethanethiol (1.5 g) and 2-(bromoethyl)methyl ether (2.70 g) in ethanol (50 mL) was added a solution of sodium methoxide in methanol (28%, 3.74 g) at room temperature. The mixture was stirred at 50° C. for 18 hr, and concentrated under reduced pressure. To a solution of the residue in tetrahydrofuran (50 mL) was added di-tert-butyl dicarbonate (4.46 mL) at room temperature, and the mixture was stirred for 4 hr. 1N Hydrochloric acid (20 mL) was added to the mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=9:1→1:1) to give the title compound (3.74 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.45 (9H, s), 2.67-2.74 (4H, m), 3.26-3.37 (2H, m), 3.37 (3H, s), 3.56 (2H, t, J=6.3 Hz), 4.93-5.08 (1H, m).
Using tert-butyl {2-[(2-methoxyethyl)thio]ethyl}carbamate (3.74 g), 3-chloroperbenzoic acid (70%, 7.84 g) and dichloromethane (100 mL), a similar reaction as in Example 142 (ii) was carried out to give the title compound (3.91 g) as a white solid.
1H-NMR (CDCl3) δ: 1.44 (9H, s), 3.22 (2H, t, J=5.3 Hz), 3.29 (2H, t, J=5.8 Hz), 3.38 (3H, s), 3.60-3.70 (2H, m), 3.81 (2H, t, J=5.3 Hz), 5.15-5.32 (1H, m).
Using tert-butyl {2-[(2-methoxyethyl)sulfonyl]ethyl}carbamate (3.91 g), 6N hydrochloric acid (10 mL) and tetrahydrofuran (40 mL), a similar reaction as in Example 138 (ii) was carried out to give the title compound (2.79 g) as colorless crystals.
1H-NMR (DMSO-d6) δ: 3.20 (2H, t, J=7.4 Hz), 3.29 (3H, s), 3.46 (2H, t, J=7.4 Hz), 3.52 (2H, t, J=3.4 Hz), 3.70 (2H, t, J=5.4 Hz), 8.12 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 2-[(2-methoxyethyl)sulfonyl]ethylamine hydrochloride (85.5 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (80.6 mg), 1-hydroxybenzotriazole monohydrate (64 mg), triethylamine (88 μL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (94 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.86 (2H, t, J=4.2 Hz), 3.27 (2H, t, J=5.3 Hz), 3.32-3.42 (5H, m), 3.50-3.55 (2H, m), 3.82 (2H, t, J=5.3 Hz), 3.92-3.98 (2H, m), 5.69-5.75 (1H, m), 6.66-6.75 (1H, m), 7.04 (1H, d, J=8.7 Hz), 7.05-7.10 (1H, m), 7.19-7.20 (1H, m), 7.30-7.36 (3H, m), 7.39-7.45 (1H, m), 7.56 (1H, dd, J=8.7, 2.7 Hz), 7.83 (1H, d, J=2.7 Hz), 8.13 (1H, s).
A solution of tert-butyl (3-bromopropyl)carbamate (1.02 g) and sodium 2-methyl-2-propanethiolate (0.53 g) in ethanol (10 mL) was stirred at 60° C. for 2 days and concentrated under reduced pressure. Water was added to the residue and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=9:1→2:1) to give the title compound (0.79 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.32 (9H, s), 1.44 (9H, s), 1.71-1.80 (2H, m), 2.55 (2H, t, J=7.2 Hz), 3.16-3.26 (2H, m), 4.53-4.68 (1H, m).
Using tert-butyl [3-(tert-butylthio)propyl]carbamate (0.79 g), 3-chloroperbenzoic acid (70%, 1.65 g) and dichloromethane (10 mL), a similar reaction as in Example 142 (ii) was carried out to give the title compound (852 mg) as a white solid.
1H-NMR (CDCl3) δ: 1.42 (9H, s), 1.44 (9H, s), 2.04-2.13 (2H, m), 2.97 (2H, t, J=7.5 Hz), 3.28-3.35 (2H, m), 4.67-4.80 (1H, m).
Using tert-butyl [3-(tert-butylsulfonyl)propyl]carbamate (852 mg), 6N hydrochloric acid (3.0 mL) and tetrahydrofuran (10 mL), a similar reaction as in Example 138 (ii) was carried out to give the title compound (611 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 1.30 (9H, s), 1.91-2.04 (2H, m), 2.93 (2H, t, J=7.8 Hz), 3.21 (2H, t, J=7.8 Hz), 7.97 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 3-(tert-butylsulfonyl)-1-propylamine hydrochloride (90.6 mg), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (80.6 mg), 1-hydroxybenzotriazole monohydrate (64 mg), triethylamine (88 μL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (57 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.34 (9H, s), 2.20-2.31 (2H, m), 2.88 (2H, t, J=4.7 Hz), 3.11 (2H, t, J=6.2 Hz), 3.50-3.61 (4H, m), 5.68-5.75 (1H, m), 6.92-7.01 (1H, m), 7.05 (1H, d, J=8.7 Hz), 7.10-7.17 (2H, m), 7.21-7.27 (1H, m), 7.31-7.34 (1H, m), 7.40-7.45 (2H, m), 7.52 (1H, dd, J=8.7, 2.7 Hz), 7.77 (1H, d, J=2.7 Hz), 8.11 (1H, s).
A solution of tert-butyl (2-bromoethyl)carbamate (2.37 g) and sodium 2-methyl-2-propanethiolate (1.32 g) in N,N-dimethylformamide (30 mL) was stirred at 40° C. for 3 days. Water was added to the reaction mixture and the mixture was extracted with hexane. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=19:1→2:1) to give the title compound (1.81 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.32 (9H, s), 1.44 (9H, s), 2.67 (2H, t, J=6.6 Hz), 3.24-3.35 (2H, m), 4.83-4.96 (1H, m).
Using tert-butyl [2-(tert-butylthio)ethyl]carbamate (1.81 g), 3-chloroperbenzoic acid (70%, 4.21 g) and dichloromethane (40 mL), a similar reaction as in Example 142 (ii) was carried out to give the title compound (1.94 g) as a white solid.
1H-NMR (CDCl3) δ: 1.42 (9H, s), 1.44 (9H, s), 3.13 (2H, t, J=5.7 Hz), 3.70-3.76 (2H, m), 5.23-5.35 (1H, m).
Using tert-butyl [2-(tert-butylsulfonyl)ethyl]carbamate (1.90 g), 2 N hydrochloric acid (10 mL) and tetrahydrofuran (20 mL), a similar reaction as in Example 138 (ii) was carried out to give the title compound (1.43 g) as colorless crystals.
1H-NMR (DMSO-d6) δ: 1.34 (9H, s), 3.21 (2H, t, J=7.4 Hz), 3.46 (2H, t, J=7.4 Hz), 3.09 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 2-(tert-butylsulfonyl)ethylamine hydrochloride (84.7 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (80.6 mg), 1-hydroxybenzotriazole monohydrate (64 mg), triethylamine (88 μL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (107 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.42 (9H, s), 2.87 (2H, t, J=4.8 Hz), 3.17-3.21 (2H, m), 3.51 (2H, q, J=4.6 Hz), 3.99-4.05 (2H, m), 5.76 (1H, t, J=4.8 Hz), 6.72-6.80 (1H, m), 7.03 (1H, d, J=9.0 Hz), 7.06-7.11 (1H, m), 7.17 (1H, s), 7.31-7.33 (2H, m), 7.39-7.45 (2H, m), 7.60 (1H, dd, J=9.0, 2.7 Hz), 7.79 (1H, d, J=2.7 Hz), 8.12 (1H, s).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (50 mg), 2-piperazin-1-ylethanol (23 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (48 mg), 1-hydroxybenzotriazole monohydrate (38 mg), triethylamine (0.10 mL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (24 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.34 (3H, s), 2.44-2.52 (7H, m), 2.59 (2H, t, J=5.4 Hz), 2.78 (2H, t, J=4.2 Hz), 3.52-3.71 (8H, m), 5.57-5.64 (1H, m), 6.45 (1H, s), 6.54-6.63 (1H, m), 6.86 (1H, d, J=8.7 Hz), 7.06-7.12 (2H, m), 7.15-7.27 (2H, m), 7.32 (1H, d, J=3.0 Hz), 8.11 (1H, s), 8.24 (1H, d, J=2.4 Hz).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (50 mg), 3-methoxy-1-propylamine (21 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (48 mg), 1-hydroxybenzotriazole monohydrate (38 mg), triethylamine (0.10 mL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (21 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.80-1.91 (2H, m), 2.23 (3H, s), 2.52 (3H, s), 2.78 (2H, t, J=4.7 Hz), 3.35 (3H, s), 3.46-3.58 (6H, m), 5.57-5.65 (1H, m), 6.58-6.67 (1H, m), 6.85 (1H, d, J=8.4 Hz), 6.93 (1H, s), 7.04-7.11 (2H, m), 7.21-7.27 (1H, m), 7.35 (1H, d, J=2.7 Hz), 7.43 (1H, s), 8.08 (1H, s), 8.25 (1H, dd, J=2.4, 1.2 Hz).
Using 4,6-dichloro-5-formylpyrimidine (2.0 g), methyl 5-[(4-methoxybenzyl)amino]pentanoate hydrochloride (3.90 g), potassium phosphate (5.76 g) and acetonitrile (30 mL), a similar reaction as in Example 1 (i) was carried out to give the title compound (3.72 g) as a pale-yellow oil.
1H-NMR (CDCl3) δ: 1.49-1.70 (4H, m), 2.30 (2H, t, J=7.1 Hz), 3.58 (2H, t, J=7.1 Hz), 3.66 (3H, s), 3.79 (3H, s), 4.58 (2H, s), 6.83 (2H, d, J=8.7 Hz), 7.01 (2H, d, J=8.7 Hz), 8.38 (1H, s), 10.19 (1H, s).
Using methyl 5-[(6-chloro-5-formylpyrimidin-4-yl)(4-methoxybenzyl)amino]pentanoate (520 mg), tert-butyl 4-(4-amino-2-chlorophenoxy)piperidine-1-carboxylate (434 mg), sodium carbonate (141 mg) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 100 (i) was carried out to give the title compound (505 mg) as pale-yellow amorphous.
1H-NMR (CDCl3) δ: 1.47 (9H, s), 1.52-1.99 (8H, m), 2.33 (2H, t, J=7.1 Hz), 3.36-3.55 (4H, m), 3.62-3.74 (5H, m), 3.81 (3H, s), 4.42-4.53 (1H, m), 4.78 (2H, s), 6.89 (2H, d, J=8.7 Hz), 6.95 (1H, d, J=9.0 Hz), 7.16 (2H, d, J=8.7 Hz), 7.41 (1H, dd, J=9.0, 3.0 Hz), 7.79 (1H, d, J=3.0 Hz), 8.28 (1H, s), 9.78 (1H, s), 11.02 (1H, s).
Using tert-butyl 4-[2-chloro-4-({5-formyl-6-[(4-methoxybenzyl)(5-methoxy-5-oxopentyl)amino]pyrimidin-4-yl}amino)phenoxy]piperidine-1-carboxylate (505 mg), 28% sodium methoxide-methanol solution (0.43 g) and dimethyl carbonate (10 mL), a similar reaction as in Example 132 (ii) was carried out to give methyl (5E)-4-[(4-{[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy}-3-chlorophenyl)amino]-10-(4-methoxybenzyl)-7,8,9,10-tetrahydropyrimido[4,5-b]azocine-6-carboxylate (316 mg) as yellow amorphous. Using methyl (5E)-4-[(4-{[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy}-3-chlorophenyl)amino]-10-(4-methoxybenzyl)-7,8,9,10-tetrahydropyrimido[4,5-b]azocine-6-carboxylate (316 mg), trifluoroacetic acid (5.0 mL), 1,2-dichloroethane (5.0 mL), tetrahydrofuran (10 mL), triethylamine (1.3 mL) and di-tert-butyl dicarbonate (0.11 mL), a similar reaction as in Example 133 was carried out to give the title compound (181 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.47 (9H, s), 1.50-1.69 (2H, m), 1.78-1.93 (4H, m), 2.64-2.85 (2H, m), 3.34-3.71 (6H, m), 3.82 (3H, s), 4.42-4.50 (1H, m), 5.18-5.25 (1H, m), 6.25 (1H, s), 6.93 (1H, d, J=9.0 Hz), 7.20-7.28 (1H, m), 7.52 (1H, d, J=2.7 Hz), 7.58 (1H, s), 8.07 (1H, s).
To a solution of methyl 5-[(6-chloro-5-formylpyrimidin-4-yl)(4-methoxybenzyl)amino]pentanoate (2.60 g) in dimethyl carbonate (26 mL) was added a solution of sodium methoxide in methanol (28%, 3.84 g) at room temperature, and the mixture was stirred at 50° C. for 24 hr. The mixture was cooled to 0° C., neutralized with 1N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=9:1→7:3→3:2) to give methyl (5E)-4-methoxy-10-(4-methoxybenzyl)-7,8,9,10-tetrahydropyrimido[4,5-b]azocine-6-carboxylate (2.1 g) as colorless amorphous. Using methyl (5E)-4-methoxy-10-(4-methoxybenzyl)-7,8,9,10-tetrahydropyrimido[4,5-b]azocine-6-carboxylate (2.1 g), trifluoroacetic acid (10 mL) and 1,2-dichloroethane (20 mL), a similar reaction as in Example 132 (iii) was carried out to give the title compound (1.35 g) as colorless crystals.
1H-NMR (CDCl3) δ: 1.33-1.57 (2H, m), 2.60-2.83 (2H, m), 3.35-3.76 (2H, m), 3.79 (3H, s), 3.96 (3H, s), 5.18-5.29 (1H, s), 7.85 (1H, s), 8.09 (1H, s).
A solution of methyl (5E)-4-methoxy-7,8,9,10-tetrahydropyrimido[4,5-b]azocine-6-carboxylate (1.0 g) in phosphoryl chloride (10 g) was stirred at 100° C. for 3 days. Phosphoryl chloride was evaporated under reduced pressure. Ethyl acetate was added to the residue, and the mixture was neutralized with aqueous sodium bicarbonate solution and potassium carbonate and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=4:1→3:2) to give the title compound (659 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.06-1.63 (2H, m), 2.21-2.41 (1H, m), 2.61-2.84 (1H, m), 3.08-3.37 (1H, m), 3.42-3.66 (1H, m), 3.74 (3H, s), 7.73 (1H, s), 7.91 (1H, t, J=6.9 Hz), 8.12 (1H, s).
The mixture of methyl (5E)-4-chloro-7,8,9,10-tetrahydropyrimido[4,5-b]azocine-6-carboxylate (100 mg), 3-chloro-4-[3-(trifluoromethyl)phenoxy]aniline (112 mg), pyridine hydrochloride (catalytic amount) and isopropyl alcohol (2 mL) was stirred at 90° C. for 4 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=1:1→ethyl acetate) to give the title compound (88 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.23-1.43 (2H, m), 2.50-2.71 (2H, m), 3.22-3.41 (2H, m), 3.74 (3H, s), 7.12 (1H, t, J=6.9 Hz), 7.17-7.23 (3H, m), 7.44-7.47 (1H, m), 7.54 (1H, dd, J=9.0, 2.7 Hz), 7.57-7.63 (1H, m), 7.70 (1H, s), 7.79 (1H, d, J=2.7 Hz), 7.96 (1H, s), 8.55 (1H, s).
A mixture of methyl (5E)-4-chloro-7,8,9,10-tetrahydropyrimido[4,5-b]azocine-6-carboxylate (100 mg), 3-chloro-4-[(3-fluorobenzyl)oxy]aniline (119 mg) and pyridinium chloride (catalytic amount) and isopropyl alcohol (2.0 mL) was stirred at 90° C. for 4 hr, Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=1:1→ethyl acetate) to give the title compound (71 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.20-1.40 (2H, m), 2.51-2.66 (2H, m), 3.15-3.41 (2H, m), 3.73 (3H, s), 5.20 (2H, s), 7.00 (1H, t, J=7.1 Hz), 7.11-7.20 (2H, m), 7.24-7.36 (3H, m), 7.42-7.49 (1H, m), 7.56 (1H, d, J=2.7 Hz), 7.66 (1H, s), 7.87 (1H, s), 8.30 (1H, s).
To a solution of 4,6-dichloro-5-formylpyrimidine (1.0 g) and 4-(methylamino)butanoic acid hydrochloride (0.87 g) in N,N-dimethylformamide (10 mL) was added sodium carbonate (1.80 g) at room temperature. The mixture was stirred at room temperature for 1 hr. Methyl iodide (0.42 mL) and sodium carbonate (0.72 g) were added to the reaction mixture, and the mixture was further stirred at room temperature for 14 hr. Water was added to reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=7:3→1:1) to give the title compound (665 mg) as a white solid.
1H-NMR (CDCl3) δ: 1.96-2.06 (2H, m), 2.37 (2H, t, J=7.2 Hz), 2.88 (3H, s), 3.67 (3H, s), 3.79 (2H, t, J=257.2 Hz), 8.31 (1H, s), 10.35 (1H, s).
Using methyl 4-[(6-chloro-5-formylpyrimidin-4-yl)(methyl)amino]butanoate (0.50 g), 3-chloro-4-[(3-fluorobenzyl)oxy]aniline (0.463 g), potassium carbonate (0.26 g) and N,N-dimethylformamide (6.0 mL), a similar reaction as in Example 100 (i) was carried out to give the title compound (787 mg) as pale-yellow amorphous.
1H-NMR (CDCl3) δ: 2.00-2.10 (2H, m), 2.38 (2H, t, J=7.4 Hz), 3.29 (3H, s), 3.68 (3H, s), 3.71 (2H, t, J=7.5 Hz), 5.13 (2H, s), 6.91 (1H, d, J=8.7 Hz), 6.97-7.03 (1H, m), 7.17-7.25 (3H, m), 7.28-7.41 (2H, m), 7.79 (1H, d, J=2.4 Hz), 8.19 (1H, s), 9.85 (1H, s).
Using methyl 4-[[6-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)-5-formylpyrimidin-4-yl](methyl)amino]butanoate (730 mg), 28% sodium methoxide-methanol solution (0.72 g) and dimethyl carbonate (10 mL), a similar reaction as in Example 100
1H-NMR (CDCl3) δ: 2.84 (2H, t, J=4.5 Hz), 3.24 (3H, s), 3.44 (2H, t, J=4.5 Hz), 3.79 (3H, s), 5.14 (2H, s), 6.67 (1H, s), 6.92 (1H, d, J=8.7 Hz), 6.97-7.06 (1H, m), 7.17-7.28 (3H, m), 7.32-7.39 (1H, m), 7.56 (1H, d, J=2.4 Hz), 7.64 (1H, s), 8.17 (1H, s).
To a solution of methyl 4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}amino)-9-methyl-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (200 mg) in tetrahydrofuran (5.0 mL) and ethanol (5.0 mL) was added 1N aqueous sodium hydroxide solution (1.5 mL) at room temperature. The mixture was stirred at room temperature for 6 hr. 1N Hydrochloric acid (1.5 mL) was added to the mixture and the mixture was concentrated under reduced pressure. Water was added to the residue, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The precipitated crystals were collected by filtration. The crystals were washed with hexane to give the title compound (186 mg) as yellow crystals.
1H-NMR (CDCl3) δ: 2.78-2.86 (2H, m), 3.25 (3H, s), 3.43-3.49 (2H, m), 5.11 (2H, s), 6.88-7.05 (3H, m), 7.16-7.41 (4H, m), 7.53 (1H, d, J=2.7 Hz), 7.71 (1H, s), 8.15 (1H, s).
Using methyl 4-[(6-chloro-5-formylpyrimidin-4-yl)(methyl)amino]butanoate (0.50 g), 3-methyl-4-[(6-methylpyridin-3-yl)oxy]aniline (0.414 g), potassium carbonate (0.26 g) and N,N-dimethylformamide (6.0 mL), a similar reaction as in Example 100 (i) was carried out to give the title compound (751 mg) as pale-yellow amorphous.
1H-NMR (CDCl3) δ: 2.01-2.11 (2H, m), 2.25 (3H, s), 2.39 (2H, t, J=7.1 Hz), 2.52 (3H, s), 3.30 (3H, s), 3.69 (3H, s), 3.72 (2H, t, J=7.2 Hz), 6.87 (1H, d, J=8.7 Hz), 7.08-7.09 (2H, m), 7.45-7.52 (2H, m), 8.22 (1H, s), 8.25-8.26 (1H, m), 9.88 (1H, s).
Using methyl 4-[[5-formyl-6-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)pyrimidin-4-yl](methyl)amino]butanoate (751 mg), 28% sodium methoxide-methanol solution (0.80 g) and dimethyl carbonate (10 mL), a similar reaction as in Example 100 (ii) was carried out to give the title compound (516 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 2.24 (3H, s), 2.52 (3H, s), 2.85 (2H, t, J=4.6 Hz), 3.24 (3H, s), 3.44 (2H, t, J=4.6 Hz), 3.79 (3H, s), 6.72 (1H, s), 6.86 (1H, d, J=9.0 Hz), 7.04-7.11 (2H, m), 7.22-7.29 (1H, m), 7.33-7.36 (1H, m), 7.66 (1H, s), 8.18 (1H, s), 8.24-8.26 (1H, m).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (131 mg), 2-methyl-1-(morpholin-4-yl)-2-propylamine (67.5 mg), 1-hydroxybenzotriazole (56.8 mg), triethylamine (0.1 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (86.8 mg), tetrahydrofuran (0.7 mL) and N,N-dimethylformamide (0.7 mL), a similar reaction as in Example 110 was carried out to give the title compound (139 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 1.29 (6H, s), 2.41-2.48 (4H, m), 2.54 (2H, s), 2.58-2.69 (2H, m), 3.28-3.40 (2H, m), 3.41-3.53 (4H, m), 7.00 (1H, s), 7.13-7.23 (2H, m), 7.26 (1H, d, J=8.9 Hz), 7.30 (1H, s), 7.45 (1H, d, J= 7.5 Hz), 7.54-7.63 (2H, m), 7.67 (1H, t, J=4.9 Hz), 7.92 (1H, d, J=2.5 Hz), 8.00 (1H, s), 9.24 (1H, s).
To a solution of tert-butyl [2-(2-hydroxyethoxy)ethyl]carbamate (499 mg) in tetrahydrofuran (5 mL) were added triphenylphosphine (957 mg) and 40% diethyl azodicarboxylate-toluene solution (1.7 mL), and the mixture was stirred at 0° C. for 10 min. 2-Hydroxy-2-methylpropanenitrile (0.35 mL) was added to the reaction mixture, and the mixture was stirred at room temperature for 6 hr. The reaction mixture was concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=67:33→20:80) and basic silica gel column chromatography (eluent, hexane:ethyl acetate=80:20→33:67) to give the title compound (292 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.45 (9H, s), 2.61 (2H, t, J=6.3 Hz), 3.34 (2H, q, J=5 Hz), 3.56 (2H, t, J=5 Hz), 3.68 (2H, t, J=6.3 Hz), 4.87 (1H, br s).
Using tert-butyl [2-(2-cyanoethoxy)ethyl]carbamate (289 mg), 6N hydrochloric acid (2.0 mL) and tetrahydrofuran (10 mL), a similar reaction as in Example 127 (vi) was carried out to give the title compound (214 mg) as a white solid.
1H-NMR (DMSO-d6) δ: 2.80 (2H, t, J=5.9 Hz), 2.97 (2H, t, J=5.3 Hz), 3.56-3.80 (4H, m), 8.05 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (129 mg), 3-(2-aminoethoxy)propylnitrile hydrochloride (62.6 mg), 1-hydroxybenzotriazole (55.0 mg), triethylamine (0.3 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (7-9.6 mg), tetrahydrofuran (0.7 mL) and N,N-dimethylformamide (0.7 mL), a similar reaction as in Example 110 was carried out to give the title compound (96.1 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 2.65-2.78 (4H, m), 3.29-3.40 (4H, m), 3.53 (2H, t, J=6.0 Hz), 3.61 (2H, t, J=6.0 Hz), 7.15-7.23 (3H, m), 7.26 (1H, d, J=8.9 Hz), 7.46 (1H, d, J=7.7 Hz), 7.55-7.65 (2H, m), 7.68 (1H, t, J=4.7 Hz), 7.90 (1H, d, J=2.6 Hz), 7.98 (1H, s), 8.06 (1H, t, J=5.7 Hz), 9.14 (1H, s).
Using [(2-bromoethoxy)methyl]benzene (3 mL), (2,2-dimethyl-1,3-dioxolan-4-yl)methanol (2.80 g), tetra-n-butylammonium hydrogen sulfate (667 mg), toluene (40 mL) and 50% aqueous sodium hydroxide solution (10 mL), a similar reaction as in Example 124 (i) was carried out to give the title compound (3.65 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.36 (3H, s), 1.42 (3H, s), 3.47-3.78 (7H, m), 4.05 (1H, dd, J=8.3, 6.3 Hz), 4.56 (2H, s), 7.19-7.43 (5H, m).
Using 4-{[2-(benzyloxy)ethoxy]methyl}-2,2-dimethyl-1,3-dioxolane (3.64 g), 10% palladium-carbon (372 mg) and methanol (40 mL), a similar reaction as in Example 123 (ii) was carried out to give the title compound (2.32 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.37 (3H, s), 1.44 (3H, s), 2.21 (1H, t, J=5.5 Hz), 3.51-3.81 (7H, m), 4.06 (1H, dd, J=8.3, 6.6 Hz), 4.25-4.37 (1H, m).
To a solution of 2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]ethanol (1.30 g) in ethyl acetate (25 mL) were added triethylamine (1.6 mL) and methanesulfonyl chloride (0.65 mL) under ice-cooling, and the mixture was stirred at 0° C. for 1 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was dissolved in N,N-dimethylformamide (20 mL). Sodium azide (629 mg) was added to the solution and the mixture was stirred at 50° C. for 16 hr. The reaction mixture was concentrated under reduced pressure. Water was added to the residue, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=90:10→50:50) to give the title compound (1.32 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.37 (3H, s), 1.43 (3H, s), 3.30-3.47 (2H, m), 3.48-3.84 (5H, m), 4.07 (1H, dd, J=8.4, 6.5 Hz), 4.22-4.36 (1H, m).
To a solution of 4-[(2-azidoethoxy)methyl]-2,2-dimethyl-1,3-dioxolane (1.31 g) in methanol (20 mL) was added pyridinium p-toluenesulfonate (1.63 g), and the mixture was stirred at room temperature for 17.5 hr. Pyridinium p-toluenesulfonate (802 mg) was added to the mixture, and the mixture was stirred at room temperature for 8 hr. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=67:33→0:100) to give the title compound (707 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 2.05 (1H, t, J=5.5 Hz), 2.60 (1H, d, J=4.5 Hz), 3.28-3.51 (2H, m), 3.51-3.82 (6H, m), 3.81-4.03 (1H, m).
Using 3-(2-azidoethoxy)propane-1,2-diol (701 mg), triphenylphosphine (1.27 g), tetrahydrofuran (7 mL), water (0.7 mL), di-tert-butyl dicarbonate (1.3 mL), triethylamine (1 mL) and methanol (10 mL), a similar reaction as in Example 127 (iv) was carried out to give the title compound (879 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.45 (9H, s), 2.34 (1H, br s), 2.86 (1H, br s), 3.33 (2H, q, J=5.0 Hz), 3.46-3.80 (6H, m), 3.79-3.97 (1H, m), 4.90 (1H, br s).
Using tert-butyl [2-(2,3-dihydroxypropoxy)ethyl]carbamate (670 mg), 60% sodium hydride (dispersion in mineral oil, 289 mg), methyl iodide (0.4 mL) and tetrahydrofuran (28 mL), a similar reaction as in Example 128 (i) was carried out to give the title compound (335 mg) as a pale-yellow oil.
1H-NMR (CDCl3) δ: 1.45 (9H, s), 3.24-3.36 (2H, m), 3.38 (3H, s), 3.42-3.66 (7H, m), 3.46 (3H, s), 4.96 (1H, br s).
Using tert-butyl [2-(2,3-dimethoxypropoxy)ethyl]carbamate (331 mg), 6N hydrochloric acid (1 mL) and ethanol (3 mL), a similar reaction as in Example 127 (vi) was carried out to give the title compound (260 mg) as a colorless oil.
1H-NMR (DMSO-d6) δ: 2.94 (2H, t, J=5.4 Hz), 3.26 (3H, s), 3.29-3.53 (5H, m), 3.32 (3H, s), 3.60 (2H, t, J=5.4 Hz), 8.05 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (130 mg), 2-(2,3-dimethoxypropoxy)ethylamine hydrochloride (82.9 mg), 1-hydroxybenzotriazole (56.7 mg), triethylamine (0.3 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (80.9 mg), tetrahydrofuran (0.7 mL) and N,N-dimethylformamide (0.7 mL), a similar reaction as in Example 110 was carried out to give the title compound (118 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 2.63-2.73 (2H, m), 3.20 (3H, s), 3.28 (3H, s), 3.29-3.53 (11H, m), 7.13-7.22 (3H, m), 7.26 (1H, d, J=8.9 Hz), 7.46 (1H, d, J=7.7 Hz), 7.55-7.65 (2H, m), 7.68 (1H, t, J=4.6 Hz), 7.88 (1H, d, J=2.6 Hz), 7.98 (1H, s), 8.04 (1H, t, J=5.5 Hz), 9.14 (1H, s).
Using [(2-bromoethoxy)methyl]benzene (4.01 g), 1-(4-methoxyphenoxy)propan-2-ol (5.05 g), tetra-n-butylammonium hydrogen sulfate (947 mg), toluene (60 mL) and 50% aqueous sodium hydroxide solution (15 mL), a similar reaction as in Example 124 (i) was carried out to give the title compound (2.72 g) as a yellow oil.
1H-NMR (CDCl3) δ: 1.28 (3H, d, J=6.2 Hz), 3.60-3.68 (2H, m), 3.74-3.80 (5H, m), 3.80-3.91 (2H, m), 3.92-4.02 (1H, m), 4.58 (2H, s), 6.74-6.93 (4H, m), 7.18-7.44 (5H, m).
To a mixed solution of 1-(2-[2-(benzyloxy)ethoxy]propoxy)-4-methoxybenzene (2.71 g) in acetonitrile (80 mL) and water (20 mL) was added diammonium cerium nitrate (7.04 g) under ice-cooling, and the mixture was stirred at 0° C. for 4 hours. Additional diammonium cerium nitrate (2.36 g) was added to the mixture and the mixture was stirred at room temperature for 2 hr. Saturated aqueous sodium sulfite solution and saturated aqueous sodium hydrogencarbonate solution were added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=80:20→33:67) and basic silica gel column chromatography (eluent, hexane:ethyl acetate=90:10→50:50) to give the title compound (1.53 g) as a pale-yellow oil.
1H-NMR (CDCl3) δ: 1.12 (3H, d, J=6.2 Hz), 2.65 (1H, dd, j=8.6, 4.1 Hz), 3.37-3.52 (1H, m), 3.51-3.70 (5H, m), 3.75-3.91 (1H, m), 4.58 (2H, s), 7.19-7.46 (5H, m).
Using 2-[2-(benzyloxy)ethoxy]propan-1-ol (1.52 g), methanesulfonyl chloride (0.65 mL), triethylamine (1.5 mL), ethyl acetate (30 mL), sodium azide (621 mg) and N,N-dimethylformamide (20 mL), a similar reaction as in Example 162 (iii) was carried out to give the title compound (1.59 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.20 (3H, d, J=6.3 Hz), 3.10-3.22 (1H, m), 3.22-3.37 (1H, m), 3.56-3.83 (5H, m), 4.58 (2H, s), 7.19-7.45 (5H, m).
Using {[2-(2-azido-1-methylethoxy)ethoxy]methyl}benzene (1.58 g), triphenylphosphine (1.90 g), tetrahydrofuran (17 mL), water (1.5 mL), di-tert-butyl dicarbonate (2 mL), triethylamine (1.5 mL) and methanol (20 mL), a similar reaction as in Example 127 (iv) was carried out to give the title compound (1.99 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.14 (3H, d, J=6.2 Hz), 1.44 (9H, s), 2.93-3.12 (1H, m), 3.24-3.43 (1H, m), 3.47-3.69 (4H, m), 3.68-3.82 (1H, m), 4.58 (2H, s), 5.14 (1H, br s), 7.20-7.44 (5H, m).
Using tert-butyl {2-[2-(benzyloxy)ethoxy]propyl}carbamate (1.98 g), 10% palladium-carbon (302 mg) and methanol (20 mL), a similar reaction as in Example 123 (ii) was carried out to give the title compound (1.38 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.15 (3H, d, J=6.1 Hz), 1.45 (9H, s), 2.13 (1H, t, J=5.9 Hz), 2.93-3.17 (1H, m), 3.24-3.44 (1H, m), 3.43-3.84 (5H, m), 4.90 (1H, br s).
Using tert-butyl [2-(2-hydroxyethoxy)propyl]carbamate (681 mg), 6N hydrochloric acid (1.5 mL) and tetrahydrofuran (7 mL), a similar reaction as in Example 127 (vi) was carried out to give the title compound (459 mg) as white crystals.
1H-NMR (DMSO-d6) δ: 1.11 (3H, d, J=6.1 Hz), 2.71 (1H, dd, J=13, 8.9 Hz), 2.91 (1H, dd, J=13, 3.4 Hz), 3.22-3.44 (2H, m), 3.43-3.79 (4H, m), 7.65 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (119 mg), 2-(2-amino-1-methylethoxy)ethanol hydrochloride (58.9 mg), 1-hydroxybenzotriazole (51.2 mg), triethylamine (0.35 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (73.5 mg), tetrahydrofuran (0.6 mL) and N,N-dimethylformamide (0.6 mL), a similar reaction as in Example 110 was carried out to give the title compound (79.0 mg) as a pale-yellow powder.
1H-NMR (DMSO-d6) δ: 1.07 (3H, d, J=6.1 Hz), 2.62-2.77 (2H, m), 3.20 (2H, t, J=5.7 Hz), 3.27-3.39 (2H, m), 3.39-3.60 (5H, m), 4.57 (1H, t, J=5.1 Hz), 7.12-7.22 (3H, m), 7.25 (1H, d, J=9.1 Hz), 7.46 (1H, d, J=7.2 Hz), 7.53-7.65 (2H, m), 7.68 (1H, t, J=4.5 Hz), 7.90 (1H, d, J=1.9 Hz), 7.94-8.05 (2H, m), 9.16 (1H, s).
Using tert-butyl [2-(2-hydroxyethoxy)propyl]carbamate (700 mg), 60% sodium hydride (dispersion in mineral oil, 153 mg), methyl iodide (0.22 mL) and tetrahydrofuran (32 mL), a similar reaction as in Example 128 (i) was carried out to give the title compound (381 mg) as a pale-yellow oil.
1H-NMR (CDCl3) δ: 1.14 (3H, d, J=6.1 Hz), 1.44 (9H, s), 2.95-3.07 (1H, m), 3.24-3.38 (1H, m), 3.40 (3H, s), 3.46-3.60 (4H, m), 3.64-3.79 (1H, m), 5.15 (1H, br s).
Using tert-butyl [2-(2-methoxyethoxy)propyl]carbamate (375 mg), 6N hydrochloric acid (1 mL) and tetrahydrofuran (4 mL), a similar reaction as in Example 127 (vi) was carried out to give the title compound (270 mg) as a colorless oil.
1H-NMR (DMSO-d6) δ: 1.11 (3H, d, J=6.4 Hz), 2.61-2.81 (1H, m), 2.79-2.97 (1H, m), 3.25 (3H, s), 3.39-3.55 (3H, m), 3.56-3.80 (2H, m), 7.98 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (119 mg), 2-(2-methoxyethoxy)-1-propylamine hydrochloride (67.8 mg), 1-hydroxybenzotriazole (52.1 mg), triethylamine (0.35 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (73.3 mg), tetrahydrofuran (0.6 mL) and N,N-dimethylformamide (0.6 mL), a similar reaction as in Example 110 was carried out to give the title compound (104 mg) as a yellow powder.
1H-NMR (DMSO-d6) δ: 1.07 (3H, d, J=6.1 Hz), 2.64-2.75 (2H, m), 3.14-3.2-3 (4H, m), 3.28-3.43 (5H, m), 3.46-3.64 (3H, m), 7.11-7.23 (3H, m), 7.26 (1H, d, J=8.7 Hz), 7.46 (1H, d, J=7.6 Hz), 7.55-7.65 (2H, m), 7.69 (1H, t, J=4.7 Hz), 7.89 (1H, d, J=2.3 Hz), 7.93-8.02 (2H, m), 9.16 (1H, s).
To a solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg) in tetrahydrofuran (1.5 mL) were successively added triethylamine (0.04 mL) and diphenylphosphoryl azide (0.05 mL), and the mixture was stirred at room temperature for 2 hr. A solution of 2-(methylsulfonyl)ethanol (50.0 mg) in tetrahydrofuran (0.5 mL) was added dropwise to the reaction solution, and the mixture was stirred at 60° C. for 3 hr. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=10:90→0:100→ethyl acetate:methanol=95:5) and basic silica gel column chromatography (eluent, hexane:ethyl acetate=10:90→0:100→ethyl acetate:methanol=90:10), and crystallized from diisopropyl ether-ethyl acetate to give the title compound (15.9 mg) as a pale-yellow powder.
1H-NMR (DMSO-d6) δ: 2.58-2.70 (2H, m), 3.07 (3H, s), 3.30-3.43 (2H, m), 3.50 (2H, t, J=5.7 Hz), 4.36 (2H, t, J=5.7 Hz), 6.60 (1H, s), 7.12-7.25 (3H, m), 7.27 (1H, t, J=4.2 Hz), 7.45 (1H, d, J=8.0 Hz), 7.53-7.65 (2H, m), 7.87 (1H, d, J=2.7 Hz), 7.94 (1H, s), 8.54 (1H, t, J=5.7 Hz), 8.72 (1H, s).
To a solution of methyl 4-[(6-chloro-5-formylpyrimidin-4-yl)(4-methoxybenzyl)amino]butanoate (15.4 g) in dimethyl carbonate (150 mL) was added 28% sodium methoxide-methanol solution (23.6 g) at room temperature. The mixture was stirred at room temperature, for 24 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=3:1→1:1) to give the title compound (12.8 g) as colorless crystals.
1H-NMR (CDCl3) δ: 2.66-2.70 (2H, m), 3.28-3.32 (2H, m), 3.78 (3H, s), 3.79 (3H, s), 4.03 (3H, s), 4.88 (2H, s), 6.85 (2H, d, J=8.7 Hz), 7.19 (2H, d, J=8.7 Hz), 8.09 (1H, t, J=1.2 Hz), 8.24 (1H, s).
To a solution of methyl 4-methoxy-9-(4-methoxybenzyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (476 mg) in toluene (5.0 mL) was added trifluoroacetic acid (2.5 mL) at room temperature. The mixture was stirred at 70° C. for 20 hr and concentrated under reduced pressure. Aqueous sodium bicarbonate solution was added to the residue and the mixture was extracted with a mixed solvent of ethyl acetate-tetrahydrofuran. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The precipitated crystals were collected by filtration and washed with diisopropyl ether to give the title compound (288 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.89 (2H, t, J=4.5 Hz), 3.46 (2H, q, J=4.5 Hz), 3.80 (3H, s), 4.01 (3H, s), 5.79-5.87 (1H, m), 8.04 (1H, d, J=1.2 Hz), 8.12 (1H, s).
A mixture of methyl 4-methoxy-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (2.55 g) and phosphoryl chloride (26 mL) was stirred at 100° C. for 96 hr. The reaction mixture was concentrated under reduced pressure, and ice was added to the residue at 0° C. The mixture was neutralized with saturated aqueous ammonia. The precipitate was collected by filtration and washed with water to give the title compound (2.40 g) as a pale-yellow powder.
1H-NMR (CDCl3) δ: 2.88-2.98 (2H, m), 3.46-3.57 (2H, m), 3.84 (3H, s), 6.18 (1H, br s), 8.14 (1H, s), 8.20 (1H, s).
To a solution of 3-(trifluoromethoxy)phenol (0.93 g) in tetrahydrofuran (10 mL) was added 60% sodium hydride (dispersion in mineral oil, 0.23 g) at 0° C. The mixture was stirred at 0° C. for 1 hr, and 2,3-dichloro-5-nitropyridine (1.0 g) was added thereto. The mixture was stirred at room temperature for 4 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=19:1->3:1) to give the title compound (1.57 g) as a pale-yellow oil.
1H-NMR (CDCl3) δ: 7.06-7.22 (3H, m), 7.49 (1H, t, J=8.3 Hz), 8.59 (1H, d, J=2.4 Hz), 8.88 (1H, d, J=2.4 Hz).
A mixture of 3-chloro-5-nitro-2-[3-(trifluoromethoxy)phenoxy]pyridine (1.57 g), reduced iron (1.31 g), calcium chloride (0.26 g) and 15% water-containing ethanol (50 mL) was heated under reflux for 10 hr. An insoluble material was removed by filtration, and the filtrate was concentrated under reduced pressure. Water was added to the residue, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=3:1→2:1) to give the title compound (1.02 g) as a yellow solid.
1H-NMR (CDCl3) δ: 3.65 (2H, br s), 6.91-7.02 (3H, m), 7.18 (1H, d, J=2.7 Hz), 7.35 (1H, t, J=8.1 Hz), 7.59 (1H, d, J=2.7 Hz).
A mixture of methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (100 mg), 5-chloro-6-[3-(trifluoromethoxy)phenoxy]pyridin-3-amine (127 mg) and pyridine hydrochloride (catalytic amount) in isopropyl alcohol (2.0 mL) was stirred at 90° C. for 24 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=1:1→ethyl acetate) to give the title compound (94 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 2.91 (2H, t, J=5.1 Hz), 3.48-3.56 (2H, m), 3.82 (3H, s), 5.78-5.85 (1H, m), 6.75 (1H, s), 7.03-7.12 (3H, m), 7.38-7.43 (1H, m), 7.65 (1H, s), 8.05-8.08 (2H, m), 8.19 (1H, d, J=2.7 Hz).
To a solution of methyl 4-[(4-{3-[(tert-butylamino) carbonyl]phenoxy}-3-chlorophenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (1.10 g) in tetrahydrofuran (45 mL) and ethanol (45 mL) was added 1N aqueous sodium hydroxide solution (6.0 mL) at room temperature. The mixture was stirred at room temperature for 14 hr, and 1N hydrochloric acid (6.0 mL) was added to the reaction mixture. The solvent was evaporated under reduced pressure, and the precipitated crystals were collected by filtration. The crystals were washed with water to give the title compound (998 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.36 (9H, s), 2.67-2.75 (2H, m), 3.32-3.42 (2H, m), 7.04 (1H, dd, J=7.8, 2.4 Hz), 7.35 (1H, br s), 7.39-7.44 (2H, m), 7.50 (1H, dd, J=8.7, 2.4 Hz), 7.55 (1H, d, J=7.8 Hz), 7.71 (1H, s), 7.80 (1H, d, J=2.4 Hz), 7.82 (1H, s), 7.92-8.09 (2H, m), 9.52 (1H, br s).
To a solution of 4-[(4-{3-[(tert-butylamino) carbonyl]phenoxy}-3-chlorophenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (300 mg) and 4-methylmorpholine (78 μL) in tetrahydrofuran (5.0 mL) was added isopropyl chlorocarbonate (88 μL) at 0° C. The mixture was stirred at 0° C. for 2 hr, and the precipitate was removed by filtration. The filtrate was added dropwise to a mixed solution of sodium borohydride (122 mg) in tetrahydrofuran (3.0 mL) and water (3.0 mL) at 0° C. The mixture was stirred at 0° C. for 1 hr and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, ethyl acetate→methyl acetate:methanol=9:1) to give the title compound (187 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.45 (9H, s), 2.53 (2H, t, J=4.8 Hz), 3.52 (2H, t, J=4.8 Hz), 4.22 (2H, s), 5.51-5.58 (1H, m), 5.95 (1H, br s), 6.31 (1H, s), 6.41 (1H, s), 6.99 (1H, d, J=8.7 Hz), 7.05-7.10 (1H, m), 7.22-7.28 (2H, m), 7.31-7.38 (2H, m), 7.61 (1H, d, J=2.7 Hz), 8.08 (1H, s).
A mixture of 2-(2-bromoethoxy)tetrahydro-2H-pyran (3.20 g) and 1,3-bisbenzyloxy-2-propanol (5.00 g) was dissolved in toluene (40 mL). Tetra-n-butylammonium hydrogen sulfate (530 mg) and 50% aqueous sodium hydroxide solution (10 mL) were added to the mixture and the mixture was stirred at 40° C. for 5.5 days. Water was added to the reaction mixture and the mixture was extracted with toluene. The organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=98:2→67:33) to give the title, compound (3.16 g) as an orange oil.
1H-NMR (CDCl3) δ: 1.38-1.92 (6H, m), 3.40-3.52 (1H, m), 3.52-3.69 (5H, m), 3.69-3.97 (5H, m), 4.54 (4H, s), 4.59-4.71 (1H, m), 7.16-7.46 (10H, m).
2-(2-{2-(Benzyloxy)-1-[(benzyloxy)methyl]ethoxy}ethoxy)tetrahydro-2H-pyran (3.15 g) was dissolved to methanol (25 mL). 6N hydrochloric acid (4.0 mL) was added to the mixture, and the solution was stirred at 60° C. for 3 days. The reaction mixture was neutralized with 8N aqueous sodium hydroxide solution and concentrated under reduced pressure. Water was added to the residue, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=80:26→33:67) to give the title compound (2.37 g) as a pale-yellow oil.
1H-NMR (CDCl3) δ: 3.10 (1H, t, J=3.8 Hz), 3.46-3.63 (4H, m), 3.62-3.90 (5H, m), 4.54 (4H, s), 7.18-7.45 (10H, m).
2-{2-(Benzyloxy)-1-[(benzyloxy)methyl]ethoxy}ethanol (2.37 g) was dissolved in ethyl acetate (30 mL), and the solution was cooled to 0° C. Triethylamine (1.6 mL) and methanesulfonyl chloride (0.65 mL) were added to the mixture and the mixture was stirred at 0° C. for 1 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was dissolved in N,N-dimethylformamide (20 mL). Sodium azide (640 mg) was added to the solution, and the mixture was stirred at 50° C. for 15 hr. Additional sodium azide (232 mg) was added to the mixture, and the mixture was stirred at 50° C. for 5 hr. The reaction mixture was concentrated under reduced pressure. Water was added to the residue and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=95:5→67:33) to give the title compound (2.40 g) as a colorless oil.
1H-NMR (CDCl3) δ: 3.33-3.41 (2H, m), 3.54-3.66 (4H, m), 3.70-3.79 (1H, m), 3.79-3.86 (2H, m), 4.54 (4H, s), 7.19-7.46 (10H, m).
1,1′-[[2-(2-Azidoethoxy)propane-1,3-diyl]bis(oxymethylene)]dibenzene (2.39 g) was dissolved in a mixture of tetrahydrofuran (23 mL) and water (2 mL). Triphenylphosphine (2.03 g) was added to the mixture, and the mixture was stirred at room temperature for 3 days. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in methanol (30 mL). The solution was cooled to 0° C. Triethylamine (2.5 mL) and di-tert-butyl dicarbonate (2.5 mL) were added to the solution and the mixture was stirred for 6.5 hr at room temperature. Water was added to the reaction mixture, methanol was evaporated under reduced pressure, and the residue was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=95:5→67:33) to give the title compound (2.76 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.43 (9H, s), 3.20-3.39 (2H, m), 3.45-3.61 (4H, m), 3.61-3.80 (3H, m), 4.54 (4H, s), 5.21-5.46 (1H, m), 7.18-7.45 (10H, m).
tert-Butyl (2-{2-(benzyloxy)-1-[(benzyloxy)methyl]ethoxy}ethyl)carbamate (2.75 g) was dissolved in methanol (30 mL). 10% Palladium-carbon (297 mg) was added to the solution, and the mixture was stirred for 2.5 days under hydrogen atmosphere. The reaction mixture was filtrated through Celite, and the filtrate was concentrated under reduced pressure. The residue was dissolved methanol (30 mL), 10% palladium-carbon (606 mg) was added to the solution, and the mixture was stirred at room temperature for 10 days under hydrogen atmosphere. The reaction mixture was filtrated through Celite, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=80:20→0:100) to give tert-butyl {2-[2-hydroxy-1-(hydroxymethyl)ethoxy]ethyl}carbamate (413 mg) and tert-butyl {2-[2-(benzyloxy)-1-(hydroxymethyl)ethoxy]ethyl}carbamate (1.20 g), each as a colorless oil.
1H-NMR (CDCl3) δ: 1.45 (9H, s), 2.48 (2H, br s), 3.34 (2H, q, J=5.5 Hz), 3.43-3.57 (1H, m), 3.60-3.87 (6H, m), 5.05 (1H, br s).
1H-NMR (CDCl3) δ: 1.44 (9H, s), 2.26 (1H, br s), 3.21-3.42 (2H, m), 3.47-3.81 (7H, m), 4.54 (2H, s), 5.07 (1H, br s), 7.19-7.45 (5H, m).
60% Sodium hydride (dispersion in mineral oil, 153 mg) was suspended in tetrahydrofuran (15 mL) and the suspension was cooled to 0° C. A solution of tert-butyl {2-[2-hydroxy-1-(hydroxymethyl)ethoxy]ethyl}carbamate (408 mg) in tetrahydrofuran (5.0 mL) was added dropwise to the suspension, and the mixture was stirred at 0° C. for 1 hr. Methyl iodide (0.227 mL) was added to the solution, and the mixture was stirred at room temperature for 3 hr. Additional methyl iodide (0.110 mL) was added to the mixture, and the mixture was stirred for 3 hr. Saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=80:20→33:67) to give the title compound (251 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.44 (9H, m), 3.30 (2H, q, J=5.4 Hz), 3.37 (6H, s), 3.39-3.50 (4H, m), 3.55-3.75 (3H, m), 5.39 (1H, br s).
tert-Butyl {2-[2-methoxy-1-(methoxymethyl)ethoxy]ethyl}carbamate (246 mg) was dissolved in tetrahydrofuran (3.0 mL). 6N hydrochloric acid (0.5 mL) was added to the solution and the mixture was stirred at 50° C. for 14 hr. The reaction mixture was concentrated under reduced pressure, and the residue was azeotropically evaporated with ethanol. The residue was dried under reduced pressure to give the title compound (185 mg) as a colorless oil.
1H-NMR (DMSO-d6) δ: 2.92 (2H, t, J=5.5 Hz), 3.26 (6H, s), 3.37-3.43 (4H, m), 3.57-3.67 (1H, m), 3.71 (2H, t, J=5.5 Hz), 7.98 (3H, br s).
A mixture of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (119 mg) and 2-[2-methoxy-1-(methoxymethyl)ethoxy]ethaneamine hydrochloride (73.0 mg) was dissolved in a mixture of tetrahydrofuran (0.60 mL) and N,N-dimethylformamide (0.60 mL). Triethylamine (0.35 mL), 1-hydroxybenzotriazole (52.8 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (77.6 mg) were successively added to the mixture, and the mixture was stirred at room temperature for 16 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=10:90→0:100→ethyl acetate:methanol=90:10). The objective fraction was concentrated under reduced pressure and crystallized from ethyl acetate-diisopropyl ether to give the title compound (32.2 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 2.63-2.72 (2H, m), 3.20 (6H, s), 3.25-3.41 (8H, m), 3.52-3.63 (3H, m), 7.12-7.23 (3H, m), 7.26 (1H, d, J=8.7 Hz), 7.46 (1H, d, J=7.6 Hz), 7.55-7.65 (2H, m), 7.70 (1H, t, J=4.7 Hz), 7.88 (1H, d, J=2.7 Hz), 7.95-8.04 (2H, m), 9.17 (1H, s).
Using tert-butyl {2-[2-(benzyloxy)-1-(hydroxymethyl)ethoxy]ethyl}carbamate (499 mg), 60% sodium hydride (dispersion in mineral oil, 73.4 mg), methyl iodide (0.11 mL) and tetrahydrofuran (20 mL), a similar reaction as in Example 168 (vi) was carried out to give the title compound (296 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.44 (9H, s), 3.30 (2H, q, J=5.3 Hz), 3.36 (3H, s), 3.39-3.59 (4H, m), 3.60-3.77 (3H, m), 4.55 (2H, s), 5.37 (1H, br s), 7.18-7.46 (5H, m).
Using tert-butyl {2-[2-(benzyloxy)-1-(methoxymethyl)ethoxy]ethyl}carbamate (290 mg), 10% palladium-carbon (47.7 mg) and methanol (3.0 mL), a similar reaction as in Example 168 (v) was carried out to give the title compound (206 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.45 (9H, s), 2.27 (1H, br s), 3.23-3.41 (2H, m), 3.38 (3H, s), 3.43-3.81 (7H, m), 5.10 (1H, br s).
Using tert-butyl {2-[2-hydroxy-1-(methoxymethyl)ethoxy]ethyl}carbamate (201 mg), 6N hydrochloric acid (0.50 mL) and tetrahydrofuran (4.0 mL), a similar reaction as in Example 168 (vii) was carried out to give the title compound (150 mg) as a colorless oil.
1H-NMR (DMSO-d6) δ: 2.84-3.03 (2H, m), 3.26 (3H, s), 3.29-3.55 (4H, m), 3.57-3.84 (3H, m), 4.80 (1H, br s), 7.94 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (119 mg), 2-(2-aminoethoxy)-3-methoxypropan-1-ol hydrochloride (71.8 mg), tetrahydrofuran (0.60 mL), N,N-dimethylformamide (0.60 mL), triethylamine (0.35 mL), 1-hydroxybenzotriazole (51.5 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (73.3 mg), a similar reaction as in Example 168 (viii) was carried out to give the title compound (94.8 mg) as white crystals.
1H-NMR (DMSO-d6) δ: 2.63-2.74 (2H, m), 3.20 (3H, s), 3.25-3.47 (9H, m), 3.58 (2H, t, J=6.1 Hz), 4.64 (1H, t, J=5.3 Hz), 7.12-7.22 (3H, m), 7.26 (1H, d, J=8.7 Hz), 7.46 (1H, d, J=8.0 Hz), 7.54-7.65 (2H, m), 7.69 (1H, t, J=4.5 Hz), 7.89 (1H, d, J=2.3 Hz), 7.93-8.04 (2H, m), 9.15 (1H, s).
Using 4-[(4-{3-[(tert-butylamino)carbonyl]phenoxy}-3-chlorophenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 2-methyl-1-(methylsulfonyl)-2-propylamine hydrochloride (74 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (75.6 mg), 1-hydroxybenzotriazole monohydrate (60 mg), triethylamine (82 μL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (87 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 1.69 (6H, s), 2.85 (2H, t, J=4.5 Hz), 2.98 (3H, s), 3.47-3.57 (2H, m), 3.63 (2H, s), 5.63-5.71 (1H, m), 5.93 (1H, br s), 6.36 (1H, s), 7.00 (1H, d, J=8.7 Hz), 7.03-7.07 (1H, m), 7.19-7.42 (4H, m), 7.48 (1H, dd, J=8.7, 2.4 Hz), 7.87 (1H, d, J=2.4 Hz), 8.13 (1H, s).
Using methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (100 mg), 3-chloro-4-{3-[(2,2,2-trifluoroethyl)sulfonyl]phenoxy}aniline (153 mg), pyridinium chloride (4.9 mg) and isopropyl alcohol (5.0 mL), a similar reaction as in Example 166 (iv) was carried out to give the title compound (130 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 2.92 (2H, t, J=4.8 Hz), 3.56 (2H, q, J=4.8 Hz), 3.83 (3H, s), 3.91 (2H, q, J=9.0 Hz), 5.81-5.89 (1H, m), 6.89 (1H, s), 7.10 (1H, d, J=8.7 Hz), 7.25-7.30 (1H, m), 7.42 (1H, dd, J=8.7, 2.7 Hz), 7.49 (1H, t, J=2.1 Hz), 7.53-7.58 (1H, m), 7.61-7.68 (2H, m), 7.79 (1H, d, J=2.7 Hz), 8.14 (1H, s).
To a solution of tert-butyl (2-hydroxy-1,1-dimethylethyl)carbamate (10.3 g) and triethylamine (15.2 mL) in tetrahydrofuran (300 mL) was added dropwise methanesulfonyl chloride (6.32 mL) at 0° C. The mixture was stirred at 0° C. for 1 hr, aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=1:1→1:3) to give a colorless oil (15.2 g). A mixture of the obtained oil (15.2 g), 2-mercaptoethanol (7.63 g) and sodium tert-butoxide (10.5 g) in N,N-dimethylformamide (100 mL) was stirred at 60° C. for 12 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=3:1→3:2) to give the title compound (9.30 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.33 (6H, s), 1.43 (9H, s), 3.01 (3H, s), 4.31 (2H, s), 4.52 (2H, br s).
To a solution of tert-butyl {2-[(2-hydroxyethyl)thio]-1,1-dimethylethyl}carbamate (9.30 g) in ethyl acetate (300 mL) was added 3-chloroperbenzoic acid (70%, 19.3 g) at 0° C., and the mixture was stirred at 0° C. for 1 hr. Aqueous sodium thiosulfate solution was added to the reaction mixture. The mixture was stirred at room temperature for 1 hr and extracted with ethyl acetate. The organic layer was washed with aqueous sodium bicarbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by basic silica gel column chromatography (eluent, hexane:ethyl acetate=3:1→ethyl acetate) and by silica gel column chromatography (eluent, hexane:ethyl acetate=3:2→1:4) to give the title compound (6.50 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.44 (9H, s), 1.52 (6H, s), 2.94 (1H, t, J=6.3 Hz), 3.18 (2H, t, J=5.3 Hz), 3.67 (2H, s), 4.06-4.13 (2H, m), 4.83 (1H, s).
To a solution of tert-butyl {2-[(2-hydroxyethyl)sulfonyl]-1,1-dimethylethyl}carbamate (6.50 g) in ethanol (130 mL) was added 2N hydrochloric acid (25 mL) at room temperature. The mixture was stirred at 60° C. for 24 hr. 6N hydrochloric acid (3.0 mL) was added to the reaction mixture. The mixture was stirred at 60° C. for 16 hr, and concentrated under reduced pressure to give the title compound (5.20 g) as a colorless oil.
1H-NMR (DMSO-d6) δ: 1.47 (6H, s), 3.33 (2H, t, J=5.4 Hz), 3.59 (2H, s), 3.81 (2H, t, J=5.4 Hz), 5.31 (1H, br s), 8.23 (3H, br s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (600 mg), 2-[(2-amino-2-methylpropyl)sulfonyl]ethanol hydrochloride (550 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (480 mg), 1-hydroxybenzotriazole monohydrate (380 mg), triethylamine (0.53 mL) and N,N-dimethylformamide (12 mL), a similar reaction as in Example 136 was carried out to give the title compound (666 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.68 (6H, s), 2.71-2.87 (3H, m), 3.22 (2H, t, J=5.0 Hz), 3.52 (2H, q, J=4.6 Hz), 3.75 (2H, s), 4.11 (2H, t, J=4.6 Hz), 5.75 (1H, t, J=4.8 Hz), 6.39 (1H, s), 7.03 (1H, d, J=9.0 Hz), 7.04-7.10 (1H, m), 7.19 (1H, br s), 7.29-7.33 (2H, m), 7.38-7.44 (1H, m), 7.52 (1H, dd, J=9.0, 2.7 Hz), 7.85 (1H, d, J=2.7 Hz), 8.11 (1H, s).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 2-[(2-aminoethyl)sulfonyl]ethanol hydrochloride (94 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (95 mg), 1-hydroxybenzotriazole monohydrate (76 mg), triethylamine (0.10 mL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (84 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 2.14 (3H, s), 2.42 (3H, s), 2.62-2.71 (2H, m), 3.20-3.45 (6H, m), 3.52-3.65 (2H, m), 3.72-3.83 (2H, m), 5.12-5.21 (1H, m), 6.89 (1H, d, J=8.1 Hz), 7.11-7.26 (3H, m), 7.34-7.41 (1H, m), 7.44 (1H, s), 7.55-7.65 (1H, m), 7.90 (1H, s), 8.11-8.18 (1H, m), 8.20-8.28 (1H, m), 8.84 (1H, s).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (99.9 mg), 2-(2-methoxyethoxy)ethaneamine hydrochloride (59.3 mg), tetrahydrofuran (0.60 mL), N,N-dimethylformamide (0.60 mL), triethylamine (0.35 mL), 1-hydroxybenzotriazole (51.9 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (71.9 mg), a similar reaction as in Example 168 (viii) was carried out to give the title compound (76.1 mg), as a white powder.
1H-NMR (DMSO-d6) δ: 2.14 (3H, s), 2.43 (3H, s), 2.62-2.70 (2H, m), 3.21 (3H, s), 3.28-3.38 (4H, m), 3.39-3.56 (6H, m), 6.90 (1H, d, J=8.9 Hz), 7.11-7.18 (2H, m), 7.19-7.25 (1H, m), 7.37 (1H, dd, J=8.8, 2.5 Hz), 7.44 (1H, d, J=2.5 Hz), 7.55 (1H, t, J=4.5 Hz), 7.90 (1H, s), 8.05 (1H, t, J=5.6 Hz), 8.14 (1H, d, J= 2.5 Hz), 8.86 (1H, s).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 3-(2-aminoethoxy)propanenitrile hydrochloride (55.7 mg), tetrahydrofuran (0.60 mL), N,N-dimethylformamide (0.60 mL), triethylamine (0.35 mL), 1-hydroxybenzotriazole (52.3 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (71.3 mg), a similar reaction as in Example 168 (viii) was carried out to give the title compound (70.0 mg) as pale-orange crystals.
1H-NMR (DMSO-d6) δ: 2.14 (3H, s), 2.43 (3H, s), 2.62-2.71 (2H, m), 2.74 (2H, t, J=6.0 Hz), 3.28-3.40 (4H, m), 3.48-3.57 (2H, m), 3.61 (2H, t, J=6.0 Hz), 6.90 (1H, d, J=8.9 Hz), 7.11-7.19 (2H, m), 7.19-7.25 (1H, m), 7.37 (1H, dd, J=8.7, 2.6 Hz), 7.44 (1H, d, J=2.6 Hz), 7.56 (1H, t, J=4.7 Hz), 7.90 (1H, s), 8.06 (1H, t, J=5.7 Hz), 8.14 (1H, d, J=2.8 Hz), 8.85 (1H, s).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 2-(2-aminoethoxy)ethanol (52.1 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (95 mg), 1-hydroxybenzotriazole monohydrate (76 mg), triethylamine (0.10 mL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (83 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.21 (3H, s), 2.51 (3H, s), 2.79-2.94 (3H, m), 3.46-3.66 (8H, m), 3.69-3.79 (2H, m), 5.65-5.71 (1H, m), 6.54-6.65 (1H, m), 6.83 (1H, d, J=8.4 Hz), 7.05-7.14 (2H, m), 7.19-7.31 (4H, m), 8.06 (1H, s), 8.19 (1H, d, J=2.7 Hz).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 2,2-dimethyl-3-(methylsulfonyl)-1-propylamine hydrochloride (100 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-hydrochloride (95 mg), 1-hydroxybenzotriazole monohydrate (76 mg), triethylamine (0.10 mL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (90 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.23 (6H, s), 2.23 (3H, s), 2.52 (3H, s), 2.86 (3H, s), 2.88 (2H, t, J=4.5 Hz), 3.07 (2H, s), 3.48-3.56 (4H, m), 5.69 (1H, t, J=4.2 Hz), 6.85 (1H, d, J=8.4 Hz), 7.04-7.12 (2H, m), 7.19 (1H, s), 7.23-7.35 (3H, m), 7.40 (1H, d, J=3.0 Hz), 8.08 (1H, s), 8.23 (1H, d, J=2.7 Hz).
Using 6-(aminomethyl)-N-{3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-amine dihydrochloride (50.0 mg), (2-methoxyethoxy)acetic acid (0.016 mL), tetrahydrofuran (0.40 mL), N,N-dimethylformamide (0.40 mL), triethylamine (0.15 mL), 1-hydroxybenzotriazole (26.0 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (36.0 mg), a Similar reaction as in Example 168 (viii) was carried out to give the title compound (32.7 mg) as white crystals.
1H-NMR (DMSO-d6) δ: 2.33-2.44 (2H, m), 3.21 (3H, s), 3.26-3.38 (2H, m), 3.38-3.47 (2H, m), 3.54-3.64 (2H, m), 3.87-3.97 (4H, m), 6.42 (1H, s), 7.13-7.21 (2H, m), 7.24 (1H, d, J=8.9 Hz), 7.37 (1H, t, J=4.5 Hz), 7.45 (1H, d, J=7.7 Hz), 7.55-7.66 (2H, m), 7.82 (1H, t, J=5.9 Hz), 7.88 (1H, d, J=2.5 Hz), 7.94 (1H, s), 8.84 (1H, s).
A mixture of 2-nitrobenzenesulfonyl chloride (3.50 g) and 2-(methylsulfonyl)ethaneamine (2.50 g) was dissolved in toluene (30 mL). tetra-n-Butylammonium hydrogen sulfate (560 mg) and 1N aqueous sodium hydroxide solution (10 mL) were added to the solution, and the mixture was stirred at 50° C. for 24 hr. Saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=50:50→0:100) to give the title compound (1.37 g) as white crystals.
1H-NMR (CDCl3) δ: 3.03 (3H, s), 3.26-3.45 (2H, m), 3.54-3.73 (2H, m), 6.08 (1H, br s), 7.70-7.84 (2H, m), 7.86-7.99° (1H, m), 8.07-8.21 (1H, m).
A mixture of [4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl]methanol (99.6 mg) and N-[2-(methylsulfonyl)ethyl]-2-nitrobenzenesulfonamide (86.2 mg) was dissolved in tetrahydrofuran (2 mL) and the solution was cooled to 0° C. Triphenylphosphine (84.7 mg) and 40% diethyl azodicarboxylate-toluene solution (0.148 mL) were added to the solution, and the mixture was stirred at 0° C. for 4 hr. The reaction mixture was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=50:50→0:100) and basic silica gel column chromatography (eluent, hexane:ethyl acetate=50:50→0:100) to give N-{[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl]methyl}-N-[2-(methylsulfonyl)ethyl]-2-nitrobenzenesulfonamide, which was dissolved in tetrahydrofuran (1 mL). Diazabicyclo[5,4,0]-7-undecene (0.0134 mL) and 2-mercaptoethanol (0.0063 mL) were added to the solution, and the mixture was stirred at room temperature for 22 hr. The reaction mixture was concentrated under reduced pressure. The residue was separated and purified by basic silica gel column chromatography (eluent, hexane:ethyl acetate=10:90→0:100→ethyl acetate:methanol=90:10) to give N-{3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-6-({[2-(methylsulfonyl)ethyl]amino}methyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-amine, which was dissolved in ethyl acetate (1.0 mL). 4N Hydrochloric acid/ethyl acetate (0.030 mL) was added to the solution, and the mixture was stirred at room temperature for 1 hr. The reaction mixture was concentrated under reduced pressure. The precipitate was collected by filtration and dried to give the title compound (17.9 mg) as a pale-orange powder.
1H-NMR (DMSO-d6) δ 2.59-2.68 (2H, m), 3.14 (3H, s), 3.26-3.73 (6H, m), 3.76-3.86 (2H, m), 6.91 (1H, s), 7.16-7.26 (2H, m), 7.30 (1H, d, J=8.8 Hz), 7.48 (1H, d, J=8.0 Hz), 7.57-7.68 (2H, m), 7.91 (1H, d, J=2.5 Hz), 8.20 (1H, s), 8.34 (1H, br s), 9.57 (2H, br s), 9.91 (1H, br s).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 2-methyl-1-(methylsulfonyl)-2-propylamine hydrochloride (93 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (95 mg), 1-hydroxybenzotriazole monohydrate (76 mg), triethylamine (0.10 mL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (86 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.67 (6H, s), 2.23 (3H, s), 2.52 (3H, s), 2.83 (2H, t, J=4.4 Hz), 2.94 (3H, s), 3.52 (2H, q, J=4.8 Hz), 3.64 (2H, s), 5.65 (1H, t, J=4.8 Hz), 6.26 (1H, s), 6.84 (1H, d, J=8.7 Hz), 7.04-7.11 (3H, m), 7.28 (1H, s), 7.33 (1H, dd, J=8.7, 2.4 Hz), 7.45 (1H, d, J=2.4 Hz), 8.09 (1H, s), 8.24-8.26 (1H, m).
60% Sodium hydride (dispersion in mineral oil, 1.45 g) was suspended in N,N-dimethylformamide (80 mL), and the suspension was cooled to 0° C. A solution of 1-(4-methoxyphenoxy)-2-propanol (5.00 g) in N,N-dimethylformamide (20 mL) was added dropwise to the suspension, and the mixture was stirred at 0° C. for 30 min. Benzyl bromide (4 mL) was added dropwise to the solution, and the mixture was stirred for 2 hr at 0° C. Saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with diethyl ether. The organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=100:0→80:20) to give the title compound (6.58 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.30 (3H, d, J=6.1 Hz), 3.77 (3H, s), 3.80-4.10 (3H, m), 4.67 (2H, s), 6.72-6.92 (4H, m), 7.16-7.46 (5H, m).
1-[2-(Benzyloxy)propoxy]-4-methoxybenzene (6.57 g) was dissolved in a mixture of acetonitrile (160 mL) and water (40 mL). Diammonium cerium nitrate (25.3 g) was added to the solution, and the mixture was stirred at room temperature for 7 hr. Saturated aqueous sodium thiosulfate solution and saturated aqueous sodium hydrogencarbonate solution were added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=95:5→50:50) to give the title compound (3.28 g) as an orange oil.
1H-NMR (CDCl3) δ: 1.19 (3H, d, J=6.1 Hz), 2.01 (1H, dd, J=8.0, 4.5 Hz), 3.39-3.80 (3H, m), 4.49 (1H, d, J=11.4 Hz), 4.66 (1H, d, J=11.4 Hz), 7.12-7.49 (5H, m).
Using 2-(benzyloxy)propan-1-ol (3.27 g), 2-(2-bromoethoxy)tetrahydro-2H-pyran (4.95 g), toluene (40 mL), tetra-n-butylammonium hydrogen sulfate (670 mg) and 50% aqueous sodium hydroxide solution (10 mL), a similar reaction as in Example 168 (i) was carried out to give the title compound (3.25 g) as a yellow oil.
1H-NMR (CDCl3) δ: 1.19 (3H, d, J=6.4 Hz), 1.40-1.93 (6H, m), 3.39-3.98 (9H, m), 4.55-4.72 (3H, m), 7.14-7.45 (5H, m).
2-{2-[2-(Benzyloxy)propoxy]ethoxy}tetrahydro-2H-pyran (3.24 g) was dissolved in methanol (35 mL). Pyridinium p-toluenesulfonate (3.96 g) was added to the solution, and the mixture was stirred at room temperature for 5 hr. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture. Methanol was evaporated under reduced pressure, and the residue was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=80:20→33:67) to give the title compound (2.22 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.20 (3H, d, J=6.4 Hz), 2.23 (1H, t, j=6.3 Hz), 3.42-3.65 (4H, m), 3.65-3.84 (3H, m), 4.52-4.70 (2H, m), 7.16-7.47 (5H, m).
Using 2-[2-(benzyloxy)propoxy]ethanol (2.21 g), methanesulfonyl chloride (0.90 mL), triethylamine (2.2 mL), ethyl acetate (30 mL), sodium azide (894 mg) and N,N-dimethylformamide (20 mL), a similar reaction as in Example 168 (iii) was carried out to give the title compound (2.34 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.21 (3H, d, J=6.3 Hz), 3.33-3.41 (2H, m), 3.43-3.52 (1H, m), 3.52-3.61 (1H, m), 3.63-3.69 (2H, m), 3.69-3.80 (1H, m), 4.56-4.67 (2H, m), 7.19-7.45 (5H, m).
Using {[2-(2-azidoethoxy)-1-methylethoxy]methyl}benzene (2.33 g), triphenylphosphine (2.86 g), tetrahydrofuran (25 mL), water (2.5 mL), di-tert-butyl dicarbonate (3.0 mL), triethylamine (2.0 mL) and methanol (30 mL), a similar reaction as in Example 168 (iv) was carried out to give the title compound (2.94 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.19 (3H, d, J=6.3 Hz), 1.44 (9H, s), 3.22-3.37 (2H, m), 3.37-3.59 (4H, m), 3.63-3.80 (1H, m), 4.50-4.70 (2H, m), 4.92 (1H, br s), 7.15-7.46 (5H, m).
Using tert-butyl {2-[2-(benzyloxy)propoxy]ethyl}carbamate (2.93 g), 10% palladium-carbon (330 mg) and methanol (30 mL), a similar reaction as in Example 168 (v) was carried out to give the title compound (2.01 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.15 (3H, d, J=6.4 Hz), 1.45 (9H, s), 2.38 (1H, br s), 3.21-3.38 (3H, m), 3.45 (1H, dd, J=9.4, 3.0 Hz), 3.48-3.63 (2H, m), 3.88-4.06 (1H, m), 4.86 (1H, br s).
tert-Butyl [2-(2-hydroxypropoxy)ethyl]carbamate (1.00 g) was dissolved in ethanol (20 mL). 6N hydrochloric acid (4.0 mL) was added to the solution, and the mixture was stirred at 50° C. for 14 hr. The reaction mixture was concentrated under reduced pressure. Ethanol was added to the residue and the mixture was concentrated again under reduced pressure to give the title compound (701 mg) as a white solid.
1H-NMR (DMSO-d6) δ: 1.03 (3H, d, J=6.1 Hz), 2.96 (2H, t, J=5.3 Hz), 3.19-3.34 (2H, m), 3.51-3.68 (2H, m), 3.70-3.85 (1H, m), 4.68 (1H, br s), 7.99 (3H, br s).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (109 mg), 1-(2-aminoethoxy)propane-2-ol hydrochloride (63.1 mg), tetrahydrofuran (0.60 mL), N,N-dimethylformamide (0.60 mL), triethylamine (0.30 mL), 1-hydroxybenzotriazole (48.0 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (66.7 mg), a similar reaction as in Example 168 (viii) was carried out to give the title compound (89.1 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 0.99 (3H, d, J=6.2 Hz), 2.63-2.72 (2H, m), 3.18-3.29 (2H, m), 3.29-3.39 (4H, m), 3.44-3.52 (2H, m), 3.64-3.79 (1H, m), 4.55 (1H, d, J=4.5 Hz), 7.13-7.23 (3H, m), 7.26 (1H, d, J=8.9 Hz), 7.46 (1H, d, J=7.7 Hz), 7.55-7.65 (2H, m), 7.69 (1H, t, J=4.7 Hz), 7.89 (1H, d, J=2.6 Hz), 7.98 (1H, s), 8.03 (1H, t, J=5.5 Hz), 9.13 (1H, s).
Using tert-butyl [2-(2-hydroxypropoxy)ethyl]carbamate (1.00 g), 60% sodium hydride (dispersion in mineral oil, 222 mg), methyl iodide (0.34 mL) and tetrahydrofuran (60 mL), a similar reaction as in Example 168 (vi) was carried out to give the title compound (552 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.14 (3H, d, J=6.0 Hz), 1.45 (9H, s), 3.32 (2H, q, J=5.2 Hz), 3.39 (3H, s), 3.41-3.46 (2H, m), 3.46-3.61 (3H, m), 4.98 (1H, br s).
Using tert-butyl 2-(2-methoxypropoxy)ethyl]carbamate (549 mg), 6N hydrochloric acid (2.0 mL) and ethanol (10 mL), a similar reaction as in Example 181 (viii) was carried, out to give the title compound (401 mg) as a pale-yellow oil.
1H-NMR (DMSO-d6) δ: 1.07 (3H, d, J=6.1 Hz), 2.95 (2H, t, J=5.3 Hz), 3.26 (3H, s), 3.31-3.52 (3H, m), 3.60 (2H, t, J=5.3 Hz), 7.99 (3H, br s).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (109 mg), 2-(2-methoxypropoxy)ethaneamine hydrochloride (59.7 mg), tetrahydrofuran (0.60 mL), N,N-dimethylformamide (0.60 mL), triethylamine (0.3 mL), 1-hydroxybenzotriazole (46.8 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (64.6 mg), a similar reaction as in Example 168 (viii) was carried out to give the title compound (102 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 1.01 (3H, d, J=6.0 Hz), 2.63-2.72 (2H, m), 3.21 (3H, s), 3.27-3.45 (7H, m), 3.44-3.53 (2H, m), 7.11-7.22 (3H, m), 7.26 (1H, d, J=8.9 Hz), 7.46 (1H, d, J=7.7 Hz), 7.55-7.65 (2H, m), 7.69 (1H, t, J=4.7 Hz), 7.87 (1H, d, J=2.6 Hz), 7.98 (1H, s), 8.03 (1H, t, J=5.7 Hz), 9.14 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (150 mg), tert-butyl (2-aminoethyl)(2-hydroxyethyl)carbamate (129 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (119 mg), 1-hydroxybenzotriazole monohydrate (95 mg), triethylamine (0.13 mL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (162 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.33-1.37 (9H, m), 2.62-2.73 (2H, m), 3.12-3.36 (4H, m), 3.41-3.52 (2H, m), 4.66-4.78 (1H, m), 7.13-7.21 (3H, m), 7.25 (1H, d, J=8.7 Hz), 7.45 (1H, d, J=8.1 Hz), 7.56-7.63 (2H, m), 7.66-7.73 (1H, m), 7.85-7.92 (1H, m), 7.97 (1H, s), 8.00-8.09 (1H, m), 9.05-9.14 (1H, m).
To a solution of tert-butyl [2-({[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl]carbonyl}amino)ethyl](2-hydroxyethyl)carbamate (120 mg) in ethanol (5.0 mL) was added 4N hydrochloric acid/ethyl acetate (3.0 mL) at room temperature. The mixture was stirred at room temperature for 24 hr and concentrated under reduced pressure. Aqueous sodium bicarbonate solution was added to the residue, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by basic silica gel column chromatography (eluent, ethyl acetate->ethyl acetate:methanol=7:3) to give the title compound (84 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.83-2.90 (6H, m), 3.45-3.57 (4H, m), 3.63-3.70 (2H, m), 5.65-5.71 (1H, m), 6.50-6.60 (1H, m), 7.03 (1H, d, J=9.0 Hz), 7.05-7.11 (1H, m), 7.18-7.21 (1H, m), 7.29-7.33 (2H, m), 7.41-7.47 (2H, m), 7.75 (1H, d, J=2.7 Hz), 7.79 (1H, s), 8.11 (1H, s).
Using methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (200 mg), 3-chloro-4-{3-[(2,2,2-trifluoroethyl)thio]phenoxy}aniline (279 mg), pyridinium chloride (9.7 mg) and isopropyl alcohol (2.0 mL), a similar reaction as in Example 166 (iv) was carried out to give the title compound (268 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.90 (2H, t, J=4.4 Hz), 3.44 (2H, q, J=9.6 Hz), 3.50-3.55 (2H, m), 3.82 (3H, s), 5.79-5.89 (1H, m), 6.82 (1H, s), 6.85-6.88 (1H, m), 7.02 (1H, d, J=9.0 Hz), 7.06-7.08 (1H, m), 7.15-7.19 (1H, m), 7.24-7.30 (1H, m), 7.35 (1H, dd, J=9.0, 2.7 Hz), 7.66 (1H, s), 7.72 (1H, d, J=2.7 Hz), 8.11 (1H, s).
To a solution of methyl 4-[(3-chloro-4-{3-[(2,2,2-trifluoroethyl)thio]phenoxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (160 mg) in ethyl acetate (30 mL) was added 3-chloroperbenzoic acid (70%, 110 mg) at −78° C. The mixture was stirred at −78° C. for 1 hr. Additional 3-chloroperbenzoic acid (70%, 80 mg) was added to the reaction mixture, and the mixture was stirred at −40° C. to −10° C. for 2 hr. Aqueous sodium thiosulfate solution was added to the reaction mixture, and the mixture was stirred at room temperature for 12 hr and extracted with ethyl acetate. The organic layer was washed with aqueous sodium bicarbonate solution, saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=1:1→methyl acetate) to give the title compound (60 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 2.91 (2H, t, J=4.8 Hz), 3.33-3.64 (4H, m), 3.83 (3H, s), 5.76-5.85 (1H, m), 6.83 (1H, s), 7.09 (1H, d, J=8.4 Hz), 7.10-7.14 (1H, m), 7.21-7.29 (1H, m), 7.35-7.42 (2H, m), 7.49-7.54 (1H, m), 7.67 (1H, s), 7.76 (1H, d, J=2.7 Hz), 8.12 (1H, s).
Using methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (100 mg), 3-chloro-4-[3-(methylsulfonyl)phenoxy]aniline (124 mg), pyridinium chloride (4.8 mg) and isopropyl alcohol (2.0 mL), a similar reaction as in Example 166 (iv) was carried out to give the title compound (117 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 2.91 (2H, t, J=4.5 Hz), 3.06 (3H, s), 3.54 (2H, q, J=4.8 Hz), 3.83 (3H, s), 5.78-5.87 (1H, m), 6.83 (1H, s), 7.09 (1H, d, J=8.7 Hz), 7.19-7.23 (1H, m), 7.40 (1H, dd, J=8.7, 2.4 Hz), 7.46-7.54 (2H, m), 7.62-7.67 (2H, m), 7.77 (1H, d, J=2.4 Hz), 8.12 (1H, s).
A mixture of [4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl]methanol (99.7 mg) and N-(2-methoxyethyl)-2-nitrobenzenesulfonamide (72.5 mg) was dissolved in tetrahydrofuran (1.5 mL). Triphenylphosphine (86.2 mg) and diisopropyl azodicarboxylate (0.068 mL) were added to the solution, and the mixture was stirred at 60° C. for 18 hr. The reaction mixture was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=10:90→0:100→ethyl acetate:methanol=90:10) and basic silica gel column chromatography (eluent, hexane:ethyl acetate=10:90→0:100→ethyl acetate:methanol=90:10) to give the title compound (30.9 mg) as a yellow oil.
1H-NMR (CDCl3) δ: 2.48 (2H, t, J=4.7 Hz), 3.19 (3H, s), 3.39-3.58 (6H, m), 4.15 (2H, s), 5.61 (1H, t, J=4.4 Hz), 6.39 (1H, s), 7.00-7.14 (3H, m), 7.20 (1H, br s), 7.28-7.36 (1H, m), 7.37-7.48 (2H, m), 7.63-7.77 (3H, m), 7.84 (1H, d, J=2.7 Hz), 8.08 (2H, m).
N-{[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl]methyl}-N-(2-methoxyethyl)-2-nitrobenzenesulfonamide (30.0 mg) was dissolved in tetrahydrofuran (1.0 mL). 2-Mercaptoethanol (0.012 mL) and diazabicyclo[5,4,0]-7-undecene (0.0254 mL) were added to the solution, and the mixture was stirred at room temperature for 24 hr. The reaction mixture was concentrated under reduced pressure. The residue was separated and purified by basic silica gel column chromatography (eluent, hexane:ethyl acetate=20:80→0:100→ethyl acetate:methanol=90:10), and the objective fraction was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (1 mL). 4N Hydrochloric acid/ethyl acetate (0.020 mL) was added to the solution, and the mixture was stirred at room temperature for 1 hr. The reaction mixture was concentrated under reduced pressure and crystallized from ethanol-ethyl acetate to give the title compound (4.8 mg) as yellow crystals.
1H-NMR (DMSO-d6) δ: 2.54-2.68 (2H, m), 3.05-3.20 (2H, m), 3.32 (3H, s), 3.36-3.79 (6H, m), 6.55 (1H, s), 6.87 (1H, s), 7.18-7.25 (2H, m), 7.30 (1H, d, J=8.7 Hz), 7.49 (1H, d, J=7.5 Hz), 7.57-7.71 (2H, m), 7.91 (1H, d, J=2.6 Hz), 8.16 (1H, s), 9.14 (2H, br s), 9.74 (1H, br s).
A mixture of [4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl]methanol (89.3 mg) and N-[2-(methylsulfonyl)ethyl]-2-nitrobenzenesulfonamide (78.4 mg) was suspended in toluene (1.5 mL). (Tributyl phosphoranylidene)acetonitrile (75.8 mg) was added to the suspension, and the mixture was stirred under reflux for 24 hr. The reaction mixture was concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=50:50→0:100) and basic silica gel column chromatography (eluent, hexane:ethyl acetate=50:50→0:100) to give the title compound (10.4 mg) and N-{[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl]methyl}-N-[2-(methylsulfonyl)ethyl]-2-nitrobenzenesulfonamide.
1H-NMR (DMSO-d6) δ: 2.37-2.58 (4H, m), 2.75 (2H, t, J=7.5 Hz), 3.25-3.39 (2H, m), 6.38 (1H, s), 7.12-7.22 (2H, m), 7.24 (1H, d, J=8.9 Hz), 7.34 (1H, t, J=4.4 Hz), 7.47 (1H, s), 7.54-7.67 (2H, m), 7.89 (1H, d, J=2.5 Hz), 7.93 (1H, s), 8.74 (1H, s).
Using (2-hydroxy-1,1-dimethylethyl) carbamate (1.00 g), benzyl(2-bromoethyl)ether (0.90 mL), tetra-n-butylammonium hydrogen sulfate (183 mg), toluene (10 mL) and 50% aqueous sodium hydroxide solution (2.5 mL), a similar reaction as in Example 168 (i) was carried out to give the title compound (590 mg) as a yellow oil.
1H-NMR (CDCl3) δ: 1.31 (6H, s), 1.43 (9H, s), 3.40 (2H, s), 3.56-3.74 (4H, m), 4.58 (2H, s), 4.89 (1H, br s), 7.21-7.44 (5H, m).
Using tert-butyl {2-[2-(benzyloxy)ethoxy]-1,1-dimethylethyl}carbamate (585 mg), 10% palladium-carbon (67.9 mg) and methanol (5.0 mL), a similar reaction as in Example 168 (v) was carried out to give the title compound (412 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.29 (6H, s), 1.43 (9H, s), 2.10 (1H, t, J=6.1 Hz), 3.48 (2H, s), 3.54-3.66 (2H, m), 3.67-3.83 (2H, m), 4.68 (1H, br s).
Using tert-butyl [2-(2-hydroxyethoxy)-1,1-dimethylethyl]carbamate (213 mg), 6N hydrochloric acid (0.80 mL) and ethanol (5.0 mL), a similar reaction as in Example 181 (viii) was carried out to give the title compound (1.60 mg) as a colorless oil.
1H-NMR (DMSO-d6) δ: 1.22 (6H, s), 3.39 (2H, s), 3.46-3.59 (4H, m), 8.01 (3H, br s).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (280 mg), 2-(2-amino-2-methylpropoxy)ethanol hydrochloride (108 mg), tetrahydrofuran (1.4 mL), N,N-dimethylformamide (1.4 mL), triethylamine (0.8 mL), 1-hydroxybenzotriazole (120 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (172 mg), a similar reaction as in Example 168 (viii) was carried out to give the title compound (246 mg) as white crystals.
1H-NMR (DMSO-d6) δ: 1.30 (6H, s), 2.59-2.68 (2H, m), 3.28-3.39 (2H, m), 3.40-3.51 (4H, m), 3.53 (2H, s), 4.52-4.60 (1H, m), 7.03 (1H, s), 7.14-7.32 (4H, m), 7.47 (1H, s), 7.53-7.64 (2H, m), 7.66 (1H, t, J=4.5 Hz), 7.94 (1H, d, J=2.6 Hz), 7.99 (1H, s), 9.18 (1H, s).
Using tert-butyl [2-(2-hydroxyethoxy)-1,1-dimethylethyl]carbamate (193 mg), 60% sodium hydride (dispersion in mineral oil, 42.7 mg), methyl iodide (0.0924 mL) and tetrahydrofuran (12 mL), a similar reaction as in Example 168 (vi) was carried out to give the title compound (166 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.29 (6H, s), 1.43 (9H, s), 3.39 (3H, s), 3.40 (2H, s), 3.51-3.57 (2H, m), 3.60-3.67 (2H, m), 4.91 (1H, br s).
Using tert-butyl [2-(2-methoxyethoxy)-1,1-dimethylethyl]carbamate (163 mg), 6N hydrochloric acid (0.60 mL) and ethanol (3.5 mL), a similar reaction as in Example 181 (viii) was carried out to give the title compound (123 mg) as a colorless oil.
1H-NMR (DMSO-d6) δ: 1.21 (6H, s), 3.27 (3H, s), 3.39 (2H, s), 3.45-3.54 (2H, m), 3.55-3.66 (2H, m), 7.94 (3H, br s).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (281 mg), 1-(2-methoxyethoxy)-2-methylpropane-2-amine hydrochloride (120 mg), tetrahydrofuran (1.4 mL), N,N-dimethylformamide (1.4 mL), triethylamine (0.80 mL), 1-hydroxybenzotriazole (122 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (177 mg), a similar reaction as in Example 168 (viii) was carried out to give the title compound (284 mg) as white crystals.
1H-NMR (DMSO-d6) δ: 1.29 (6H, s), 2.58-2.69 (2H, m), 3.18 (3H, s), 3.28-3.38 (2H, m), 3.38-3.44 (2H, m), 3.48-3.57 (4H, m), 7.00 (1H, s); 7.13-7.34 (4H, m), 7.46 (1H, d, J=7.9 Hz), 7.54-7.64 (2H, m), 7.66 (1H, t, J=4.6 Hz), 7.95 (1H, d, J=2.5 Hz), 7.99 (1H, s), 9.20 (1H, s).
Using 4-[(4-{3-[(tert-butylamino) carbonyl]phenoxy}-3-chlorophenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 2-amino-2-methyl-1-propanol (35 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (75.6 mg), 1-hydroxybenzotriazole monohydrate (60 mg), triethylamine (82 μL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (91.7 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 1.26 (6H, s), 1.36 (9H, s), 2.60-2.68 (2H, m), 3.26-3.38 (2H, m), 3.46 (2H, d, J=5.7 Hz), 4.92 (1H, t, J=5.7 Hz), 7.00-7.06 (2H, m), 7.15 (1H, d, J=9.0 Hz), 7.26 (1H, s), 7.30-7.32 (1H, m), 7.37-7.43 (1H, m), 7.51-7.55 (2H, m), 7.63 (1H, t, J=5.1 Hz), 7.80 (1H, s), 7.91 (1H, d, J=2.7 Hz), 7.97 (1H, s), 9.16 (1H, s).
2-Chloro-4-nitrobenzoic acid (5.01 g) was dissolved in tetrahydrofuran (50 mL). N,N-Dimethylformamide (0.20 mL) and thionyl chloride (3.6 mL) were added to the solution, and the mixture was stirred at room temperature for 2 hr. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in tetrahydrofuran (40 mL). The solution was added dropwise to a solution of tert-butyl piperidin-4-ylcarbamate (5.01 g) and triethylamine (10 mL) in tetrahydrofuran (50 mL), and the mixture was stirred at 0° C. for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The precipitate was collected by filtration and washed with diisopropyl ether-hexane to give the title compound (9.08 g) as a pale-orange powder.
1H-NMR (CDCl3) δ: 1.35-1.61 (11H, m), 1.88-2.19 (2H, m), 2.90-3.44 (3H, m), 3.62-3.82 (1H, m), 4.47 (1H, br s), 4.56-4.78 (1H, m), 7.47 (1H, dd, J=12.2, 8.4 Hz), 8.15-8.23 (1H, m), 8.31 (1H, dd, J=3.5, 2.2 Hz).
tert-Butyl [1-(2-chloro-4-nitrobenzoyl)piperidin-4-yl]carbamate (9.04 g) was dissolved in a mixture of ethanol (215 mL) and water (25 mL). Reduced iron (6.64 g) and calcium chloride (1.30 g) were added to the solution, and the mixture was stirred for 21 hr while heating under reflux. The reaction mixture was filtrated through Celite, and the filtrate was concentrated under reduced pressure. The residue was dissolved in ethyl acetate. The solution was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=80:20→33:67) to give the title compound (7.86 g) as pale-orange amorphous.
1H-NMR (CDCl3) δ: 1.33-1.54 (11H, m), 1.81-2.11 (2H, m), 2.82-3.24 (2H, m), 3.40-3.76 (2H, m), 3.85 (2H, s), 4.37-4.54 (1H, m), 4.63 (1H, d, J=12.4 Hz), 6.50-6.61 (1H, m), 6.67 (1H, br s), 6.95-7.11 (1H, m).
A mixture of methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (200 mg) and tert-butyl [1-(4-amino-2-chlorobenzoyl)piperidin-4-yl]carbamate (327 mg) was dissolved in 1-methyl-2-pyrrolidone (5 mL). Pyridinium chloride (5.0 mg) was added to the solution, and the mixture was stirred at 80° C. for 17 hr. Pyridinium chloride (50.3 mg) was added to the mixture, the mixture was stirred at 100° C. for 2 days. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=50:50→0:100) and basic silica gel column chromatography (eluent, hexane:ethyl acetate=50:50→0:100) to give the title compound (38.1 mg) as white crystals.
1H-NMR (DMSO-d6) δ: 1.38 (9H, s), 1.30-1.44 (2H, m), 1.62-1.89 (2H, m), 2.68-2.78 (2H, m), 2.83-3.17 (2H, m), 3.24-3.43 (3H, m), 3.43-3.60 (1H, m), 3.71 (3H, s), 4.35 (1H, d, J=13.2 Hz), 6.84-6.98 (1H, m), 7.21 (1H, d, J=8.7 Hz), 7.47-7.57 (1H, m), 7.71 (2H, s), 7.94-8.03 (1H, m), 8.00 (1H, s), 9.48 (1H, s).
[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl]methanol (110 mg) was dissolved in acetone (2.0 mL). Manganese dioxide (554 mg) was added to the solution, and the mixture was stirred at room temperature for 5.5 hr. The reaction mixture was filtrated through Celite, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=50:50→0:100) to give the title compound (80.9 mg) as a yellow solid.
1H-NMR (CDCl3) δ: 2.78-2.86 (2H, m), 3.48-3.57 (2H, m), 6.03 (1H, t, J=5.0 Hz), 6.79 (1H, s), 7.07 (1H, d, J=8.9 Hz), 7.12 (1H, dd, J=8.0, 1.8 Hz), 7.17-7.23 (2H, m), 7.31-7.41 (2H, m), 7.44 (1H, t, J=8.0 Hz), 7.74 (1H, d, J=2.6 Hz), 8.17 (1H, s), 9.48 (1H, s).
4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-carbaldehyde (60.5 mg) and 2-aminoethoxyethanol (0.032 mL) were dissolved in tetrahydrofuran (2.0 mL), and the mixture was stirred for 20 min. Sodium triacetoxyborohydride (83.7 mg) was added to the mixture, and the mixture was stirred at room temperature for 1 hr. Sodium triacetoxyborohydride (83.7 mg) was added to the reaction mixture, and the mixture was stirred at room temperature for 1 hr. Additional sodium triacetoxyborohydride (86.6 mg) was added to the mixture, and the mixture was stirred at room temperature for 1 hr. Saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by basic silica gel column chromatography (ethyl acetate:methanol=100:0→90:10), and the objective fraction was concentrated under reduced pressure. The residue was dissolved in ethyl acetate, and 4N hydrochloric acid/ethyl acetate (0.02 mL) was added to the solution. The reaction mixture was concentrated under reduced pressure and crystallized from ethanol-ethyl acetate to give the title compound (9.1 mg) as white crystals.
1H-NMR (DMSO-d6) δ: 2.56-2.66 (2H, m), 3.07-3.22 (2H, m), 3.38-3.59 (6H, m), 3.70-3.82 (4H, m), 6.90 (1H, s), 7.17-7.26 (2H, m), 7.31 (1H, d, J=8.9 Hz), 7.49 (1H, d, J=7.5 Hz), 7.57-7.69 (2H, m), 7.91 (1H, d, J=2.5 Hz), 8.19 (1H, s), 8.28 (1H, br s), 9.16 (2H, br s), 9.86 (1H, br s).
To a solution of methyl 4-({5-chloro-6-[3-(trifluoromethoxy)phenoxy]pyridin-3-yl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (235 mg) in tetrahydrofuran (5.0 mL) and ethanol (5.0 mL) was added 1N aqueous sodium hydroxide solution (1.5 mL) at room temperature, and the mixture was stirred at room temperature for 3 days. 1N Hydrochloric acid (1.5 mL) was added to the mixture, and the mixture was concentrated under reduced pressure. The precipitated crystals were collected by filtration and washed with water to give the title compound (195 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 2.65-2.74 (2H, m), 3.23-3.39 (2H, m), 7.13-7.24 (3H, m), 7.51-7.57 (1H, m), 7.71 (1H, s), 7.83-7.91 (1H, m), 7.94 (1H, s), 8.21 (1H, d, J=2.4 Hz), 8.25 (1H, d, J=2.4 Hz), 9.43 (1H, s).
Using 4-({5-chloro-6-[3-(trifluoromethoxy)phenoxy]pyridin-3-yl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (80 mg), 2-(2-methoxyethoxy)ethaneamine hydrochloride (50 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (62 mg), 1-hydroxybenzotriazole monohydrate (50 mg), triethylamine (70 μL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (94.4 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 2.83 (2H, t, J=4.5 Hz), 3.35 (3H, s), 3.48-3.69 (10H, m), 5.71-5.80 (1H, m), 6.70-6.79 (1H, m), 7.04-7.10 (3H, m), 7.32 (1H, s), 7.37-7.42 (1H, m), 7.73 (1H, br s), 8.07 (1H, s), 8.11 (1H, d, J=2.7 Hz), 8.22 (1H, d, J=2.7 Hz).
2-Mercaptoethanol (3.0 mL) was dissolved in N,N-dimethylformamide (100 mL). Imidazole (4.39 g) and tert-butyldimethylsilyl chloride (7.09 g) were added to the solution, and the mixture was stirred at room temperature for 2.5 hr. Additional tert-butyldimethylsilyl chloride (1.90 g) was added to the mixture, and the mixture was stirred for 2 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=10 0:0→90:10) to give the title compound (7.22 g) as a colorless oil.
1H-NMR (CDCl3) δ: 0-08 (6H, s), 0.91 (9H, s), 1.54 (1H, t, J=8.3 Hz), 2.63 (2H, dt, J=8.3, 6.4 Hz), 3.73 (2H, t, J=6.4 Hz).
A mixture of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl]methanol (94.6 mg) and 2-{[tert-butyl(dimethyl)silyl]oxy}ethanethiol (126 mg) was dissolved in tetrahydrofuran (2.0 mL). Triphenylphosphine (68.1 mg) and 40% diethyl azodicarboxylate-toluene solution (0.117 mL) were added to the solution, and the mixture was stirred at room temperature for 2.5 hr. Additional 40% diethyl azodicarboxylate-toluene solution (0.03 mL) was added to the mixture, and the mixture was stirred at 50° C. for 2 days. The reaction mixture was concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=90:10→33:67) to give the title compound (65.8 mg) as a white solid.
1H-NMR (CDCl3) δ: 0.03 (3H, s), 0.04 (3H, s), 0.86 (9H, s), 2.58-2.86 (4H, m), 3.27-3.43 (1H, m), 3.70-3.87 (1H, m), 3.90-4.03 (1H, m), 4.04-4.17 (1H, m), 4.78 (1H, s), 5.04 (1H, s), 5.11 (1H, s), 5.15-5.22 (1H, m), 7.07 (1H, d, J=8.7 Hz), 7.08-7.13 (1H, m), 7.14-7.17 (1H, m), 7.31 (1H, d, J=7.9 Hz), 7.42 (1H, t, J=7.9 Hz), 7.47 (1H, dd, J=8.8, 2.5 Hz), 7.74 (1H, d, J=2.5 Hz), 7.98 (1H, br s), 8.14 (1H, s).
5-[(2-{[tert-Butyl(dimethyl)silyl]oxy}ethyl)thio]-N-{3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-6-methyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-amine (64.0 mg) was dissolved in tetrahydrofuran (4 mL). 1N Tetra-n-butylammonium fluoride-tetrahydrofuran solution (0.110 mL) was added to the solution, and the mixture was stirred at room temperature for 2 hr. Saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=80:20→33:67), and the objective fraction was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (1.0 mL). 4N Hydrochloric acid/ethyl acetate (0.05 mL) was added to the solution, and the mixture was stirred at room temperature for 1 hr. The reaction mixture was concentrated under reduced pressure and crystallized from ethyl acetate to give the title compound (39.5 mg) as white crystals.
1H-NMR (DMSO-d6) δ: 2.58-2.82 (4H, m), 3.33-3.50 (1H, m), 3.59-3.82 (3H, m), 3.93 (1H, dt, J=11.0, 4.5 Hz), 4.78 (1H, s), 5.07 (1H, s), 5.14 (1H, s), 7.18-7.28 (2H, m), 7.32 (1H, d, J=8.7 Hz), 7.50 (1H, d, J=7.2 Hz), 7.54-7.70 (2H, m), 7.86 (1H, br s), 7.93 (1H, d, J=2.7 Hz), 8.23 (1H, s), 9.30 (1H, br s).
A mixture of tert-butyl 2-bromoisobutyrate (2.0 g), tert-butyl (2-mercaptoethyl)carbamate (1.51 mL) and potassium carbonate (1.23 g) in N,N-dimethylformamide (40 mL) was stirred at 70° C. for 2 days. Water was added to the reaction mixture, and the mixture was extracted with diethyl ether. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=9:1→1:1) to give the title compound (2.22 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.44 (9H, s), 1.47 (15H, s), 2.78 (2H, t, J=6.5 Hz), 3.23-3.34 (2H, m), 4.83-4.95 (1H, m).
To a solution of tert-butyl 2-({2-[(tert-butoxycarbonyl)amino]ethyl}thio)-2-methylpropanoate (2.22 g) in toluene (20 mL) was added dropwise 1.5 M diisobutylaluminum hydride-toluene solution (20 mL) at 0° C. The mixture was stirred at 0° C. for 2 hr. Sodium sulfate decahydrate (15.5 g) was added to the reaction mixture, and the mixture was stirred at room temperature for 12 hr. Anhydrous magnesium sulfate was added to the mixture, and the insoluble material was removed by filtration. The filtrate was concentrated, and the residue was separated and purified by column chromatography (eluent, hexane:ethyl acetate=3:1→3:7) to give the title compound (1.19 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.28 (6H, s), 1.45 (9H, s), 2.30-2.41 (1H, m), 2.61 (2H, t, J=6.6 Hz), 3.29 (2H, q, J=6.6 Hz), 3.38 (2H, d, J=6.3 Hz), 4.79-4.93 (1H, m).
Using tert-butyl {2-[(2-hydroxy-1,1-dimethylethyl)thio]ethyl}carbamate (1.19 g), 3-chloroperbenzoic acid (70%, 2.59 g) and ethyl acetate (20 mL), a similar reaction as in Example 172 (ii) was carried out to give the title compound (1.30 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.40 (6H, s), 1.44 (9H, s), 2.48 (1H, t, J=5.7 Hz), 3.27 (2H, t, J=5.9 Hz), 3.72 (2H, q, J=5.9 Hz), 3.83 (2H, d, J=5.7 Hz), 5.18-5.30 (1H, m).
To a solution of tert-butyl {2-[(2-hydroxy-1,1-dimethylethyl)sulfonyl]ethyl}carbamate (1.30 g) in tetrahydrofuran (20 mL) was added 6N hydrochloric acid (5.0 mL) at room temperature. The mixture was stirred at 60° C. for 14 hr, and concentrated under reduced pressure. Ethanol was added to the residue, and the mixture was concentrated again. Crystallization from ethanol-diisopropyl ether gave the title compound (938 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 1.25 (6H, s), 3.20 (2H, t, J=7.5 Hz), 3.54 (2H, t, J=7.5 Hz), 3.59 (2H, d, J=3.6 Hz), 5.58-5.70 (1H, m), 8.14 (3H, m).
A mixture of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-carbaldehyde (100 mg) and 2-[(2-aminoethyl)sulfonyl]-2-methylpropan-1-ol hydrochloride (93.0 mg) was dissolved in a mixture of tetrahydrofuran (1.5 mL) and N,N-dimethylformamide (1.5 mL). Sodium triacetoxyborohydride (284 mg) was added to the solution, and the mixture was stirred at room temperature for 13 hr. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced, pressure. The residue was separated and purified by basic silica gel column chromatography (eluent, hexane:ethyl acetate=10:90→0:100→ethyl acetate:methanol=90:10) and crystallized from ethyl acetate-diisopropyl ether to give the title compound (78.7 mg) as white crystals.
1H-NMR (DMSO-d6) δ: 1.22 (6H, s), 2.21 (1H, br s), 2.41-2.47 (2H, m), 2.94 (2H, t, J=7.1 Hz), 3.25-3.31 (6H, m), 3.57 (2H, d, J=3.8 Hz), 5.36-5.47 (1H, m), 6.43 (1H, s), 7.14-7.21 (2H, m), 7.23 (1H, d, J=8.9 Hz), 7.32 (1H, t, J=4.3 Hz), 7.45 (1H, d, J=7.7 Hz), 1.55-7.65 (2H, m), 7.87 (1H, d, J=2.6 Hz), 7.92 (1H, s), 8.69 (1H, s).
N,N-Dimethylaminoethyltriphenylphosphonium bromide (357 mg) was suspended in tetrahydrofuran (3.0 mL), and the suspension was cooled to −78° C. n-Butyllithium-hexane solution (1.6 M, 0.6 mL) was added to the suspension, and the mixture was stirred for 1 hr while rising the temperature to room temperature. A solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-carbaldehyde (96.4 mg) in tetrahydrofuran (1.0 mL) was dropwise added to the solution at −78° C., the mixture was stirred at 50° C. for 3 days. Saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with, saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by basic silica gel column chromatography (eluent, hexane:ethyl acetate=20:80→0:100→ethyl acetate:methanol=95:5), and the objective fraction was concentrated under reduced pressure. The residue was treated with 4N hydrochloric acid/ethyl acetate and crystallized from ethanol-ethyl acetate to give the title compound (6.4 mg) as orange crystals.
1H-NMR (DMSO-d6) δ: 2.61-2.69 (2H, m), 2.72 (3H, s), 2.74 (3H, s), 3.42-3.53 (2H, m), 3.74-3.84 (2H, m), 5.73 (1H, dt, J=15.2, 7.6 Hz), 6.63 (1H, d, J=15.2 Hz), 6.76 (1H, s), 7.19-7.26 (2H, m), 7.30 (1H, d, J=8.7 Hz), 7.49 (1H, d, J=8.0 Hz), 7.55 (1H, dd, J=8.7, 2.5 Hz), 7.59-7.68 (1H, m), 7.84 (1H, d, J=2.5 Hz), 8.15 (1H, s), 8.34 (1H, br s), 9.79 (1H, br s), 10.30 (1H, br s).
A mixture of N-(tert-butyl)-3-(2-chloro-4-{[6-(hydroxymethyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl]amino}phenoxy)benzamide (250 mg) and active manganese dioxide (1.25 g) in acetone (12.5 mL) was stirred at room temperature for 24 hr. Manganese dioxide was removed by filtration, and the filtrate was concentrated. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=1:1→ethyl acetate) to give the title compound (154 mg) as yellow crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.80 (2H, t, J=4.5 Hz), 3.48-3.53 (2H, m), 5.93 (1H, br s), 5.97-6.05 (1H, m), 6.92 (1H, br s), 7.00 (1H, d, J=8.7 Hz), 7.05-7.09 (1H, m), 7.25 (1H, s), 7.27-7.39 (4H, m), 7.68 (1H, d, J=2.7 Hz), 8.14 (1H, s), 9.46 (1H, s).
To a solution of N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (140 mg) and 2-aminoethanol (35 mg) in tetrahydrofuran (10 mL) was added sodium triacetoxyborohydride (120 mg) at room temperature. The mixture was stirred at room temperature for 20 hr. Sodium triacetoxyborohydride (120 mg) was added to the reaction mixture, and the mixture was stirred for 16 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by basic silica gel column chromatography (eluent, ethyl acetate→ethyl acetate:methanol=4:1) to give pale-yellow amorphous. 4N Hydrochloric acid/ethyl acetate (0.5 mL) was added to a solution of the obtained amorphous in ethanol (5.0 mL) at room temperature. The mixture was concentrated under reduced pressure and crystallized from ethanol-ethyl acetate to give the title compound (96.7 mg) as pale-brown crystals.
1H-NMR (DMSO-d6) δ: 1.36 (9H, s), 2.55-2.67 (2H, m), 2.96-3.07 (2H, m), 3.39-3.49 (2H, m), 3.68-3.81 (4H, m), 6.89 (1H, s), 7.10 (1H, dd, J=7.8, 2.4 Hz), 7.18 (1H, d, J=9.0 Hz), 7.28-7.34 (1H, m), 7.41-7.46 (1H, m), 7.54-7.59 (2H, m), 7.80-7.88 (2H, m), 8.19 (1H, s), 8.26-8.46 (1H, m), 9.05-9.18 (2H, m), 9.84-10.00 (1H, m).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (120 mg), 2-[(2-amino-2-methylpropyl)sulfonyl]ethanol hydrochloride (130 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (114 mg), 1-hydroxybenzotriazole monohydrate (91 mg), triethylamine (0.10 mL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (70 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.66 (6H, s), 2.23 (3H, s), 2.51 (3H, s), 2.83 (2H, t, J=4.7 Hz), 2.93-3.03 (1H, m), 3.18 (2H, t, J=5.0 Hz), 3.66-3.75 (2H, m), 3.74 (2H, s), 4.03-4.11 (2H, m), 5.64-5.70 (1H, m), 6.29 (1H, s), 6.84 (1H, d, J=8.7 Hz), 7.04-7.13 (2H, m), 7.15 (1H, s), 7.23-7.32 (2H, m), 7.42-7.43 (1H, m), 8.08 (1H, s), 8.20-8.22 (1H, m).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 2-[(2-aminoethyl)sulfonyl]-2-methyl-1-propanol hydrochloride (108 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (95 mg), 1-hydroxybenzotriazole monohydrate (76 mg), triethylamine (0.10 mL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (70 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 1.23 (6H, s), 2.14 (3H, s), 2.43 (3H, s), 2.63-2.69 (2H, m), 3.25-3.39 (4H, m), 3.53-3.66 (4H, m), 5.44 (1H, t, J=5.0 Hz), 6.90 (1H, d, J=8.4 Hz), 7.13-7.24 (3H, m), 7.37-7.42 (1H, m), 7.43-7.46 (1H, m), 7.58 (1H, t, J=4.7 Hz), 7.91 (1H, s), 8.14 (1H, d, J= 3.0 Hz), 8.21 (1H, t, J=6.0 Hz), 8.84 (1H, s).
Using 2-chloro-4-nitrobenzoic acid (5.01 g), tetrahydrofuran (20 mL), N,N-dimethylformamide (0.1 mL), thionyl chloride (0.85 mL), 3-(trifluoromethyl)piperidine (1.10 g) and triethylamine (1.8 mL), a similar reaction as in Example 192 (i) was carried out to give the title compound (1.90 g) as a pale-yellow oil.
1H-NMR (CDCl3) δ: 1.31-1.86 (2H, m), 1.88-2.24 (2H, m), 2.28-2.53 (1H, m), 2.69-3.22 (2H, m), 3.26-3.54 (1H, m), 4.49-5.02 (1H, m), 7.42-7.53 (1H, m), 8.16-8.25 (1H, m), 8.29-8.35 (1H, m).
(ii) Production of 3-chloro-4-{[3-(trifluoromethyl)piperidin-1-yl]carbonyl}aniline
Using 1-(2-chloro-4-nitrobenzoyl)-3-(trifluoromethyl)piperidine (1.88 g), ethanol (54 mL), water (6 mL), reduced iron (1.59 g) and calcium chloride (338 mg), a similar reaction as in Example 192
1H-NMR (CDCl3) δ: 1.25-1.98 (3H, m), 1.97-2.20 (1H, m), 2.21-2.56 (1H, m), 2.60-3.16 (2H, m), 3.43-3.76 (1H, m), 3.87 (2H, br s), 4.54-5.07 (1H, m), 6.47-6.62 (1H, m), 6.68 (1H, br s), 6.93-7.16 (1H, m).
A mixture of methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (150 mg) and 3-chloro-4-{[3-(trifluoromethyl)piperidin-1-yl]carbonyl}aniline (210 mg) was dissolved in a mixture of diisopropyl ether (2.0 mL) and 1-methyl-2-pyrrolidone (2.0 mL). Pyridinium chloride (8.1 mg) was added to the solution, and the mixture was stirred at 100° C. for 16 hr. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=50:50→0:100) and basic silica gel column chromatography (eluent, hexane:ethyl acetate=67:33→10:90) and crystallized from ethyl acetate-diisopropyl ether to give the title compound (182 mg) as a white powder.
1H-NMR (DMSO-d5) δ: 1.33-2.08 (4H, m), 2.38-2.66 (1H, m), 2.67-2.79 (2H, m), 2.84-3.23 (2H, m), 3.23-3.53 (3H, m), 3.71 (3H, s), 4.19-4.67 (1H, m), 7.16-7.43 (1H, m), 7.49-7.60 (1H, m), 7.68-7.78 (2H, m), 7.94-8.05 (2H, m), 9.49 (1H, s).
A solution of methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (200 mg), 3-chloro-4-[3-(isopropylsulfonyl)phenoxy]aniline (272 mg) and pyridinium chloride (9.6 mg) in 1-methyl-2-pyrrolidone (5.0 mL) was stirred at 100° C. for 2 days. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=1:1→ethyl acetate) to give the title compound (277 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.30 (6H, d, J=6.9 Hz), 2.91 (2H, t, J=4.7 Hz), 3.13-3.25 (1H, m), 3.51-3.56 (2H, m), 3.83 (3H, s), 5.74-5.84 (1H, m), 6.86 (1H, s), 7.07 (1H, d, J=8.4 Hz), 7.18-7.27 (1H, m), 7.37-7.41 (2H, m), 7.47-7.53 (1H, m), 7.55-7.61 (1H, m), 7.67 (1H, s), 7.77 (1H, d, J=2.4 Hz), 8.12 (1H, s).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (251 mg), 1-amino-3,3-dimethylbutan-2-one (104 mg), tetrahydrofuran (1.3 mL), N,N-dimethylformamide (1.3 mL), triethylamine (0.2 mL), 1-hydroxybenzotriazole (109 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (150 mg), a similar reaction as in Example 168 (viii) was carried out to give the title compound (160 mg) as a pale-yellow powder.
1H-NMR (CDCl3) δ: 1.23 (9H, s), 2.83-2.91 (2H, m), 3.53-3.62 (2H, m), 4.38 (2H, d, J=4.1 Hz), 5.73 (1H, t, J=4.7 Hz), 6.69 (1H, t, J=4.1 Hz), 7.04 (1H, d, J=9.0 Hz), 7.10 (1H, dd, J=8.0, 2.3 Hz), 7.15 (1H, s), 7.22 (1H, br s), 7.33 (1H, d, J=8.0 Hz), 7.37-7.46 (2H, m), 7.50 (1H, s), 7.77 (1H, d, J=2.7 Hz), 8.13 (1H, s).
4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-N-(3,3-dimethyl-2-oxobutyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxamide (154 mg) was dissolved in pyridine (8.0 mL). Phosphoryl chloride (2.0 mL) was added dropwise to the solution, and the mixture was stirred at room temperature for 3 hr. The reaction mixture was poured into saturated aqueous sodium hydrogencarbonate solution at 0° C., and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=33:67→0:100) and crystallized from ethyl acetate-diisopropyl ether to give the title compound (29.7 mg) as a yellow powder.
1H-NMR (CDCl3) δ: 1.32 (9H, s), 3.05-3.13 (2H, m), 3.57-3.67 (2H, m), 6.03 (1H, t, J=4.2 Hz), 6.73 (1H, s), 7.04 (1H, d, J=8.9 Hz), 7.08 (1H, dd, J=8.4, 2.2 Hz), 7.15 (1H, s), 7.21 (1H, br s), 7.29-7.46 (4H, m), 7.75 (1H, d, J=2.5 Hz), 8.12 (1H, s).
(3-Bromopropoxy)-tert-butyldimethylsilane (3.00 g) was dissolved in acetonitrile (15 mL). Triphenylphosphine (3.26 g) was added to the solution, and the mixture was stirred for 4 days while heating under reflux. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in methanol, and extracted with hexane to remove excess triphenylphosphine. The methanol layer was concentrated under reduced pressure, and the precipitate was collected by filtration to give the title compound (5.89 g) as colorless crystals.
1H-NMR (CDCl3) δ: 0.04 (6H, s), 0.86 (9H, s), 1.81-2.01 (2H, m), 3.79-4.03 (4H, m), 7.53-8.02 (15H, m).
(3-{[tert-Butyl(dimethyl)silyl]oxy}propyl)(triphenyl)phosphonium bromide (558 mg) was suspended in tetrahydrofuran (2.0 mL), and the suspension was cooled to 0° C. n-Butyllithium-hexane solution (1.6 M, 0.75 mL) was added dropwise to the suspension, and the mixture was stirred at room temperature for 30 min. A solution of 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carbaldehyde (100 mg) in tetrahydrofuran (1.0 mL) was added dropwise to the solution at 0° C., the mixture was stirred at 50° C. for 16 hr. Saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=80:20→33:67) and crystallized from diisopropyl ether-hexane to give the title compound (70.6 mg) as a white powder.
1H-NMR (CDCl3) δ: 0.07 (6H, s), 0.91 (9H, s), 2.34-2.46 (2H, m), 2.64-2.74 (2H, m), 3.49-3.59 (2H, m), 3.70 (2H, t, J=6.7 Hz), 5.61-5.82 (2H, m), 6.17 (1H, s), 6.27 (1H, d, J=15.7 Hz), 6.58 (1H, s), 7.05 (1H, d, J=8.7 Hz), 7.09 (1H, dd, J=8.3, 2.1 Hz), 7.19 (1H, br s), 7.28-7.49 (3H, m), 7.74 (1H, d, J=2.6 Hz), 8.10 (1H, s).
6-[(1E)-4-{[tert-Butyl(dimethyl)silyl]oxy}but-1-en-1-yl]-N-{3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-amine (70.0 mg) was dissolved in tetrahydrofuran (1.0 mL). IN tetra-n-butylammonium fluoride-tetrahydrofuran solution (0.20 mL) was added to the solution, and the mixture was stirred at room temperature for 6 hr. Saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=50:50→0:100), and crystallized from ethyl acetate-diisopropyl ether to give the title compound (14.0 mg) as a pale-yellow powder.
1H-NMR (DMSO-d6) δ: 2.24-2.35 (2H, m), 2.52-2.59 (2H, m), 3.28-3.39 (2H, m), 3.42-3.52 (2H, m), 4.55 (1H, t, J=5.4 Hz), 5.59-5.74 (1H, m), 6.31 (1H, d, J=15.8 Hz), 6.49 (1H, s), 7.15-7.21 (2H, m), 7.24 (1H, d, J=8.9 Hz), 7.41-7.49 (2H, m), 7.56-7.67 (2H, m), 7.92 (1H, d, J=2.6 Hz), 7.93 (1H, s), 8.92 (1H, s).
Using methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (200 mg), 3-chloro-4-{3-[(cyclopropylmethyl)sulfonyl]phenoxy}aniline (310 mg), pyridinium chloride (9.7 mg) and 1-methyl-2-pyrrolidone (4.0 mL), a similar reaction as in Example 202 was carried out to give the title compound (373 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 0.12-0.18 (2H, m), 0.54-0.61 (2H, m), 0.92-1.06 (1H, m), 2.91 (2H, t, J=4.8 Hz), 3.01 (2H, d, J=6.9 Hz), 3.53 (2H, q, J=4.8 Hz), 3.83 (3H, s), 5.79-5.89 (1H, m), 6.88 (1H, s), 7.08 (1H, d, J=8.7 Hz), 7.20-7.28 (1H, m), 7.39 (1H, dd, J=8.7, 2.7 Hz), 7.44-7.46 (1H, m), 7.47-7.53 (1H, m), 7.62-7.64 (1H, m), 7.67 (1H, s), 7.77 (1H, d, J=2.7 Hz), 8.12 (1H, s).
Using 4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carbaldehyde (95.0 mg), 2-(2-amino-2-methylpropoxy)ethanol hydrochloride (40.1 mg), sodium triacetoxyborohydride (264 mg), tetrahydrofuran (1.5 mL) and N,N-dimethylformamide (1.5 mL), a similar reaction as in Example 193 (ii) was carried out to give the title compound (15.8 mg) as a yellow powder.
1H-NMR (DMSO-d6) δ: 1.37 (6H, s), 2.57-2.67 (2H, m), 3.29-3.62 (8H, m), 3.64-3.78 (2H, m), 6.89 (1H, s), 7.17-7.26 (2H, m), 7.30 (1H, d, J=8.9 Hz), 7.48 (1H, d, J=−7.9 Hz), 7.62 (1H, t, J=7.9 Hz), 7.70 (1H, dd, J=8.9, 2.2 Hz), 7.98 (1H, d, J=2.2 Hz), 8.11 (1H, br s), 8.16 (1H, s), 8.90 (2H, br s), 9.82 (1H, br s).
A mixture of methyl 4-chloro-8,9-dihydride-7H-pyrimido[4,5-b]azepine-6-carboxylate (102 mg), 3-chloro-4-[3-(cyclopropylmethoxy)phenoxy]aniline (147 mg), pyridinium chloride (8.2 mg) in 1-methyl-2-pyrrolidone (4 mL) and 2-propanol (2 mL) was stirred at 90° C. for 60 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=100:0→25:75) to give the title compound (137 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 0.27-0.34 (2H, m), 0.50-0.61 (2H, m), 1.11-1.27 (1H, m), 2.70-2.77 (2H, m), 2.89 (1H, s), 3.33-3.42 (1H, m), 3.72 (3H, s), 3.79 (2H, d, J=6.8 Hz), 6.42 (1H, dd, J=7.6, 1.9 Hz), 6.46 (1H, t, J=2.3 Hz), 6.65 (1H, dd, J=7.6, 2.3 Hz), 7.12 (1H, d, J=8.7 Hz), 7.22 (1H, t, J=8.1 Hz), 7.50 (1H, dd, J=8.9, 2.5 Hz), 7.73 (1H, s), 7.79 (1H, d, J=2.3 Hz), 7.92 (1H, t, J=4.9 Hz), 7.98 (1H, s), 9.37 (1H, s).
A mixture of methyl 4-chloro-8,9-dihydride-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (101 mg), 3-(4-amino-2-chlorophenoxy)benzonitrile (113 mg), pyridinium chloride (12.4 mg) in 1-methyl-2-pyrrolidone (5 mL) was stirred at 90° C. for 17 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=100:0→0:100) to give the title compound (96.9 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 2.70-2.78 (2H, m), 3.37 (2H, q, J=4.8 Hz), 3.72 (3H, s), 7.19-7.28 (2H, m), 7.42 (1H, d, J=3.0 Hz), 7.57 (3H, d, J=4.9 Hz), 7.73 (1H, s), 7.84 (1H, d, J=2.6 Hz), 7.95 (1H, t, J=5.1 Hz), 7.99 (1H, s), 9.44 (1H, s).
A mixture of methyl 4-chloro-8,9-dihydride-7H-pyrimido[4,5-b]azepine-6-carboxylate (102 mg), 3-chloro-4-(3-isobutoxyphenoxy)aniline (141 mg), pyridinium chloride (10.3 mg), 1-methyl-2-pyrrolidone (4 mL) and 2-propanol (2 mL) was stirred at 90° C. for 16 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine; dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=100:0→25:75) to give the title compound (150 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 0.96 (6H, d, J=6.4 Hz), 1.83-2.07 (1H, m), 2.71-2.76 (2H, m), 2.89 (2H, s), 3.33-3.41 (2H, m), 3.69-3.75 (3H, m), 6.39-6.48 (2H, m), 6.66 (1H, dd, J=7.9, 1.9 Hz), 7.13 (1H, d, J=9.0 Hz), 7.23 (1H, t, J=8.1 Hz), 7.50 (1H, dd, J=8.9, 2.5 Hz), 7.73 (1H, s), 7.79 (1H, d, J=2.6 Hz), 7.93 (1H, t, J=4.9 Hz), 7.98 (1H, s), 9.38 (1H, s).
To a suspension of N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (120 mg), 2-[(2-aminoethyl)sulfonyl]-2-methyl-1-propanol hydrochloride (106 mg) and triethylamine (68 μL) in tetrahydrofuran (10 mL) was added sodium triacetoxyborohydride (0.31 g) at room temperature. The mixture was stirred at room temperature for 2 days. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by basic silica gel column chromatography (eluent, ethyl acetate→ethyl acetate:methanol=4:1) to give pale-yellow amorphous. To the solution of the obtained amorphous in ethanol (5.0 mL) was added 4N hydrochloric acid/ethyl acetate (0.5 mL) at room temperature. The mixture was concentrated under reduced pressure and crystallized from ethanol-ethyl acetate to give the title compound (67.4 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.26 (6H, s), 1.36 (9H, s), 2.57-2.64 (2H, m), 3.31-3.49 (4H, m), 3.60 (2H, s), 3.67-3.73 (2H, m), 3.75-3.88 (2H, m), 6.89 (1H, s), 7.08-7.12 (1H, m), 7.19 (1H, d, J=8.7 Hz), 7.30-7.35 (1H, m), 7.44 (1H, t, J=8.0 Hz), 7.55-7.63 (2H, m), 7.82 (1H, s), 7.85 (1H, d, J=2.7 Hz), 8.18 (1H, s), 8.20-8.38 (1H, m), 9.36-9.49 (2H, m), 9.72-9.91 (1H, m).
4-({3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (1.00 g) was dissolved in tetrahydrofuran (20 mL) and cooled to −10° C.
Triethylamine (0.50 mL) and isobutyl chloroformate
(0.354 mL) were added to the solution, and the mixture was stirred at −10° C. for 1 hr. The insoluble material was filtrated off. A solution of sodium borohydride (192 mg) in water (15 mL) was added dropwise to the filtrate at −10° C., and the mixture was stirred for 2 hr. Saturated aqueous sodium hydrogencarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=10:90→0:100→ethyl acetate:methanol=90:10) and crystallized from ethyl acetate-diisopropyl ether to give the title compound (632 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 2.12 (3H, s), 2.37-2.45 (2H, m), 2.42 (3H, s), 3.26-3.38 (2H, m), 4.01 (2H, d, J=5.5 Hz), 4.81 (1H, t, J=5.5 Hz), 6.46 (1H, s), 6.87 (1H, d, J=8.7 Hz), 7.10-7.25 (3H, m), 7.33-7.48 (2H, m), 7.86 (1H, s), 8.14 (1H, d, J=2.5 Hz), 8.51 (1H, s).
Using tert-butyl (3S)-3-hydroxypyrrolidine-1-carboxylate (1.02 g), isobutyl bromide (1.00 g), tetra-n-butylammonium hydrogen sulfate (242 mg), toluene (10 mL) and 50% aqueous sodium hydroxide solution (2.5 mL), a similar reaction as in Example 168 (i) was carried out to give the title compound (670 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 0.89 (6H, d, J=6.6 Hz), 1.46 (9H, s), 1.72-2.06 (3H, m), 3.09-3.23 (2H, m), 3.26-3.50 (4H, m), 3.92-4.05 (1H, m).
Using tert-butyl (3S)-3-isobutoxypyrrolidine-1-carboxylate (970 mg), 6N hydrochloric acid (3.5 mL) and tetrahydrofuran (20 mL), a similar reaction as in Example 168 (vii) was carried out to give the title compound (711 mg) as a brown oil.
1H-NMR (DMSO-d6) 0.86 (6H, d, J=6.8 Hz), 1.64-2.09 (3H, m), 3.02-3.28 (4H, m), 3.16 (2H, d, J=6.6 Hz), 4.07-4.22 (1H, m), 9.11 (1H, br s), 9.29 (1H, br s).
Using 2-chloro-4-nitrobenzoic acid (791 mg), thionyl chloride (0.50 mL), N,N-dimethylformamide (one drop), tetrahydrofuran (13 mL), (3S)-3-isobutoxypyrrolidine hydrochloride (707 mg) and triethylamine (1.7 mL), a similar reaction as in Example 192 (i) was carried out to give the title compound (819 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 0.79-0.97 (6H, m), 1.70-2.22 (3H, m), 3.01-3.47 (4H, m), 3.59-3.92 (2H, m), 3.96-4.20 (1H, m), 7.52 (1H, d, J=8.5 Hz), 8.12-8.23 (1H, m), 8.30 (1H, d, J=2.1 Hz).
Using (3S)-1-(2-chloro-4-nitrobenzoyl)-3-isobutoxypyrrolidine (816 mg), reduced iron (703 mg), calcium chloride (143 mg), ethanol (27 mL) and water (3.0 mL), a similar reaction as in Example 192 (ii) was carried out to give the title compound (554 mg) as white crystals.
1H-NMR (CDCl3) δ: 0.82-0.97 (6H, m), 1.70-2.15 (3H, m), 3.02-3.33 (3H, m), 3.34-3.51 (1H, m), 3.61-3.79 (2H, m), 3.83 (2H, br s), 3.93-4.15 (1H, m), 6.53-6.60 (1H, m), 6.67 (1H, d, J=1.9 Hz), 7.09 (1H, d, J=8.3 Hz).
Using methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (122 mg), 3-chloro-4-{[(3S)-3-isobutoxypyrrolidin-1-yl]carbonyl}aniline (177 mg), pyridinium chloride (3.0 mg) and 1-methyl-2-pyrrolidone (1.5 mL), a similar reaction as in Example 192 (iii) was carried out to give the title compound (69.2 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 0.78-0.91 (6H, m), 1.65-1.83 (1H, m), 1.86-2.05 (2H, m), 2.73 (2H, t, J=4.0 Hz), 3.01-3.65 (8H, m), 3.71 (3H, s), 3.96-4.15 (1H, m), 7.21-7.30 (1H, m), 7.53 (1H, dd, J=8.5, 2.1 Hz), 7.66-7.76 (2H, m), 7.96 (1H, t, J=4.9 Hz), 7.99-8.02 (1H, m), 9.46 (1H, s).
Using tert-butyl (3R)-3-hydroxypyrrolidine-1-carboxylate (1.02 g), isobutyl bromide (1.6 mL), tetra-n-butylammonium hydrogen sulfate (216 mg), toluene (10 mL) and 50% aqueous sodium hydroxide solution (2.5 mL), a similar reaction as in Example 168 (i) was carried out to give the title compound (700 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 0.89 (6H, d, J=6.6 Hz), 1.46 (9H, s), 1.73-2.05 (3H, m), 3.10-3.23 (2H, m), 3.27-3.50 (4H, m), 3.92-4.05 (1H, m).
Using tert-butyl (3R)-3-isobutoxypyrrolidine-1-carboxylate (1.00 g), 6N hydrochloric acid (3.5 mL) and tetrahydrofuran (20 mL), a similar reaction as in Example 168 (vii) was carried out to give the title compound (735 mg) as a brown oil.
1H-NMR (DMSO-d6) δ: 0.86 (6H, d, J=6.6 Hz), 1.65-2.10 (3H, m), 3.01-3.28 (4H, m), 3.16 (2H, d, J=6.6 Hz), 4.08-4.20 (1H, m), 9.16 (1H, br s), 9.39 (1H, br s).
Using 2-chloro-4-nitrobenzoic acid (820 mg), thionyl chloride (0.5 mL), N,N-dimethylformamide (one drop), tetrahydrofuran (13 mL), (3S)-3-isobutoxypyrrolidine hydrochloride (731 mg) and triethylamine (1.7 mL), a similar reaction as in Example 192 (i) was carried out to give the title compound (9.53 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 0.79-0.98 (6H, m), 1.70-2.23 (3H, m), 2.99-3.47 (4H, m), 3.58-3.92 (2H, m), 3.95-4.22 (1H, m), 7.52 (1H, d, J=8.5 Hz), 8.10-8.27 (1H, m), 8.30 (1H, d, J=2.1 Hz).
Using (3R)-1-(2-chloro-4-nitrobenzoyl)-3-isobutoxypyrrolidine (947 mg), reduced iron (815 mg), calcium chloride (162 mg), ethanol (27 mL) and water (3.0 mL), a similar reaction as in Example 192 (ii) was carried out to give the title compound (633 mg) as white crystals.
1H-NMR (CDCl3) δ: 0.83-0.95 (6H, m), 1.68-2.17 (3H, m), 2.99-3.33 (3H, m), 3.33-3.50 (1H, m), 3.58-3.80 (2H, m), 3.83 (2H, br s), 3.92-4.16 (1H, m), 6.53-6.60 (1H, m), 6.67 (1H, d, J=2.3 Hz), 7.09 (1H, d, J=8.0 Hz).
Using methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (122 mg), 3-chloro-4-{[(3R)-3-isobutoxypyrrolidin-1-yl]carbonyl}aniline (181 mg), pyridinium chloride (3.0 mg) and 1-methyl-2-pyrrolidone (1.5 mL), a similar reaction as in Example 192 (iii) was carried out to give the title compound (170 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 0.78-0.91 (6H, m), 1.62-1.84 (1H, m), 1.84-2.06 (2H, m), 2.73 (2H, t, J=4.2 Hz), 3.01-3.65 (8H, m), 3.71 (3H, s), 3.95-4.15 (1H, m), 7.21-7.29 (1H, m), 7.53 (1H, dd, J=8.3, 1.9 Hz), 7.68-7.75 (2H, m), 7.96 (1H, t, J=4.2 Hz), 7.99-8.02 (1H, m), 9.46 (1H, s).
To a suspension of N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (120 mg), 2-[(2-amino-2-methylpropyl)sulfonyl]ethanol hydrochloride (106 mg) and triethylamine (68 μL) in tetrahydrofuran (15 mL) and N,N-dimethylformamide (5.0 mL), sodium triacetoxyborohydride (0.31 g) was added at room temperature. The mixture was stirred at room temperature for 2 days. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by basic silica gel column chromatography (eluent, ethyl acetate→ethyl acetate:methanol=4:1) to give pale-yellow amorphous. 4N Hydrochloric acid/ethyl acetate (0.5 mL) was added to the solution of the obtained amorphous in ethanol (5.0 mL) at room temperature. The mixture was concentrated under reduced pressure and crystallized from ethanol-ethyl acetate to give the title compound (29.2 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.35 (9H, s), 1.62 (6H, s), 2.55-2.66 (2H, m), 3.32-3.87 (10H, m), 6.86 (1H, s), 7.04-7.10 (1H, m), 7.18 (1H, d, J=8.4 Hz), 7.26-7.31 (1H, m), 7.42 (1H, t, J=7.8 Hz), 7.53-7.66 (2H, m), 7.78-8.02 (3H, m), 8.09 (1H, s), 8.93-9.10 (2H, m).
A suspension of N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (120 mg), O-ethylhydroxylamine hydrochloride (117 mg) and sodium acetate (98.4 mg) in ethanol (15 mL) was stirred at room temperature for 3 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=1:1→ethyl acetate) to give the title compound (80.5 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.30 (3H, t, J=7.1 Hz), 1.46 (9H, s), 2.87 (2H, t, J=4.8 Hz), 3.53 (2H, q, J=4.8 Hz), 4.16 (2H, q, J=7.2 Hz), 5.65-5.73 (1H, m), 5.91 (1H, br s), 6.40 (1H, s), 6.57 (1H, s), 6.99 (1H, d, J=9.0 Hz), 7.02-7.05 (1H, m), 7.25-7.40 (4H, m), 7.67 (1H, d, J=2.7 Hz), 7.80 (1H, s), 8.10 (1H, s).
A mixture of 2-chloro-1-fluoro-4-nitrobenzene (1.98 g), 3-(trifluoromethyl)benzenethiol (2.01 g), potassium carbonate (2.04 g) and N,N-dimethylformamide (20 mL) was stirred at room temperature for 59 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=100:0→95:5) to give the title compound (3.64 g) as pale-yellow amorphous.
1H-NMR (CDCl3) δ: 6.80 (1H, d, J=9.1 Hz), 7.64 (1H, t, J=7.8 Hz), 7.77 (2H, t, J=7.6 Hz), 7.84 (1H, s), 7.94 (1H, dd, J=8.9, 2.5 Hz), 8.26 (1H, d, J=2.7 Hz).
The mixture of 2-chloro-4-nitro-1-{[3-(trifluoromethyl)phenyl]thio}benzene (3.64 g), reduced iron (3.38 g), calcium chloride (688 mg) and 15% water-containing ethanol (120 mL) was stirred at 100° C. for 15 hr. Iron was removed by filtration, and the solvent was evaporated under reduced pressure. Aqueous sodium bicarbonate solution was added to the residue, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=95:5→75:25) to give the title compound (2.07 g) as colorless amorphous.
1H-NMR (CDCl3) δ: 3.94 (2H, s), 6.58 (1H, dd, J=8.3, 2.7 Hz), 6.84 (1H, d, J=2.7 Hz), 7.16-7.24 (2H, m), 7.28-7.40 (3H, m).
A mixture of methyl 4-chloro-8,9-dihydride-7H-pyrimido[4,5-b]azepine-6-carboxylate (102 mg), 3-chloro-4-{[3-(trifluoromethyl)phenyl]thio}aniline (142 mg), pyridinium chloride (17.0 mg) and 1-methyl-2-pyrrolidone (5.0 mL) was stirred at 120° C. for 18 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=100:0→50:50) to give the title compound (69.2 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 2.71-2.77 (2H, m), 2.89 (1H, s), 3.38 (2H, q, J=4.4 Hz), 3.72 (3H, s), 7.33-7.41 (1H, m), 7.47 (1H, s), 7.54-7.60 (4H, m), 7.72 (1H, s), 7.93 (1H, d, J=2.3 Hz), 8.03 (1H, s), 9.58 (1H, s).
A suspension of N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (120 mg), 2-methyl-1-(methylsulfonyl)-2-propylamine hydrochloride (90 mg) and triethylamine (68 μL) in tetrahydrofuran (15 mL) and N,N-dimethylformamide (5.0 mL) was stirred at room temperature for 1 hr. Sodium triacetoxyborohydride (0.31 g) was added to the suspension at room temperature, and the mixture was stirred for 2 days. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by basic silica gel column chromatography (eluent, ethyl acetate-methyl acetate:methanol=4:1) to give pale-yellow amorphous. 4N Hydrochloric acid/ethyl acetate (0.5 mL) was added to the solution of the obtained amorphous in ethanol (1.0 mL) at room temperature. The mixture was concentrated under reduced pressure and crystallized from ethanol-ethyl acetate to give the title compound (100 mg), as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.36 (9H, s), 1.64 (6H, s), 2.58-2.66 (2H, m), 3.15 (3H, s), 3.40-3.49 (2H, m), 3.71-3.80 (2H, m), 3.83 (2H, s), 6.92 (1H, s), 7.08 (1H, dd, J=7.2, 2.7 Hz), 7.17 (1H, d, J=8.7 Hz), 7.29-7.32 (1H, m), 7.40-7.45 (1H, m), 7.55-7.66 (2H, m), 7.81 (1H, s), 7.91 (1H, d, J=2.4 Hz), 8.09-8.14 (2H, m), 9.21-9.34 (2H, m), 9.76-9.97 (1H, m).
Using methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (200 mg), 3-chloro-4-[3-(isobutylsulfonyl)phenoxy]aniline (314 mg), pyridinium chloride (9.6 mg) and 1-methyl-2-pyrrolidone (5.0 mL), a similar reaction as in Example 202 was carried out to give the title compound (335 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.06 (6H, d, J=6.3 Hz), 2.18-2.29 (1H, m), 2.91 (2H, t, J=4.8 Hz), 2.98 (2H, d, J=6.3 Hz), 3.51-3.56 (2H, m), 3.83 (3H, s), 5.78-5.85 (1H, m), 6.83 (1H, s), 7.09 (1H, d, J=9.0 Hz), 7.19-7.23 (1H, m), 7.40 (1H, dd, J=9.0, 2.7 Hz), 7.43-7.45 (1H, m), 7.48-7.53 (1H, m), 7.59-7.63 (1H, m), 7.68 (1H, s), 7.78 (1H, s), 8.13 (1H, s).
Using 3-(2-chloro-4-nitrophenoxy)benzoic acid (500 mg), 1-amino-2-methylpropan-2-ol (199 mg), tetrahydrofuran (5.0 mL), N,N-dimethylformamide (5.0 mL), triethylamine (0.70 mL), 1-hydroxybenzotriazole (347 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (496 mg), a similar reaction as in Example 168 (viii) was carried out to give the title compound (448 mg) as a white powder.
1H-NMR (CDCl3) δ: 1.30 (6H, s), 3.48 (2H, d, J=5.8 Hz), 6.60 (1H, br s), 6.92 (1H, d, J=9.1 Hz), 7.19-7.25 (1H, m), 7.47-7.58 (2H, m), 7.61-7.69 (1H, m), 8.07 (1H, dd, J=9.1, 2.8 Hz), 8.39 (1H, d, J=2.8 Hz).
Using 3-(2-chloro-4-nitrophenoxy)-N-(2-hydroxy-2-methylpropyl)benzamide (446 mg), ethanol (13.5 mL), water (1.5 mL), reduced iron (347 mg) and calcium chloride (68.4 mg), a similar reaction as in Example 192 (ii) was carried out to give the title compound (349 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.27 (6H, s), 2.38 (1H, br s), 3.44 (2H, d, J=6.0 Hz), 3.71 (2H, br s), 6.53-6.64 (1H, m), 6.57 (1H, dd, J=8.7, 2.8 Hz), 6.78 (1H, d, J=2.8 Hz), 6.90 (1H, d, J=8.7 Hz), 6.97-7.03 (1H, m), 7.29-7.37 (2H, m), 7.38-7.44 (1H, m).
Using methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (110 mg), 3-(4-amino-2-chlorophenoxy)-N-(2-hydroxy-2-methylpropyl)benzamide (197 mg), pyridinium chloride (3.0 mg) and 1-methyl-2-pyrrolidone (1.5 mL), a similar reaction as in Example 192 (iii) was carried out to give the title compound (181 mg) as a pale-orange powder.
1H-NMR (DMSO-d6) δ: 1.09 (6H, s), 2.70-2.78 (2H, m), 3.23 (2H, d, J=6.2 Hz), 3.34-3.42 (2H, m), 3.72 (3H, s), 4.53 (1H, s), 7.07 (1H, ddd, J=8.0, 2.3, 1.0 Hz), 7.16 (1H, d, J=9.0 Hz), 7.40 (1H, dd, J=2.3, 1.0 Hz), 7.45 (1H, t, J=8.0 Hz), 7.52 (1H, dd, J=9.0, 2.5 Hz), 7.61 (1H, d, J=8.0 Hz), 7.74 (1H, s), 7.82 (1H, d, J=2.5 Hz), 7.92 (1H, t, J=5.0 Hz), 7.98 (1H, s), 8.30 (1H, t, J=6.1 Hz), 9.40 (1H, s).
Using methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (100 mg), 3-[(5-amino-3-chloropyridin-2-yl)oxy]-N-(tert-butyl)benzamide (133 mg), pyridinium chloride (4.8 mg) and 1-methyl-2-pyrrolidone (2.0 mL), a similar reaction as in Example 202 was carried out to give the title compound (163.5 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.90 (2H, t, J=4.5 Hz), 3.50-3.54 (2H, m), 3.82 (3H, s), 5.76-5.85 (1H, m), 5.88-5.96 (1H, m), 6.83 (1H, s), 7.21-7.29 (1H, m), 7.42-7.48 (2H, m), 7.54-7.58 (1H, m), 7.65 (1H, s), 8.03 (1H, d, J=2.7 Hz), 8.07 (1H, s), 8.16 (1H, d, J=2.7 Hz).
To a solution of N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (120 mg) and 2-amino-2-methyl-1-propanol (42.8 mg) in tetrahydrofuran (5.0 mL) was added sodium triacetoxyborohydride (0.31 g) at room temperature. The mixture was stirred at room temperature for 20 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by basic silica gel column chromatography (eluent, ethyl acetate-methyl acetate:methanol=4:1) to give pale-yellow amorphous. 4N Hydrochloric acid/ethyl acetate (0.5 mL) was added to a solution of the obtained amorphous in ethanol (5.0 mL) at room temperature. The mixture was concentrated under reduced pressure and crystallized from ethanol-ethyl acetate to give the title compound (102 mg) as yellow crystals.
1H-NMR (DMSO-d6) δ: 1.31 (6H, s), 1.36 (9H, s), 2.55-2.63 (2H, m), 3.40-3.50 (2H, m), 3.51 (2H, s), 3.62-3.73 (2H, m), 6.89 (1H, s), 7.04-7.10 (1H, m), 7.17 (1H, d, J=8.7 Hz), 7.28-7.34 (1H, m), 7.40-7.45 (1H, m), 7.52-7.64 (2H, m), 7.81 (1H, s), 7.86-7.91 (1H, m), 8.08-8.24 (2H, m), 8.64-8.80 (2H, m), 9.73-9.99 (1H, m).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (120 mg), 2,2-dimethyl-3-(methylsulfonyl)-1-propylamine hydrochloride (97 mg), triethylamine (0.134 mL), sodium triacetoxyborohydride (0.31 g), tetrahydrofuran (5.0 mL), N,N-dimethylformamide (1.0 mL), ethanol (5.0 mL) and 4N hydrochloric acid/ethyl acetate (0.5 mL), a similar reaction as in Example 217 was carried out to give the title compound (50.5 mg) as yellow crystals.
1H-NMR (DMSO-d6) δ: 1.25 (6H, s), 1.36 (9H, s), 2.60-2.66 (2H, m), 3.01 (3H, s), 3.06-3.16 (2H, m), 3.41-3.49 (2H, m), 3.56 (2H, s), 3.71-3.81 (2H, m), 6.95 (1H, s), 7.09 (1H, dd, J=8.1, 2.7 Hz), 7.18 (1H, d, J=9.0 Hz), 7.31-7.32 (1H, m), 7.40-7.45 (1H, m), 7.53-7.62 (2H, m), 7.81 (1H, s), 7.86 (1H, d, J=2.7 Hz), 8.18 (1H, s), 8.20-8.38 (1H, m), 8.86-9.04 (2H, m), 9.82-10.00 (1H, m).
[4-({3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl]methanol (201 mg) was dissolved in tetrahydrofuran (2.0 mL). Diphenylphosphorylazide (0.166 mL) and diazabicyclo[5,4,0]-7-undecene (0.229 mL) were added to the solution, and the mixture was stirred at room temperature for 1 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=33:67→0:100→ethyl acetate:methanol=95:5) to give the title compound (198 mg) as a pale-yellow oil.
1H-NMR (CDCl3) δ: 2.23 (3H, s), 2.52 (3H, s), 2.55-2.64 (2H, m), 3.47-3.58 (2H, m), 3.91 (2H, s), 5.88 (1H, t, J=8.7 Hz), 6.30 (1H, s), 6.61 (1H, s), 6.86 (1H, d, J=8.7 Hz), 7.03-7.13 (2H, m), 7.23 (1H, dd, J=8.7, 2.6 Hz), 7.32 (1H, d, J=2.6 Hz), 8.08 (1H, s), 8.25 (1H, dd, J=2.5, 0.9 Hz).
Using 6-(azidomethyl)-N-{3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-amine (195 mg), triphenylphosphine (138 mg), tetrahydrofuran (2.0 mL), water (0.20 mL), di-tert-butyl dicarbonate (0.35 mL), triethylamine (0.35 mL) and methanol (3.0 mL), a similar reaction as in Example 168 (iv) was carried out to give the title compound (160 mg) as white crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.22 (3H, s), 2.47-2.57 (5H, m), 3.45-3.56 (2H, m), 3.85 (2H, d, J=6.0 Hz), 4.75 (1H, br s), 5.44 (1H, t, J=4.1 Hz), 6.18 (1H, s), 6.50 (1H, s), 6.86 (1H, d, J=8.7 Hz), 7.02-7.14 (2H, m), 7.21-7.30 (1H, m), 7.33 (1H, d, J=2.6 Hz), 8.08 (1H, s), 8.25 (1H, dd, J=2.6 Hz, 0.9 Hz),
Using tert-butyl {[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl]methyl}carbamate (158 mg), 6N hydrochloric acid (0.50 mL) and ethanol (3.0 mL), a similar reaction as in Example 181 (viii) was carried out to give the title compound (152 mg) as a white powder.
1H-NMR (DMSO-d6) δ: 2.20 (3H, s), 2.54-2.64 (2H, m), 2.61 (3H, s), 3.46-3.54 (2H, m), 3.59-3.69 (2H, m), 6.77 (1H, s), 7.08 (1H, d, J=8.7 Hz), 7.38 (1H, dd, J=8.7, 2.5 Hz), 7.49 (1H, d, J=2.1 Hz), 7.66 (1H, d, J=8.9 Hz), 7.79 (1H, dd, J=8.9, 2.1 Hz), 8.22 (1H, s), 8.39 (1H, d, J=2.5 Hz), 8.54 (3H, br s), 8.70 (1H, br s), 10.23 (1H, br s).
Using 6-(aminomethyl)-N-{3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-amine trihydrochloride (72.1 mg), (2-methoxyethoxy)acetic acid (0.0328 mL), triethylamine (0.2 mL), 1-hydroxybenzotriazole (43.1 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (56.0 mg), tetrahydrofuran (0.50 mL) and N,N-dimethylformamide (0.50 mL), a similar reaction as in Example 168 (viii) was carried out to give the title compound (49.5 mg) as pale-orange crystals.
1H-NMR (DMSO-d6) δ: 2.13 (3H, s), 2.38 (2H, t, J=4.3 Hz), 2.42 (3H, s), 3.21 (3H, s), 3.25-3.36 (2H, m), 3.40-3.47 (2H, m), 3.54-3.63 (2H, m), 3.86-3.95 (2H, m), 3.92 (2H, s), 6.43 (1H, s), 6.87 (1H, d, J=8.7 Hz), 7.14 (1H, dd, J=8.7, 3.0 Hz), 7.18-7.26 (2H, m), 7.38 (1H, dd, J=8.6, 2.5 Hz), 7.44 (1H, d, J=2.5 Hz), 7.78 (1H, t, J=6.0 Hz), 7.87 (1H, s), 8.14 (1H, d, J=3.0 Hz), 8.54 (1H, s).
Using methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (100 mg), 3-chloro-4-{3-[(2,2-dimethylpropyl)sulfonyl]phenoxy}aniline (162 mg), pyridinium chloride (4.8 mg) and 1-methyl-2-pyrrolidone (5.0 mL), a similar reaction as in Example 202 was carried out to give the title compound (129 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.18 (9H, s), 2.91 (2H, t, J=4.7 Hz), 3.03 (2H, s), 3.53 (2H, q, J=4.7 Hz), 3.83 (3H, s), 5.82 (1H, t, J=4.7 Hz), 6.82 (1H, s), 7.06 (1H, d, J=8.7 Hz), 7.13-7.20 (1H, m), 7.38 (1H, dd, J=8.7, 2.7 Hz), 7.45-7.51 (2H, m), 7.59-7.62 (1H, m), 7.67 (1H, s), 7.76 (1H, d, J=2.7 Hz), 8.12 (1H, s).
A mixture of 3-chloro-4-fluoro-1-nitrobenzene (2.0 g), methyl 4-hydroxybenzoate (1.82 g) and potassium carbonate (1.65 g) in N,N-dimethylformamide (40 mL) was stirred at room temperature for 20 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=19:1→7:3→1:1) and basic silica gel column chromatography (eluent, hexane:ethyl acetate=3:1) to give the title compound (3.48 g) as colorless crystals.
1H-NMR (CDCl3) δ: 3.93 (3H, s), 7.01-7.10 (3H, m), 8.08-8.13 (3H, m), 8.40 (1H, d, J=3.0 Hz).
To a solution of methyl 4-(2-chloro-4-nitrophenoxy)benzoate (3.40 g) in tetrahydrofuran (50 mL) and isopropyl alcohol (25 mL) was added 1N aqueous sodium hydroxide solution (13 mL) at room temperature. The mixture was stirred at room temperature for 16 hr, and extracted with diethyl ether. The aqueous layer was acidified with 1N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The precipitated crystals were collected by filtration, and washed with diisopropyl ether to give the title compound (2.79 g) as colorless crystals.
1H-NMR (CDCl3) δ: 7.07-7.11 (3H, m), 8.12-8.18 (3H, m), 8.42 (1H, d, J=2.7 Hz).
To a solution of 4-(2-chloro-4-nitrophenoxy)benzoic acid (1.5 g) and N,N-dimethylformamide (one drop) in tetrahydrofuran (15 mL) was added thionyl chloride (0.56 mL) at room temperature. The mixture was stirred at room temperature for 1 hr, and concentrated under reduced pressure. A solution of the residue in tetrahydrofuran (39 mL) was added dropwise to a solution of 2,2-dimethyl-1-propylamine (0.67 g) and triethylamine (2.1 mL) in tetrahydrofuran (5.0 mL) at 0° C. The mixture was stirred at room temperature for 3 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=9:1→3:2→1:4) to give the title compound (1.88 g) as colorless crystals.
1H-NMR (CDCl3) δ: 1.00 (9H, s), 3.30 (2H, d, J=6.3 Hz), 6.04-6.15 (1H, m), 6.98 (1H, d, J=9.0 Hz), 7.11 (2H, d, J=8.9 Hz), 7.85 (2H, d, J=8.9 Hz), 8.10 (1H, dd, J=9.0, 2.7 Hz), 8.41 (1H, d, J=2.7 Hz).
Using 4-(2-chloro-4-nitrophenoxy)-N-(2,2-dimethylpropyl)benzamide (1.80 g), reduced iron (1.39 g), calcium chloride (0.28 g) and 15% water-containing ethanol (50 mL), a similar reaction as in Example 135.
1H-NMR (CDCl3) δ: 0.97 (9H, s), 3.26 (2H, d, J=6.3 Hz), 3.71 (2H, br s), 5.99-6.09 (1H, m), 6.58 (1H, dd, J=8.4, 2.7 Hz), 6.78 (1H, d, J=2.7 Hz), 6.86-6.93 (3H, m), 7.70 (2H, d, J=8.7 Hz).
Using methyl 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (200 mg), 4-(4-amino-2-chlorophenoxy)-N-(2,2-dimethylpropyl)benzamide (363 mg), pyridinium chloride (9.6 mg) and 1-methyl-2-pyrrolidone (5.0 mL), a similar reaction as in Example 202 was carried out to give the title compound (362 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 0.98 (9H, s), 2.90 (2H, t, J=4.8 Hz), 3.27 (2H, d, J=6.3 Hz), 3.53 (2H, q, J=4.8 Hz), 3.82 (3H, s), 5.79-5.85 (1H, m), 6.02-6.12 (1H, m), 6.84 (1H, s), 6.97 (2H, d, J=8.7 Hz), 7.07 (1H, d, J=8.7 Hz), 7.37 (1H, dd, J=8.7, 2.4 Hz), 7.66 (1H, s), 7.71-7.75 (3H, m), 8.12 (1H, s).
[4-({3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-yl]methanol (628 mg) was dissolved in a mixture of acetone (20 mL) and N,N-dimethylformamide (2.0 mL). Manganese dioxide (3.37 g) was added to the solution, and the mixture was stirred at room temperature for 1 day. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=20:80→0:100→ethyl acetate:methanol=90:10) to give the title compound (242 mg) as a yellow powder.
1H-NMR (CDCl3) δ: 2.26 (3H, s), 2.53 (3H, s), 2.76-2.84 (2H, m), 3.46-3.55 (2H, m), 6.02 (1H, t, J=4.6 Hz), 6.81 (1H, s), 6.87 (1H, d, J=8.5 Hz), 7.05-7.16 (2H, m), 7.18-7.30 (2H, m), 7.34 (1H, d, J=2.5 Hz), 8.13 (1H, s), 8.25 (1H, d, J=2.6 Hz), 9.43 (1H, s).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepin-6-carbaldehyde (79.4 mg), 2-(2-methoxyethoxy)ethaneamine hydrochloride (65.3 mg), tetrahydrofuran (1.0 mL), N,N-dimethylformamide (1.0 mL) and sodium triacetoxyborohydride (265 mg), a similar reaction as in Example 193 (ii) was carried out to give the title compound (67.9 mg) as a pale-orange powder.
1H-NMR (DMSO-d6) δ: 2.20 (3H, s), 2.58 (3H, s), 2.61-2.69 (2H, m), 3.07-3.19 (2H, m), 3.25 (3H, s), 3.44-3.53 (4H, m), 3.56-3.62 (2H, m), 3.72-3.82 (4H, m), 6.95 (1H, s), 7.06 (1H, d, J=8.7 Hz), 7.37 (1H, dd, J=8.7, 2.5 Hz), 7.48 (1H, d, J=2.5 Hz), 7.60 (1H, d, J=8.7 Hz), 7.66-7.75 (1H, m), 8.20 (1H, s), 8.37 (1H, d, J=2.6 Hz), 8.68 (1H, br s), 9.35 (2H, br s), 10.20 (1H, br s).
To a solution of methyl 4-[(3-chloro-4-{3-[(cyclopropylmethyl)sulfonyl]phenoxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (253 mg) in tetrahydrofuran (2.0 mL) and ethanol (2.0 mL) was added 1N aqueous sodium hydroxide solution (2.0 mL) at room temperature. The mixture was stirred at room temperature for 2 days, and 1N hydrochloric acid (2.0 mL) was added thereto. The mixture was concentrated under reduced pressure, and the precipitated crystals were collected by filtration. The crystals were washed with water to give the title compound (232 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 0.05-0.16 (2H, m), 0.38-0.46 (2H, m), 0.74-0.90 (1H, m), 2.65-2.75 (2H, m), 3.22-3.40 (4H, m), 7.24 (1H, d, J=8.7 Hz), 7.28-7.32 (2H, m), 7.54-7.71 (4H, m), 7.83-7.92 (2H, m), 7.98 (1H, s), 9.39 (1H, s), 12.11-12.25 (1H, m).
Using 4-[(3-chloro-4-{3-[(cyclopropylmethyl)sulfonyl]phenoxy}phenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 2-[(2-amino-2-methylpropyl)sulfonyl]ethanol hydrochloride (83 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (73 mg), 1-hydroxybenzotriazole monohydrate (58 mg), triethylamine (0.13 mL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (78.8 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 0.10-0.16 (2H, m), 0.53-0.60 (2H, m), 0.91-1.05 (1H, m), 1.69 (6H, s), 2.68-2.75 (1H, m), 2.85 (2H, t, J=4.5 Hz), 3.00 (2H, d, J=6.9 Hz), 3.22 (2H, t, J=5.1 Hz), 3.52 (2H, q, J=4.5 Hz), 3.69 (2H, s), 4.10 (2H, q, J=5.1 Hz), 5.66-5.72 (1H, m), 6.49 (1H, s), 7.06 (1H, d, J=8.7 Hz), 7.22-7.26 (2H, m), 7.34 (1H, s), 7.36-7.37 (1H, m), 7.47-7.55 (2H, m), 7.59-7.61 (1H, m), 7.87 (1H, d, J=2.7 Hz), 8.12 (1H, s).
To a solution of N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (120 mg) and 2-methoxyethylamine (30.5 mg) in tetrahydrofuran (5.0 mL) was added sodium triacetoxyborohydride (0.31 g) at room temperature. The mixture was stirred at room temperature for 24 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, ethyl acetate→methanol:ethyl acetate=10:1) and basic silica gel column chromatography (eluent, ethyl acetate:ethanol:triethylamine=100:20:5) to give colorless amorphous. To the solution of the obtained amorphous in ethanol (5.0 mL) was added 4N hydrochloric acid/ethyl acetate (0.5 mL) at room temperature. The mixture was concentrated under reduced pressure. Ethyl acetate was added to the concentrate and the generated crystals were collected by filtration. The crystals were washed with diisopropyl ether to give the title compound (70.1 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.36 (9H, s), 2.52-2.61 (2H, m), 3.06-3.18 (2H, m), 3.32 (3H, s), 3.38-3.47 (2H, m), 3.65 (2H, t, J=5.0 Hz), 3.68-3.77 (2H, m), 6.85 (1H, br s), 7.05-7.10 (1H, m), 7.17 (1H, d, J=8.7 Hz), 7.30 (1H, br s), 7.40-7.46 (1H, m), 7.52-7.60 (2H, m), 7.81 (1H, s), 7.85 (1H, d, J=2.7 Hz), 8.05-8.21 (2H, m), 9.01-9.17 (2H, m), 9.58-9.78 (1H, m).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg), tetrahydro-2H-pyran-4-amine (40 mg), sodium triacetoxyborohydride (0.31 g), tetrahydrofuran (5.0 mL), ethanol (5.0 mL) and 4N hydrochloric acid/ethyl acetate (0.5 mL), a similar reaction as in Example 221 was carried out to give the title compound (73.6 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.36 (9H, s), 1.62-1.79 (2H, m), 2.00-2.09 (2H, m), 2.59-2.65 (2H, m), 3.24-4.00 (9H, m), 6.88 (1H, s), 7.06-7.10 (1H, m), 1.11 (1H, d, J=8.7 Hz), 7.28-7, 33 (1H, m), 7.40-7.45 (1H, m), 7.53-7.63 (2H, m), 7.81 (1H, s), 7.89 (1H, d, J=2.7 Hz), 8.08-8.30 (2H, m), 9.20-9.32 (2H, m), 9.80-9.91 (1H, m).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg), O-tert-butylhydroxylamine hydrochloride (126 mg), sodium acetate (82 mg) and ethanol (5.0 mL), a similar reaction as in Example 215 was carried out to give the title compound (81.6 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.32 (9H, s), 1.46 (9H, s), 2.90 (2H, t, J=4.8 Hz), 3.54 (2H, q, J=4.8 Hz), 5.62-5.68 (1H, m), 5.90 (1H, br s), 6.35 (1H, s), 6.49 (1H, s), 7.00 (1H, d, J=9.0 Hz), 7.01-7.05 (1H, m), 7.25-7.41 (4H, m), 7.68 (1H, d, J=2.7 Hz), 7.78 (1H, s), 8.10 (1H, s).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg), 2-(aminooxy)ethanol hydrochloride (114 mg), sodium acetate (82 mg) and ethanol (5.0 mL), a similar reaction as in Example 215 was carried out to give the title compound (82.6 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.23-2.32 (1H, m), 2.80-2.88 (2H, m), 3.50-3.56 (2H, m), 3.86-3.95 (2H, m), 4.22-4.25 (2H, m), 5.67-5.73 (1H, m), 5.86-5.95 (1H, m), 6.45 (1H, s), 6.53 (1H, s), 7.00 (1H, d, J=9.0 Hz), 7.02-7.08 (1H, m), 7.25-7.38 (4H, m), 7.67 (1H, d, J=2.7 Hz), 7.86 (1H, s), 8.10 (1H, s).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg) and 2-(methylamino)ethanol (30 mg), sodium triacetoxyborohydride (0.31 g), tetrahydrofuran (5.0 mL), ethanol (5.0 mL) and 4N hydrochloric acid/ethyl acetate (0.5 mL), a similar reaction as in Example 221 was carried out to give the title compound (83.7 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.35 (9H, s), 2.60-2.67 (2H, m), 2.77-2.79 (3H, m), 3.05-3.30 (2H, m), 3.39-3.46 (2H, m), 3.75-4.08 (4H, m), 6.91 (1H, s), 7.06-7.10 (1H, m), 7.17 (1H, d, J=8.7 Hz), 7.26-7.30 (1H, m), 7.40-7.45 (1H, m), 7.50-7.60 (2H, m), 7.78-7.86 (2H, m), 8.09-8.27 (2H, m), 9.56-9.92 (2H, m).
To a mixture of tert-butyl (2-hydroxy-1,1-dimethylethyl)carbamate (2.0 g) and tetrabutylammonium hydrogen sulfate (0.36 g) in toluene (20 mL) and 50% aqueous sodium hydroxide solution (4.0 mL) was added methyl iodide (0.98 mL) at room temperature, and the mixture was stirred at room temperature for 24 hr. Methyl iodide (0.98 mL) was added to the reaction mixture, and the mixture was stirred for 3 days. Additional methyl iodide (0.98 mL) was added to the reaction mixture, and the mixture was stirred for 2 days. Water was added to the reaction mixture, and the mixture was extracted with diethyl ether. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=9:1→3:1) to give the title compound (1.46 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.29 (6H, s), 1.43 (9H, s), 3.31 (2H, s), 3.37 (3H, s), 4.74 (1H, br s).
To a solution of tert-butyl (2-methoxy-1,1-dimethylethyl)carbamate (1.46 g) in ethanol (10 mL) was added 6N hydrochloric acid (3.0 mL) at room temperature. The mixture was stirred at 50° C. for 2 days and concentrated under reduced pressure. Ethanol was added to the residue, and the mixture was concentrated again. Crystallization from ethanol-diisopropyl ether gave the title compound (930 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 1.21 (6H, s), 3.30-3.74 (5H, m), 7.99 (3H, br s).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (120 mg), 1-methoxy-2-methyl-2-propylamine hydrochloride (56 mg), triethylamine (40), sodium triacetoxyborohydride (0.31 g), tetrahydrofuran (5.0 mL), N,N-dimethylformamide (1.0 mL), ethanol (5.0 mL) and 4N hydrochloric acid/ethyl acetate (0.5 mL), a similar reaction as in Example 214 was carried out to give the title compound (88 mg) as pale-yellow crystals.
1H-NMR (DNSO-d6) δ: 1.36 (15H, s), 2.56-2.64 (2H, m), 3.36 (3H, s), 3.40-3.70 (6H, m), 6.88 (1H, s), 7.05-7.11 (1H, m), 7.17 (1H, d, J=8.7 Hz), 7.30-7.35 (1H, m), 7.40-7.45 (1H, m), 7.53-7.65 (2H, m), 7.81 (1H, s), 7.89 (1H, d, J=2.1 Hz), 8.10-8.30 (2H, m), 8.89-9.00 (2H, m), 9.87-10.02 (1H, m):
To a solution of N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg), 2-fluoroethylamine hydrochloride (40 mg) and triethylamine (56 μL) in tetrahydrofuran (5.0 mL) and N,N-dimethylformamide (1.0 mL) was added sodium triacetoxyborohydride (0.31 g) at room temperature. The mixture was stirred at room temperature for 24 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, ethyl acetate) to give the title compound (42 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.55 (2H, t, J=4.8 Hz), 2.95 (2H, dt, J=29.1, 4.8 Hz), 3.41 (2H, s), 3.51 (2H, q, J=4.8 Hz), 4.58 (2H, dt, J=47.4, 4.8 Hz), 5.43-5.50 (1H, m), 5.91 (1H, br s), 6.31 (1H, s), 6.76 (1H, s), 6.99 (1H, d, J=8.4 Hz), 7.01-7.06 (1H, m), 7.30-7.40 (4H, m), 7.71 (1H, d, J=2.4 Hz), 8.08 (1H, s).
To a solution of N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg) and 2,2-difluoroethylamine (32 mg) in tetrahydrofuran (5.0 mL) was added sodium triacetoxyborohydride (0.31 g) at room temperature. The mixture was stirred at room temperature for 2 days. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, ethyl acetate→ethyl acetate:methanol=19:1) to give the title compound (76 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.56 (2H, t, J=4.8 Hz), 2.99 (2H, td, J=15.3, 4.2 Hz), 3.43 (2H, s), 3.52 (2H, q, J=4.8 Hz), 5.45-5.55 (1H, m), 5.87 (2H, tt, J=56.1, 4.2 Hz), 5.88-5.94 (1H, m), 6.28 (1H, s), 6.61 (1H, s), 6.99 (1H, d, J=9.0 Hz), 7.01-7.06 (1H, m), 7.26-7.41 (4H, m), 7.68 (1H, d, J=2.7 Hz), 8.09 (1H, s).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg), 2,2,2-trifluoroethylamine (39.6 mg), sodium triacetoxyborohydride (0.31 g) and tetrahydrofuran (5.0 mL), a similar reaction as in Example 235 was carried out to give the title compound (54 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.56 (2H, t, J=4.8 Hz), 3.21 (2H, q, J=9.4 Hz), 3.47 (2H, s), 3.51 (2H, q, J=4.8 Hz), 5.49-5.57 (1H, m), 5.91 (1H, br s), 6.29 (1H, s), 6.58 (1H, s), 6.99 (1H, d, J=9.0 Hz), 7.02-7.06 (1H, m), 7.27-7.40 (4H, m), 7.68 (1H, d, J=2.7 Hz), 8.09 (1H, s).
To a solution of N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg) and 2-(methylsulfonyl)ethylamine (49 mg) in tetrahydrofuran (5.0 mL) and N,N-dimethylformamide (1.0 mL) was added sodium triacetoxyborohydride (0.31 g) at room temperature. The mixture was stirred at room temperature for 24 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, ethyl acetate→methanol:ethyl acetate=3:7) to give pale-yellow amorphous. 4N Hydrochloric acid/ethyl acetate (0.5 mL) was added to a solution of obtained amorphous in ethanol (5.0 mL) at room temperature. The mixture was concentrated under reduced pressure. Ethyl acetate was added to the residue, and the precipitated crystals were collected by filtration. The crystals were washed with ethyl acetate to give the title compound (93.9 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.36 (9H, s), 2.54-2.65 (2H, m), 3.14 (3H, s), 3.32-3.47 (4H, m), 3.59-3.70 (2H, m), 3.75-3.84 (2H, m), 6.88 (1H, s), 7.07-7.11 (1H, m), 7.18 (1H, d, J=8.7 Hz), 7.28-7.32 (1H, m), 7.40-7.46 (1H, m), 7.54-7.62 (2H, m), 7.81 (1H, s), 7.86 (1H, d, J=2.4 Hz), 8.08-8.25 (2H, m), 9.36-9.49 (2H, m), 9.64-9.85 (1H, m).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg), cyclopropylamine (22.8 mg), sodium triacetoxyborohydride (0.26 g) and tetrahydrofuran (5.0 mL), a similar reaction as in Example 234 was carried out to give the title compound (63 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 0.33-0.41 (2H, m), 0.43-0.51 (2H, m), 1.46 (9H, s), 2.14-2.20 (1H, m), 2.56 (2H, t, J=4.8 Hz), 3.42 (2H, s), 3.51 (2H, q, J=4.8 Hz), 5.43-5.50 (1H, m), 5.90 (1H, br s), 6.21 (1H, s), 6.58 (1H, s), 6.99 (1H, d, J=8.7 Hz), 7.02-7.06 (1H, m), 7.29-7.4.0 (4H, m), 7.68 (1H, d, J=2.7 Hz), 8.08 (1H, s).
To a mixture of tert-butyl (2-hydroxyethoxy)carbamate (1.00 g), triphenylphosphine (1.77 g) and imidazole (0.46 g) in toluene (10 mL) was added iodine (1.57 g) at room temperature. The mixture was stirred at room temperature for 16 hr and at 50° C. for 4 hr. Triphenylphosphine (1.46 g), imidazole (0.38 g) and iodine (1.14 g) were added to the reaction mixture, and the mixture was stirred at 50° C. for 8 hr. Water was added to reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with aqueous sodium thiosulfate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Diethyl ether was added to the residue, and the precipitated crystals were removed by filtration. The filtrate was concentrated. Diethyl ether was added to the residue again, and the crystals were removed by filtration. The filtrate was concentrated, and the residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=19:1→3:1) to give the title compound (1.15 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.49 (9H, s), 3.33 (2H, t, J=6.9 Hz), 4.09 (2H, t, J=6.9 Hz), 7.16 (1H, s).
A mixture of tert-butyl (2-iodoethoxy)carbamate (1.15 g), sodium methanesulfinate (0.49 g) and pyridine (0.39 mL) in N,N-dimethylformamide (10 mL) was stirred at 80° C. for 24 hr. Water was added to reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=3:1→1:4) to give the title compound (646.2 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.48 (9H, s), 3.07 (3H, s), 3.33 (2H, t, J=5.4 Hz), 4.32 (2H, t, J=5.4 Hz), 7.30 (1H, s).
Using tert-butyl [2-(methylsulfonyl)ethoxy]carbamate (620 mg), 6N hydrochloric acid (5.0 mL) and ethanol (5.0 mL), a similar reaction as in Example 233 (ii) was carried out to give the title compound (437 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 3.02 (3H, s), 3.57 (2H, t, J=5.7 Hz), 4.33 (2H, t, J=5.7 Hz).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg), 1-(aminooxy)-2-(methylsulfonyl)ethane hydrochloride (70.3 mg), sodium acetate (33 mg) and ethanol (5.0 mL), a similar reaction as in Example 215 was carried out to give the title compound (102 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.84 (2H, t, J=4.8 Hz), 2.96 (3H, s), 3.40 (2H, d, J=5.4 Hz), 3.54 (2H, q, J=4.8 Hz), 4.56 (2H, t, J=5.4 Hz), 5.70-5.80 (1H, m), 5.92 (1H, s), 6.48 (1H, s), 6.58 (1H, s), 7.00 (1H, d, J=8.7 Hz), 7.04-7.08 (1H, m), 7.25-7.37 (4H, m), 7.65 (1H, d, J=2.7 Hz), 7.84 (1H, s), 8.11 (1H, s).
To a solution of tert-butyl N-hydroxycarbamate (2.0 g) in N,N-dimethylformamide (30 mL) was added 60% sodium hydride (dispersion in mineral oil, 0.90 g) at 0° C., and the mixture was stirred at room temperature for 30 min. 2-Bromoethylmethyl ether (1.41 mL) was added to the reaction mixture, and the mixture was stirred at 50° C. for 12 hr. Water was added to reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=3:1→3:7) to give the title compound (954 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.49 (9H, s), 3.39 (3H, s), 3.60-3.63 (2H, m), 4.01-4.04 (2H, m), 7.27 (1H, br s).
To a solution of tert-butyl (2-methoxyethoxy)carbamate (954 mg) in ethanol (10 mL) was added 6N hydrochloric acid at room temperature. The mixture was stirred at 50° C. for 24 hr and concentrated under reduced pressure. Ethanol was added to the residue, and the mixture was concentrated again to give the title compound (642 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 3.26 (3H, s), 3.54-3.56 (2H, m), 4.09-4.12 (2H, m), 10.81 (3H, br s).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg), 1-(aminooxy)-2-methoxyethane hydrochloride (51 mg), sodium acetate (33 mg) and ethanol (5.0 mL), a similar reaction as in Example 215 was carried out to give the title compound (82 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.86 (2H, t, J=4.8 Hz), 3.41 (3H, s), 3.52 (2H, q, J=4.8 Hz), 3.66 (2H, t, J=4.7 Hz), 4.27 (2H, t, J=4.7 Hz), 5.65-5.71 (1H, m), 5.91 (1H, br s), 6.40 (1H, s), 6.5.6 (1H, s), 6.99 (1H, d, J=8.4 Hz), 7.02-7.06 (1H, m), 7.25-7.41 (4H, m), 7.68 (1H, d, J=2.7 Hz), 7.85 (1H, s), 8.10 (1H, s).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg), aminoacetonitrile (34 mg), sodium triacetoxyborohydride (0.34 g), tetrahydrofuran (5.0 mL), ethanol (5.0 mL) and 4N hydrochloric acid/ethyl acetate (0.5 mL), a similar reaction as in Example 221 was carried out to give the title compound (61.2 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.36 (9H, s), 2.54-2.63 (2H, m), 3.30-3.78 (4H, m), 4.21-4.31 (2H, m), 6.80 (1H, br s), 7.05-7.11 (1H, m), 7.18 (1H, d, J=9.0 Hz), 7.28-7.32 (1H, m), 7.40-7.46 (1H, m), 7.51-7.61 (2H, m), 7.79-7.88 (2H, m), 8.05-8.29 (2H, m), 9.50-9.70 (1H, m).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg), N-methyl-2-(methylsulfonyl)ethylamine (80 mg), sodium triacetoxyborohydride (0.25 g) and tetrahydrofuran (5.0 mL), a similar reaction as in Example 235 was carried out to give the title compound (55.3 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.31 (3H, s), 2.53 (2H, t, J=4.8 Hz), 3.01 (3H, s), 3.03 (2H, t, J=6.4 Hz), 3.10 (2H, s), 3.21 (2H, t, J=6.4 Hz), 3.50 (2H, q, J=4.8 Hz), 5.43-5.50 (1H, m), 5.91 (1H, br s), 6.35 (1H, br s), 6.98 (1H, d, J=9.0 Hz), 7.02-7.08 (2H, m), 7.31-7.40 (4H, m), 7.71 (1H, d, J=2.4 Hz), 8.08 (1H, s).
Using 4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid (100 mg), 1-(aminooxy)-2-(methylsulfonyl)ethane hydrochloride (87 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (95 mg), 1-hydroxybenzotriazole monohydrate (76 mg), triethylamine (0.18 mL) and N,N-dimethylformamide (5.0 mL), a similar reaction as in Example 136 was carried out to give the title compound (93.9 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 2.14 (3H, s), 2.43 (3H, s), 2.62-2.68 (2H, m), 3.12 (3H, s), 3.23-3.38 (2H, m), 3.48 (2H, t, J=5.7 Hz), 4.20 (2H, t, J=5.7 Hz), 6.89 (1H, d, J=8.7 Hz), 7.13-7.23 (3H, m), 7.36-7.40 (1H, m), 7.45-7.46 (1H, m), 7.59-7.68 (1H, m), 7.91 (1H, s), 8.14 (1H, d, J=2.4 Hz), 8.92 (1H, s), 11.29-11.41 (1H, m).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg), morpholine (35 mg), sodium triacetoxyborohydride (0.25 g) and tetrahydrofuran (5.0 mL), a similar reaction as in Example 235 was carried out to give the title compound (61 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.38-2.46 (4H, m), 2.56-2.64 (2H, m), 3.04 (2H, s), 3.47-3.51 (2H, m), 3.69-3.72 (4H, m), 5.49-5.51 (1H, m), 5.92 (1H, br s), 6.20 (1H, s), 6.57 (1H, s), 7.00 (1H, d, J=9.0 Hz), 7.02-7.06 (1H, m), 7.27-7.39 (4H, m), 7.64 (1H, d, J=2.4 Hz), 8.08 (1H, s).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (120 mg), (methylamino)acetonitrile hydrochloride (66 mg), triethylamine (56 μL), sodium triacetoxyborohydride (0.25 g), tetrahydrofuran (5.0 mL), N,N-dimethylformamide (1.0 mL), ethanol (5.0 mL) and 4N hydrochloric acid/ethyl acetate (0.5 mL), a similar reaction as in Example 214 was carried out to give the title compound (25.4 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.36 (9H, s), 2.26 (3H, s), 2.40-2.57 (2H, m), 3.18 (2H, s), 3.36-3.49 (2H, m), 3.77 (2H, s), 6.53 (1H, s), 7.05-7.11 (1H, m), 7.19 (1H, d, J=8.7 Hz), 7.33-7.38 (1H, m), 7.42-7.48 (2H, m), 7.56-7.62 (1H, m), 7.73 (1H, d, J=2.1 Hz), 7.83 (1H, s), 8.17 (1H, s), 9.56-9.75 (1H, m).
A solution of N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg) and (carboethoxymethylene)triphenylphosphorane (209 mg) in toluene (5.0 mL) was stirred at 100° C. for 4 hr. Water was added to reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by basic silica gel column chromatography (eluent, hexane:ethyl acetate=1:1→ethyl acetate) to give the title compound (81 mg) as yellow crystals.
1H-NMR (CDCl3) δ: 1.32 (3H, t, J=7.2 Hz), 1.46 (9H, s), 2.71 (2H, t, J=4.8 Hz), 3.56 (2H, q, J=4.8 Hz), 4.24 (2H, q, J=7.2 Hz), 5.67-5.74 (1H, m), 5.85 (1H, d, J=15.6 Hz), 5.91 (1H, br s), 6.62-6.68 (2H, m), 7.01 (1H, d, J=9.0 Hz), 7.02-7.06 (1H, m), 7.30-7.42 (4H, m), 7.45 (1H, d, J=15.6 Hz), 7.73 (1H, d, J=2.4 Hz), 8.10 (1H, s).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg); trans-4-aminocyclohexanol (46 mg), sodium triacetoxyborohydride (0.50 g), tetrahydrofuran (10 mL), ethanol (5.0 mL) and 4N hydrochloric acid/ethyl acetate, (0.5 mL), a similar reaction as in Example 221 was carried out to give the title compound (34.7 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.08-1.25 (2H, m), 1.36 (9H, s), 1.38-1.58 (2H, m), 1.82-1.95 (2H, m), 2.06-2.18 (2H, m), 2.54-2.63 (2H, m), 2.92-3.10 (1H, m), 3.30-4.00 (5H, m), 6.84 (1H, s), 7.07-7.10 (1H, m), 7.17 (1H, d, J=8.7 Hz), 7.31 (1H, br s), 7.43 (1H, t, J=7.8 Hz), 7.56-7.63 (2H, m), 7.81 (1H, s), 7.89 (1H, d, J=2.4 Hz), 8.02-8.27 (2H, m), 8.95-9.09 (2H, m), 9.70-9.93 (1H, m).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg), thiomorpholine 1,1-dioxide (54 mg), sodium triacetoxyborohydride (0.25 g), tetrahydrofuran (5.0 mL), ethanol (5.0 mL) and 4N hydrochloric acid/ethyl acetate (0.5 mL), a similar reaction as in Example 221 was carried out to give the title compound (25.5 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.36 (9H, s), 2.53-2.65 (2H, m), 3.13-3.80 (12H, m), 7.05-7.12 (1H, m), 7.18 (1H, d, J=9.0 Hz), 7.27-7.32 (1H, m), 7.41-7.53 (2H, m), 7.56-7.59 (1H, m), 1.11 (1H, br s), 7.81 (1H, s), 8.05-8.29 (2H, m), 9.43-9.65 (1H, m).
To a solution of cyclopropylamine (274 mg) in methanol (10 mL) was added dropwise methylvinylsulfone (0.42 mL) at room temperature. The mixture was stirred at room temperature for 16 hr. Di-tert-butyl dicarbonate (1.10 mL) was added to the reaction mixture. The mixture was stirred at room temperature for 4 hr, and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=9:1→3:7) to give the title compound (1.10 g) as colorless crystals.
1H-NMR (CDCl3) δ: 0.62-0.67 (2H, m), 0.75-0.85 (2H, m), 1.47 (9H, s), 2.51-2.59 (1H, m), 2.95 (3H, s), 3.25-3.30 (2H, m), 3.67-3.72 (2H, m).
Using tert-butyl cyclopropyl[2-(methylsulfonyl)ethyl]carbamate (1.10 g), 6N hydrochloric acid (4.0 mL) and ethanol (20 mL), a similar reaction as in Example 233 (ii) was carried out to give the title compound (785 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 0.72-0.79 (2H, m), 0.88-0.93 (2H, m), 2.72-2.79 (1H, m), 3.13 (3H, s), 3.36-3.42 (2H, m), 3.55-3.60 (2H, m), 9.45 (2H, br s).
To a mixture of N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg), N-[2-(methylsulfonyl)ethyl]cyclopropaneamine hydrochloride (80 mg) and triethylamine (55.8 μL) in tetrahydrofuran (10 mL) and N,N-dimethylformamide (2.0 mL) was added sodium triacetoxyborohydride (0.26 g) at room temperature. The mixture was stirred at room temperature for 24 hr. To the reaction mixture were added N-[2-(methylsulfonyl)ethyl]cyclopropaneamine hydrochloride (160 mg), triethylamine (0.10 mL) and sodium triacetoxyborohydride (0.52 g), and the mixture was stirred at room temperature for 5 days. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, ethyl acetate-methyl acetate:methanol=4:1) to give the title compound (45.4 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 0.43-0.60 (4H, m), 1.46 (9H, s), 1.85-1.93 (1H, m), 2.48 (2H, t, J=4.8 Hz), 2.97 (3H, s), 3.21-3.34 (6H, m), 3.47 (2H, q, J=4.8 Hz), 5.41-5.48 (1H, m), 5.91 (1H, br s), 6.29 (1H, s), 6.98 (1H, d, J=8.7 Hz), 7.02-7.06 (1H, m), 7.30-7.39 (4H, m), 7.45 (1H, dd, J=8.7, 2.7 Hz), 7.77 (1H, d, J=2.7 Hz), 8.07 (1H, s).
To a solution of 2-fluoroethylamine hydrochloride (478 mg) and triethylamine (0.67 mL) in methanol (10 mL) was added dropwise methylvinylsulfone (0.42 mL) at room temperature. The mixture was stirred at room temperature for 5 days. Di-tert-butyl dicarbonate (1.10 mL) was added to the reaction mixture. The mixture was stirred at room temperature for 4 hr and concentrated under reduced pressure. Water was added to the residue, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=7:3→1:4) to give the title compound (1.13 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.48 (9H, s), 2.94 (3H, s), 3.25-3.40 (2H, m), 3.49-3.65 (2H, m), 3.71-3.76 (2H, m), 4.40-4.67 (2H, m).
Using tert-butyl (2-fluoroethyl) [2-(methylsulfonyl)ethyl]carbamate (1.13 g), 6N hydrochloric acid (5.0 mL) and ethanol (10 mL), a similar reaction as in Example 233 (ii) was carried out to give the title compound (838 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 3.13 (3H, s), 3.29-3.45 (4H, m), 3.52-3.61 (2H, m), 4.75 (2H, dt, J=47.1, 4.5 Hz), 9.25-9.47 (2H, m).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (100 mg), 2-fluoro-N-[2-(methylsulfonyl)ethyl]ethylamine hydrochloride (123 mg), triethylamine (83 μL), sodium triacetoxyborohydride (0.50 g), tetrahydrofuran (10 mL), N,N-dimethylformamide (2.0 mL), ethanol (5.0 mL) and 4N hydrochloric acid/ethyl acetate (0.5 mL), a similar reaction as in Example 214 was carried out to give the title compound (40.1 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.36 (9H, s), 2.58-2.73 (2H, m), 3.08 (3H, br s), 3.25-5.13 (12H, m), 7.09-7.13 (1H, m), 7.19 (1H, d, J=8.7 Hz), 7.33 (1H, br s), 7.40-7.51 (2H, m), 7.57-7.60 (1H, m), 7.68-7.86 (2H, m), 8.21 (1H, s), 8.39-8.65 (1H, m), 9.71-9.14 (1H, m).
To a suspension of methyl 4-[(4-{[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy}-3-chlorophenyl)amino]-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (1.0 g) in toluene (20 mL) was added trifluoroacetic acid (8.0 mL) at room temperature. The mixture was stirred at 60° C. for 20 hr and concentrated under reduced pressure. The residue was basified by addition of aqueous sodium bicarbonate solution and extracted with ethyl acetate-tetrahydrofuran (1:1). The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The precipitated crystals were collected by filtration and washed with diisopropyl ether to give the title compound (896 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.68-1.82 (2H, m), 1.94-2.05 (2H, m), 2.66-2.77 (2H, m), 2.89 (2H, t, J=4.7 Hz), 3.10-3.21 (2H, m), 3.51 (2H, q, J=4.7 Hz), 3.81 (3H, s), 4.30-4.41 (1H, m), 5.72-5.81 (1H, m), 6.76 (1H, s), 6.95 (1H, d, J=8.7 Hz), 7.24-7.27 (1H, m), 7.53 (1H, t, J=2.7 Hz), 7.65 (1H, s), 8.07 (1H, s).
To a solution of methyl 4-{[3-chloro-4-(piperidin-4-yloxy)phenyl]amino}-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate (100 mg) and pyridine (38 μL) in tetrahydrofuran (5.0 mL) was added dropwise a solution of 1,3-dimethyl-1H-pyrazole-5-carbonylchloride (55 mg) in tetrahydrofuran (3.0 mL) at 0° C. The mixture was stirred at room temperature for 16 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, ethyl acetate→ethyl acetate:methanol=4:1) to give the title compound (27 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.84-2.05 (4H, m), 2.27 (3H, s), 2.89 (2H, t, J=4.8 Hz), 3.52 (2H, q, J=4.8 Hz), 3.57-4.07 (10H, m), 4.56-4.64 (1H, m), 5.75-5.84 (1H, m), 6.09 (1H, s), 6.78 (1H, s), 6.95 (1H, d, J=8.7 Hz), 7.29 (1H, dd, J=8.7, 2.7 Hz), 7.56 (1H, d, J=2.7 Hz), 7.65 (1H, s), 8.07 (1H, s).
To a solution of tert-butyl 4-bromopiperidine-1-carboxylate (2.27 g) in N,N-dimethylformamide (40 mL) was added sodium methanethiolate (0.69 g) at room temperature. The mixture was stirred at 80° C. for 24 hr. Water was added to reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. 3-Chloroperbenzoic acid (70%, 4.02 g) was added to a solution of the residue in ethyl acetate (40 mL) at 0° C., and the mixture was stirred at 0° C. for 2 hr. Aqueous sodium thiosulfate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with aqueous sodium bicarbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=3:1→1:3) to give the title compound (0.69 g) as colorless crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 1.65-1.79 (2H, m), 2.07-2.17 (2H, m), 2.66-2.82 (2H, m), 2.84 (3H, s), 2.91-3.02 (1H, m), 4.23-4.40 (2H, m).
Using tert-butyl 4-(methylsulfonyl)piperidine-1-carboxylate (0.69 g), 6N hydrochloric acid (5.0 mL) and ethanol (10 mL), a similar reaction as in Example 233 (ii) was carried out to give the title compound (498 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 1.72-1.91 (2H, m), 2.11-2.22 (2H, m), 2.85-2.95 (2H, m), 2.99 (3H, s), 3.25-3.46 (3H, m), 8.84-9.09 (2H, m).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (120 mg), 4-(methylsulfonyl)piperidine hydrochloride (95.9 mg), triethylamine (67 μL), sodium triacetoxyborohydride (0.31 g), tetrahydrofuran (5.0 mL), N,N-dimethylformamide (1.0 mL), ethanol (5.0 mL) and 4N hydrochloric acid/ethyl acetate (0.5 mL), a similar reaction as in Example 214 was carried out to give the title compound (107 mg) as pale-yellow crystals.
1H-NMR (DMSO-d6) δ: 1.35 (9H, s), 2.02-2.38 (4H, m), 2.63-2.73 (2H, m), 2.90-3.07 (4H, m), 3.28-3.93 (8H, m), 6.98 (1H, s), 7.08-7.11 (1H, m), 7.17 (1H, d, J=8.4 Hz), 7.25-7.32 (1H, m), 7.40-7.45 (1H, m), 7.55-7.58 (2H, m), 7.81 (1H, s), 7.84 (1H, d, J=2.4 Hz), 8.15 (1H, s), 8.18-8.39 (1H, m), 9.70-9.94 (1H, m), 10.29-10.48 (1H, m).
To a mixture of tert-butyl 4-hydroxypiperidine-1-carboxylate (2.0 g), tetra-n-butylammonium hydrogen sulfate (0.34 g), toluene (40 mL) and 50% aqueous sodium hydroxide solution (20 mL) was added methyl iodide (0.93 mL) at room temperature. The mixture was stirred at room temperature for 4 days, and methyl iodide (0.93 mL) was added to the reaction mixture. The mixture was stirred at room temperature for 3 days. Water was added to the mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=4:1→1:1) to give the title compound (1.66 g) as a colorless oil.
1H-NMR (CDCl3) δ: 1.42-1.55 (11H, m), 1.79-1.89 (2H, m), 3.04-3.13 (2H, m), 3.30-3.40 (4H, m), 3.70-3.81 (2H, m).
Using tert-butyl 4-methoxypiperidine-1-carboxylate (1.66 g), 6N hydrochloric acid (10 mL) and ethanol (20 mL), a similar reaction as in Example 233 (ii) was carried out to give the title compound (1.12 g) as colorless crystals.
1H-NMR (DMSO-d6) δ: 1.60-1.71 (2H, m), 1.89-1.99 (2H, m), 2.88-2.96 (2H, m), 3.06-3.14 (2H, m), 3.24 (3H, s), 3.39-3.47 (1H, m), 8.71 (2H, br s).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (120 mg), 4-methoxypiperidine hydrochloride (73 mg), triethylamine (67 μL), sodium triacetoxyborohydride (0.31 g), tetrahydrofuran (5.0 mL) and N,N-dimethylformamide (1.0 mL), a similar reaction as in Example 234 was carried out to give the title compound (69.2 mg) as colorless crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 1.51-1.71 (2H, m), 1.84-1.96 (2H, m), 2.06-2.19 (2H, m), 2.57 (2H, t, J=4.7 Hz), 2.65-2.79 (2H, m), 3.02 (2H, s), 3.16-3.28 (1H, m), 3.34 (3H, s), 3.48 (2H, q, J=4.7 Hz), 5.52 (1H, t, J=4.2 Hz), 5.91 (1H, br s), 6.21 (1H, s), 6.72 (1H, s), 6.99 (1H, d, J=8.7 Hz), 7.01-7.05 (1H, m), 7.28-7.40 (4H, m), 7.67 (1H, d, J=2.4 Hz), 8.07 (1H, s).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (120 mg), 3-(methylsulfonyl)pyrrolidine (94 mg), sodium triacetoxyborohydride (0.31 g), tetrahydrofuran (5.0 mL) and N,N-dimethylformamide (2.0 mL), a similar reaction as in Example 235 was carried out to give the title compound (50 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.21-2.37 (2H, m), 2.50-2.64 (3H, m), 2.71-2.78 (1H, m), 2.85-2.97 (4H, m), 3.07-3.12 (1H, m), 3.22-3.33 (2H, m), 3.44-3.64 (3H, m), 5.45-5.54 (1H, m), 5.91 (1H, br s), 6.36 (1H, s), 6.82 (1H, s), 6.98 (1H, t, J=8.7 Hz), 7.02-7.06 (1H, m), 7.31-7.40 (4H, m), 7.69 (1H, d, J=2.7 Hz), 8.07 (1H, s).
To a solution of tert-butyl (2-hydroxyethoxy)carbamate (1.0 g) and triethylamine (1.57 mL) in tetrahydrofuran (30 mL) was added methanesulfonyl chloride (0.66 mL) at 0° C. The mixture was stirred at 0° C. for 2 hr. Aqueous sodium bicarbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Morpholine (0.99 mL) and potassium carbonate (1.56 g) were added to a solution of the residue (1.66 g) in N,N-dimethylformamide (30 mL) at room temperature. The mixture was stirred at 90° C. for 2 days. Water was added to reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent, hexane:ethyl acetate=1:1→ethyl acetate) to give the title compound (1.01 g) as a yellow oil.
1H-NMR (CDCl3) δ: 1.48 (9H, s), 2.45-2.55 (2H, m), 2.66 (2H, t, J=5.4 Hz), 3.72-3↓(4H, m), 3.99 (2H, t, J=5.4 Hz), 7.69 (1H, m).
Using tert-butyl (2-morpholin-4-ylethoxy)carbamate (1.01 g), 6N hydrochloric acid (10 mL) and ethanol (20 mL), a similar reaction as in Example 233 (ii) was carried out to give the title compound (654 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 3.21-3.30 (4H, m), 3.43 (2H, t, J=4.8 Hz), 3.87 (4H, t, J=4.7 Hz), 4.30-4.40 (2H, m), 10.29-11.03 (3H, m).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (120 mg), 4-[2-(aminooxy)ethyl]morpholine dihydrochloride (105 mg), sodium acetate (39 mg) and ethanol (5.0 mL), a similar reaction as in Example 215 was carried out to give the title compound (97 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.53 (4H, t, J=4.5 Hz), 2.70 (2H, t, J=5.7 Hz), 2.86 (2H, t, J=5.7 Hz), 3.48-3.58 (2H, m), 3.73 (4H, t, J=4.5 Hz), 4.26 (2H, t, J=5.7 Hz), 5.66-5.74 (1H, m), 5.89-5.95 (1H, m), 6.41 (1H, s), 6.54 (1H, s), 7.00 (1H, d, J=9.0 Hz), 7.03-7.06 (1H, m), 7.26-7.40 (4H, m), 7.67 (1H, d, J=2.4 Hz), 7.83 (1H, s), 8.10 (1H, s).
Using tert-butyl (2-hydroxyethoxy)carbamate (1.0 g), triethylamine (1.57 mL), methanesulfonyl chloride (0.66 mL), tetrahydrofuran (30 mL), dimethylamine hydrochloride (1.40 g), potassium carbonate (2.88 g) and N,N-dimethylformamide (20 mL), a similar reaction as in Example 255 (i) was carried out to give the title compound (580 mg) as a colorless oil.
1H-NMR (CDCl3) δ: 1.48 (9H, s), 2.28 (6H, s), 2.57 (2H, t, J=5.4 Hz), 3.95 (2H, t, J=5.4 Hz), 7.66 (1H, br s).
Using tert-butyl [2-(dimethylamino)ethoxy]carbamate (580 mg), 6N hydrochloric acid (5.0 mL) and ethanol (10 mL), a similar reaction as in Example 233 (ii) was carried out to give the title compound (358 mg) as colorless crystals.
1H-NMR (DMSO-d6) δ: 2.79 (6H, s), 3.40 (2H, t, J=4.7 Hz), 4.36 (2H, t, J=4.7 Hz), 10.53-11.10 (3H, m).
Using N-(tert-butyl)-3-{2-chloro-4-[(6-formyl-8,9-dihydro-7H-pyrimido[4,5-b]azepin-4-yl)amino]phenoxy}benzamide (120 mg), 2-(aminooxy)-N,N-dimethylethylamine dihydrochloride (85 mg), sodium acetate (39 mg) and ethanol (5.0 mL), a similar reaction as in Example 215 was carried out to give the title compound (47 mg) as pale-yellow crystals.
1H-NMR (CDCl3) δ: 1.46 (9H, s), 2.30 (6H, s), 2.62 (2H, t, J=5.7 Hz), 2.86 (2H, t, J=4.8 Hz), 3.53 (2H, q, J=4.8 Hz), 4.21 (2H, t, J=5.7 Hz), 5.65-5.74 (1H, m), 5.91 (1H, br s), 6.39 (1H, s), 6.58 (1H, s), 6.99 (1H, d, J=8.7 Hz), 7.01-7.06 (1H, m), 7.23-7.41 (4H, m), 7.67 (1H, d, J=2.4 Hz), 7.84 (1H, s), 8.09 (1H, s).
A mixture of 10.0 mg of the compound obtained in Example 119, 60.0 mg of lactose and 35.0 mg of corn starch is granulated through a 1 mm-mesh sieve using 0.03 ml of a 10% by weight aqueous solution of gelatin (3.0 mg of gelatin), after which the granules are dried at 40° C. and filtered again. The obtained granules are mixed with 2.0 mg of magnesium stearate and compressed. The obtained core tablets are coated with a sugar coat comprising a suspension of sucrose, titanium dioxide, talc and gum arabic and polished with beeswax to yield sugar-coated tablets.
10.0 mg of the compound obtained in Example 119 and 3.0 mg of magnesium stearate are granulated using 0.07 ml of an aqueous solution of soluble starch (7.0 mg of soluble starch), after which these granules are dried and mixed with 70.0 mg of lactose and 50.0 mg of corn starch. This mixture is compressed to yield tablets.
Human HER2 gene was cloned by RT-PCR using total RNA prepared from MCF7 cells as a template. The primer used for RT-PCR was prepared from base sequence (Genbank Accession No. M11730) information of HER2 gene, adding base sequence encoding DYKDDDD peptide and a restriction enzyme recognition sequence to a nucleotide sequence (2176-3918 of Genbank Accession No. M11730 as a base, and corresponding to 676-1255 amino acid of Genbank Accession No. NP—004439 as a protein) encoding the HER2 intracellular domain region, so that a DYKDDDD peptide tag would be attached to the N-terminus of the protein. The base sequence of the primer is shown in below.
The RT reaction was performed using Superscript First-Strand Synthesis System for RT-PCR (Invitrogen) and the PCR reaction was performed using KOD-plus kit (TOYOBO). The obtained PCR product was electrophoresed on agarose gel (1%), and the DNA fragment amplified by PCR was recovered from the gel, and then digested with restriction enzymes Sal I and Sph I. The DNA treated with the restriction enzymes was electrophoresed on agarose gel (1%), and the obtained DNA fragment was recovered and ligated to plasmid pFASTBAC1 (Invitrogen) digested with restriction enzymes Sal I and Sph I to give expression plasmid pFB-HER2. The base sequence of the inserted fragment was confirmed and found to be identical with the base sequence of HER2 intracellular domain (2176-3918 of Genbank Accession M11730). Furthermore, using BAC-TO-BAC Baculovirus Expression System (Invitrogen), recombinant baculovirus BAC-HER2 was prepared.
SF-21 cells were sown at 1×106 cells/mL to 1 L of Sf-900II SFM medium (Invitrogen) containing 10% fetal calf serum (trace), 50 mg/L gentamicin (Invitrogen) and 0.1% Pluronic F-68 (Invitrogen), and cultured with shaking in 2 L volume Erlenmeyer flask at 27° C., 100 rpm. After culturing for 24 hr, recombinant baculovirus BAC-HER2 (13.4 mL) was added thereto, and the cells were further cultured for 3 days. The culture medium was centrifuged at 2,000 rpm for 5 min to give virus-infected cells. The infected cells were washed with phosphate buffered saline (Invitrogen), centrifuged under the same conditions, and preserved at −80° C. The cryopreserved cells were thawed in ice and suspended in buffer A (50 mM Tris buffer (30 mL, pH 7.4) containing 20% glycerol, 0.15 M NaCl) supplemented with Complete Protease Inhibitor (Boehringer). The cells were ruptured 3 times with a Polytron homogenizer (Kinematica) at 20,000 rpm for 30 sec. The disrupt was clarified by centrifugation at 40,000 rpm for 30 min and filtered with a 0.45 μm filter. The filtrate was passed through a column packed with Anti-FLAG M2 Affinity Gel (4 mL, Sigma Aldrich CO.) at a flow rate of about 0.5 mL/min. The column was washed with buffer A, and eluted with buffer A containing 100 μg/mL of FLAG peptide. The eluate was concentrated with Vivaspin 20 (Vivascience) having a molecular weight cut off of 30K. The concentrate was purified by gel filtration using Hi-Load 16/60 Superdex 200pg (GE Healthcare Bioscience) equilibrated with buffer A. The fractions containing HER2 intracellular domain were collected and cryopreserved at −80° C.
HER2 kinase reaction was carried out using 96-well plate. As a buffer for Kinase reaction, a buffer of a composition of 50 mM Tris-HCl (pH 7.5), 5 mM MnCl2, 2 mM dithiothreitol and 0.01% Tween-20 was used. The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO), and diluted with a buffer for kinase reaction so that the DMSO concentration would become 0.1% during kinase reaction. The compound solution (10 μL) was mixed with a buffer for kinase reaction (20 μL) containing the HER2 intracellular domain (0.625 μg/mL) obtained in Experimental Example 1B and a polypeptide substrate poly-Glu:Tyr (4:1) (12.5 μg/mL, Sigma Ltd.) and the mixture was stood for 5 min at room temperature. Then, a buffer for kinase reaction (20 μL) containing 125 μM ATP and 45 μCi/mL [γ-32P]ATP was added thereto, and the kinase reaction was started at the final reaction mixture amount of 50 μL. After kinase reaction at room temperature for 10 min, a 20% TCA solution (50 μL) was added to quench the kinase reaction. The mixture after reaction completion was stood at room temperature for 30 min, acid insoluble fractions in the mixture after reaction completion were collected iii a 96-well GF/C filter plate (PerkinElmer) using a cell harvester (PerkinElmer), and a filter containing the acid-insoluble fractions was washed with a 3% phosphoric acid solution. The filter plate after washing was dried at 45° C. for 60 min, 25 μL of microscinti 0 (PerkinElmer) was added, and the radioactivity was determined using a Top Count (PerkinElmer). The HER2 kinase inhibitory rate (%) of the test compound was calculated by the following formula:
Inhibitory rate (%)=(1−(count of test compound−blank)÷(control−blank))×100
The count of the solution reacted without addition of the compound was used as a “control”, and the count of the solution without the compound and HER2 intracellular domain was used as a “blank”. The results of the inhibitory rate of the compounds are shown in Table 1.
From the foregoing, it has been shown that the compound of the present invention strongly inhibits the activity of HER2 kinase.
Human EGFR gene was cloned by RT-PCR using total RNA prepared from A431 cell as a template. The primer used for RT-PCR was prepared from base sequence (Genbank Accession No. X00588) information of EGFR gene, adding DYKDDDD base sequence encoding the peptide and a restriction enzyme recognition sequence to a base sequence (2191-3819 of Genbank Accession No. X00588 as a base, and corresponding to 669-1210 amino acid of Genbank Accession No. NP—005219 as a protein) encoding the EGFR intracellular domain, so that a DYKDDDD peptide tag would be attached to the N-terminus of the protein. The base sequence of the primer is shown in below.
The RT reaction was performed using Superscript First-Strand Synthesis System for RT-PCR (Invitrogen), and PCR reaction was performed using KOD-plus kit (TOYOBO). The obtained PCR product was electrophoresed on agarose gel (1%), and the DNA fragment amplified by PCR was recovered from the gel, and then digested with restriction enzymes Sal I and Sph I. The DNA treated with the restriction enzymes was electrophoresed on agarose gel (1%), and the obtained DNA fragment was recovered and ligated to plasmid pFASTBAC1 (Invitrogen) digested with restriction enzymes Sal I and Sph I to give expression plasmid pFB-EGFR. The base sequence of the inserted fragment was confirmed and found to be identical with the base sequence of the EGFR intracellular domain (2191-3819 of Genbank Accession X00588). Furthermore, virus stock BAG-EGFR of recombinant Baculovirus was prepared using BAC-TO-BAC Baculovirus Expression System (Invitrogen).
SF-21 cells were sown at 1×106 cells/mL to 1 L of Sf-900II SFM medium (Invitrogen) containing 10% fetal calf serum (trace), 50 mg/L Gentamicin (Invitrogen) and 0.1% Pluronic F-68 (Invitrogen), and cultured with shaking in a 2 L Erlenmeyer flask at 27° C., 100 rpm. After culture for 24 hr, recombinant Baculovirus BAC-EGFR (13.4 mL) was added thereto, and the cells were further cultured for 3 days. The culture medium was centrifuged at 2,000 rpm for 5 min to give virus infected cells. The infected cells were washed with phosphate buffered saline (Invitrogen), centrifuged under the same conditions, and preserved at −80° C. The cryopreserved cells were thawed in ice and suspended in 30 mL of buffer A containing Complete Protease Inhibitor (Boehringer) (50 mM tris buffer (pH 7.4) containing 20% Glycerol, 0.15 M NaCl). The cells were disrupted 3 times at 20,000 rpm for 30 sec using a polytron homogenizer (Kinematica). The disrupt was clarified by centrifugation at 40,000 rpm for 30 min and filtered through a 0.45 μm filter. The filtrate was passed through a column packed with 4 mL of Anti-FLAG M2 Affinity Gel (Sigma Aldrich Co.) at a flow rate of about 0.5 mL/min. The column was washed with buffer A, and eluted with buffer A containing 100 μg/mL of FLAG peptide. The eluate was concentrated with Vivaspin 20 having a molecular weight cut off of 30 K (Vivascience). The concentrate was purified by gel filtration using Hi-Load 16/60 Superdex 200 pg (GE Healthcare Bioscience) equilibrated with buffer A. The fractions containing EGFR intracellular domain were collected and cryopreserved at −80° C.
EGFR kinase reaction was carried out using a 96-well plate. As a buffer for Kinase reaction, a buffer of a composition of 50 mM Tris-HCl (pH 7.5), 5 mM MnCl2, 2 mM dithiothreitol and 0.01% Tween-20 was used. The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO), and diluted with a buffer for kinase reaction so that the DMSO concentration would become 0.1% during kinase reaction. The compound solution (10 μL) was mixed with a buffer for kinase reaction (20 μL) containing the EGFR intracellular domain (0.625 μg/mL) obtained in Experimental Example 2B and a polypeptide substrate poly-Glu:Tyr (4:1) (12.5 μg/mL, Sigma Ltd.) and the mixture was stood for 5 min at room temperature. Then, a buffer for kinase reaction (20 μL) containing 125 ATP and 45 μCi/mL [γ-32P]ATP was added thereto, and the kinase reaction was started at the final reaction mixture amount of 50 μL. After kinase reaction at room temperature for 10 min, a 20% TCA solution (50 μL) was added to quench the kinase reaction. The mixture after reaction completion was stood at room temperature for 30 min, acid insoluble fractions in the mixture after reaction completion were collected in a 96-well GF/C filter plate (PerkinElmer) using a cell harvester (PerkinElmer), and a filter containing the acid-insoluble fractions was washed with a 3% phosphoric acid solution. The filter plats after washing was dried at 45° C. for 60 min, 25 μL of microscinti 0 (PerkinElmer) was added, and the radioactivity was determined using a Top Count (PerkinElmer). The EGFR kinase inhibitory rate (%) of the test compound was calculated by the following formula:
Inhibitory rate (%)=(1−(count of test compound−blank)÷(control−blank))×100
The count of the solution reacted without addition of the compound was used as a “control”, and the count of the solution without the compound and EGFR intracellular domain was used as a “blank”. The results of the inhibitory rate of the compounds are shown in Table 2.
From the foregoing, it has been shown that the compound of the present invention strongly inhibits the activity of EGFR kinase.
A suspension of human breast cancer cell BT-474 (100 μl (6,000 cells)) were plated to 96-well microplate and cultured in an incubator (37° C., 5% carbon dioxide). On the following day, 100 μl of a solution of each test compound previously diluted serially in 2-fold, was added to give indicated dose, and the cells were cultured for 5 days. The culture medium containing the test compound was removed, and the cells were washed, and fixed with 50% trichloroacetic acid, and 0.4% w/v) SRB solution (dissolved in 1% acetic acid) was added to stain the cell protein (Skehan et al., Journal of the National Cancer Institute, Vol. 82, pp. 1107-1112, 1990). After washing with a 1% acetic acid solution, 100 μl of Tris solution (10 mM) was added to extract the pigment and the absorbance was measured at a wavelength of 550 nm to quantify the amount of cells as protein content. Taking as 100% the protein content for the control group, which received no test compound solution, the ratio of the residual protein content for each treatment group was determined, and the compound concentration required to achieve 50% suppression of the residual cell content relative to the control (IC50 value) was calculated. The results are shown in Table 3.
According to the present invention, pyrimidoazepin compound and pyrimidoazocine compound, production methods thereof and use thereof are provided. These condensed pyrimidine compounds have a superior tyrosine kinase inhibitory action, are highly safe, and are sufficiently satisfactory as pharmaceutical products.
This application is based on U.S. Provisional application No. 60/775,777 filed in the United States, the contents of which are hereby incorporated by reference. All of the references cited herein, including patents, patent applications and publications, are hereby incorporated in their entireties by reference.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/JP2007/053859 | 2/22/2007 | WO | 00 | 8/21/2008 |
| Number | Date | Country | |
|---|---|---|---|
| 60775777 | Feb 2006 | US |
